a0021
ambulance service, outside state per mile, transport (medicaid only)
a0080
non-emergency transportation, per mile - vehicle provided by volunteer (individual or organization), with no vested interest
a0090
non-emergency transportation, per mile - vehicle provided by individual (family member, self, neighbor) with vested interest
a0100
non-emergency transportation; taxi
a0110
non-emergency transportation and bus, intra or inter state carrier
a0120
non-emergency transportation: mini-bus, mountain area transports, or other transportation systems
a0130
non-emergency transportation: wheelchair van
a0140
non-emergency transportation and air travel (private or commercial) intra or inter state
a0160
non-emergency transportation: per mile - case worker or social worker
a0170
transportation ancillary: parking fees, tolls, other
a0180
non-emergency transportation: ancillary: lodging-recipient
a0190
non-emergency transportation: ancillary: meals-recipient
a0200
non-emergency transportation: ancillary: lodging escort
a0210
non-emergency transportation: ancillary: meals-escort
a0225
ambulance service, neonatal transport, base rate, emergency transport, one way
a0380
bls mileage (per mile)
a0382
bls routine disposable supplies
a0384
bls specialized service disposable supplies; defibrillation (used by als ambulances and bls ambulances in jurisdictions where defibrillation is permitted in bls ambulances)
a0390
als mileage (per mile)
a0392
als specialized service disposable supplies; defibrillation (to be used only in jurisdictions where defibrillation cannot be performed in bls ambulances)
a0394
als specialized service disposable supplies; iv drug therapy
a0396
als specialized service disposable supplies; esophageal intubation
a0398
als routine disposable supplies
a0420
ambulance waiting time (als or bls), one half (1/2) hour increments
a0422
ambulance (als or bls) oxygen and oxygen supplies, life sustaining situation
a0424
extra ambulance attendant, ground (als or bls) or air (fixed or rotary winged); (requires medical review)
a0425
ground mileage, per statute mile
a0426
ambulance service, advanced life support, non-emergency transport, level 1 (als 1)
a0427
ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency)
a0428
ambulance service, basic life support, non-emergency transport, (bls)
a0429
ambulance service, basic life support, emergency transport (bls-emergency)
a0430
ambulance service, conventional air services, transport, one way (fixed wing)
a0431
ambulance service, conventional air services, transport, one way (rotary wing)
a0432
paramedic intercept (pi), rural area, transport furnished by a volunteer ambulance company which is prohibited by state law from billing third party payers
a0433
advanced life support, level 2 (als 2)
a0434
specialty care transport (sct)
a0435
fixed wing air mileage, per statute mile
a0436
rotary wing air mileage, per statute mile
a0888
noncovered ambulance mileage, per mile (e.g., for miles traveled beyond closest appropriate facility)
a0998
ambulance response and treatment, no transport
a0999
unlisted ambulance service
a2001
innovamatrix ac, per square centimeter
a2002
mirragen advanced wound matrix, per square centimeter
a2004
xcellistem, 1 mg
a2005
microlyte matrix, per square centimeter
a2006
novosorb synpath dermal matrix, per square centimeter
a2007
restrata, per square centimeter
a2008
theragenesis, per square centimeter
a2009
symphony, per square centimeter
a2010
apis, per square centimeter
a2011
supra sdrm, per square centimeter
a2012
suprathel, per square centimeter
a2013
innovamatrix fs, per square centimeter
a2014
omeza collagen matrix, per 100 mg
a2015
phoenix wound matrix, per square centimeter
a2016
permeaderm b, per square centimeter
a2017
permeaderm glove, each
a2018
permeaderm c, per square centimeter
a4100
skin substitute, fda cleared as a device, not otherwise specified
a4206
syringe with needle, sterile, 1 cc or less, each
a4207
syringe with needle, sterile 2 cc, each
a4208
syringe with needle, sterile 3 cc, each
a4209
syringe with needle, sterile 5 cc or greater, each
a4210
needle-free injection device, each
a4211
supplies for self-administered injections
a4212
non-coring needle or stylet with or without catheter
a4213
syringe, sterile, 20 cc or greater, each
a4215
needle, sterile, any size, each
a4216
sterile water, saline and/or dextrose, diluent/flush, 10 ml
a4217
sterile water/saline, 500 ml
a4218
sterile saline or water, metered dose dispenser, 10 ml
a4220
refill kit for implantable infusion pump
a4221
supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)
a4222
infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)
a4223
infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately)
a4224
supplies for maintenance of insulin infusion catheter, per week
a4225
supplies for external insulin infusion pump, syringe type cartridge, sterile, each
a4226
supplies for maintenance of insulin infusion pump with dosage rate adjustment using therapeutic continuous glucose sensing, per week
a4230
infusion set for external insulin pump, non needle cannula type
a4231
infusion set for external insulin pump, needle type
a4232
syringe with needle for external insulin pump, sterile, 3 cc
a4233
replacement battery, alkaline (other than j cell), for use with medically necessary home blood glucose monitor owned by patient, each
a4234
replacement battery, alkaline, j cell, for use with medically necessary home blood glucose monitor owned by patient, each
a4235
replacement battery, lithium, for use with medically necessary home blood glucose monitor owned by patient, each
a4236
replacement battery, silver oxide, for use with medically necessary home blood glucose monitor owned by patient, each
a4238
supply allowance for adjunctive continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service
a4244
alcohol or peroxide, per pint
a4245
alcohol wipes, per box
a4246
betadine or phisohex solution, per pint
a4247
betadine or iodine swabs/wipes, per box
a4248
chlorhexidine containing antiseptic, 1 ml
a4250
urine test or reagent strips or tablets (100 tablets or strips)
a4252
blood ketone test or reagent strip, each
a4253
blood glucose test or reagent strips for home blood glucose monitor, per 50 strips
a4255
platforms for home blood glucose monitor, 50 per box
a4256
normal, low and high calibrator solution / chips
a4257
replacement lens shield cartridge for use with laser skin piercing device, each
a4258
spring-powered device for lancet, each
a4259
lancets, per box of 100
a4261
cervical cap for contraceptive use
a4262
temporary, absorbable lacrimal duct implant, each
a4263
permanent, long term, non-dissolvable lacrimal duct implant, each
a4264
permanent implantable contraceptive intratubal occlusion device(s) and delivery system
a4265
paraffin, per pound
a4266
diaphragm for contraceptive use
a4267
contraceptive supply, condom, male, each
a4268
contraceptive supply, condom, female, each
a4269
contraceptive supply, spermicide (e.g., foam, gel), each
a4270
disposable endoscope sheath, each
a4280
adhesive skin support attachment for use with external breast prosthesis, each
a4281
tubing for breast pump, replacement
a4282
adapter for breast pump, replacement
a4283
cap for breast pump bottle, replacement
a4284
breast shield and splash protector for use with breast pump, replacement
a4285
polycarbonate bottle for use with breast pump, replacement
a4286
locking ring for breast pump, replacement
a4290
sacral nerve stimulation test lead, each
a4300
implantable access catheter, (e.g., venous, arterial, epidural subarachnoid, or peritoneal, etc.) external access
a4301
implantable access total catheter, port/reservoir (e.g., venous, arterial, epidural, subarachnoid, peritoneal, etc.)
a4305
disposable drug delivery system, flow rate of 50 ml or greater per hour
a4306
disposable drug delivery system, flow rate of less than 50 ml per hour
a4310
insertion tray without drainage bag and without catheter (accessories only)
a4311
insertion tray without drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.)
a4312
insertion tray without drainage bag with indwelling catheter, foley type, two-way, all silicone
a4313
insertion tray without drainage bag with indwelling catheter, foley type, three-way, for continuous irrigation
a4314
insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.)
a4315
insertion tray with drainage bag with indwelling catheter, foley type, two-way, all silicone
a4316
insertion tray with drainage bag with indwelling catheter, foley type, three-way, for continuous irrigation
a4320
irrigation tray with bulb or piston syringe, any purpose
a4321
therapeutic agent for urinary catheter irrigation
a4322
irrigation syringe, bulb or piston, each
a4326
male external catheter with integral collection chamber, any type, each
a4327
female external urinary collection device; meatal cup, each
a4328
female external urinary collection device; pouch, each
a4330
perianal fecal collection pouch with adhesive, each
a4331
extension drainage tubing, any type, any length, with connector/adaptor, for use with urinary leg bag or urostomy pouch, each
a4332
lubricant, individual sterile packet, each
a4333
urinary catheter anchoring device, adhesive skin attachment, each
a4334
urinary catheter anchoring device, leg strap, each
a4335
incontinence supply; miscellaneous
a4336
incontinence supply, urethral insert, any type, each
a4337
incontinence supply, rectal insert, any type, each
a4338
indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each
a4340
indwelling catheter; specialty type, (e.g., coude, mushroom, wing, etc.), each
a4344
indwelling catheter, foley type, two-way, all silicone, each
a4346
indwelling catheter; foley type, three way for continuous irrigation, each
a4349
male external catheter, with or without adhesive, disposable, each
a4351
intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each
a4352
intermittent urinary catheter; coude (curved) tip, with or without coating (teflon, silicone, silicone elastomeric, or hydrophilic, etc.), each
a4353
intermittent urinary catheter, with insertion supplies
a4354
insertion tray with drainage bag but without catheter
a4355
irrigation tubing set for continuous bladder irrigation through a three-way indwelling foley catheter, each
a4356
external urethral clamp or compression device (not to be used for catheter clamp), each
a4357
bedside drainage bag, day or night, with or without anti-reflux device, with or without tube, each
a4358
urinary drainage bag, leg or abdomen, vinyl, with or without tube, with straps, each
a4360
disposable external urethral clamp or compression device, with pad and/or pouch, each
a4361
ostomy faceplate, each
a4362
skin barrier; solid, 4 x 4 or equivalent; each
a4363
ostomy clamp, any type, replacement only, each
a4364
adhesive, liquid or equal, any type, per oz
a4366
ostomy vent, any type, each
a4367
ostomy belt, each
a4368
ostomy filter, any type, each
a4369
ostomy skin barrier, liquid (spray, brush, etc.), per oz
a4371
ostomy skin barrier, powder, per oz
a4372
ostomy skin barrier, solid 4 x 4 or equivalent, standard wear, with built-in convexity, each
a4373
ostomy skin barrier, with flange (solid, flexible or accordion), with built-in convexity, any size, each
a4375
ostomy pouch, drainable, with faceplate attached, plastic, each
a4376
ostomy pouch, drainable, with faceplate attached, rubber, each
a4377
ostomy pouch, drainable, for use on faceplate, plastic, each
a4378
ostomy pouch, drainable, for use on faceplate, rubber, each
a4379
ostomy pouch, urinary, with faceplate attached, plastic, each
a4380
ostomy pouch, urinary, with faceplate attached, rubber, each
a4381
ostomy pouch, urinary, for use on faceplate, plastic, each
a4382
ostomy pouch, urinary, for use on faceplate, heavy plastic, each
a4383
ostomy pouch, urinary, for use on faceplate, rubber, each
a4384
ostomy faceplate equivalent, silicone ring, each
a4385
ostomy skin barrier, solid 4 x 4 or equivalent, extended wear, without built-in convexity, each
a4387
ostomy pouch, closed, with barrier attached, with built-in convexity (1 piece), each
a4388
ostomy pouch, drainable, with extended wear barrier attached, (1 piece), each
a4389
ostomy pouch, drainable, with barrier attached, with built-in convexity (1 piece), each
a4390
ostomy pouch, drainable, with extended wear barrier attached, with built-in convexity (1 piece), each
a4391
ostomy pouch, urinary, with extended wear barrier attached (1 piece), each
a4392
ostomy pouch, urinary, with standard wear barrier attached, with built-in convexity (1 piece), each
a4393
ostomy pouch, urinary, with extended wear barrier attached, with built-in convexity (1 piece), each
a4394
ostomy deodorant, with or without lubricant, for use in ostomy pouch, per fluid ounce
a4395
ostomy deodorant for use in ostomy pouch, solid, per tablet
a4396
ostomy belt with peristomal hernia support
a4397
irrigation supply; sleeve, each terminated december 31, 2021.
a4398
ostomy irrigation supply; bag, each
a4399
ostomy irrigation supply; cone/catheter, with or without brush
a4400
ostomy irrigation set
a4402
lubricant, per ounce
a4404
ostomy ring, each
a4405
ostomy skin barrier, non-pectin based, paste, per ounce
a4406
ostomy skin barrier, pectin-based, paste, per ounce
a4407
ostomy skin barrier, with flange (solid, flexible, or accordion), extended wear, with built-in convexity, 4 x 4 inches or smaller, each
a4408
ostomy skin barrier, with flange (solid, flexible or accordion), extended wear, with built-in convexity, larger than 4 x 4 inches, each
a4409
ostomy skin barrier, with flange (solid, flexible or accordion), extended wear, without built-in convexity, 4 x 4 inches or smaller, each
a4410
ostomy skin barrier, with flange (solid, flexible or accordion), extended wear, without built-in convexity, larger than 4 x 4 inches, each
a4411
ostomy skin barrier, solid 4 x 4 or equivalent, extended wear, with built-in convexity, each
a4412
ostomy pouch, drainable, high output, for use on a barrier with flange (2 piece system), without filter, each
a4413
ostomy pouch, drainable, high output, for use on a barrier with flange (2 piece system), with filter, each
a4414
ostomy skin barrier, with flange (solid, flexible or accordion), without built-in convexity, 4 x 4 inches or smaller, each
a4415
ostomy skin barrier, with flange (solid, flexible or accordion), without built-in convexity, larger than 4 x 4 inches, each
a4416
ostomy pouch, closed, with barrier attached, with filter (1 piece), each
a4417
ostomy pouch, closed, with barrier attached, with built-in convexity, with filter (1 piece), each
a4418
ostomy pouch, closed; without barrier attached, with filter (1 piece), each
a4419
ostomy pouch, closed; for use on barrier with non-locking flange, with filter (2 piece), each
a4420
ostomy pouch, closed; for use on barrier with locking flange (2 piece), each
a4421
ostomy supply; miscellaneous
a4422
ostomy absorbent material (sheet/pad/crystal packet) for use in ostomy pouch to thicken liquid stomal output, each
a4423
ostomy pouch, closed; for use on barrier with locking flange, with filter (2 piece), each
a4424
ostomy pouch, drainable, with barrier attached, with filter (1 piece), each
a4425
ostomy pouch, drainable; for use on barrier with non-locking flange, with filter (2 piece system), each
a4426
ostomy pouch, drainable; for use on barrier with locking flange (2 piece system), each
a4427
ostomy pouch, drainable; for use on barrier with locking flange, with filter (2 piece system), each
a4428
ostomy pouch, urinary, with extended wear barrier attached, with faucet-type tap with valve (1 piece), each
a4429
ostomy pouch, urinary, with barrier attached, with built-in convexity, with faucet-type tap with valve (1 piece), each
a4430
ostomy pouch, urinary, with extended wear barrier attached, with built-in convexity, with faucet-type tap with valve (1 piece), each
a4431
ostomy pouch, urinary; with barrier attached, with faucet-type tap with valve (1 piece), each
a4432
ostomy pouch, urinary; for use on barrier with non-locking flange, with faucet-type tap with valve (2 piece), each
a4433
ostomy pouch, urinary; for use on barrier with locking flange (2 piece), each
a4434
ostomy pouch, urinary; for use on barrier with locking flange, with faucet-type tap with valve (2 piece), each
a4435
ostomy pouch, drainable, high output, with extended wear barrier (one-piece system), with or without filter, each
a4436
irrigation supply; sleeve, reusable, per month
a4437
irrigation supply; sleeve, disposable, per month
a4450
tape, non-waterproof, per 18 square inches
a4452
tape, waterproof, per 18 square inches
a4453
rectal catheter for use with the manual pump-operated enema system, replacement only
a4455
adhesive remover or solvent (for tape, cement or other adhesive), per ounce
a4456
adhesive remover, wipes, any type, each
a4458
enema bag with tubing, reusable
a4459
manual pump-operated enema system, includes balloon, catheter and all accessories, reusable, any type
a4461
surgical dressing holder, non-reusable, each
a4463
surgical dressing holder, reusable, each
a4465
non-elastic binder for extremity
a4466
garment, belt, sleeve or other covering, elastic or similar stretchable material, any type, each terminated december 31, 2016.
a4467
belt, strap, sleeve, garment, or covering, any type
a4470
gravlee jet washer
a4480
vabra aspirator
a4481
tracheostoma filter, any type, any size, each
a4483
moisture exchanger, disposable, for use with invasive mechanical ventilation
a4490
surgical stockings above knee length, each
a4495
surgical stockings thigh length, each
a4500
surgical stockings below knee length, each
a4510
surgical stockings full length, each
a4520
incontinence garment, any type, (e.g., brief, diaper), each
a4550
surgical trays
a4553
non-disposable underpads, all sizes
a4554
disposable underpads, all sizes
a4555
electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only
a4556
electrodes, (e.g., apnea monitor), per pair
a4557
lead wires, (e.g., apnea monitor), per pair
a4558
conductive gel or paste, for use with electrical device (e.g., tens, nmes), per oz
a4559
coupling gel or paste, for use with ultrasound device, per oz
a4561
pessary, rubber, any type
a4562
pessary, non rubber, any type
a4563
rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each
a4565
slings
a4566
shoulder sling or vest design, abduction restrainer, with or without swathe control, prefabricated, includes fitting and adjustment
a4570
splint
a4575
topical hyperbaric oxygen chamber, disposable
a4580
cast supplies (e.g., plaster)
a4590
special casting material (e.g., fiberglass)
a4595
electrical stimulator supplies, 2 lead, per month, (e.g., tens, nmes)
a4596
cranial electrotherapy stimulation (ces) system supplies and accessories, per month
a4600
sleeve for intermittent limb compression device, replacement only, each
a4601
lithium ion battery, rechargeable, for non-prosthetic use, replacement
a4602
replacement battery for external infusion pump owned by patient, lithium, 1.5 volt, each
a4604
tubing with integrated heating element for use with positive airway pressure device
a4605
tracheal suction catheter, closed system, each
a4606
oxygen probe for use with oximeter device, replacement
a4608
transtracheal oxygen catheter, each
a4611
battery, heavy duty; replacement for patient owned ventilator
a4612
battery cables; replacement for patient-owned ventilator
a4613
battery charger; replacement for patient-owned ventilator
a4614
peak expiratory flow rate meter, hand held
a4615
cannula, nasal
a4616
tubing (oxygen), per foot
a4617
mouth piece
a4618
breathing circuits
a4619
face tent
a4620
variable concentration mask
a4623
tracheostomy, inner cannula
a4624
tracheal suction catheter, any type other than closed system, each
a4625
tracheostomy care kit for new tracheostomy
a4626
tracheostomy cleaning brush, each
a4627
spacer, bag or reservoir, with or without mask, for use with metered dose inhaler
a4628
oropharyngeal suction catheter, each
a4629
tracheostomy care kit for established tracheostomy
a4630
replacement batteries, medically necessary, transcutaneous electrical stimulator, owned by patient
a4633
replacement bulb/lamp for ultraviolet light therapy system, each
a4634
replacement bulb for therapeutic light box, tabletop model
a4635
underarm pad, crutch, replacement, each
a4636
replacement, handgrip, cane, crutch, or walker, each
a4637
replacement, tip, cane, crutch, walker, each.
a4638
replacement battery for patient-owned ear pulse generator, each
a4639
replacement pad for infrared heating pad system, each
a4640
replacement pad for use with medically necessary alternating pressure pad owned by patient
a4641
radiopharmaceutical, diagnostic, not otherwise classified
a4642
indium in-111 satumomab pendetide, diagnostic, per study dose, up to 6 millicuries
a4648
tissue marker, implantable, any type, each
a4649
surgical supply; miscellaneous
a4650
implantable radiation dosimeter, each
a4651
calibrated microcapillary tube, each
a4652
microcapillary tube sealant
a4653
peritoneal dialysis catheter anchoring device, belt, each
a4657
syringe, with or without needle, each
a4660
sphygmomanometer/blood pressure apparatus with cuff and stethoscope
a4663
blood pressure cuff only
a4670
automatic blood pressure monitor
a4671
disposable cycler set used with cycler dialysis machine, each
a4672
drainage extension line, sterile, for dialysis, each
a4673
extension line with easy lock connectors, used with dialysis
a4674
chemicals/antiseptics solution used to clean/sterilize dialysis equipment, per 8 oz
a4680
activated carbon filter for hemodialysis, each
a4690
dialyzer (artificial kidneys), all types, all sizes, for hemodialysis, each
a4706
bicarbonate concentrate, solution, for hemodialysis, per gallon
a4707
bicarbonate concentrate, powder, for hemodialysis, per packet
a4708
acetate concentrate solution, for hemodialysis, per gallon
a4709
acid concentrate, solution, for hemodialysis, per gallon
a4714
treated water (deionized, distilled, or reverse osmosis) for peritoneal dialysis, per gallon
a4719
y set tubing for peritoneal dialysis
a4720
dialysate solution, any concentration of dextrose, fluid volume greater than 249 cc, but less than or equal to 999 cc, for peritoneal dialysis
a4721
dialysate solution, any concentration of dextrose, fluid volume greater than 999 cc but less than or equal to 1999 cc, for peritoneal dialysis
a4722
dialysate solution, any concentration of dextrose, fluid volume greater than 1999 cc but less than or equal to 2999 cc, for peritoneal dialysis
a4723
dialysate solution, any concentration of dextrose, fluid volume greater than 2999 cc but less than or equal to 3999 cc, for peritoneal dialysis
a4724
dialysate solution, any concentration of dextrose, fluid volume greater than 3999 cc but less than or equal to 4999 cc, for peritoneal dialysis
a4725
dialysate solution, any concentration of dextrose, fluid volume greater than 4999 cc but less than or equal to 5999 cc, for peritoneal dialysis
a4726
dialysate solution, any concentration of dextrose, fluid volume greater than 5999 cc, for peritoneal dialysis
a4728
dialysate solution, non-dextrose containing, 500 ml
a4730
fistula cannulation set for hemodialysis, each
a4736
topical anesthetic, for dialysis, per gram
a4737
injectable anesthetic, for dialysis, per 10 ml
a4740
shunt accessory, for hemodialysis, any type, each
a4750
blood tubing, arterial or venous, for hemodialysis, each
a4755
blood tubing, arterial and venous combined, for hemodialysis, each
a4760
dialysate solution test kit, for peritoneal dialysis, any type, each
a4765
dialysate concentrate, powder, additive for peritoneal dialysis, per packet
a4766
dialysate concentrate, solution, additive for peritoneal dialysis, per 10 ml
a4770
blood collection tube, vacuum, for dialysis, per 50
a4771
serum clotting time tube, for dialysis, per 50
a4772
blood glucose test strips, for dialysis, per 50
a4773
occult blood test strips, for dialysis, per 50
a4774
ammonia test strips, for dialysis, per 50
a4802
protamine sulfate, for hemodialysis, per 50 mg
a4860
disposable catheter tips for peritoneal dialysis, per 10
a4870
plumbing and/or electrical work for home hemodialysis equipment
a4890
contracts, repair and maintenance, for hemodialysis equipment
a4911
drain bag/bottle, for dialysis, each
a4913
miscellaneous dialysis supplies, not otherwise specified
a4918
venous pressure clamp, for hemodialysis, each
a4927
gloves, non-sterile, per 100
a4928
surgical mask, per 20
a4929
tourniquet for dialysis, each
a4930
gloves, sterile, per pair
a4931
oral thermometer, reusable, any type, each
a4932
rectal thermometer, reusable, any type, each
a5051
ostomy pouch, closed; with barrier attached (1 piece), each
a5052
ostomy pouch, closed; without barrier attached (1 piece), each
a5053
ostomy pouch, closed; for use on faceplate, each
a5054
ostomy pouch, closed; for use on barrier with flange (2 piece), each
a5055
stoma cap
a5056
ostomy pouch, drainable, with extended wear barrier attached, with filter, (1 piece), each
a5057
ostomy pouch, drainable, with extended wear barrier attached, with built in convexity, with filter, (1 piece), each
a5061
ostomy pouch, drainable; with barrier attached, (1 piece), each
a5062
ostomy pouch, drainable; without barrier attached (1 piece), each
a5063
ostomy pouch, drainable; for use on barrier with flange (2 piece system), each
a5071
ostomy pouch, urinary; with barrier attached (1 piece), each
a5072
ostomy pouch, urinary; without barrier attached (1 piece), each
a5073
ostomy pouch, urinary; for use on barrier with flange (2 piece), each
a5081
stoma plug or seal, any type
a5082
continent device; catheter for continent stoma
a5083
continent device, stoma absorptive cover for continent stoma
a5093
ostomy accessory; convex insert
a5102
bedside drainage bottle with or without tubing, rigid or expandable, each
a5105
urinary suspensory with leg bag, with or without tube, each
a5112
urinary drainage bag, leg or abdomen, latex, with or without tube, with straps, each
a5113
leg strap; latex, replacement only, per set
a5114
leg strap; foam or fabric, replacement only, per set
a5120
skin barrier, wipes or swabs, each
a5121
skin barrier; solid, 6 x 6 or equivalent, each
a5122
skin barrier; solid, 8 x 8 or equivalent, each
a5126
adhesive or non-adhesive; disk or foam pad
a5131
appliance cleaner, incontinence and ostomy appliances, per 16 oz.
a5200
percutaneous catheter/tube anchoring device, adhesive skin attachment
a5500
for diabetics only, fitting (including follow-up), custom preparation and supply of off-the-shelf depth-inlay shoe manufactured to accommodate multi-density insert(s), per shoe
a5501
for diabetics only, fitting (including follow-up), custom preparation and supply of shoe molded from cast(s) of patient's foot (custom molded shoe), per shoe
a5503
for diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe with roller or rigid rocker bottom, per shoe
a5504
for diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe with wedge(s), per shoe
a5505
for diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe with metatarsal bar, per shoe
a5506
for diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe with off-set heel(s), per shoe
a5507
for diabetics only, not otherwise specified modification (including fitting) of off-the-shelf depth-inlay shoe or custom-molded shoe, per shoe
a5508
for diabetics only, deluxe feature of off-the-shelf depth-inlay shoe or custom-molded shoe, per shoe
a5510
for diabetics only, direct formed, compression molded to patient's foot without external heat source, multiple-density insert(s) prefabricated, per shoe
a5512
for diabetics only, multiple density insert, direct formed, molded to foot after external heat source of 230 degrees fahrenheit or higher, total contact with patient's foot, including arch, base layer minimum of 1/4 inch material of shore a 35 durometer or 3/16 inch material of shore a 40 durometer (or higher), prefabricated, each
a5513
for diabetics only, multiple density insert, custom molded from model of patient's foot, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each
a5514
for diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each
a6000
non-contact wound warming wound cover for use with the non-contact wound warming device and warming card
a6010
collagen based wound filler, dry form, sterile, per gram of collagen
a6011
collagen based wound filler, gel/paste, per gram of collagen
a6021
collagen dressing, sterile, size 16 sq. in. or less, each
a6022
collagen dressing, sterile, size more than 16 sq. in. but less than or equal to 48 sq. in., each
a6023
collagen dressing, sterile, size more than 48 sq. in., each
a6024
collagen dressing wound filler, sterile, per 6 inches
a6025
gel sheet for dermal or epidermal application, (e.g., silicone, hydrogel, other), each
a6154
wound pouch, each
a6196
alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing
a6197
alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing
a6198
alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 48 sq. in., each dressing
a6199
alginate or other fiber gelling dressing, wound filler, sterile, per 6 inches
a6203
composite dressing, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing
a6204
composite dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing
a6205
composite dressing, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing
a6206
contact layer, sterile, 16 sq. in. or less, each dressing
a6207
contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing
a6208
contact layer, sterile, more than 48 sq. in., each dressing
a6209
foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6210
foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
a6211
foam dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing
a6212
foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing
a6213
foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing
a6214
foam dressing, wound cover, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing
a6215
foam dressing, wound filler, sterile, per gram
a6216
gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6217
gauze, non-impregnated, non-sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
a6218
gauze, non-impregnated, non-sterile, pad size more than 48 sq. in., without adhesive border, each dressing
a6219
gauze, non-impregnated, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing
a6220
gauze, non-impregnated, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing
a6221
gauze, non-impregnated, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing
a6222
gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6223
gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing
a6224
gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 48 sq. in., without adhesive border, each dressing
a6228
gauze, impregnated, water or normal saline, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6229
gauze, impregnated, water or normal saline, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
a6230
gauze, impregnated, water or normal saline, sterile, pad size more than 48 sq. in., without adhesive border, each dressing
a6231
gauze, impregnated, hydrogel, for direct wound contact, sterile, pad size 16 sq. in. or less, each dressing
a6232
gauze, impregnated, hydrogel, for direct wound contact, sterile, pad size greater than 16 sq. in., but less than or equal to 48 sq. in., each dressing
a6233
gauze, impregnated, hydrogel, for direct wound contact, sterile, pad size more than 48 sq. in., each dressing
a6234
hydrocolloid dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6235
hydrocolloid dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
a6236
hydrocolloid dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing
a6237
hydrocolloid dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing
a6238
hydrocolloid dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing
a6239
hydrocolloid dressing, wound cover, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing
a6240
hydrocolloid dressing, wound filler, paste, sterile, per ounce
a6241
hydrocolloid dressing, wound filler, dry form, sterile, per gram
a6242
hydrogel dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6243
hydrogel dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
a6244
hydrogel dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing
a6245
hydrogel dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing
a6246
hydrogel dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing
a6247
hydrogel dressing, wound cover, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing
a6248
hydrogel dressing, wound filler, gel, per fluid ounce
a6250
skin sealants, protectants, moisturizers, ointments, any type, any size
a6251
specialty absorptive dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6252
specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
a6253
specialty absorptive dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing
a6254
specialty absorptive dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing
a6255
specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing
a6256
specialty absorptive dressing, wound cover, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing
a6257
transparent film, sterile, 16 sq. in. or less, each dressing
a6258
transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing
a6259
transparent film, sterile, more than 48 sq. in., each dressing
a6260
wound cleansers, any type, any size
a6261
wound filler, gel/paste, per fluid ounce, not otherwise specified
a6262
wound filler, dry form, per gram, not otherwise specified
a6266
gauze, impregnated, other than water, normal saline, or zinc paste, sterile, any width, per linear yard
a6402
gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6403
gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing
a6404
gauze, non-impregnated, sterile, pad size more than 48 sq. in., without adhesive border, each dressing
a6407
packing strips, non-impregnated, sterile, up to 2 inches in width, per linear yard
a6410
eye pad, sterile, each
a6411
eye pad, non-sterile, each
a6412
eye patch, occlusive, each
a6413
adhesive bandage, first-aid type, any size, each
a6441
padding bandage, non-elastic, non-woven/non-knitted, width greater than or equal to three inches and less than five inches, per yard
a6442
conforming bandage, non-elastic, knitted/woven, non-sterile, width less than three inches, per yard
a6443
conforming bandage, non-elastic, knitted/woven, non-sterile, width greater than or equal to three inches and less than five inches, per yard
a6444
conforming bandage, non-elastic, knitted/woven, non-sterile, width greater than or equal to 5 inches, per yard
a6445
conforming bandage, non-elastic, knitted/woven, sterile, width less than three inches, per yard
a6446
conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard
a6447
conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to five inches, per yard
a6448
light compression bandage, elastic, knitted/woven, width less than three inches, per yard
a6449
light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard
a6450
light compression bandage, elastic, knitted/woven, width greater than or equal to five inches, per yard
a6451
moderate compression bandage, elastic, knitted/woven, load resistance of 1.25 to 1.34 foot pounds at 50% maximum stretch, width greater than or equal to three inches and less than five inches, per yard
a6452
high compression bandage, elastic, knitted/woven, load resistance greater than or equal to 1.35 foot pounds at 50% maximum stretch, width greater than or equal to three inches and less than five inches, per yard
a6453
self-adherent bandage, elastic, non-knitted/non-woven, width less than three inches, per yard
a6454
self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to three inches and less than five inches, per yard
a6455
self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to five inches, per yard
a6456
zinc paste impregnated bandage, non-elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard
a6457
tubular dressing with or without elastic, any width, per linear yard
a6460
synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
a6461
synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
a6501
compression burn garment, bodysuit (head to foot), custom fabricated
a6502
compression burn garment, chin strap, custom fabricated
a6503
compression burn garment, facial hood, custom fabricated
a6504
compression burn garment, glove to wrist, custom fabricated
a6505
compression burn garment, glove to elbow, custom fabricated
a6506
compression burn garment, glove to axilla, custom fabricated
a6507
compression burn garment, foot to knee length, custom fabricated
a6508
compression burn garment, foot to thigh length, custom fabricated
a6509
compression burn garment, upper trunk to waist including arm openings (vest), custom fabricated
a6510
compression burn garment, trunk, including arms down to leg openings (leotard), custom fabricated
a6511
compression burn garment, lower trunk including leg openings (panty), custom fabricated
a6512
compression burn garment, not otherwise classified
a6513
compression burn mask, face and/or neck, plastic or equal, custom fabricated
a6530
gradient compression stocking, below knee, 18-30 mmhg, each
a6531
gradient compression stocking, below knee, 30-40 mmhg, each
a6532
gradient compression stocking, below knee, 40-50 mmhg, each
a6533
gradient compression stocking, thigh length, 18-30 mmhg, each
a6534
gradient compression stocking, thigh length, 30-40 mmhg, each
a6535
gradient compression stocking, thigh length, 40-50 mmhg, each
a6536
gradient compression stocking, full length/chap style, 18-30 mmhg, each
a6537
gradient compression stocking, full length/chap style, 30-40 mmhg, each
a6538
gradient compression stocking, full length/chap style, 40-50 mmhg, each
a6539
gradient compression stocking, waist length, 18-30 mmhg, each
a6540
gradient compression stocking, waist length, 30-40 mmhg, each
a6541
gradient compression stocking, waist length, 40-50 mmhg, each
a6544
gradient compression stocking, garter belt
a6545
gradient compression wrap, non-elastic, below knee, 30-50 mm hg, each
a6549
gradient compression stocking/sleeve, not otherwise specified
a6550
wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories
a7000
canister, disposable, used with suction pump, each
a7001
canister, non-disposable, used with suction pump, each
a7002
tubing, used with suction pump, each
a7003
administration set, with small volume nonfiltered pneumatic nebulizer, disposable
a7004
small volume nonfiltered pneumatic nebulizer, disposable
a7005
administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable
a7006
administration set, with small volume filtered pneumatic nebulizer
a7007
large volume nebulizer, disposable, unfilled, used with aerosol compressor
a7008
large volume nebulizer, disposable, prefilled, used with aerosol compressor
a7009
reservoir bottle, non-disposable, used with large volume ultrasonic nebulizer
a7010
corrugated tubing, disposable, used with large volume nebulizer, 100 feet
a7011
corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet terminated december 31, 2015.
a7012
water collection device, used with large volume nebulizer
a7013
filter, disposable, used with aerosol compressor or ultrasonic generator
a7014
filter, nondisposable, used with aerosol compressor or ultrasonic generator
a7015
aerosol mask, used with dme nebulizer
a7016
dome and mouthpiece, used with small volume ultrasonic nebulizer
a7017
nebulizer, durable, glass or autoclavable plastic, bottle type, not used with oxygen
a7018
water, distilled, used with large volume nebulizer, 1000 ml
a7020
interface for cough stimulating device, includes all components, replacement only
a7025
high frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each
a7026
high frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each
a7027
combination oral/nasal mask, used with continuous positive airway pressure device, each
a7028
oral cushion for combination oral/nasal mask, replacement only, each
a7029
nasal pillows for combination oral/nasal mask, replacement only, pair
a7030
full face mask used with positive airway pressure device, each
a7031
face mask interface, replacement for full face mask, each
a7032
cushion for use on nasal mask interface, replacement only, each
a7033
pillow for use on nasal cannula type interface, replacement only, pair
a7034
nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap
a7035
headgear used with positive airway pressure device
a7036
chinstrap used with positive airway pressure device
a7037
tubing used with positive airway pressure device
a7038
filter, disposable, used with positive airway pressure device
a7039
filter, non disposable, used with positive airway pressure device
a7040
one way chest drain valve
a7041
water seal drainage container and tubing for use with implanted chest tube
a7042
implanted pleural catheter, each terminated december 31, 2014.
a7043
vacuum drainage bottle and tubing for use with implanted catheter terminated december 31, 2014.
a7044
oral interface used with positive airway pressure device, each
a7045
exhalation port with or without swivel used with accessories for positive airway devices, replacement only
a7046
water chamber for humidifier, used with positive airway pressure device, replacement, each
a7047
oral interface used with respiratory suction pump, each
a7048
vacuum drainage collection unit and tubing kit, including all supplies needed for collection unit change, for use with implanted catheter, each
a7501
tracheostoma valve, including diaphragm, each
a7502
replacement diaphragm/faceplate for tracheostoma valve, each
a7503
filter holder or filter cap, reusable, for use in a tracheostoma heat and moisture exchange system, each
a7504
filter for use in a tracheostoma heat and moisture exchange system, each
a7505
housing, reusable without adhesive, for use in a heat and moisture exchange system and/or with a tracheostoma valve, each
a7506
adhesive disc for use in a heat and moisture exchange system and/or with tracheostoma valve, any type each
a7507
filter holder and integrated filter without adhesive, for use in a tracheostoma heat and moisture exchange system, each
a7508
housing and integrated adhesive, for use in a tracheostoma heat and moisture exchange system and/or with a tracheostoma valve, each
a7509
filter holder and integrated filter housing, and adhesive, for use as a tracheostoma heat and moisture exchange system, each
a7520
tracheostomy/laryngectomy tube, non-cuffed, polyvinylchloride (pvc), silicone or equal, each
a7521
tracheostomy/laryngectomy tube, cuffed, polyvinylchloride (pvc), silicone or equal, each
a7522
tracheostomy/laryngectomy tube, stainless steel or equal (sterilizable and reusable), each
a7523
tracheostomy shower protector, each
a7524
tracheostoma stent/stud/button, each
a7525
tracheostomy mask, each
a7526
tracheostomy tube collar/holder, each
a7527
tracheostomy/laryngectomy tube plug/stop, each
a8000
helmet, protective, soft, prefabricated, includes all components and accessories
a8001
helmet, protective, hard, prefabricated, includes all components and accessories
a8002
helmet, protective, soft, custom fabricated, includes all components and accessories
a8003
helmet, protective, hard, custom fabricated, includes all components and accessories
a8004
soft interface for helmet, replacement only
a9150
non-prescription drugs
a9152
single vitamin/mineral/trace element, oral, per dose, not otherwise specified
a9153
multiple vitamins, with or without minerals and trace elements, oral, per dose, not otherwise specified
a9155
artificial saliva, 30 ml
a9180
pediculosis (lice infestation) treatment, topical, for administration by patient/caretaker
a9270
non-covered item or service
a9272
wound suction, disposable, includes dressing, all accessories and components, any type, each
a9273
cold or hot fluid bottle, ice cap or collar, heat and/or cold wrap, any type
a9274
external ambulatory insulin delivery system, disposable, each, includes all supplies and accessories
a9275
home glucose disposable monitor, includes test strips
a9276
sensor; invasive (e.g., subcutaneous), disposable, for use with interstitial continuous glucose monitoring system, one unit = 1 day supply
a9277
transmitter; external, for use with interstitial continuous glucose monitoring system
a9278
receiver (monitor); external, for use with interstitial continuous glucose monitoring system
a9279
monitoring feature/device, stand-alone or integrated, any type, includes all accessories, components and electronics, not otherwise classified
a9280
alert or alarm device, not otherwise classified
a9281
reaching/grabbing device, any type, any length, each
a9282
wig, any type, each
a9283
foot pressure off loading/supportive device, any type, each
a9284
spirometer, non-electronic, includes all accessories
a9285
inversion/eversion correction device
a9286
hygienic item or device, disposable or non-disposable, any type, each
a9291
prescription digital cognitive and/or behavioral therapy, fda cleared, per course of treatment
a9300
exercise equipment
a9500
technetium tc-99m sestamibi, diagnostic, per study dose
a9501
technetium tc-99m teboroxime, diagnostic, per study dose
a9502
technetium tc-99m tetrofosmin, diagnostic, per study dose
a9503
technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries
a9504
technetium tc-99m apcitide, diagnostic, per study dose, up to 20 millicuries
a9505
thallium tl-201 thallous chloride, diagnostic, per millicurie
a9507
indium in-111 capromab pendetide, diagnostic, per study dose, up to 10 millicuries
a9508
iodine i-131 iobenguane sulfate, diagnostic, per 0.5 millicurie
a9509
iodine i-123 sodium iodide, diagnostic, per millicurie
a9510
technetium tc-99m disofenin, diagnostic, per study dose, up to 15 millicuries
a9512
technetium tc-99m pertechnetate, diagnostic, per millicurie
a9513
lutetium lu 177, dotatate, therapeutic, 1 millicurie
a9515
choline c-11, diagnostic, per study dose up to 20 millicuries
a9516
iodine i-123 sodium iodide, diagnostic, per 100 microcuries, up to 999 microcuries
a9517
iodine i-131 sodium iodide capsule(s), therapeutic, per millicurie
a9520
technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries
a9521
technetium tc-99m exametazime, diagnostic, per study dose, up to 25 millicuries
a9524
iodine i-131 iodinated serum albumin, diagnostic, per 5 microcuries
a9526
nitrogen n-13 ammonia, diagnostic, per study dose, up to 40 millicuries
a9527
iodine i-125, sodium iodide solution, therapeutic, per millicurie
a9528
iodine i-131 sodium iodide capsule(s), diagnostic, per millicurie
a9529
iodine i-131 sodium iodide solution, diagnostic, per millicurie
a9530
iodine i-131 sodium iodide solution, therapeutic, per millicurie
a9531
iodine i-131 sodium iodide, diagnostic, per microcurie (up to 100 microcuries)
a9532
iodine i-125 serum albumin, diagnostic, per 5 microcuries
a9536
technetium tc-99m depreotide, diagnostic, per study dose, up to 35 millicuries
a9537
technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries
a9538
technetium tc-99m pyrophosphate, diagnostic, per study dose, up to 25 millicuries
a9539
technetium tc-99m pentetate, diagnostic, per study dose, up to 25 millicuries
a9540
technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries
a9541
technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries
a9542
indium in-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries
a9543
yttrium y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries
a9544
iodine i-131 tositumomab, diagnostic, per study dose terminated december 31, 2016.
a9545
iodine i-131 tositumomab, therapeutic, per treatment dose terminated december 31, 2016.
a9546
cobalt co-57/58, cyanocobalamin, diagnostic, per study dose, up to 1 microcurie
a9547
indium in-111 oxyquinoline, diagnostic, per 0.5 millicurie
a9548
indium in-111 pentetate, diagnostic, per 0.5 millicurie
a9550
technetium tc-99m sodium gluceptate, diagnostic, per study dose, up to 25 millicurie
a9551
technetium tc-99m succimer, diagnostic, per study dose, up to 10 millicuries
a9552
fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
a9553
chromium cr-51 sodium chromate, diagnostic, per study dose, up to 250 microcuries
a9554
iodine i-125 sodium iothalamate, diagnostic, per study dose, up to 10 microcuries
a9555
rubidium rb-82, diagnostic, per study dose, up to 60 millicuries
a9556
gallium ga-67 citrate, diagnostic, per millicurie
a9557
technetium tc-99m bicisate, diagnostic, per study dose, up to 25 millicuries
a9558
xenon xe-133 gas, diagnostic, per 10 millicuries
a9559
cobalt co-57 cyanocobalamin, oral, diagnostic, per study dose, up to 1 microcurie
a9560
technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries
a9561
technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries
a9562
technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries
a9563
sodium phosphate p-32, therapeutic, per millicurie
a9564
chromic phosphate p-32 suspension, therapeutic, per millicurie
a9566
technetium tc-99m fanolesomab, diagnostic, per study dose, up to 25 millicuries
a9567
technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries
a9568
technetium tc-99m arcitumomab, diagnostic, per study dose, up to 45 millicuries
a9569
technetium tc-99m exametazime labeled autologous white blood cells, diagnostic, per study dose
a9570
indium in-111 labeled autologous white blood cells, diagnostic, per study dose
a9571
indium in-111 labeled autologous platelets, diagnostic, per study dose
a9572
indium in-111 pentetreotide, diagnostic, per study dose, up to 6 millicuries
a9575
injection, gadoterate meglumine, 0.1 ml
a9576
injection, gadoteridol, (prohance multipack), per ml
a9577
injection, gadobenate dimeglumine (multihance), per ml
a9578
injection, gadobenate dimeglumine (multihance multipack), per ml
a9579
injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml
a9580
sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries
a9581
injection, gadoxetate disodium, 1 ml
a9582
iodine i-123 iobenguane, diagnostic, per study dose, up to 15 millicuries
a9583
injection, gadofosveset trisodium, 1 ml
a9584
iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries
a9585
injection, gadobutrol, 0.1 ml
a9586
florbetapir f18, diagnostic, per study dose, up to 10 millicuries
a9587
gallium ga-68, dotatate, diagnostic, 0.1 millicurie
a9588
fluciclovine f-18, diagnostic, 1 millicurie
a9589
instillation, hexaminolevulinate hydrochloride, 100 mg
a9590
iodine i-131, iobenguane, 1 millicurie
a9591
fluoroestradiol f 18, diagnostic, 1 millicurie
a9592
copper cu-64, dotatate, diagnostic, 1 millicurie
a9593
gallium ga-68 psma-11, diagnostic, (ucsf), 1 millicurie
a9594
gallium ga-68 psma-11, diagnostic, (ucla), 1 millicurie
a9595
piflufolastat f-18, diagnostic, 1 millicurie
a9596
gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie
a9597
positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified
a9598
positron emission tomography radiopharmaceutical, diagnostic, for non-tumor identification, not otherwise classified
a9599
radiopharmaceutical, diagnostic, for beta-amyloid positron emission tomography (pet) imaging, per study dose, not otherwise specified terminated december 31, 2017.
a9600
strontium sr-89 chloride, therapeutic, per millicurie
a9601
flortaucipir f 18 injection, diagnostic, 1 millicurie
a9602
fluorodopa f-18, diagnostic, per millicurie
a9604
samarium sm-153 lexidronam, therapeutic, per treatment dose, up to 150 millicuries
a9606
radium ra-223 dichloride, therapeutic, per microcurie
a9607
lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie
a9698
non-radioactive contrast imaging material, not otherwise classified, per study
a9699
radiopharmaceutical, therapeutic, not otherwise classified
a9700
supply of injectable contrast material for use in echocardiography, per study
a9800
gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie
a9900
miscellaneous dme supply, accessory, and/or service component of another hcpcs code
a9901
dme delivery, set up, and/or dispensing service component of another hcpcs code
a9999
miscellaneous dme supply or accessory, not otherwise specified
b4034
enteral feeding supply kit; syringe fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape
b4035
enteral feeding supply kit; pump fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape
b4036
enteral feeding supply kit; gravity fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape
b4081
nasogastric tubing with stylet
b4082
nasogastric tubing without stylet
b4083
stomach tube - levine type
b4087
gastrostomy/jejunostomy tube, standard, any material, any type, each
b4088
gastrostomy/jejunostomy tube, low-profile, any material, any type, each
b4100
food thickener, administered orally, per ounce
b4102
enteral formula, for adults, used to replace fluids and electrolytes (e.g., clear liquids), 500 ml = 1 unit
b4103
enteral formula, for pediatrics, used to replace fluids and electrolytes (e.g., clear liquids), 500 ml = 1 unit
b4104
additive for enteral formula (e.g., fiber)
b4105
in-line cartridge containing digestive enzyme(s) for enteral feeding, each
b4149
enteral formula, manufactured blenderized natural foods with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4150
enteral formula, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4152
enteral formula, nutritionally complete, calorically dense (equal to or greater than 1.5 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4153
enteral formula, nutritionally complete, hydrolyzed proteins (amino acids and peptide chain), includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4154
enteral formula, nutritionally complete, for special metabolic needs, excludes inherited disease of metabolism, includes altered composition of proteins, fats, carbohydrates, vitamins and/or minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4155
enteral formula, nutritionally incomplete/modular nutrients, includes specific nutrients, carbohydrates (e.g., glucose polymers), proteins/amino acids (e.g., glutamine, arginine), fat (e.g., medium chain triglycerides) or combination, administered through an enteral feeding tube, 100 calories = 1 unit
b4157
enteral formula, nutritionally complete, for special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4158
enteral formula, for pediatrics, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber and/or iron, administered through an enteral feeding tube, 100 calories = 1 unit
b4159
enteral formula, for pediatrics, nutritionally complete soy based with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber and/or iron, administered through an enteral feeding tube, 100 calories = 1 unit
b4160
enteral formula, for pediatrics, nutritionally complete calorically dense (equal to or greater than 0.7 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4161
enteral formula, for pediatrics, hydrolyzed/amino acids and peptide chain proteins, includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4162
enteral formula, for pediatrics, special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
b4164
parenteral nutrition solution: carbohydrates (dextrose), 50% or less (500 ml = 1 unit) - home mix
b4168
parenteral nutrition solution; amino acid, 3.5%, (500 ml = 1 unit) - home mix
b4172
parenteral nutrition solution; amino acid, 5.5% through 7%, (500 ml = 1 unit) - home mix
b4176
parenteral nutrition solution; amino acid, 7% through 8.5%, (500 ml = 1 unit) - home mix
b4178
parenteral nutrition solution: amino acid, greater than 8.5% (500 ml = 1 unit) - home mix
b4180
parenteral nutrition solution; carbohydrates (dextrose), greater than 50% (500 ml = 1 unit) - home mix
b4185
parenteral nutrition solution, not otherwise specified, 10 grams lipids
b4187
omegaven, 10 grams lipids
b4189
parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, 10 to 51 grams of protein - premix
b4193
parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, 52 to 73 grams of protein - premix
b4197
parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, 74 to 100 grams of protein - premix
b4199
parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, over 100 grams of protein - premix
b4216
parenteral nutrition; additives (vitamins, trace elements, heparin, electrolytes), home mix, per day
b4220
parenteral nutrition supply kit; premix, per day
b4222
parenteral nutrition supply kit; home mix, per day
b4224
parenteral nutrition administration kit, per day
b5000
parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal-aminosyn-rf, nephramine, renamine-premix
b5100
parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic, hepatamine-premix
b5200
parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress-branch chain amino acids-freamine-hbc-premix
b9000
enteral nutrition infusion pump - without alarm terminated december 31, 2016.
b9002
enteral nutrition infusion pump, any type
b9004
parenteral nutrition infusion pump, portable
b9006
parenteral nutrition infusion pump, stationary
b9998
noc for enteral supplies
b9999
noc for parenteral supplies
c1052
hemostatic agent, gastrointestinal, topical
c1062
intravertebral body fracture augmentation with implant (e.g., metal, polymer)
c1300
hyperbaric oxygen under pressure, full body chamber, per 30 minute interval terminated december 31, 2014.
c1713
anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)
c1714
catheter, transluminal atherectomy, directional
c1715
brachytherapy needle
c1716
brachytherapy source, non-stranded, gold-198, per source
c1717
brachytherapy source, non-stranded, high dose rate iridium-192, per source
c1719
brachytherapy source, non-stranded, non-high dose rate iridium-192, per source
c1721
cardioverter-defibrillator, dual chamber (implantable)
c1722
cardioverter-defibrillator, single chamber (implantable)
c1724
catheter, transluminal atherectomy, rotational
c1725
catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)
c1726
catheter, balloon dilatation, non-vascular
c1727
catheter, balloon tissue dissector, non-vascular (insertable)
c1728
catheter, brachytherapy seed administration
c1729
catheter, drainage
c1730
catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes)
c1731
catheter, electrophysiology, diagnostic, other than 3d mapping (20 or more electrodes)
c1732
catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping
c1733
catheter, electrophysiology, diagnostic/ablation, other than 3d or vector mapping, other than cool-tip
c1734
orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable)
c1748
endoscope, single-use (i.e. disposable), upper gi, imaging/illumination device (insertable)
c1749
endoscope, retrograde imaging/illumination colonoscope device (implantable)
c1750
catheter, hemodialysis/peritoneal, long-term
c1751
catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)
c1752
catheter, hemodialysis/peritoneal, short-term
c1753
catheter, intravascular ultrasound
c1754
catheter, intradiscal
c1755
catheter, intraspinal
c1756
catheter, pacing, transesophageal
c1757
catheter, thrombectomy/embolectomy
c1758
catheter, ureteral
c1759
catheter, intracardiac echocardiography
c1760
closure device, vascular (implantable/insertable)
c1761
catheter, transluminal intravascular lithotripsy, coronary
c1762
connective tissue, human (includes fascia lata)
c1763
connective tissue, non-human (includes synthetic)
c1764
event recorder, cardiac (implantable)
c1765
adhesion barrier
c1766
introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away
c1767
generator, neurostimulator (implantable), non-rechargeable
c1768
graft, vascular
c1769
guide wire
c1770
imaging coil, magnetic resonance (insertable)
c1771
repair device, urinary, incontinence, with sling graft
c1772
infusion pump, programmable (implantable)
c1773
retrieval device, insertable (used to retrieve fractured medical devices)
c1776
joint device (implantable)
c1777
lead, cardioverter-defibrillator, endocardial single coil (implantable)
c1778
lead, neurostimulator (implantable)
c1779
lead, pacemaker, transvenous vdd single pass
c1780
lens, intraocular (new technology)
c1781
mesh (implantable)
c1782
morcellator
c1783
ocular implant, aqueous drainage assist device
c1784
ocular device, intraoperative, detached retina
c1785
pacemaker, dual chamber, rate-responsive (implantable)
c1786
pacemaker, single chamber, rate-responsive (implantable)
c1787
patient programmer, neurostimulator
c1788
port, indwelling (implantable)
c1789
prosthesis, breast (implantable)
c1813
prosthesis, penile, inflatable
c1814
retinal tamponade device, silicone oil
c1815
prosthesis, urinary sphincter (implantable)
c1816
receiver and/or transmitter, neurostimulator (implantable)
c1817
septal defect implant system, intracardiac
c1818
integrated keratoprosthesis
c1819
surgical tissue localization and excision device (implantable)
c1820
generator, neurostimulator (implantable), with rechargeable battery and charging system
c1821
interspinous process distraction device (implantable)
c1822
generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system
c1823
generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads
c1824
generator, cardiac contractility modulation (implantable)
c1825
generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s)
c1830
powered bone marrow biopsy needle
c1831
personalized, anterior and lateral interbody cage (implantable)
c1832
autograft suspension, including cell processing and application, and all system components
c1833
monitor, cardiac, including intracardiac lead and all system components (implantable)
c1834
pressure sensor system, includes all components (e.g., introducer, sensor), intramuscular (implantable), excludes mobile (wireless) software application
c1839
iris prosthesis
c1840
lens, intraocular (telescopic)
c1841
retinal prosthesis, includes all internal and external components
c1842
retinal prosthesis, includes all internal and external components; add-on to c1841
c1849
skin substitute, synthetic, resorbable, per square centimeter
c1874
stent, coated/covered, with delivery system
c1875
stent, coated/covered, without delivery system
c1876
stent, non-coated/non-covered, with delivery system
c1877
stent, non-coated/non-covered, without delivery system
c1878
material for vocal cord medialization, synthetic (implantable)
c1880
vena cava filter
c1881
dialysis access system (implantable)
c1882
cardioverter-defibrillator, other than single or dual chamber (implantable)
c1883
adapter/extension, pacing lead or neurostimulator lead (implantable)
c1884
embolization protective system
c1885
catheter, transluminal angioplasty, laser
c1886
catheter, extravascular tissue ablation, any modality (insertable)
c1887
catheter, guiding (may include infusion/perfusion capability)
c1888
catheter, ablation, non-cardiac, endovascular (implantable)
c1889
implantable/insertable device, not otherwise classified
c1890
no implantable/insertable device used with device-intensive procedures
c1891
infusion pump, non-programmable, permanent (implantable)
c1892
introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away
c1893
introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away
c1894
introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser
c1895
lead, cardioverter-defibrillator, endocardial dual coil (implantable)
c1896
lead, cardioverter-defibrillator, other than endocardial single or dual coil (implantable)
c1897
lead, neurostimulator test kit (implantable)
c1898
lead, pacemaker, other than transvenous vdd single pass
c1899
lead, pacemaker/cardioverter-defibrillator combination (implantable)
c1900
lead, left ventricular coronary venous system
c1982
catheter, pressure-generating, one-way valve, intermittently occlusive
c2596
probe, image-guided, robotic, waterjet ablation
c2613
lung biopsy plug with delivery system
c2614
probe, percutaneous lumbar discectomy
c2615
sealant, pulmonary, liquid
c2616
brachytherapy source, non-stranded, yttrium-90, per source
c2617
stent, non-coronary, temporary, without delivery system
c2618
probe/needle, cryoablation
c2619
pacemaker, dual chamber, non rate-responsive (implantable)
c2620
pacemaker, single chamber, non rate-responsive (implantable)
c2621
pacemaker, other than single or dual chamber (implantable)
c2622
prosthesis, penile, non-inflatable
c2623
catheter, transluminal angioplasty, drug-coated, non-laser
c2624
implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components
c2625
stent, non-coronary, temporary, with delivery system
c2626
infusion pump, non-programmable, temporary (implantable)
c2627
catheter, suprapubic/cystoscopic
c2628
catheter, occlusion
c2629
introducer/sheath, other than guiding, other than intracardiac electrophysiological, laser
c2630
catheter, electrophysiology, diagnostic/ablation, other than 3d or vector mapping, cool-tip
c2631
repair device, urinary, incontinence, without sling graft
c2634
brachytherapy source, non-stranded, high activity, iodine-125, greater than 1.01 mci (nist), per source
c2635
brachytherapy source, non-stranded, high activity, palladium-103, greater than 2.2 mci (nist), per source
c2636
brachytherapy linear source, non-stranded, palladium-103, per 1 mm
c2637
brachytherapy source, non-stranded, ytterbium-169, per source
c2638
brachytherapy source, stranded, iodine-125, per source
c2639
brachytherapy source, non-stranded, iodine-125, per source
c2640
brachytherapy source, stranded, palladium-103, per source
c2641
brachytherapy source, non-stranded, palladium-103, per source
c2642
brachytherapy source, stranded, cesium-131, per source
c2643
brachytherapy source, non-stranded, cesium-131, per source
c2644
brachytherapy source, cesium-131 chloride solution, per millicurie
c2645
brachytherapy planar source, palladium-103, per square millimeter
c2698
brachytherapy source, stranded, not otherwise specified, per source
c2699
brachytherapy source, non-stranded, not otherwise specified, per source
c5271
application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
c5272
application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)
c5273
application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
c5274
application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)
c5275
application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
c5276
application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)
c5277
application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
c5278
application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)
c8900
magnetic resonance angiography with contrast, abdomen
c8901
magnetic resonance angiography without contrast, abdomen
c8902
magnetic resonance angiography without contrast followed by with contrast, abdomen
c8903
magnetic resonance imaging with contrast, breast; unilateral
c8904
magnetic resonance imaging without contrast, breast; unilateral terminated december 31, 2018.
c8905
magnetic resonance imaging without contrast followed by with contrast, breast; unilateral
c8906
magnetic resonance imaging with contrast, breast; bilateral
c8907
magnetic resonance imaging without contrast, breast; bilateral terminated december 31, 2018.
c8908
magnetic resonance imaging without contrast followed by with contrast, breast; bilateral
c8909
magnetic resonance angiography with contrast, chest (excluding myocardium)
c8910
magnetic resonance angiography without contrast, chest (excluding myocardium)
c8911
magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)
c8912
magnetic resonance angiography with contrast, lower extremity
c8913
magnetic resonance angiography without contrast, lower extremity
c8914
magnetic resonance angiography without contrast followed by with contrast, lower extremity
c8918
magnetic resonance angiography with contrast, pelvis
c8919
magnetic resonance angiography without contrast, pelvis
c8920
magnetic resonance angiography without contrast followed by with contrast, pelvis
c8921
transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete
c8922
transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study
c8923
transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography
c8924
transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study
c8925
transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, real time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report
c8926
transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report
c8927
transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis
c8928
transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report
c8929
transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography
c8930
transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision
c8931
magnetic resonance angiography with contrast, spinal canal and contents
c8932
magnetic resonance angiography without contrast, spinal canal and contents
c8933
magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents
c8934
magnetic resonance angiography with contrast, upper extremity
c8935
magnetic resonance angiography without contrast, upper extremity
c8936
magnetic resonance angiography without contrast followed by with contrast, upper extremity
c8937
computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)
c8957
intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump
c9014
injection, cerliponase alfa, 1 mg terminated december 31, 2018.
c9015
injection, c-1 esterase inhibitor (human), haegarda, 10 units terminated december 31, 2018.
c9016
injection, triptorelin extended release, 3.75 mg terminated december 31, 2018.
c9021
injection, obinutuzumab, 10 mg terminated december 31, 2014.
c9022
injection, elosulfase alfa, 1mg terminated december 31, 2014.
c9023
injection, testosterone undecanoate, 1 mg terminated december 31, 2014.
c9024
injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine terminated december 31, 2018.
c9025
injection, ramucirumab, 5 mg terminated december 31, 2015.
c9026
injection, vedolizumab, 1 mg terminated december 31, 2015.
c9027
injection, pembrolizumab, 1 mg terminated december 31, 2015.
c9028
injection, inotuzumab ozogamicin, 0.1 mg terminated december 31, 2018.
c9029
injection, guselkumab, 1 mg terminated december 31, 2018.
c9030
injection, copanlisib, 1 mg terminated december 31, 2018.
c9031
lutetium lu 177, dotatate, therapeutic, 1 mci terminated december 31, 2018.
c9032
injection, voretigene neparvovec-rzyl, 1 billion vector genome terminated december 31, 2018.
c9033
injection, fosnetupitant 235 mg and palonosetron 0.25 mg terminated december 31, 2018.
c9034
injection, dexamethasone 9%, intraocular, 1 mcg terminated december 31, 2018.
c9035
injection, aripiprazole lauroxil (aristada initio), 1 mg terminated september 30, 2019.
c9036
injection, patisiran, 0.1 mg terminated september 30, 2019.
c9037
injection, risperidone (perseris), 0.5 mg terminated september 30, 2019.
c9038
injection, mogamulizumab-kpkc, 1 mg terminated september 30, 2019.
c9039
injection, plazomicin, 5 mg terminated september 30, 2019.
c9040
injection, fremanezumab-vfrm, 1mg terminated september 30, 2019.
c9041
injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mg terminated june 30, 2020.
c9042
injection, bendamustine hcl (belrapzo), 1 mg terminated june 30, 2019.
c9043
injection, levoleucovorin, 1 mg terminated december 31, 2019.
c9044
injection, cemiplimab-rwlc, 1 mg terminated september 30, 2019.
c9045
injection, moxetumomab pasudotox-tdfk, 0.01 mg terminated september 30, 2019.
c9046
cocaine hydrochloride nasal solution for topical administration, 1 mg
c9047
injection, caplacizumab-yhdp, 1 mg
c9048
dexamethasone, lacrimal ophthalmic insert, 0.1 mg terminated september 30, 2019.
c9049
injection, tagraxofusp-erzs, 10 mcg terminated september 30, 2019.
c9050
injection, emapalumab-lzsg, 1 mg terminated september 30, 2019.
c9051
injection, omadacycline, 1 mg terminated september 30, 2019.
c9052
injection, ravulizumab-cwvz, 10 mg terminated september 30, 2019.
c9053
injection, crizanlizumab-tmca, 1 mg terminated june 30, 2020.
c9054
injection, lefamulin (xenleta), 1 mg terminated june 30, 2020.
c9055
injection, brexanolone, 1mg terminated september 30, 2020.
c9056
injection, givosiran, 0.5 mg terminated june 30, 2020.
c9057
injection, cetirizine hydrochloride, 1 mg terminated june 30, 2020.
c9058
injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mg terminated june 30, 2020.
c9059
injection, meloxicam, 1 mg terminated september 30, 2020.
c9060
fluoroestradiol f18, diagnostic, 1 mci terminated december 31, 2020.
c9061
injection, teprotumumab-trbw, 10 mg terminated september 30, 2020.
c9062
injection, daratumumab 10 mg and hyaluronidase-fihj terminated december 31, 2020.
c9063
injection, eptinezumab-jjmr, 1 mg terminated september 30, 2020.
c9064
mitomycin pyelocalyceal instillation, 1 mg terminated december 31, 2020.
c9065
injection, romidepsin, non-lyophilized (e.g. liquid), 1mg terminated september 30, 2021.
c9066
injection, sacituzumab govitecan-hziy, 2.5 mg terminated december 31, 2020.
c9067
gallium ga-68, dotatoc, diagnostic, 0.01 mci
c9068
copper cu-64, dotatate, diagnostic, 1 millicurie terminated march 31, 2021.
c9069
injection, belantamab mafodontin-blmf, 0.5 mg terminated march 31, 2021.
c9070
injection, tafasitamab-cxix, 2 mg terminated march 31, 2021.
c9071
injection, viltolarsen, 10 mg terminated march 31, 2021.
c9072
injection, immune globulin (asceniv), 500 mg terminated march 31, 2021.
c9073
brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose terminated march 31, 2021.
c9074
injection, lumasiran, 0.5 mg terminated june 30, 2021.
c9075
injection, casimersen, 10 mg terminated september 30, 2021.
c9076
lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose terminated september 30, 2021.
c9077
injection, cabotegravir and rilpivirine, 2mg/3mg terminated september 30, 2021.
c9078
injection, trilaciclib, 1 mg terminated september 30, 2021.
c9079
injection, evinacumab-dgnb, 5 mg terminated september 30, 2021.
c9080
injection, melphalan flufenamide hydrochloride, 1 mg terminated september 30, 2021.
c9081
idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose terminated december 31, 2021.
c9082
injection, dostarlimab-gxly, 100 mg terminated december 31, 2021.
c9083
injection, amivantamab-vmjw, 10 mg terminated december 31, 2021.
c9084
injection, loncastuximab tesirine-lpyl, 0.1 mg terminated march 31, 2022.
c9085
injection, avalglucosidase alfa-ngpt, 4 mg terminated march 31, 2022.
c9086
injection, anifrolumab-fnia, 1 mg terminated march 31, 2022.
c9087
injection, cyclophosphamide, (auromedics), 10 mg terminated march 31, 2022.
c9088
instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
c9089
bupivacaine, collagen-matrix implant, 1 mg
c9090
injection, plasminogen, human-tvmh, 1 mg terminated june 30, 2022.
c9091
injection, sirolimus protein-bound particles, 1 mg terminated june 30, 2022.
c9092
injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg terminated june 30, 2022.
c9093
injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg terminated june 30, 2022.
c9094
inj, sutimlimab-jome, 10 mg terminated september 30, 2022.
c9095
inj, tebentafusp-tebn, 1 mcg terminated september 30, 2022.
c9096
injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram terminated september 30, 2022.
c9097
inj, faricimab-svoa, 0.1 mg terminated september 30, 2022.
c9098
ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose terminated september 30, 2022.
c9101
injection, oliceridine, 0.1 mg
c9113
injection, pantoprazole sodium, per vial
c9121
injection, argatroban, per 5 mg terminated december 31, 2016.
c9122
mometasone furoate sinus implant, 10 micrograms (sinuva) terminated march 31, 2021.
c9132
prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity terminated june 30, 2021.
c9133
factor ix (antihemophilic factor, recombinant), rixubis, per i.u. terminated december 31, 2014.
c9134
factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u. terminated december 31, 2014.
c9135
factor ix (antihemophilic factor, recombinant), alprolix, per i.u. terminated december 31, 2014.
c9136
injection, factor viii, fc fusion protein, (recombinant), per i.u. terminated march 31, 2015.
c9137
injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u. terminated december 31, 2016.
c9138
injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u. terminated december 31, 2016.
c9139
injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u. terminated december 31, 2016.
c9140
injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u. terminated december 31, 2017.
c9141
injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u. terminated june 30, 2019.
c9142
injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
c9248
injection, clevidipine butyrate, 1 mg
c9250
human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml
c9254
injection, lacosamide, 1 mg
c9257
injection, bevacizumab, 0.25 mg
c9275
injection, hexaminolevulinate hydrochloride, 100 mg, per study dose terminated december 31, 2018.
c9285
lidocaine 70 mg/tetracaine 70 mg, per patch
c9290
injection, bupivacaine liposome, 1 mg
c9293
injection, glucarpidase, 10 units
c9349
puraply, and puraply antimicrobial, any type, per square centimeter terminated december 31, 2016.
c9352
microporous collagen implantable tube (neuragen nerve guide), per centimeter length
c9353
microporous collagen implantable slit tube (neurawrap nerve protector), per centimeter length
c9354
acellular pericardial tissue matrix of non-human origin (veritas), per square centimeter
c9355
collagen nerve cuff (neuromatrix), per 0.5 centimeter length
c9356
tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (tenoglide tendon protector sheet), per square centimeter
c9358
dermal substitute, native, non-denatured collagen, fetal bovine origin (surgimend collagen matrix), per 0.5 square centimeters
c9359
porous purified collagen matrix bone void filler (integra mozaik osteoconductive scaffold putty, integra os osteoconductive scaffold putty), per 0.5 cc
c9360
dermal substitute, native, non-denatured collagen, neonatal bovine origin (surgimend collagen matrix), per 0.5 square centimeters
c9361
collagen matrix nerve wrap (neuromend collagen nerve wrap), per 0.5 centimeter length
c9362
porous purified collagen matrix bone void filler (integra mozaik osteoconductive scaffold strip), per 0.5 cc
c9363
skin substitute, integra meshed bilayer wound matrix, per square centimeter
c9364
porcine implant, permacol, per square centimeter
c9399
unclassified drugs or biologicals
c9407
iodine i-131 iobenguane, diagnostic, 1 millicurie terminated december 31, 2019.
c9408
iodine i-131 iobenguane, therapeutic, 1 millicurie terminated december 31, 2019.
c9441
injection, ferric carboxymaltose, 1 mg terminated june 30, 2014.
c9442
injection, belinostat, 10 mg terminated december 31, 2015.
c9443
injection, dalbavancin, 10 mg terminated december 31, 2015.
c9444
injection, oritavancin, 10 mg terminated december 31, 2015.
c9445
injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units terminated december 31, 2015.
c9446
injection, tedizolid phosphate, 1 mg terminated december 31, 2015.
c9447
injection, phenylephrine and ketorolac, 4 ml vial terminated september 30, 2019.
c9448
netupitant 300 mg and palonosetron 0.5 mg, oral terminated june 30, 2015.
c9449
injection, blinatumomab, 1 mcg terminated december 31, 2015.
c9450
injection, fluocinolone acetonide intravitreal implant, 0.01 mg terminated december 31, 2015.
c9451
injection, peramivir, 1 mg terminated december 31, 2015.
c9452
injection, ceftolozane 50 mg and tazobactam 25 mg terminated december 31, 2015.
c9453
injection, nivolumab, 1 mg terminated december 31, 2015.
c9454
injection, pasireotide long acting, 1 mg terminated december 31, 2015.
c9455
injection, siltuximab, 10 mg terminated december 31, 2015.
c9456
injection, isavuconazonium sulfate, 1 mg terminated december 31, 2015.
c9457
injection, sulfur hexafluoride lipid microsphere, per ml terminated december 31, 2015.
c9458
florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries terminated june 30, 2016.
c9459
flutemetamol f18, diagnostic, per study dose, up to 5 millicuries terminated june 30, 2016.
c9460
injection, cangrelor, 1 mg
c9461
choline c 11, diagnostic, per study dose terminated december 31, 2016.
c9462
injection, delafloxacin, 1 mg
c9463
injection, aprepitant, 1 mg terminated december 31, 2018.
c9464
injection, rolapitant, 0.5 mg terminated december 31, 2018.
c9465
hyaluronan or derivative, durolane, for intra-articular injection, per dose terminated december 31, 2018.
c9466
injection, benralizumab, 1 mg terminated december 31, 2018.
c9467
injection, rituximab and hyaluronidase, 10 mg terminated december 31, 2018.
c9468
injection, factor ix (antihemophilic factor, recombinant), glycopegylated, rebinyn, 1 i.u. terminated december 31, 2018.
c9469
injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg terminated june 30, 2018.
c9470
injection, aripiprazole lauroxil, 1 mg terminated december 31, 2016.
c9471
hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg terminated december 31, 2016.
c9472
injection, talimogene laherparepvec, 1 million plaque forming units (pfu) terminated december 31, 2016.
c9473
injection, mepolizumab, 1 mg terminated december 31, 2016.
c9474
injection, irinotecan liposome, 1 mg terminated december 31, 2016.
c9475
injection, necitumumab, 1 mg terminated december 31, 2016.
c9476
injection, daratumumab, 10 mg terminated december 31, 2016.
c9477
injection, elotuzumab, 1 mg terminated december 31, 2016.
c9478
injection, sebelipase alfa, 1 mg terminated december 31, 2016.
c9479
instillation, ciprofloxacin otic suspension, 6 mg terminated december 31, 2016.
c9480
injection, trabectedin, 0.1 mg terminated december 31, 2016.
c9481
injection, reslizumab, 1 mg terminated december 31, 2016.
c9482
injection, sotalol hydrochloride, 1 mg
c9483
injection, atezolizumab, 10 mg terminated december 31, 2017.
c9484
injection, eteplirsen, 10 mg terminated december 31, 2017.
c9485
injection, olaratumab, 10 mg terminated december 31, 2017.
c9486
injection, granisetron extended release, 0.1 mg terminated december 31, 2017.
c9487
ustekinumab, for intravenous injection, 1 mg terminated june 30, 2017.
c9488
injection, conivaptan hydrochloride, 1 mg
c9489
injection, nusinersen, 0.1 mg terminated december 31, 2017.
c9490
injection, bezlotoxumab, 10 mg terminated december 31, 2017.
c9491
injection, avelumab, 10 mg terminated december 31, 2017.
c9492
injection, durvalumab, 10 mg terminated december 31, 2018.
c9493
injection, edaravone, 1 mg terminated december 31, 2018.
c9494
injection, ocrelizumab, 1 mg terminated december 31, 2017.
c9497
loxapine, inhalation powder, 10 mg terminated december 31, 2018.
c9507
plasma, high titer covid-19 convalescent, each unit
c9600
percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch
c9601
percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)
c9602
percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch
c9603
percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)
c9604
percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel
c9605
percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)
c9606
percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel
c9607
percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel
c9608
percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary procedure)
c9724
endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy terminated december 31, 2015.
c9725
placement of endorectal intracavitary applicator for high intensity brachytherapy
c9726
placement and removal (if performed) of applicator into breast for intraoperative radiation therapy, add-on to primary breast procedure
c9727
insertion of implants into the soft palate; minimum of three implants
c9728
placement of interstitial device(s) for radiation therapy/surgery guidance (e.g., fiducial markers, dosimeter), for other than the following sites (any approach): abdomen, pelvis, prostate, retroperitoneum, thorax, single or multiple
c9733
non-ophthalmic fluorescent vascular angiography
c9734
focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (mr) guidance
c9735
anoscopy; with directed submucosal injection(s), any substance terminated december 31, 2014.
c9737
laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band) terminated june 30, 2015.
c9738
adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure)
c9739
cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants
c9740
cystourethroscopy, with insertion of transprostatic implant; 4 or more implants
c9741
right heart catheterization with implantation of wireless pressure sensor in the pulmonary artery, including any type of measurement, angiography, imaging supervision, interpretation, and report terminated december 31, 2018.
c9742
laryngoscopy, flexible fiberoptic, with injection into vocal cord(s), therapeutic, including diagnostic laryngoscopy, if performed terminated december 31, 2016.
c9743
injection/implantation of bulking or spacer material (any type) with or without image guidance (not to be used if a more specific code applies) terminated june 30, 2016.
c9744
ultrasound, abdominal, with contrast terminated december 31, 2018.
c9745
nasal endoscopy, surgical; balloon dilation of eustachian tube terminated december 31, 2020.
c9746
transperineal implantation of permanent adjustable balloon continence device, with cystourethroscopy, when performed and/or fluoroscopy, when performed terminated june 30, 2019.
c9747
ablation of prostate, transrectal, high intensity focused ultrasound (hifu), including imaging guidance terminated december 31, 2020.
c9748
transurethral destruction of prostate tissue; by radiofrequency water vapor (steam) thermal therapy terminated december 31, 2018.
c9749
repair of nasal vestibular lateral wall stenosis with implant(s) terminated december 31, 2020.
c9750
insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode) terminated december 31, 2018.
c9751
bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)
c9752
destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum terminated december 31, 2021.
c9753
destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure) terminated december 31, 2021.
c9754
creation of arteriovenous fistula, percutaneous; direct, any site, including all imaging and radiologic supervision and interpretation, when performed and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization, when performed) terminated june 30, 2020.
c9755
creation of arteriovenous fistula, percutaneous using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, when performed) and fistulogram(s), angiography, venography, and/or ultrasound, with radiologic supervision and interpretation, when performed terminated june 30, 2020.
c9756
intraoperative near-infrared fluorescence lymphatic mapping of lymph node(s) (sentinel or tumor draining) with administration of indocyanine green (icg) (list separately in addition to code for primary procedure)
c9757
laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar
c9758
blinded procedure for nyha class iii/iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study
c9759
transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed
c9760
non-randomized, non-blinded procedure for nyha class ii, iii, iv heart failure; transcatheter implantation of interatrial shunt, including right and left heart catheterization, transeptal puncture, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study
c9761
cystourethroscopy, with ureteroscopy and/or pyeloscopy, with lithotripsy, and ureteral catheterization for steerable vacuum aspiration of the kidney, collecting system, ureter, bladder, and urethra if applicable
c9762
cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging
c9763
cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging
c9764
revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed
c9765
revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed
c9766
revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed
c9767
revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed
c9768
endoscopic ultrasound-guided direct measurement of hepatic portosystemic pressure gradient by any method (list separately in addition to code for primary procedure)
c9769
cystourethroscopy, with insertion of temporary prostatic implant/stent with fixation/anchor and incisional struts
c9770
vitrectomy, mechanical, pars plana approach, with subretinal injection of pharmacologic/biologic agent
c9771
nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral
c9772
revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with intravascular lithotripsy, includes angioplasty within the same vessel (s), when performed
c9773
revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed
c9774
revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel (s), when performed
c9775
revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel (s), when performed
c9776
intraoperative near-infrared fluorescence imaging of major extra-hepatic bile duct(s) (e.g., cystic duct, common bile duct and common hepatic duct) with intravenous administration of indocyanine green (icg) (list separately in addition to code for primary procedure)
c9777
esophageal mucosal integrity testing by electrical impedance, transoral, includes esophagoscopy or esophagogastroduodenoscopy
c9778
colpopexy, vaginal; minimally invasive extra-peritoneal approach (sacrospinous)
c9779
endoscopic submucosal dissection (esd), including endoscopy or colonoscopy, mucosal closure, when performed
c9780
insertion of central venous catheter through central venous occlusion via inferior and superior approaches (e.g., inside-out technique), including imaging guidance
c9781
arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed
c9782
blinded procedure for new york heart association (nyha) class ii or iii heart failure, or canadian cardiovascular society (ccs) class iii or iv chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells (e.g., mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory services, and all imaging with or without guidance (e.g., transthoracic echocardiography, ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study
c9783
blinded procedure for transcatheter implantation of coronary sinus reduction device or placebo control, including vascular access and closure, right heart catherization, venous and coronary sinus angiography, imaging guidance and supervision and interpretation when performed in an approved investigational device exemption (ide) study
c9800
dermal injection procedure(s) for facial lipodystrophy syndrome (lds) and provision of radiesse or sculptra dermal filler, including all items and supplies terminated december 31, 2016.
c9803
hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source
c9898
radiolabeled product provided during a hospital inpatient stay
c9899
implanted prosthetic device, payable only for inpatients who do not have inpatient coverage
e0100
cane, includes canes of all materials, adjustable or fixed, with tip
e0105
cane, quad or three prong, includes canes of all materials, adjustable or fixed, with tips
e0110
crutches, forearm, includes crutches of various materials, adjustable or fixed, pair, complete with tips and handgrips
e0111
crutch forearm, includes crutches of various materials, adjustable or fixed, each, with tip and handgrips
e0112
crutches underarm, wood, adjustable or fixed, pair, with pads, tips and handgrips
e0113
crutch underarm, wood, adjustable or fixed, each, with pad, tip and handgrip
e0114
crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips
e0116
crutch, underarm, other than wood, adjustable or fixed, with pad, tip, handgrip, with or without shock absorber, each
e0117
crutch, underarm, articulating, spring assisted, each
e0118
crutch substitute, lower leg platform, with or without wheels, each
e0130
walker, rigid (pickup), adjustable or fixed height
e0135
walker, folding (pickup), adjustable or fixed height
e0140
walker, with trunk support, adjustable or fixed height, any type
e0141
walker, rigid, wheeled, adjustable or fixed height
e0143
walker, folding, wheeled, adjustable or fixed height
e0144
walker, enclosed, four sided framed, rigid or folding, wheeled with posterior seat
e0147
walker, heavy duty, multiple braking system, variable wheel resistance
e0148
walker, heavy duty, without wheels, rigid or folding, any type, each
e0149
walker, heavy duty, wheeled, rigid or folding, any type
e0153
platform attachment, forearm crutch, each
e0154
platform attachment, walker, each
e0155
wheel attachment, rigid pick-up walker, per pair
e0156
seat attachment, walker
e0157
crutch attachment, walker, each
e0158
leg extensions for walker, per set of four (4)
e0159
brake attachment for wheeled walker, replacement, each
e0160
sitz type bath or equipment, portable, used with or without commode
e0161
sitz type bath or equipment, portable, used with or without commode, with faucet attachment/s
e0162
sitz bath chair
e0163
commode chair, mobile or stationary, with fixed arms
e0165
commode chair, mobile or stationary, with detachable arms
e0167
pail or pan for use with commode chair, replacement only
e0168
commode chair, extra wide and/or heavy duty, stationary or mobile, with or without arms, any type, each
e0170
commode chair with integrated seat lift mechanism, electric, any type
e0171
commode chair with integrated seat lift mechanism, non-electric, any type
e0172
seat lift mechanism placed over or on top of toilet, any type
e0175
foot rest, for use with commode chair, each
e0181
powered pressure reducing mattress overlay/pad, alternating, with pump, includes heavy duty
e0182
pump for alternating pressure pad, for replacement only
e0183
powered pressure reducing underlay/pad, alternating, with pump, includes heavy duty
e0184
dry pressure mattress
e0185
gel or gel-like pressure pad for mattress, standard mattress length and width
e0186
air pressure mattress
e0187
water pressure mattress
e0188
synthetic sheepskin pad
e0189
lambswool sheepskin pad, any size
e0190
positioning cushion/pillow/wedge, any shape or size, includes all components and accessories
e0191
heel or elbow protector, each
e0193
powered air flotation bed (low air loss therapy)
e0194
air fluidized bed
e0196
gel pressure mattress
e0197
air pressure pad for mattress, standard mattress length and width
e0198
water pressure pad for mattress, standard mattress length and width
e0199
dry pressure pad for mattress, standard mattress length and width
e0200
heat lamp, without stand (table model), includes bulb, or infrared element
e0202
phototherapy (bilirubin) light with photometer
e0203
therapeutic lightbox, minimum 10,000 lux, table top model
e0205
heat lamp, with stand, includes bulb, or infrared element
e0210
electric heat pad, standard
e0215
electric heat pad, moist
e0217
water circulating heat pad with pump
e0218
fluid circulating cold pad with pump, any type
e0221
infrared heating pad system
e0225
hydrocollator unit, includes pads
e0231
non-contact wound warming device (temperature control unit, ac adapter and power cord) for use with warming card and wound cover
e0232
warming card for use with the non contact wound warming device and non contact wound warming wound cover
e0235
paraffin bath unit, portable (see medical supply code a4265 for paraffin)
e0236
pump for water circulating pad
e0239
hydrocollator unit, portable
e0240
bath/shower chair, with or without wheels, any size
e0241
bath tub wall rail, each
e0242
bath tub rail, floor base
e0243
toilet rail, each
e0244
raised toilet seat
e0245
tub stool or bench
e0246
transfer tub rail attachment
e0247
transfer bench for tub or toilet with or without commode opening
e0248
transfer bench, heavy duty, for tub or toilet with or without commode opening
e0249
pad for water circulating heat unit, for replacement only
e0250
hospital bed, fixed height, with any type side rails, with mattress
e0251
hospital bed, fixed height, with any type side rails, without mattress
e0255
hospital bed, variable height, hi-lo, with any type side rails, with mattress
e0256
hospital bed, variable height, hi-lo, with any type side rails, without mattress
e0260
hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
e0261
hospital bed, semi-electric (head and foot adjustment), with any type side rails, without mattress
e0265
hospital bed, total electric (head, foot and height adjustments), with any type side rails, with mattress
e0266
hospital bed, total electric (head, foot and height adjustments), with any type side rails, without mattress
e0270
hospital bed, institutional type includes: oscillating, circulating and stryker frame, with mattress
e0271
mattress, innerspring
e0272
mattress, foam rubber
e0273
bed board
e0274
over-bed table
e0275
bed pan, standard, metal or plastic
e0276
bed pan, fracture, metal or plastic
e0277
powered pressure-reducing air mattress
e0280
bed cradle, any type
e0290
hospital bed, fixed height, without side rails, with mattress
e0291
hospital bed, fixed height, without side rails, without mattress
e0292
hospital bed, variable height, hi-lo, without side rails, with mattress
e0293
hospital bed, variable height, hi-lo, without side rails, without mattress
e0294
hospital bed, semi-electric (head and foot adjustment), without side rails, with mattress
e0295
hospital bed, semi-electric (head and foot adjustment), without side rails, without mattress
e0296
hospital bed, total electric (head, foot and height adjustments), without side rails, with mattress
e0297
hospital bed, total electric (head, foot and height adjustments), without side rails, without mattress
e0300
pediatric crib, hospital grade, fully enclosed, with or without top enclosure
e0301
hospital bed, heavy duty, extra wide, with weight capacity greater than 350 pounds, but less than or equal to 600 pounds, with any type side rails, without mattress
e0302
hospital bed, extra heavy duty, extra wide, with weight capacity greater than 600 pounds, with any type side rails, without mattress
e0303
hospital bed, heavy duty, extra wide, with weight capacity greater than 350 pounds, but less than or equal to 600 pounds, with any type side rails, with mattress
e0304
hospital bed, extra heavy duty, extra wide, with weight capacity greater than 600 pounds, with any type side rails, with mattress
e0305
bed side rails, half length
e0310
bed side rails, full length
e0315
bed accessory: board, table, or support device, any type
e0316
safety enclosure frame/canopy for use with hospital bed, any type
e0325
urinal; male, jug-type, any material
e0326
urinal; female, jug-type, any material
e0328
hospital bed, pediatric, manual, 360 degree side enclosures, top of headboard, footboard and side rails up to 24 inches above the spring, includes mattress
e0329
hospital bed, pediatric, electric or semi-electric, 360 degree side enclosures, top of headboard, footboard and side rails up to 24 inches above the spring, includes mattress
e0350
control unit for electronic bowel irrigation/evacuation system
e0352
disposable pack (water reservoir bag, speculum, valving mechanism and collection bag/box) for use with the electronic bowel irrigation/evacuation system
e0370
air pressure elevator for heel
e0371
nonpowered advanced pressure reducing overlay for mattress, standard mattress length and width
e0372
powered air overlay for mattress, standard mattress length and width
e0373
nonpowered advanced pressure reducing mattress
e0424
stationary compressed gaseous oxygen system, rental; includes container, contents, regulator, flowmeter, humidifier, nebulizer, cannula or mask, and tubing
e0425
stationary compressed gas system, purchase; includes regulator, flowmeter, humidifier, nebulizer, cannula or mask, and tubing
e0430
portable gaseous oxygen system, purchase; includes regulator, flowmeter, humidifier, cannula or mask, and tubing
e0431
portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing
e0433
portable liquid oxygen system, rental; home liquefier used to fill portable liquid oxygen containers, includes portable containers, regulator, flowmeter, humidifier, cannula or mask and tubing, with or without supply reservoir and contents gauge
e0434
portable liquid oxygen system, rental; includes portable container, supply reservoir, humidifier, flowmeter, refill adaptor, contents gauge, cannula or mask, and tubing
e0435
portable liquid oxygen system, purchase; includes portable container, supply reservoir, flowmeter, humidifier, contents gauge, cannula or mask, tubing and refill adaptor
e0439
stationary liquid oxygen system, rental; includes container, contents, regulator, flowmeter, humidifier, nebulizer, cannula or mask, & tubing
e0440
stationary liquid oxygen system, purchase; includes use of reservoir, contents indicator, regulator, flowmeter, humidifier, nebulizer, cannula or mask, and tubing
e0441
stationary oxygen contents, gaseous, 1 month's supply = 1 unit
e0442
stationary oxygen contents, liquid, 1 month's supply = 1 unit
e0443
portable oxygen contents, gaseous, 1 month's supply = 1 unit
e0444
portable oxygen contents, liquid, 1 month's supply = 1 unit
e0445
oximeter device for measuring blood oxygen levels non-invasively
e0446
topical oxygen delivery system, not otherwise specified, includes all supplies and accessories
e0447
portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)
e0450
volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube) terminated december 31, 2015.
e0455
oxygen tent, excluding croup or pediatric tents
e0457
chest shell (cuirass)
e0459
chest wrap
e0460
negative pressure ventilator; portable or stationary terminated december 31, 2015.
e0461
volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask) terminated december 31, 2015.
e0462
rocking bed with or without side rails
e0463
pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube) terminated december 31, 2015.
e0464
pressure support ventilator with volume control mode, may include pressure control mode, used with non-invasive interface (e.g., mask) terminated december 31, 2015.
e0465
home ventilator, any type, used with invasive interface, (e.g., tracheostomy tube)
e0466
home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)
e0467
home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions
e0470
respiratory assist device, bi-level pressure capability, without backup rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)
e0471
respiratory assist device, bi-level pressure capability, with back-up rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)
e0472
respiratory assist device, bi-level pressure capability, with backup rate feature, used with invasive interface, e.g., tracheostomy tube (intermittent assist device with continuous positive airway pressure device)
e0480
percussor, electric or pneumatic, home model
e0481
intrapulmonary percussive ventilation system and related accessories
e0482
cough stimulating device, alternating positive and negative airway pressure
e0483
high frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each
e0484
oscillatory positive expiratory pressure device, non-electric, any type, each
e0485
oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, prefabricated, includes fitting and adjustment
e0486
oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
e0487
spirometer, electronic, includes all accessories
e0500
ippb machine, all types, with built-in nebulization; manual or automatic valves; internal or external power source
e0550
humidifier, durable for extensive supplemental humidification during ippb treatments or oxygen delivery
e0555
humidifier, durable, glass or autoclavable plastic bottle type, for use with regulator or flowmeter
e0560
humidifier, durable for supplemental humidification during ippb treatment or oxygen delivery
e0561
humidifier, non-heated, used with positive airway pressure device
e0562
humidifier, heated, used with positive airway pressure device
e0565
compressor, air power source for equipment which is not self-contained or cylinder driven
e0570
nebulizer, with compressor
e0572
aerosol compressor, adjustable pressure, light duty for intermittent use
e0574
ultrasonic/electronic aerosol generator with small volume nebulizer
e0575
nebulizer, ultrasonic, large volume
e0580
nebulizer, durable, glass or autoclavable plastic, bottle type, for use with regulator or flowmeter
e0585
nebulizer, with compressor and heater
e0600
respiratory suction pump, home model, portable or stationary, electric
e0601
continuous positive airway pressure (cpap) device
e0602
breast pump, manual, any type
e0603
breast pump, electric (ac and/or dc), any type
e0604
breast pump, hospital grade, electric (ac and / or dc), any type
e0605
vaporizer, room type
e0606
postural drainage board
e0607
home blood glucose monitor
e0610
pacemaker monitor, self-contained, (checks battery depletion, includes audible and visible check systems)
e0615
pacemaker monitor, self contained, checks battery depletion and other pacemaker components, includes digital/visible check systems
e0616
implantable cardiac event recorder with memory, activator and programmer
e0617
external defibrillator with integrated electrocardiogram analysis
e0618
apnea monitor, without recording feature
e0619
apnea monitor, with recording feature
e0620
skin piercing device for collection of capillary blood, laser, each
e0621
sling or seat, patient lift, canvas or nylon
e0625
patient lift, bathroom or toilet, not otherwise classified
e0627
seat lift mechanism, electric, any type
e0628
separate seat lift mechanism for use with patient owned furniture-electric terminated december 31, 2016.
e0629
seat lift mechanism, non-electric, any type
e0630
patient lift, hydraulic or mechanical, includes any seat, sling, strap(s) or pad(s)
e0635
patient lift, electric with seat or sling
e0636
multipositional patient support system, with integrated lift, patient accessible controls
e0637
combination sit to stand frame/table system, any size including pediatric, with seat lift feature, with or without wheels
e0638
standing frame/table system, one position (e.g., upright, supine or prone stander), any size including pediatric, with or without wheels
e0639
patient lift, moveable from room to room with disassembly and reassembly, includes all components/accessories
e0640
patient lift, fixed system, includes all components/accessories
e0641
standing frame/table system, multi-position (e.g., three-way stander), any size including pediatric, with or without wheels
e0642
standing frame/table system, mobile (dynamic stander), any size including pediatric
e0650
pneumatic compressor, non-segmental home model
e0651
pneumatic compressor, segmental home model without calibrated gradient pressure
e0652
pneumatic compressor, segmental home model with calibrated gradient pressure
e0655
non-segmental pneumatic appliance for use with pneumatic compressor, half arm
e0656
segmental pneumatic appliance for use with pneumatic compressor, trunk
e0657
segmental pneumatic appliance for use with pneumatic compressor, chest
e0660
non-segmental pneumatic appliance for use with pneumatic compressor, full leg
e0665
non-segmental pneumatic appliance for use with pneumatic compressor, full arm
e0666
non-segmental pneumatic appliance for use with pneumatic compressor, half leg
e0667
segmental pneumatic appliance for use with pneumatic compressor, full leg
e0668
segmental pneumatic appliance for use with pneumatic compressor, full arm
e0669
segmental pneumatic appliance for use with pneumatic compressor, half leg
e0670
segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full legs and trunk
e0671
segmental gradient pressure pneumatic appliance, full leg
e0672
segmental gradient pressure pneumatic appliance, full arm
e0673
segmental gradient pressure pneumatic appliance, half leg
e0675
pneumatic compression device, high pressure, rapid inflation/deflation cycle, for arterial insufficiency (unilateral or bilateral system)
e0676
intermittent limb compression device (includes all accessories), not otherwise specified
e0691
ultraviolet light therapy system, includes bulbs/lamps, timer and eye protection; treatment area 2 square feet or less
e0692
ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, 4 foot panel
e0693
ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, 6 foot panel
e0694
ultraviolet multidirectional light therapy system in 6 foot cabinet, includes bulbs/lamps, timer and eye protection
e0700
safety equipment, device or accessory, any type
e0705
transfer device, any type, each
e0710
restraints, any type (body, chest, wrist or ankle)
e0720
transcutaneous electrical nerve stimulation (tens) device, two lead, localized stimulation
e0730
transcutaneous electrical nerve stimulation (tens) device, four or more leads, for multiple nerve stimulation
e0731
form fitting conductive garment for delivery of tens or nmes (with conductive fibers separated from the patient's skin by layers of fabric)
e0740
non-implanted pelvic floor electrical stimulator, complete system
e0744
neuromuscular stimulator for scoliosis
e0745
neuromuscular stimulator, electronic shock unit
e0746
electromyography (emg), biofeedback device
e0747
osteogenesis stimulator, electrical, non-invasive, other than spinal applications
e0748
osteogenesis stimulator, electrical, non-invasive, spinal applications
e0749
osteogenesis stimulator, electrical, surgically implanted
e0755
electronic salivary reflex stimulator (intra-oral/non-invasive)
e0760
osteogenesis stimulator, low intensity ultrasound, non-invasive
e0761
non-thermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device
e0762
transcutaneous electrical joint stimulation device system, includes all accessories
e0764
functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program
e0765
fda approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting
e0766
electrical stimulation device used for cancer treatment, includes all accessories, any type
e0769
electrical stimulation or electromagnetic wound treatment device, not otherwise classified
e0770
functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified
e0776
iv pole
e0779
ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater
e0780
ambulatory infusion pump, mechanical, reusable, for infusion less than 8 hours
e0781
ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient
e0782
infusion pump, implantable, non-programmable (includes all components, e.g., pump, catheter, connectors, etc.)
e0783
infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.)
e0784
external ambulatory infusion pump, insulin
e0785
implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement
e0786
implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter)
e0787
external ambulatory infusion pump, insulin, dosage rate adjustment using therapeutic continuous glucose sensing
e0791
parenteral infusion pump, stationary, single or multi-channel
e0830
ambulatory traction device, all types, each
e0840
traction frame, attached to headboard, cervical traction
e0849
traction equipment, cervical, free-standing stand/frame, pneumatic, applying traction force to other than mandible
e0850
traction stand, free standing, cervical traction
e0855
cervical traction equipment not requiring additional stand or frame
e0856
cervical traction device, with inflatable air bladder(s)
e0860
traction equipment, overdoor, cervical
e0870
traction frame, attached to footboard, extremity traction, (e.g., buck's)
e0880
traction stand, free standing, extremity traction
e0890
traction frame, attached to footboard, pelvic traction
e0900
traction stand, free standing, pelvic traction, (e.g., buck's)
e0910
trapeze bars, a/k/a patient helper, attached to bed, with grab bar
e0911
trapeze bar, heavy duty, for patient weight capacity greater than 250 pounds, attached to bed, with grab bar
e0912
trapeze bar, heavy duty, for patient weight capacity greater than 250 pounds, free standing, complete with grab bar
e0920
fracture frame, attached to bed, includes weights
e0930
fracture frame, free standing, includes weights
e0935
continuous passive motion exercise device for use on knee only
e0936
continuous passive motion exercise device for use other than knee
e0940
trapeze bar, free standing, complete with grab bar
e0941
gravity assisted traction device, any type
e0942
cervical head harness/halter
e0944
pelvic belt/harness/boot
e0945
extremity belt/harness
e0946
fracture, frame, dual with cross bars, attached to bed, (e.g., balken, 4 poster)
e0947
fracture frame, attachments for complex pelvic traction
e0948
fracture frame, attachments for complex cervical traction
e0950
wheelchair accessory, tray, each
e0951
heel loop/holder, any type, with or without ankle strap, each
e0952
toe loop/holder, any type, each
e0953
wheelchair accessory, lateral thigh or knee support, any type including fixed mounting hardware, each
e0954
wheelchair accessory, foot box, any type, includes attachment and mounting hardware, each foot
e0955
wheelchair accessory, headrest, cushioned, any type, including fixed mounting hardware, each
e0956
wheelchair accessory, lateral trunk or hip support, any type, including fixed mounting hardware, each
e0957
wheelchair accessory, medial thigh support, any type, including fixed mounting hardware, each
e0958
manual wheelchair accessory, one-arm drive attachment, each
e0959
manual wheelchair accessory, adapter for amputee, each
e0960
wheelchair accessory, shoulder harness/straps or chest strap, including any type mounting hardware
e0961
manual wheelchair accessory, wheel lock brake extension (handle), each
e0966
manual wheelchair accessory, headrest extension, each
e0967
manual wheelchair accessory, hand rim with projections, any type, replacement only, each
e0968
commode seat, wheelchair
e0969
narrowing device, wheelchair
e0970
no. 2 footplates, except for elevating leg rest
e0971
manual wheelchair accessory, anti-tipping device, each
e0973
wheelchair accessory, adjustable height, detachable armrest, complete assembly, each
e0974
manual wheelchair accessory, anti-rollback device, each
e0978
wheelchair accessory, positioning belt/safety belt/pelvic strap, each
e0980
safety vest, wheelchair
e0981
wheelchair accessory, seat upholstery, replacement only, each
e0982
wheelchair accessory, back upholstery, replacement only, each
e0983
manual wheelchair accessory, power add-on to convert manual wheelchair to motorized wheelchair, joystick control
e0984
manual wheelchair accessory, power add-on to convert manual wheelchair to motorized wheelchair, tiller control
e0985
wheelchair accessory, seat lift mechanism
e0986
manual wheelchair accessory, push-rim activated power assist system
e0988
manual wheelchair accessory, lever-activated, wheel drive, pair
e0990
wheelchair accessory, elevating leg rest, complete assembly, each
e0992
manual wheelchair accessory, solid seat insert
e0994
arm rest, each
e0995
wheelchair accessory, calf rest/pad, replacement only, each
e1002
wheelchair accessory, power seating system, tilt only
e1003
wheelchair accessory, power seating system, recline only, without shear reduction
e1004
wheelchair accessory, power seating system, recline only, with mechanical shear reduction
e1005
wheelchair accessory, power seatng system, recline only, with power shear reduction
e1006
wheelchair accessory, power seating system, combination tilt and recline, without shear reduction
e1007
wheelchair accessory, power seating system, combination tilt and recline, with mechanical shear reduction
e1008
wheelchair accessory, power seating system, combination tilt and recline, with power shear reduction
e1009
wheelchair accessory, addition to power seating system, mechanically linked leg elevation system, including pushrod and leg rest, each
e1010
wheelchair accessory, addition to power seating system, power leg elevation system, including leg rest, pair
e1011
modification to pediatric size wheelchair, width adjustment package (not to be dispensed with initial chair)
e1012
wheelchair accessory, addition to power seating system, center mount power elevating leg rest/platform, complete system, any type, each
e1014
reclining back, addition to pediatric size wheelchair
e1015
shock absorber for manual wheelchair, each
e1016
shock absorber for power wheelchair, each
e1017
heavy duty shock absorber for heavy duty or extra heavy duty manual wheelchair, each
e1018
heavy duty shock absorber for heavy duty or extra heavy duty power wheelchair, each
e1020
residual limb support system for wheelchair, any type
e1028
wheelchair accessory, manual swingaway, retractable or removable mounting hardware for joystick, other control interface or positioning accessory
e1029
wheelchair accessory, ventilator tray, fixed
e1030
wheelchair accessory, ventilator tray, gimbaled
e1031
rollabout chair, any and all types with casters 5" or greater
e1035
multi-positional patient transfer system, with integrated seat, operated by care giver, patient weight capacity up to and including 300 lbs
e1036
multi-positional patient transfer system, extra-wide, with integrated seat, operated by caregiver, patient weight capacity greater than 300 lbs
e1037
transport chair, pediatric size
e1038
transport chair, adult size, patient weight capacity up to and including 300 pounds
e1039
transport chair, adult size, heavy duty, patient weight capacity greater than 300 pounds
e1050
fully-reclining wheelchair, fixed full length arms, swing away detachable elevating leg rests
e1060
fully-reclining wheelchair, detachable arms, desk or full length, swing away detachable elevating legrests
e1070
fully-reclining wheelchair, detachable arms (desk or full length) swing away detachable footrest
e1083
hemi-wheelchair, fixed full length arms, swing away detachable elevating leg rest
e1084
hemi-wheelchair, detachable arms desk or full length arms, swing away detachable elevating leg rests
e1085
hemi-wheelchair, fixed full length arms, swing away detachable foot rests
e1086
hemi-wheelchair detachable arms desk or full length, swing away detachable footrests
e1087
high strength lightweight wheelchair, fixed full length arms, swing away detachable elevating leg rests
e1088
high strength lightweight wheelchair, detachable arms desk or full length, swing away detachable elevating leg rests
e1089
high strength lightweight wheelchair, fixed length arms, swing away detachable footrest
e1090
high strength lightweight wheelchair, detachable arms desk or full length, swing away detachable foot rests
e1092
wide heavy duty wheel chair, detachable arms (desk or full length), swing away detachable elevating leg rests
e1093
wide heavy duty wheelchair, detachable arms desk or full length arms, swing away detachable footrests
e1100
semi-reclining wheelchair, fixed full length arms, swing away detachable elevating leg rests
e1110
semi-reclining wheelchair, detachable arms (desk or full length) elevating leg rest
e1130
standard wheelchair, fixed full length arms, fixed or swing away detachable footrests
e1140
wheelchair, detachable arms, desk or full length, swing away detachable footrests
e1150
wheelchair, detachable arms, desk or full length swing away detachable elevating legrests
e1160
wheelchair, fixed full length arms, swing away detachable elevating legrests
e1161
manual adult size wheelchair, includes tilt in space
e1170
amputee wheelchair, fixed full length arms, swing away detachable elevating legrests
e1171
amputee wheelchair, fixed full length arms, without footrests or legrest
e1172
amputee wheelchair, detachable arms (desk or full length) without footrests or legrest
e1180
amputee wheelchair, detachable arms (desk or full length) swing away detachable footrests
e1190
amputee wheelchair, detachable arms (desk or full length) swing away detachable elevating legrests
e1195
heavy duty wheelchair, fixed full length arms, swing away detachable elevating legrests
e1200
amputee wheelchair, fixed full length arms, swing away detachable footrest
e1220
wheelchair; specially sized or constructed, (indicate brand name, model number, if any) and justification
e1221
wheelchair with fixed arm, footrests
e1222
wheelchair with fixed arm, elevating legrests
e1223
wheelchair with detachable arms, footrests
e1224
wheelchair with detachable arms, elevating legrests
e1225
wheelchair accessory, manual semi-reclining back, (recline greater than 15 degrees, but less than 80 degrees), each
e1226
wheelchair accessory, manual fully reclining back, (recline greater than 80 degrees), each
e1227
special height arms for wheelchair
e1228
special back height for wheelchair
e1229
wheelchair, pediatric size, not otherwise specified
e1230
power operated vehicle (three or four wheel nonhighway) specify brand name and model number
e1231
wheelchair, pediatric size, tilt-in-space, rigid, adjustable, with seating system
e1232
wheelchair, pediatric size, tilt-in-space, folding, adjustable, with seating system
e1233
wheelchair, pediatric size, tilt-in-space, rigid, adjustable, without seating system
e1234
wheelchair, pediatric size, tilt-in-space, folding, adjustable, without seating system
e1235
wheelchair, pediatric size, rigid, adjustable, with seating system
e1236
wheelchair, pediatric size, folding, adjustable, with seating system
e1237
wheelchair, pediatric size, rigid, adjustable, without seating system
e1238
wheelchair, pediatric size, folding, adjustable, without seating system
e1239
power wheelchair, pediatric size, not otherwise specified
e1240
lightweight wheelchair, detachable arms, (desk or full length) swing away detachable, elevating legrest
e1250
lightweight wheelchair, fixed full length arms, swing away detachable footrest
e1260
lightweight wheelchair, detachable arms (desk or full length) swing away detachable footrest
e1270
lightweight wheelchair, fixed full length arms, swing away detachable elevating legrests
e1280
heavy duty wheelchair, detachable arms (desk or full length) elevating legrests
e1285
heavy duty wheelchair, fixed full length arms, swing away detachable footrest
e1290
heavy duty wheelchair, detachable arms (desk or full length) swing away detachable footrest
e1295
heavy duty wheelchair, fixed full length arms, elevating legrest
e1296
special wheelchair seat height from floor
e1297
special wheelchair seat depth, by upholstery
e1298
special wheelchair seat depth and/or width, by construction
e1300
whirlpool, portable (overtub type)
e1310
whirlpool, non-portable (built-in type)
e1352
oxygen accessory, flow regulator capable of positive inspiratory pressure
e1353
regulator
e1354
oxygen accessory, wheeled cart for portable cylinder or portable concentrator, any type, replacement only, each
e1355
stand/rack
e1356
oxygen accessory, battery pack/cartridge for portable concentrator, any type, replacement only, each
e1357
oxygen accessory, battery charger for portable concentrator, any type, replacement only, each
e1358
oxygen accessory, dc power adapter for portable concentrator, any type, replacement only, each
e1372
immersion external heater for nebulizer
e1390
oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate
e1391
oxygen concentrator, dual delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate, each
e1392
portable oxygen concentrator, rental
e1399
durable medical equipment, miscellaneous
e1405
oxygen and water vapor enriching system with heated delivery
e1406
oxygen and water vapor enriching system without heated delivery
e1500
centrifuge, for dialysis
e1510
kidney, dialysate delivery syst kidney machine, pump recirculating, air removal syst, flowrate meter, power off, heater and temperature control with alarm, i.v. poles, pressure gauge, concentrate container
e1520
heparin infusion pump for hemodialysis
e1530
air bubble detector for hemodialysis, each, replacement
e1540
pressure alarm for hemodialysis, each, replacement
e1550
bath conductivity meter for hemodialysis, each
e1560
blood leak detector for hemodialysis, each, replacement
e1570
adjustable chair, for esrd patients
e1575
transducer protectors/fluid barriers, for hemodialysis, any size, per 10
e1580
unipuncture control system for hemodialysis
e1590
hemodialysis machine
e1592
automatic intermittent peritoneal dialysis system
e1594
cycler dialysis machine for peritoneal dialysis
e1600
delivery and/or installation charges for hemodialysis equipment
e1610
reverse osmosis water purification system, for hemodialysis
e1615
deionizer water purification system, for hemodialysis
e1620
blood pump for hemodialysis, replacement
e1625
water softening system, for hemodialysis
e1629
tablo hemodialysis system for the billable dialysis service
e1630
reciprocating peritoneal dialysis system
e1632
wearable artificial kidney, each
e1634
peritoneal dialysis clamps, each
e1635
compact (portable) travel hemodialyzer system
e1636
sorbent cartridges, for hemodialysis, per 10
e1637
hemostats, each
e1639
scale, each
e1699
dialysis equipment, not otherwise specified
e1700
jaw motion rehabilitation system
e1701
replacement cushions for jaw motion rehabilitation system, pkg. of 6
e1702
replacement measuring scales for jaw motion rehabilitation system, pkg. of 200
e1800
dynamic adjustable elbow extension/flexion device, includes soft interface material
e1801
static progressive stretch elbow device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories
e1802
dynamic adjustable forearm pronation/supination device, includes soft interface material
e1805
dynamic adjustable wrist extension / flexion device, includes soft interface material
e1806
static progressive stretch wrist device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories
e1810
dynamic adjustable knee extension / flexion device, includes soft interface material
e1811
static progressive stretch knee device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories
e1812
dynamic knee, extension/flexion device with active resistance control
e1815
dynamic adjustable ankle extension/flexion device, includes soft interface material
e1816
static progressive stretch ankle device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories
e1818
static progressive stretch forearm pronation / supination device, with or without range of motion adjustment, includes all components and accessories
e1820
replacement soft interface material, dynamic adjustable extension/flexion device
e1821
replacement soft interface material/cuffs for bi-directional static progressive stretch device
e1825
dynamic adjustable finger extension/flexion device, includes soft interface material
e1830
dynamic adjustable toe extension/flexion device, includes soft interface material
e1831
static progressive stretch toe device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories
e1840
dynamic adjustable shoulder flexion / abduction / rotation device, includes soft interface material
e1841
static progressive stretch shoulder device, with or without range of motion adjustment, includes all components and accessories
e1902
communication board, non-electronic augmentative or alternative communication device
e2000
gastric suction pump, home model, portable or stationary, electric
e2100
blood glucose monitor with integrated voice synthesizer
e2101
blood glucose monitor with integrated lancing/blood sample
e2102
adjunctive continuous glucose monitor or receiver
e2120
pulse generator system for tympanic treatment of inner ear endolymphatic fluid
e2201
manual wheelchair accessory, nonstandard seat frame, width greater than or equal to 20 inches and less than 24 inches
e2202
manual wheelchair accessory, nonstandard seat frame width, 24-27 inches
e2203
manual wheelchair accessory, nonstandard seat frame depth, 20 to less than 22 inches
e2204
manual wheelchair accessory, nonstandard seat frame depth, 22 to 25 inches
e2205
manual wheelchair accessory, handrim without projections (includes ergonomic or contoured), any type, replacement only, each
e2206
manual wheelchair accessory, wheel lock assembly, complete, replacement only, each
e2207
wheelchair accessory, crutch and cane holder, each
e2208
wheelchair accessory, cylinder tank carrier, each
e2209
accessory, arm trough, with or without hand support, each
e2210
wheelchair accessory, bearings, any type, replacement only, each
e2211
manual wheelchair accessory, pneumatic propulsion tire, any size, each
e2212
manual wheelchair accessory, tube for pneumatic propulsion tire, any size, each
e2213
manual wheelchair accessory, insert for pneumatic propulsion tire (removable), any type, any size, each
e2214
manual wheelchair accessory, pneumatic caster tire, any size, each
e2215
manual wheelchair accessory, tube for pneumatic caster tire, any size, each
e2216
manual wheelchair accessory, foam filled propulsion tire, any size, each
e2217
manual wheelchair accessory, foam filled caster tire, any size, each
e2218
manual wheelchair accessory, foam propulsion tire, any size, each
e2219
manual wheelchair accessory, foam caster tire, any size, each
e2220
manual wheelchair accessory, solid (rubber/plastic) propulsion tire, any size, replacement only, each
e2221
manual wheelchair accessory, solid (rubber/plastic) caster tire (removable), any size, replacement only, each
e2222
manual wheelchair accessory, solid (rubber/plastic) caster tire with integrated wheel, any size, replacement only, each
e2224
manual wheelchair accessory, propulsion wheel excludes tire, any size, replacement only, each
e2225
manual wheelchair accessory, caster wheel excludes tire, any size, replacement only, each
e2226
manual wheelchair accessory, caster fork, any size, replacement only, each
e2227
manual wheelchair accessory, gear reduction drive wheel, each
e2228
manual wheelchair accessory, wheel braking system and lock, complete, each
e2230
manual wheelchair accessory, manual standing system
e2231
manual wheelchair accessory, solid seat support base (replaces sling seat), includes any type mounting hardware
e2291
back, planar, for pediatric size wheelchair including fixed attaching hardware
e2292
seat, planar, for pediatric size wheelchair including fixed attaching hardware
e2293
back, contoured, for pediatric size wheelchair including fixed attaching hardware
e2294
seat, contoured, for pediatric size wheelchair including fixed attaching hardware
e2295
manual wheelchair accessory, for pediatric size wheelchair, dynamic seating frame, allows coordinated movement of multiple positioning features
e2300
wheelchair accessory, power seat elevation system, any type
e2301
wheelchair accessory, power standing system, any type
e2310
power wheelchair accessory, electronic connection between wheelchair controller and one power seating system motor, including all related electronics, indicator feature, mechanical function selection switch, and fixed mounting hardware
e2311
power wheelchair accessory, electronic connection between wheelchair controller and two or more power seating system motors, including all related electronics, indicator feature, mechanical function selection switch, and fixed mounting hardware
e2312
power wheelchair accessory, hand or chin control interface, mini-proportional remote joystick, proportional, including fixed mounting hardware
e2313
power wheelchair accessory, harness for upgrade to expandable controller, including all fasteners, connectors and mounting hardware, each
e2321
power wheelchair accessory, hand control interface, remote joystick, nonproportional, including all related electronics, mechanical stop switch, and fixed mounting hardware
e2322
power wheelchair accessory, hand control interface, multiple mechanical switches, nonproportional, including all related electronics, mechanical stop switch, and fixed mounting hardware
e2323
power wheelchair accessory, specialty joystick handle for hand control interface, prefabricated
e2324
power wheelchair accessory, chin cup for chin control interface
e2325
power wheelchair accessory, sip and puff interface, nonproportional, including all related electronics, mechanical stop switch, and manual swingaway mounting hardware
e2326
power wheelchair accessory, breath tube kit for sip and puff interface
e2327
power wheelchair accessory, head control interface, mechanical, proportional, including all related electronics, mechanical direction change switch, and fixed mounting hardware
e2328
power wheelchair accessory, head control or extremity control interface, electronic, proportional, including all related electronics and fixed mounting hardware
e2329
power wheelchair accessory, head control interface, contact switch mechanism, nonproportional, including all related electronics, mechanical stop switch, mechanical direction change switch, head array, and fixed mounting hardware
e2330
power wheelchair accessory, head control interface, proximity switch mechanism, nonproportional, including all related electronics, mechanical stop switch, mechanical direction change switch, head array, and fixed mounting hardware
e2331
power wheelchair accessory, attendant control, proportional, including all related electronics and fixed mounting hardware
e2340
power wheelchair accessory, nonstandard seat frame width, 20-23 inches
e2341
power wheelchair accessory, nonstandard seat frame width, 24-27 inches
e2342
power wheelchair accessory, nonstandard seat frame depth, 20 or 21 inches
e2343
power wheelchair accessory, nonstandard seat frame depth, 22-25 inches
e2351
power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface
e2358
power wheelchair accessory, group 34 non-sealed lead acid battery, each
e2359
power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)
e2360
power wheelchair accessory, 22nf non-sealed lead acid battery, each
e2361
power wheelchair accessory, 22nf sealed lead acid battery, each, (e.g., gel cell, absorbed glassmat)
e2362
power wheelchair accessory, group 24 non-sealed lead acid battery, each
e2363
power wheelchair accessory, group 24 sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)
e2364
power wheelchair accessory, u-1 non-sealed lead acid battery, each
e2365
power wheelchair accessory, u-1 sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)
e2366
power wheelchair accessory, battery charger, single mode, for use with only one battery type, sealed or non-sealed, each
e2367
power wheelchair accessory, battery charger, dual mode, for use with either battery type, sealed or non-sealed, each
e2368
power wheelchair component, drive wheel motor, replacement only
e2369
power wheelchair component, drive wheel gear box, replacement only
e2370
power wheelchair component, integrated drive wheel motor and gear box combination, replacement only
e2371
power wheelchair accessory, group 27 sealed lead acid battery, (e.g., gel cell, absorbed glassmat), each
e2372
power wheelchair accessory, group 27 non-sealed lead acid battery, each
e2373
power wheelchair accessory, hand or chin control interface, compact remote joystick, proportional, including fixed mounting hardware
e2374
power wheelchair accessory, hand or chin control interface, standard remote joystick (not including controller), proportional, including all related electronics and fixed mounting hardware, replacement only
e2375
power wheelchair accessory, non-expandable controller, including all related electronics and mounting hardware, replacement only
e2376
power wheelchair accessory, expandable controller, including all related electronics and mounting hardware, replacement only
e2377
power wheelchair accessory, expandable controller, including all related electronics and mounting hardware, upgrade provided at initial issue
e2378
power wheelchair component, actuator, replacement only
e2381
power wheelchair accessory, pneumatic drive wheel tire, any size, replacement only, each
e2382
power wheelchair accessory, tube for pneumatic drive wheel tire, any size, replacement only, each
e2383
power wheelchair accessory, insert for pneumatic drive wheel tire (removable), any type, any size, replacement only, each
e2384
power wheelchair accessory, pneumatic caster tire, any size, replacement only, each
e2385
power wheelchair accessory, tube for pneumatic caster tire, any size, replacement only, each
e2386
power wheelchair accessory, foam filled drive wheel tire, any size, replacement only, each
e2387
power wheelchair accessory, foam filled caster tire, any size, replacement only, each
e2388
power wheelchair accessory, foam drive wheel tire, any size, replacement only, each
e2389
power wheelchair accessory, foam caster tire, any size, replacement only, each
e2390
power wheelchair accessory, solid (rubber/plastic) drive wheel tire, any size, replacement only, each
e2391
power wheelchair accessory, solid (rubber/plastic) caster tire (removable), any size, replacement only, each
e2392
power wheelchair accessory, solid (rubber/plastic) caster tire with integrated wheel, any size, replacement only, each
e2394
power wheelchair accessory, drive wheel excludes tire, any size, replacement only, each
e2395
power wheelchair accessory, caster wheel excludes tire, any size, replacement only, each
e2396
power wheelchair accessory, caster fork, any size, replacement only, each
e2397
power wheelchair accessory, lithium-based battery, each
e2398
wheelchair accessory, dynamic positioning hardware for back
e2402
negative pressure wound therapy electrical pump, stationary or portable
e2500
speech generating device, digitized speech, using pre-recorded messages, less than or equal to 8 minutes recording time
e2502
speech generating device, digitized speech, using pre-recorded messages, greater than 8 minutes but less than or equal to 20 minutes recording time
e2504
speech generating device, digitized speech, using pre-recorded messages, greater than 20 minutes but less than or equal to 40 minutes recording time
e2506
speech generating device, digitized speech, using pre-recorded messages, greater than 40 minutes recording time
e2508
speech generating device, synthesized speech, requiring message formulation by spelling and access by physical contact with the device
e2510
speech generating device, synthesized speech, permitting multiple methods of message formulation and multiple methods of device access
e2511
speech generating software program, for personal computer or personal digital assistant
e2512
accessory for speech generating device, mounting system
e2599
accessory for speech generating device, not otherwise classified
e2601
general use wheelchair seat cushion, width less than 22 inches, any depth
e2602
general use wheelchair seat cushion, width 22 inches or greater, any depth
e2603
skin protection wheelchair seat cushion, width less than 22 inches, any depth
e2604
skin protection wheelchair seat cushion, width 22 inches or greater, any depth
e2605
positioning wheelchair seat cushion, width less than 22 inches, any depth
e2606
positioning wheelchair seat cushion, width 22 inches or greater, any depth
e2607
skin protection and positioning wheelchair seat cushion, width less than 22 inches, any depth
e2608
skin protection and positioning wheelchair seat cushion, width 22 inches or greater, any depth
e2609
custom fabricated wheelchair seat cushion, any size
e2610
wheelchair seat cushion, powered
e2611
general use wheelchair back cushion, width less than 22 inches, any height, including any type mounting hardware
e2612
general use wheelchair back cushion, width 22 inches or greater, any height, including any type mounting hardware
e2613
positioning wheelchair back cushion, posterior, width less than 22 inches, any height, including any type mounting hardware
e2614
positioning wheelchair back cushion, posterior, width 22 inches or greater, any height, including any type mounting hardware
e2615
positioning wheelchair back cushion, posterior-lateral, width less than 22 inches, any height, including any type mounting hardware
e2616
positioning wheelchair back cushion, posterior-lateral, width 22 inches or greater, any height, including any type mounting hardware
e2617
custom fabricated wheelchair back cushion, any size, including any type mounting hardware
e2619
replacement cover for wheelchair seat cushion or back cushion, each
e2620
positioning wheelchair back cushion, planar back with lateral supports, width less than 22 inches, any height, including any type mounting hardware
e2621
positioning wheelchair back cushion, planar back with lateral supports, width 22 inches or greater, any height, including any type mounting hardware
e2622
skin protection wheelchair seat cushion, adjustable, width less than 22 inches, any depth
e2623
skin protection wheelchair seat cushion, adjustable, width 22 inches or greater, any depth
e2624
skin protection and positioning wheelchair seat cushion, adjustable, width less than 22 inches, any depth
e2625
skin protection and positioning wheelchair seat cushion, adjustable, width 22 inches or greater, any depth
e2626
wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, adjustable
e2627
wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, adjustable rancho type
e2628
wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, reclining
e2629
wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, friction arm support (friction dampening to proximal and distal joints)
e2630
wheelchair accessory, shoulder elbow, mobile arm support, monosuspension arm and hand support, overhead elbow forearm hand sling support, yoke type suspension support
e2631
wheelchair accessory, addition to mobile arm support, elevating proximal arm
e2632
wheelchair accessory, addition to mobile arm support, offset or lateral rocker arm with elastic balance control
e2633
wheelchair accessory, addition to mobile arm support, supinator
e8000
gait trainer, pediatric size, posterior support, includes all accessories and components
e8001
gait trainer, pediatric size, upright support, includes all accessories and components
e8002
gait trainer, pediatric size, anterior support, includes all accessories and components
g0008
administration of influenza virus vaccine
g0009
administration of pneumococcal vaccine
g0010
administration of hepatitis b vaccine
g0027
semen analysis; presence and/or motility of sperm excluding huhner
g0028
documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reason)
g0029
tobacco screening not performed or tobacco cessation intervention not provided on the date of the encounter or within the previous 12 months, reason not otherwise specified
g0030
patient screened for tobacco use and received tobacco cessation intervention on the date of the encounter or within the previous 12 months (counseling, pharmacotherapy, or both), if identified as a tobacco user
g0031
palliative care services given to patient any time during the measurement period
g0032
two or more antipsychotic prescriptions ordered for patients who had a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder on or between january 1 of the year prior to the measurement period and the index prescription start date (ipsd) for antipsychotics
g0033
two or more benzodiazepine prescriptions ordered for patients who had a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between january 1 of the year prior to the measurement period and the ipsd for benzodiazepines
g0034
patients receiving palliative care during the measurement period
g0035
patient has any emergency department encounter during the performance period with place of service indicator 23
g0036
patient or care partner decline assessment
g0037
on date of encounter, patient is not able to participate in assessment or screening, including non-verbal patients, delirious, severely aphasic, severely developmentally delayed, severe visual or hearing impairment and for those patients, no knowledgeable informant available
g0038
clinician determines patient does not require referral
g0039
patient not referred, reason not otherwise specified
g0040
patient already receiving physical/occupational/speech/recreational therapy during the measurement period
g0041
patient and/or care partner decline referral
g0042
referral to physical, occupational, speech, or recreational therapy
g0043
patients with mechanical prosthetic heart valve
g0044
patients with moderate or severe mitral stenosis
g0045
clinical follow-up and mrs score assessed at 90 days following endovascular stroke intervention
g0046
clinical follow-up and mrs score not assessed at 90 days following endovascular stroke intervention
g0047
pediatric patient with minor blunt head trauma and pecarn prediction criteria are not assessed
g0048
patients who receive palliative care services any time during the intake period through the end of the measurement year
g0049
with maintenance hemodialysis (in-center and home hd) for the complete reporting month
g0050
patients with a catheter that have limited life expectancy
g0051
patients under hospice care in the current reporting month
g0052
patients on peritoneal dialysis for any portion of the reporting month
g0053
advancing rheumatology patient care mips value pathways
g0054
coordinating stroke care to promote prevention and cultivate positive outcomes mips value pathways
g0055
advancing care for heart disease mips value pathways
g0056
optimizing chronic disease management mips value pathways
g0057
proposed adopting best practices and promoting patient safety within emergency medicine mips value pathways
g0058
improving care for lower extremity joint repair mips value pathways
g0059
patient safety and support of positive experiences with anesthesia mips value pathways
g0060
allergy/immunology mips specialty set
g0061
anesthesiology mips specialty set
g0062
audiology mips specialty set
g0063
cardiology mips specialty set
g0064
certified nurse midwife mips specialty set
g0065
chiropractic medicine mips specialty set
g0066
clinical social work mips specialty set
g0067
dentistry mips specialty set
g0068
professional services for the administration of anti-infective, pain management, chelation, pulmonary hypertension, inotropic, or other intravenous infusion drug or biological (excluding chemotherapy or other highly complex drug or biological) for each infusion drug administration calendar day in the individual's home, each 15 minutes
g0069
professional services for the administration of subcutaneous immunotherapy or other subcutaneous infusion drug or biological for each infusion drug administration calendar day in the individual's home, each 15 minutes
g0070
professional services for the administration of intravenous chemotherapy or other intravenous highly complex drug or biological infusion for each infusion drug administration calendar day in the individual's home, each 15 minutes
g0071
payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only
g0076
brief (20 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0077
limited (30 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0078
moderate (45 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0079
comprehensive (60 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0080
extensive (75 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0081
brief (20 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0082
limited (30 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0083
moderate (45 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0084
comprehensive (60 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0085
extensive (75 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0086
limited (30 minutes) care management home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0087
comprehensive (60 minutes) care management home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
g0088
professional services, initial visit, for the administration of anti-infective, pain management, chelation, pulmonary hypertension, inotropic, or other intravenous infusion drug or biological (excluding chemotherapy or other highly complex drug or biological) for each infusion drug administration calendar day in the individual's home, each 15 minutes
g0089
professional services, initial visit, for the administration of subcutaneous immunotherapy or other subcutaneous infusion drug or biological for each infusion drug administration calendar day in the individual's home, each 15 minutes
g0090
professional services, initial visit, for the administration of intravenous chemotherapy or other highly complex infusion drug or biological for each infusion drug administration calendar day in the individual's home, each 15 minutes
g0101
cervical or vaginal cancer screening; pelvic and clinical breast examination
g0102
prostate cancer screening; digital rectal examination
g0103
prostate cancer screening; prostate specific antigen test (psa)
g0104
colorectal cancer screening; flexible sigmoidoscopy
g0105
colorectal cancer screening; colonoscopy on individual at high risk
g0106
colorectal cancer screening; alternative to g0104, screening sigmoidoscopy, barium enema
g0108
diabetes outpatient self-management training services, individual, per 30 minutes
g0109
diabetes outpatient self-management training services, group session (2 or more), per 30 minutes
g0117
glaucoma screening for high risk patients furnished by an optometrist or ophthalmologist
g0118
glaucoma screening for high risk patient furnished under the direct supervision of an optometrist or ophthalmologist
g0120
colorectal cancer screening; alternative to g0105, screening colonoscopy, barium enema.
g0121
colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk
g0122
colorectal cancer screening; barium enema
g0123
screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision
g0124
screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician
g0127
trimming of dystrophic nails, any number
g0128
direct (face-to-face with patient) skilled nursing services of a registered nurse provided in a comprehensive outpatient rehabilitation facility, each 10 minutes beyond the first 5 minutes
g0129
occupational therapy services requiring the skills of a qualified occupational therapist, furnished as a component of a partial hospitalization treatment program, per session (45 minutes or more)
g0130
single energy x-ray absorptiometry (sexa) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)
g0141
screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician
g0143
screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision
g0144
screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision
g0145
screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision
g0147
screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision
g0148
screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening
g0151
services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes
g0152
services performed by a qualified occupational therapist in the home health or hospice setting, each 15 minutes
g0153
services performed by a qualified speech-language pathologist in the home health or hospice setting, each 15 minutes
g0154
direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes terminated february 29, 2016.
g0155
services of clinical social worker in home health or hospice settings, each 15 minutes
g0156
services of home health/hospice aide in home health or hospice settings, each 15 minutes
g0157
services performed by a qualified physical therapist assistant in the home health or hospice setting, each 15 minutes
g0158
services performed by a qualified occupational therapist assistant in the home health or hospice setting, each 15 minutes
g0159
services performed by a qualified physical therapist, in the home health setting, in the establishment or delivery of a safe and effective physical therapy maintenance program, each 15 minutes
g0160
services performed by a qualified occupational therapist, in the home health setting, in the establishment or delivery of a safe and effective occupational therapy maintenance program, each 15 minutes
g0161
services performed by a qualified speech-language pathologist, in the home health setting, in the establishment or delivery of a safe and effective speech-language pathology maintenance program, each 15 minutes
g0162
skilled services by a registered nurse (rn) for management and evaluation of the plan of care; each 15 minutes (the patient's underlying condition or complication requires an rn to ensure that essential non-skilled care achieves its purpose in the home health or hospice setting)
g0163
skilled services of a licensed nurse (lpn or rn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting) terminated december 31, 2016.
g0164
skilled services of a licensed nurse (lpn or rn), in the training and/or education of a patient or family member, in the home health or hospice setting, each 15 minutes terminated december 31, 2016.
g0166
external counterpulsation, per treatment session
g0168
wound closure utilizing tissue adhesive(s) only
g0173
linear accelerator based stereotactic radiosurgery, complete course of therapy in one session terminated december 31, 2014.
g0175
scheduled interdisciplinary team conference (minimum of three exclusive of patient care nursing staff) with patient present
g0176
activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more)
g0177
training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more)
g0179
physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care
g0180
physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care
g0181
physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allowed practitioner development and/or revision of care plans
g0182
physician supervision of a patient under a medicare-approved hospice (patient not present) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of laboratory and other studies, communication (including telephone calls) with other health care professionals involved in the patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month, 30 minutes or more
g0186
destruction of localized lesion of choroid (for example, choroidal neovascularization); photocoagulation, feeder vessel technique (one or more sessions)
g0202
screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed terminated december 31, 2017.
g0204
diagnostic mammography, including computer-aided detection (cad) when performed; bilateral terminated december 31, 2017.
g0206
diagnostic mammography, including computer-aided detection (cad) when performed; unilateral terminated december 31, 2017.
g0219
pet imaging whole body; melanoma for non-covered indications
g0235
pet imaging, any site, not otherwise specified
g0237
therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring)
g0238
therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring)
g0239
therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring)
g0245
initial physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) which must include: (1) the diagnosis of lops, (2) a patient history, (3) a physical examination that consists of at least the following elements: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of a protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear and (4) patient education
g0246
follow-up physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include at least the following: (1) a patient history, (2) a physical examination that includes: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (3) patient education
g0247
routine foot care by a physician of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include, the local care of superficial wounds (i.e. superficial to muscle and fascia) and at least the following if present: (1) local care of superficial wounds, (2) debridement of corns and calluses, and (3) trimming and debridement of nails
g0248
demonstration, prior to initiation of home inr monitoring, for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria, under the direction of a physician; includes: face-to-face demonstration of use and care of the inr monitor, obtaining at least one blood sample, provision of instructions for reporting home inr test results, and documentation of patient's ability to perform testing and report results
g0249
provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include 4 tests
g0250
physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequently than once a week; billing units of service include 4 tests
g0251
linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment terminated december 31, 2014.
g0252
pet imaging, full and partial-ring pet scanners only, for initial diagnosis of breast cancer and/or surgical planning for breast cancer (e.g., initial staging of axillary lymph nodes)
g0255
current perception threshold/sensory nerve conduction test, (snct) per limb, any nerve
g0257
unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility
g0259
injection procedure for sacroiliac joint; arthrography
g0260
injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography
g0268
removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing
g0269
placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug)
g0270
medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes
g0271
medical nutrition therapy, reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal disease), group (2 or more individuals), each 30 minutes
g0276
blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (pild) or placebo-control, performed in an approved coverage with evidence development (ced) clinical trial
g0277
hyperbaric oxygen under pressure, full body chamber, per 30 minute interval
g0278
iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation (list separately in addition to primary procedure)
g0279
diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)
g0281
electrical stimulation, (unattended), to one or more areas, for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care, as part of a therapy plan of care
g0282
electrical stimulation, (unattended), to one or more areas, for wound care other than described in g0281
g0283
electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care
g0288
reconstruction, computed tomographic angiography of aorta for surgical planning for vascular surgery
g0289
arthroscopy, knee, surgical, for removal of loose body, foreign body, debridement/shaving of articular cartilage (chondroplasty) at the time of other surgical knee arthroscopy in a different compartment of the same knee
g0293
noncovered surgical procedure(s) using conscious sedation, regional, general or spinal anesthesia in a medicare qualifying clinical trial, per day
g0294
noncovered procedure(s) using either no anesthesia or local anesthesia only, in a medicare qualifying clinical trial, per day
g0295
electromagnetic therapy, to one or more areas, for wound care other than described in g0329 or for other uses
g0296
counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making)
g0297
low dose ct scan (ldct) for lung cancer screening terminated december 31, 2020.
g0299
direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes
g0300
direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutes
g0302
pre-operative pulmonary surgery services for preparation for lvrs, complete course of services, to include a minimum of 16 days of services
g0303
pre-operative pulmonary surgery services for preparation for lvrs, 10 to 15 days of services
g0304
pre-operative pulmonary surgery services for preparation for lvrs, 1 to 9 days of services
g0305
post-discharge pulmonary surgery services after lvrs, minimum of 6 days of services
g0306
complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count
g0307
complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count)
g0308
creation of subcutaneous pocket with insertion of 180 day implantable interstitial glucose sensor, including system activation and patient training
g0309
removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 180 day implantable sensor, including system activation
g0310
immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time (this code is used for medicaid billing purposes)
g0311
immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 16-30 mins time (this code is used for medicaid billing purposes)
g0312
immunization counseling by a physician or other qualify ed health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time (this code is used for medicaid billing purposes)
g0313
immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 16-30 mins time (this code is used for medicaid billing purposes)
g0314
immunization counseling by a physician or other qualified health care professional for covid-19, ages under 21, 16-30 mins time (this code is used for the medicaid early and periodic screening, diagnostic, and treatment benefit (epsdt)
g0315
immunization counseling by a physician or other qualified health care professional for covid-19, ages under 21, 5-15 mins time (this code is used for the medicaid early and periodic screening, diagnostic, and treatment benefit (epsdt)
g0327
colorectal cancer screening; blood-based biomarker
g0328
colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous
g0329
electromagnetic therapy, to one or more areas for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care
g0333
pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary
g0337
hospice evaluation and counseling services, pre-election
g0339
image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment
g0340
image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatment
g0341
percutaneous islet cell transplant, includes portal vein catheterization and infusion
g0342
laparoscopy for islet cell transplant, includes portal vein catheterization and infusion
g0343
laparotomy for islet cell transplant, includes portal vein catheterization and infusion
g0364
bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service terminated december 31, 2017.
g0365
vessel mapping of vessels for hemodialysis access (services for preoperative vessel mapping prior to creation of hemodialysis access using an autogenous hemodialysis conduit, including arterial inflow and venous outflow) terminated december 31, 2019.
g0372
physician service required to establish and document the need for a power mobility device
g0378
hospital observation service, per hour
g0379
direct admission of patient for hospital observation care
g0380
level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)
g0381
level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)
g0382
level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)
g0383
level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)
g0384
level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)
g0389
ultrasound b-scan and/or real time with image documentation; for abdominal aortic aneurysm (aaa) screening terminated december 31, 2016.
g0390
trauma response team associated with hospital critical care service
g0396
alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes
g0397
alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes
g0398
home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation
g0399
home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation
g0400
home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels
g0402
initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment
g0403
electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report
g0404
electrocardiogram, routine ecg with 12 leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination
g0405
electrocardiogram, routine ecg with 12 leads; interpretation and report only, performed as a screening for the initial preventive physical examination
g0406
follow-up inpatient consultation, limited, physicians typically spend 15 minutes communicating with the patient via telehealth
g0407
follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth
g0408
follow-up inpatient consultation, complex, physicians typically spend 35 minutes communicating with the patient via telehealth
g0409
social work and psychological services, directly relating to and/or furthering the patient's rehabilitation goals, each 15 minutes, face-to-face; individual (services provided by a corf-qualified social worker or psychologist in a corf)
g0410
group psychotherapy other than of a multiple-family group, in a partial hospitalization setting, approximately 45 to 50 minutes
g0411
interactive group psychotherapy, in a partial hospitalization setting, approximately 45 to 50 minutes
g0412
open treatment of iliac spine(s), tuberosity avulsion, or iliac wing fracture(s), unilateral or bilateral for pelvic bone fracture patterns which do not disrupt the pelvic ring includes internal fixation, when performed
g0413
percutaneous skeletal fixation of posterior pelvic bone fracture and/or dislocation, for fracture patterns which disrupt the pelvic ring, unilateral or bilateral, (includes ilium, sacroiliac joint and/or sacrum)
g0414
open treatment of anterior pelvic bone fracture and/or dislocation for fracture patterns which disrupt the pelvic ring, unilateral or bilateral, includes internal fixation when performed (includes pubic symphysis and/or superior/inferior rami)
g0415
open treatment of posterior pelvic bone fracture and/or dislocation, for fracture patterns which disrupt the pelvic ring, unilateral or bilateral, includes internal fixation, when performed (includes ilium, sacroiliac joint and/or sacrum)
g0416
surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method
g0417
surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens terminated december 31, 2014.
g0418
surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens terminated december 31, 2014.
g0419
surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, >60 specimens terminated december 31, 2014.
g0420
face-to-face educational services related to the care of chronic kidney disease; individual, per session, per one hour
g0421
face-to-face educational services related to the care of chronic kidney disease; group, per session, per one hour
g0422
intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session
g0423
intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session
g0424
pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day terminated december 31, 2021.
g0425
telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth
g0426
telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth
g0427
telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth
g0428
collagen meniscus implant procedure for filling meniscal defects (e.g., cmi, collagen scaffold, menaflex)
g0429
dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)
g0431
drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter terminated december 31, 2015.
g0432
infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening
g0433
infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening
g0434
drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter terminated december 31, 2015.
g0435
infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening
g0436
smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes terminated september 30, 2016.
g0437
smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes terminated september 30, 2016.
g0438
annual wellness visit; includes a personalized prevention plan of service (pps), initial visit
g0439
annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit
g0442
annual alcohol misuse screening, 15 minutes
g0443
brief face-to-face behavioral counseling for alcohol misuse, 15 minutes
g0444
annual depression screening, 15 minutes
g0445
high intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes
g0446
annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes
g0447
face-to-face behavioral counseling for obesity, 15 minutes
g0448
insertion or replacement of a permanent pacing cardioverter-defibrillator system with transvenous lead(s), single or dual chamber with insertion of pacing electrode, cardiac venous system, for left ventricular pacing
g0451
development testing, with interpretation and report, per standardized instrument form
g0452
molecular pathology procedure; physician interpretation and report
g0453
continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure)
g0454
physician documentation of face-to-face visit for durable medical equipment determination performed by nurse practitioner, physician assistant or clinical nurse specialist
g0455
preparation with instillation of fecal microbiota by any method, including assessment of donor specimen
g0456
negative pressure wound therapy, (e.g. vacuum assisted drainage collection) using a mechanically-powered device, not durable medical equipment, including provision of cartridge and dressing(s), topical application(s), wound assessment, and instructions for ongoing care, per session; total wounds(s) surface area less than or equal to 50 square centimeters terminated december 31, 2014.
g0457
negative pressure wound therapy, (e.g. vacuum assisted drainage collection) using a mechanically-powered device, not durable medical equipment, including provision of cartridge and dressing(s), topical application(s), wound assessment, and instructions for ongoing care, per session; total wounds(s) surface area greater than 50 square centimeters terminated december 31, 2014.
g0458
low dose rate (ldr) prostate brachytherapy services, composite rate
g0459
inpatient telehealth pharmacologic management, including prescription, use, and review of medication with no more than minimal medical psychotherapy
g0460
autologous platelet rich plasma for non-diabetic chronic wounds/ulcers, including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment
g0461
immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain terminated december 31, 2014.
g0462
immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) terminated december 31, 2014.
g0463
hospital outpatient clinic visit for assessment and management of a patient
g0464
colorectal cancer screening; stool-based dna and fecal occult hemoglobin (e.g., kras, ndrg4 and bmp3) terminated december 31, 2015.
g0465
autologous platelet rich plasma (prp) for diabetic chronic wounds/ulcers, using an fda-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment)
g0466
federally qualified health center (fqhc) visit, new patient; a medically-necessary, face-to-face encounter (one-on-one) between a new patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit
g0467
federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit
g0468
federally qualified health center (fqhc) visit, ippe or awv; a fqhc visit that includes an initial preventive physical examination (ippe) or annual wellness visit (awv) and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving an ippe or awv
g0469
federally qualified health center (fqhc) visit, mental health, new patient; a medically-necessary, face-to-face mental health encounter (one-on-one) between a new patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a mental health visit
g0470
federally qualified health center (fqhc) visit, mental health, established patient; a medically-necessary, face-to-face mental health encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a mental health visit
g0471
collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)
g0472
hepatitis c antibody screening, for individual at high risk and other covered indication(s)
g0473
face-to-face behavioral counseling for obesity, group (2-10), 30 minutes
g0475
hiv antigen/antibody, combination assay, screening
g0476
infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test
g0477
drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g., immunoassay) capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service terminated december 31, 2016.
g0478
drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g., immunoassay) read by instrument-assisted direct optical observation (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service terminated december 31, 2016.
g0479
drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, tof, maldi, ldtd, desi, dart, ghpc, gc mass spectrometry), includes sample validation when performed, per date of service terminated december 31, 2016.
g0480
drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed
g0481
drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed
g0482
drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed
g0483
drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed
g0490
face-to-face home health nursing visit by a rural health clinic (rhc) or federally qualified health center (fqhc) in an area with a shortage of home health agencies; (services limited to rn or lpn only)
g0491
dialysis procedure at a medicare certified esrd facility for acute kidney injury without esrd
g0492
dialysis procedure with single evaluation by a physician or other qualified health care professional for acute kidney injury without esrd
g0493
skilled services of a registered nurse (rn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting)
g0494
skilled services of a licensed practical nurse (lpn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting)
g0495
skilled services of a registered nurse (rn), in the training and/or education of a patient or family member, in the home health or hospice setting, each 15 minutes
g0496
skilled services of a licensed practical nurse (lpn), in the training and/or education of a patient or family member, in the home health or hospice setting, each 15 minutes
g0498
chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion
g0499
hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result
g0500
moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)
g0501
resource-intensive services for patients for whom the use of specialized mobility-assistive technology (such as adjustable height chairs or tables, patient lift, and adjustable padded leg supports) is medically necessary and used during the provision of an office/outpatient, evaluation and management visit (list separately in addition to primary service)
g0502
initial psychiatric collaborative care management, first 70 minutes in the first calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: outreach to and engagement in treatment of a patient directed by the treating physician or other qualified health care professional; initial assessment of the patient, including administration of validated rating scales, with the development of an individualized treatment plan; review by the psychiatric consultant with modifications of the plan if recommended; entering patient in a registry and tracking patient follow-up and progress using the registry, with appropriate documentation, and participation in weekly caseload consultation with the psychiatric consultant; and provision of brief interventions using evidence-based techniques such as behavioral activation, motivational interviewing, and other focused treatment strategies terminated december 31, 2017.
g0503
subsequent psychiatric collaborative care management, first 60 minutes in a subsequent month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: tracking patient follow-up and progress using the registry, with appropriate documentation; participation in weekly caseload consultation with the psychiatric consultant; ongoing collaboration with and coordination of the patient's mental health care with the treating physician or other qualified health care professional and any other treating mental health providers; additional review of progress and recommendations for changes in treatment, as indicated, including medications, based on recommendations provided by the psychiatric consultant; provision of brief interventions using evidence-based techniques such as behavioral activation, motivational interviewing, and other focused treatment strategies; monitoring of patient outcomes using validated rating scales; and relapse prevention planning with patients as they achieve remission of symptoms and/or other treatment terminated december 31, 2017.
g0504
initial or subsequent psychiatric collaborative care management, each additional 30 minutes in a calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional (list separately in addition to code for primary procedure); (use g0504 in conjunction with g0502, g0503) terminated december 31, 2017.
g0505
cognition and functional assessment using standardized instruments with development of recorded care plan for the patient with cognitive impairment, history obtained from patient and/or caregiver, in office or other outpatient setting or home or domiciliary or rest home terminated december 31, 2017.
g0506
comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service)
g0507
care management services for behavioral health conditions, at least 20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team terminated december 31, 2017.
g0508
telehealth consultation, critical care, initial , physicians typically spend 60 minutes communicating with the patient and providers via telehealth
g0509
telehealth consultation, critical care, subsequent, physicians typically spend 50 minutes communicating with the patient and providers via telehealth
g0511
rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month
g0512
rural health clinic or federally qualified health center (rhc/fqhc) only, psychiatric collaborative care model (psychiatric cocm), 60 minutes or more of clinical staff time for psychiatric cocm services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm) and including services furnished by a behavioral health care manager and consultation with a psychiatric consultant, per calendar month
g0513
prolonged preventive service(s) (beyond the typical service time of the primary procedure), in the office or other outpatient setting requiring direct patient contact beyond the usual service; first 30 minutes (list separately in addition to code for preventive service)
g0514
prolonged preventive service(s) (beyond the typical service time of the primary procedure), in the office or other outpatient setting requiring direct patient contact beyond the usual service; each additional 30 minutes (list separately in addition to code g0513 for additional 30 minutes of preventive service)
g0515
development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes terminated december 31, 2019.
g0516
insertion of non-biodegradable drug delivery implants, 4 or more (services for subdermal rod implant)
g0517
removal of non-biodegradable drug delivery implants, 4 or more (services for subdermal implants)
g0518
removal with reinsertion, non-biodegradable drug delivery implants, 4 or more (services for subdermal implants)
g0659
drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes
g0908
most recent hemoglobin (hgb) level > 12.0 g/dl terminated december 31, 2014.
g0909
hemoglobin level measurement not documented, reason not given terminated december 31, 2014.
g0910
most recent hemoglobin level <= 12.0 g/dl terminated december 31, 2014.
g0913
improvement in visual function achieved within 90 days following cataract surgery
g0914
patient care survey was not completed by patient
g0915
improvement in visual function not achieved within 90 days following cataract surgery
g0916
satisfaction with care achieved within 90 days following cataract surgery
g0917
patient satisfaction survey was not completed by patient
g0918
satisfaction with care not achieved within 90 days following cataract surgery
g0919
influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit terminated december 31, 2014.
g0920
type, anatomic location, and activity all documented terminated december 31, 2014.
g0921
documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment) terminated december 31, 2014.
g0922
no documentation of disease type, anatomic location, and activity, reason not given terminated december 31, 2014.
g1000
clinical decision support mechanism applied pathways, as defined by the medicare appropriate use criteria program terminated march 31, 2020.
g1001
clinical decision support mechanism evicore, as defined by the medicare appropriate use criteria program
g1002
clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program
g1003
clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program
g1004
clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program
g1005
clinical decision support mechanism national imaging associates, as defined by the medicare appropriate use criteria program terminated december 31, 2020.
g1006
clinical decision support mechanism test appropriate, as defined by the medicare appropriate use criteria program terminated december 31, 2020.
g1007
clinical decision support mechanism aim specialty health, as defined by the medicare appropriate use criteria program
g1008
clinical decision support mechanism cranberry peak, as defined by the medicare appropriate use criteria program
g1009
clinical decision support mechanism sage health management solutions, as defined by the medicare appropriate use criteria program terminated march 31, 2022.
g1010
clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program
g1011
clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program
g1012
clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program
g1013
clinical decision support mechanism evidencecare imagingcare, as defined by the medicare appropriate use criteria program
g1014
clinical decision support mechanism inveniqa semantic answers in medicine, as defined by the medicare appropriate use criteria program
g1015
clinical decision support mechanism reliant medical group, as defined by the medicare appropriate use criteria program
g1016
clinical decision support mechanism speed of care, as defined by the medicare appropriate use criteria program
g1017
clinical decision support mechanism healthhelp, as defined by the medicare appropriate use criteria program
g1018
clinical decision support mechanism infinx, as defined by the medicare appropriate use criteria program
g1019
clinical decision support mechanism logicnets, as defined by the medicare appropriate use criteria program
g1020
clinical decision support mechanism curbside clinical augmented workflow, as defined by the medicare appropriate use criteria program
g1021
clinical decision support mechanism ehealthline clinical decision support mechanism, as defined by the medicare appropriate use criteria program
g1022
clinical decision support mechanism intermountain clinical decision support mechanism, as defined by the medicare appropriate use criteria program
g1023
clinical decision support mechanism persivia clinical decision support, as defined by the medicare appropriate use criteria program
g1024
clinical decision support mechanism radrite, as defined by the medicare appropriate use criteria program
g1025
patient-months where there are more than one medicare capitated payment (mcp) provider listed for the month
g1026
the number of adult patient-months in the denominator who were on maintenance hemodialysis using a catheter continuously for three months or longer under the care of the same practitioner or group partner as of the last hemodialysis session of the reporting month
g1027
the number of adult patient-months in the denominator who were on maintenance hemodialysis under the care of the same practitioner or group partner as of the last hemodialysis session of the reporting month using a catheter continuously for less than three months
g1028
take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
g2000
blinded administration of convulsive therapy procedure, either electroconvulsive therapy (ect, current covered gold standard) or magnetic seizure therapy (mst, non-covered experimental therapy), performed in an approved ide-based clinical trial, per treatment session
g2001
brief (20 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2002
limited (30 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2003
moderate (45 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2004
comprehensive (60 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2005
extensive (75 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2006
brief (20 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2007
limited (30 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2008
moderate (45 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2009
comprehensive (60 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2010
remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment
g2011
alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes
g2012
brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion
g2013
extensive (75 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2014
limited (30 minutes) care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
g2015
comprehensive (60 mins) home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility.)
g2020
services for high intensity clinical services associated with the initial engagement and outreach of beneficiaries assigned to the sip component of the pcf model (do not bill with chronic care management codes)
g2021
health care practitioners rendering treatment in place (tip)
g2022
a model participant (ambulance supplier/provider), the beneficiary refuses services covered under the model (transport to an alternate destination/treatment in place)
g2023
specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source
g2024
specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source
g2025
payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only
g2058
chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)). terminated december 31, 2020.
g2061
qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 5-10 minutes terminated december 31, 2020.
g2062
qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 11-20 minutes terminated december 31, 2020.
g2063
qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 21 or more minutes terminated december 31, 2020.
g2064
comprehensive care management services for a single high-risk disease, e.g., principal care management, at least 30 minutes of physician or other qualified health care professional time per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been the cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities terminated december 31, 2021.
g2065
comprehensive care management for a single high-risk disease services, e.g. principal care management, at least 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities terminated december 31, 2021.
g2066
interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results
g2067
medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2068
medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2069
medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2070
medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2071
medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2072
medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2073
medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2074
medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2075
medication assisted treatment, medication not otherwise specified; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program)
g2076
intake activities, including initial medical examination that is a complete, fully documented physical evaluation and initial assessment by a program physician or a primary care physician, or an authorized healthcare professional under the supervision of a program physician qualified personnel that includes preparation of a treatment plan that includes the patient's short-term goals and the tasks the patient must perform to complete the short-term goals; the patient's requirements for education, vocational rehabilitation, and employment; and the medical, psycho- social, economic, legal, or other supportive services that a patient needs, conducted by qualified personnel (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
g2077
periodic assessment; assessing periodically by qualified personnel to determine the most appropriate combination of services and treatment (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
g2078
take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
g2079
take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
g2080
each additional 30 minutes of counseling in a week of medication assisted treatment, (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
g2081
patients age 66 and older in institutional special needs plans (snp) or residing in long-term care with a pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period
g2082
office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation
g2083
office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation
g2086
office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month
g2087
office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month
g2088
office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; each additional 30 minutes beyond the first 120 minutes (list separately in addition to code for primary procedure)
g2089
most recent hemoglobin a1c (hba1c) level 7.0 to 9.0% terminated december 31, 2020.
g2090
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
g2091
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period
g2092
angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) or angiotensin receptor-neprilysin inhibitor (arni) therapy prescribed or currently being taken
g2093
documentation of medical reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., hypotensive patients who are at immediate risk of cardiogenic shock, hospitalized patients who have experienced marked azotemia, allergy, intolerance, other medical reasons)
g2094
documentation of patient reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., patient declined, other patient reasons)
g2095
documentation of system reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., other system reasons)
g2096
angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) or angiotensin receptor-neprilysin inhibitor (arni) therapy was not prescribed, reason not given
g2097
episodes where the patient had a competing diagnosis on or within three days after the episode date (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, chronic sinusitis, infection of the adenoids, prostatitis, cellulitis, mastoiditis, or bone infections, acute lymphadenitis, impetigo, skin staph infections, pneumonia/gonococcal infections, venereal disease (syphilis, chlamydia, inflammatory diseases [female reproductive organs]), infections of the kidney, cystitis or uti)
g2098
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
g2099
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period
g2100
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
g2101
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period
g2102
dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed terminated december 31, 2020.
g2103
seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist documented and reviewed terminated december 31, 2020.
g2104
eye imaging validated to match diagnosis from seven standard field stereoscopic photos results documented and reviewed terminated december 31, 2020.
g2105
patient age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period
g2106
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
g2107
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period
g2108
patient age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period
g2109
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
g2110
patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period
g2112
patient receiving <=5 mg daily prednisone (or equivalent), or ra activity is worsening, or glucocorticoid use is for less than 6 months
g2113
patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity
g2114
patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period terminated december 31, 2020.
g2115
patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
g2116
patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period
g2117
patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period terminated december 31, 2020.
g2118
patients 81 years of age and older with at least one claim/encounter for frailty during the measurement period
g2119
within the past 2 years, calcium and/or vitamin d optimization has been ordered or performed terminated december 31, 2020.
g2120
within the past 2 years, calcium and/or vitamin d optimization has not been ordered or performed terminated december 31, 2020.
g2121
depression, anxiety, apathy, and psychosis assessed
g2122
depression, anxiety, apathy, and psychosis not assessed
g2123
patients 66-80 years of age and had at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period terminated december 31, 2020.
g2124
patients 66-80 years of age and had at least one claim/encounter for frailty during the measurement period and a dispensed dementia medication terminated december 31, 2020.
g2125
patients 81 years of age and older with at least one claim/encounter for frailty during the six months prior to the measurement period through december 31 of the measurement period
g2126
patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period
g2127
patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
g2128
documentation of medical reason(s) for not on a daily aspirin or other antiplatelet (e.g. history of gastrointestinal bleed, intra-cranial bleed, blood disorders, idiopathic thrombocytopenic purpura (itp), gastric bypass or documentation of active anticoagulant use during the measurement period)
g2129
procedure-related bp's not taken during an outpatient visit. examples include same day surgery, ambulatory service center, g.i. lab, dialysis, infusion center, chemotherapy
g2130
patients age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 days during the measurement period terminated december 31, 2020.
g2131
patients 81 years and older with a diagnosis of frailty terminated december 31, 2020.
g2132
patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period terminated december 31, 2020.
g2133
patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period terminated december 31, 2020.
g2134
patients 66 years of age or older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period terminated december 31, 2020.
g2135
patients 66 years of age or older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period terminated december 31, 2020.
g2136
back pain measured by the visual analog scale (vas) at three months (6 - 20 weeks) postoperatively was less than or equal to 3.0 or back pain measured by the visual analog scale (vas) within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated an improvement of 5.0 points or greater
g2137
back pain measured by the visual analog scale (vas) at three months (6 - 20 weeks) postoperatively was greater than 3.0 and back pain measured by the visual analog scale (vas) within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated a change of less than an improvement of 5.0 points
g2138
back pain as measured by the visual analog scale (vas) at one year (9 to 15 months) postoperatively was less than or equal to 3.0 or back pain measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated a change of 5.0 points or greater
g2139
back pain measured by the visual analog scale (vas) pain at one year (9 to 15 months) postoperatively was greater than 3.0 and back pain measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated a change of less than 5.0
g2140
leg pain measured by the visual analog scale (vas) at three months (6 - 20 weeks) postoperatively was less than or equal to 3.0 or leg pain measured by the visual analog scale (vas) within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated an improvement of 5.0 points or greater
g2141
leg pain measured by the visual analog scale (vas) at three months (6 - 20 weeks) postoperatively was greater than 3.0 and leg pain measured by the visual analog scale (vas) within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated less than an improvement of 5.0 points
g2142
functional status measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively was less than or equal to 22 or functional status measured by the odi version 2.1a within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated an improvement of 30 points or greater
g2143
functional status measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively was greater than 22 and functional status measured by the odi version 2.1a within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated an improvement of less than 30 points
g2144
functional status measured by the oswestry disability index (odi version 2.1a) at three months (6-20 weeks) postoperatively was less than or equal to 22 or functional status measured by the odi version 2.1a within three months preoperatively and at three months (6-20 weeks) postoperatively demonstrated an improvement of 30 points or greater
g2145
functional status measured by the oswestry disability index (odi version 2.1a) at three months (6 - 20 weeks) postoperatively was greater than 22 and functional status measured by the odi version 2.1a within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated an improvement of less than 30 points
g2146
leg pain as measured by the visual analog scale (vas) at one year (9 to 15 months) postoperatively was less than or equal to 3.0 or leg pain measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated an improvement of 5.0 points or greater
g2147
leg pain measured by the visual analog scale (vas) at one year (9 to 15 months) postoperatively was greater than 3.0 and leg pain measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated less than an improvement of 5.0 points
g2148
multimodal pain management was used
g2149
documentation of medical reason(s) for not using multimodal pain management (e.g., allergy to multiple classes of analgesics, intubated patient, hepatic failure, patient reports no pain during pacu stay, other medical reason(s))
g2150
multimodal pain management was not used
g2151
documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care
g2152
risk-adjusted functional status change residual score for the neck impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
g2153
in hospice or using hospice services during the measurement period terminated december 31, 2020.
g2154
patient received at least one td vaccine or one tdap vaccine between nine years prior to the start of the measurement period and the end of the measurement period terminated december 31, 2020.
g2155
patient had history of at least one of the following contraindications any time during or before the measurement period: anaphylaxis due to tdap vaccine, anaphylaxis due to td vaccine or its components; encephalopathy due to tdap or td vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis or post pertussis vaccination encephalitis.) terminated december 31, 2020.
g2156
patient did not receive at least one td vaccine or one tdap vaccine between nine years prior to the start of the measurement period and the end of the measurement period; or have history of at least one of the following contraindications any time during or before the measurement period: anaphylaxis due to tdap vaccine, anaphylaxis due to td vaccine or its components; encephalopathy due to tdap or td vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis or post pertussis vaccination encephalitis.) terminated december 31, 2020.
g2157
patients received both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period terminated december 31, 2020.
g2158
patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement period terminated december 31, 2020.
g2159
patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period terminated december 31, 2020.
g2160
patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period terminated december 31, 2020.
g2161
patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period terminated december 31, 2020.
g2162
patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period terminated december 31, 2020.
g2163
patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period terminated december 31, 2020.
g2164
patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period terminated december 31, 2020.
g2165
patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period terminated december 31, 2020.
g2166
patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason terminated december 31, 2020.
g2167
risk-adjusted functional status change residual score for the neck impairment successfully calculated and the score was less than zero (< 0)
g2168
services performed by a physical therapist assistant in the home health setting in the delivery of a safe and effective physical therapy maintenance program, each 15 minutes
g2169
services performed by an occupational therapist assistant in the home health setting in the delivery of a safe and effective occupational therapy maintenance program, each 15 minutes
g2170
percutaneous arteriovenous fistula creation (avf), direct, any site, by tissue approximation using thermal resistance energy, and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization) when performed, and includes all imaging and radiologic guidance, supervision and interpretation, when performed
g2171
percutaneous arteriovenous fistula creation (avf), direct, any site, using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, wen performed) and fistulogram(s), angiography, enography, and/or ultrasound, with radiologic supervision and interpretation, when performed
g2172
all inclusive payment for services related to highly coordinated and integrated opioid use disorder (oud) treatment services furnished for the demonstration project
g2173
uri episodes where the patient had a comorbid condition during the 12 months prior to or on the episode date (e.g., tuberculosis, neutropenia, cystic fibrosis, chronic bronchitis, pulmonary edema, respiratory failure, rheumatoid lung disease)
g2174
uri episodes when the patient had an active prescription of antibiotics (table 1) in the 30 days prior to the episode date
g2175
episodes where the patient had a comorbid condition during the 12 months prior to or on the episode date (e.g., tuberculosis, neutropenia, cystic fibrosis, chronic bronchitis, pulmonary edema, respiratory failure, rheumatoid lung disease)
g2176
outpatient, ed, or observation visits that result in an inpatient admission
g2177
acute bronchitis/bronchiolitis episodes when the patient had a new or refill prescription of antibiotics (table 1) in the 30 days prior to the episode date
g2178
clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure, for example patient bilateral amputee; patient has condition that would not allow them to accurately respond to a neurological exam (dementia, alzheimer's, etc.); patient has previously documented diabetic peripheral neuropathy with loss of protective sensation
g2179
clinician documented that patient had medical reason for not performing lower extremity neurological exam
g2180
clinician documented that patient was not an eligible candidate for evaluation of footwear as patient is bilateral lower extremity amputee
g2181
bmi not documented due to medical reason or patient refusal of height or weight measurement
g2182
patient receiving first-time biologic disease modifying anti-rheumatic drug therapy
g2183
documentation patient unable to communicate and informant not available
g2184
patient does not have a caregiver
g2185
documentation caregiver is trained and certified in dementia care
g2186
patient /caregiver dyad has been referred to appropriate resources and connection to those resources is confirmed
g2187
patients with clinical indications for imaging of the head: head trauma
g2188
patients with clinical indications for imaging of the head: new or change in headache above 50 years of age
g2189
patients with clinical indications for imaging of the head: abnormal neurologic exam
g2190
patients with clinical indications for imaging of the head: headache radiating to the neck
g2191
patients with clinical indications for imaging of the head: positional headaches
g2192
patients with clinical indications for imaging of the head: temporal headaches in patients over 55 years of age
g2193
patients with clinical indications for imaging of the head: new onset headache in pre-school children or younger (<6 years of age)
g2194
patients with clinical indications for imaging of the head: new onset headache in pediatric patients with disabilities for which headache is a concern as inferred from behavior
g2195
patients with clinical indications for imaging of the head: occipital headache in children
g2196
patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method
g2197
patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user
g2198
documentation of medical reason(s) for not screening for unhealthy alcohol use using a systematic screening method (e.g., limited life expectancy, other medical reasons)
g2199
patient not screened for unhealthy alcohol use using a systematic screening method, reason not given
g2200
patient identified as an unhealthy alcohol user received brief counseling
g2201
documentation of medical reason(s) for not providing brief counseling (e.g., limited life expectancy, other medical reasons)
g2202
patient did not receive brief counseling if identified as an unhealthy alcohol user, reason not given
g2203
documentation of medical reason(s) for not providing brief counseling if identified as an unhealthy alcohol user (e.g., limited life expectancy, other medical reasons)
g2204
patients between 50 and 85 years of age who received a screening colonoscopy during the performance period
g2205
patients with pregnancy during adjuvant treatment course
g2206
patient received adjuvant treatment course including both chemotherapy and her2-targeted therapy
g2207
reason for not administering adjuvant treatment course including both chemotherapy and her2-targeted therapy (e.g. poor performance status (ecog 3-4; karnofsky =50), cardiac contraindications, insufficient renal function, insufficient hepatic function, other active or secondary cancer diagnoses, other medical contraindications, patients who died during initial treatment course or transferred during or after initial treatment course)
g2208
patient did not receive adjuvant treatment course including both chemotherapy and her2-targeted therapy
g2209
patient refused to participate
g2210
risk-adjusted functional status change residual score for the neck impairment not measured because the patient did not complete the neck fs prom at initial evaluation and/or near discharge, reason not given
g2211
visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)
g2212
prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99354, 99355, 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes)
g2213
initiation of medication for the treatment of opioid use disorder in the emergency department setting, including assessment, referral to ongoing care, and arranging access to supportive services (list separately in addition to code for primary procedure)
g2214
initial or subsequent psychiatric collaborative care management, first 30 minutes in a month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional
g2215
take-home supply of nasal naloxone; 2-pack of 4mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
g2216
take-home supply of injectable naloxone (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
g2250
remote assessment of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment
g2251
brief communication technology-based service, e.g. virtual check-in, by a qualified health care professional who cannot report evaluation and management services, provided to an established patient, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of clinical discussion
g2252
brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion
g3001
administration and supply of tositumomab, 450 mg terminated december 31, 2016.
g4000
dermatology mips specialty set
g4001
diagnostic radiology mips specialty set
g4002
electrophysiology cardiac specialist mips specialty set
g4003
emergency medicine mips specialty set
g4004
endocrinology mips specialty set
g4005
family medicine mips specialty set
g4006
gastro-enterology mips specialty set
g4007
general surgery mips specialty set
g4008
geriatrics mips specialty set
g4009
hospitalists mips specialty set
g4010
infectious disease mips specialty set
g4011
internal medicine mips specialty set
g4012
interventional radiology mips specialty set
g4013
mental/behavioral health mips specialty set
g4014
nephrology mips specialty set
g4015
neurology mips specialty set
g4016
neurosurgical mips specialty set
g4017
nutrition/dietician mips specialty set
g4018
obstetrics/gynecology mips specialty set
g4019
oncology/hematology mips specialty set
g4020
ophthalmology mips specialty set
g4021
orthopedic surgery mips specialty set
g4022
otolaryngology mips specialty set
g4023
pathology mips specialty set
g4024
pediatrics mips specialty set
g4025
physical medicine mips specialty set
g4026
physical therapy/occupational therapy mips specialty set
g4027
plastic surgery mips specialty set
g4028
podiatry mips specialty set
g4029
preventive medicine mips specialty set
g4030
pulmonology mips specialty set
g4031
radiation oncology mips specialty set
g4032
rheumatology mips specialty set
g4033
skilled nursing facility mips specialty set
g4034
speech language pathology mips specialty set
g4035
thoracic surgery mips specialty set
g4036
urgent care mips specialty set
g4037
urology mips specialty set
g4038
vascular surgery mips specialty set
g6001
ultrasonic guidance for placement of radiation therapy fields
g6002
stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy
g6003
radiation treatment delivery, single treatment area,single port or parallel opposed ports, simple blocks or no blocks: up to 5 mev
g6004
radiation treatment delivery, single treatment area,single port or parallel opposed ports, simple blocks or no blocks: 6-10 mev
g6005
radiation treatment delivery, single treatment area,single port or parallel opposed ports, simple blocks or no blocks: 11-19 mev
g6006
radiation treatment delivery, single treatment area,single port or parallel opposed ports, simple blocks or no blocks: 20 mev or greater
g6007
radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: up to 5 mev
g6008
radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 6-10 mev
g6009
radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 11-19 mev
g6010
radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 20 mev or greater
g6011
radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 mev
g6012
radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev
g6013
radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev
g6014
radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 mev or greater
g6015
intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
g6016
compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session
g6017
intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (eg,3d positional tracking, gating, 3d surface tracking), each fraction of treatment
g6018
ileoscopy, through stoma; with transendoscopic stent placement (includes predilation) terminated december 31, 2015.
g6019
colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique terminated december 31, 2015.
g6020
colonoscopy through stoma; with transendoscopic stent placement (includes predilation) terminated december 31, 2015.
g6021
unlisted procedure, intestine terminated december 31, 2015.
g6022
sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique terminated december 31, 2015.
g6023
sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation) terminated december 31, 2015.
g6024
colonoscopy, flexible; proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique terminated december 31, 2015.
g6025
colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation) terminated december 31, 2015.
g6027
anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed terminated december 31, 2015.
g6028
anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies) terminated december 31, 2015.
g6030
amitriptyline terminated december 31, 2015.
g6031
benzodiazepines terminated december 31, 2015.
g6032
desipramine terminated december 31, 2015.
g6034
doxepin terminated december 31, 2015.
g6035
gold terminated december 31, 2015.
g6036
assay of imipramine terminated december 31, 2015.
g6037
nortriptyline terminated december 31, 2015.
g6038
salicylate terminated december 31, 2015.
g6039
acetaminophen terminated december 31, 2015.
g6040
alcohol (ethanol); any specimen except breath terminated december 31, 2015.
g6041
alkaloids, urine, quantitative terminated december 31, 2015.
g6042
amphetamine or methamphetamine terminated december 31, 2015.
g6043
barbiturates, not elsewhere specified terminated december 31, 2015.
g6044
cocaine or metabolite terminated december 31, 2015.
g6045
dihydrocodeinone terminated december 31, 2015.
g6046
dihydromorphinone terminated december 31, 2015.
g6047
dihydrotestosterone terminated december 31, 2015.
g6048
dimethadione terminated december 31, 2015.
g6049
epiandrosterone terminated december 31, 2015.
g6050
ethchlorvynol terminated december 31, 2015.
g6051
flurazepam terminated december 31, 2015.
g6052
meprobamate terminated december 31, 2015.
g6053
methadone terminated december 31, 2015.
g6054
methsuximide terminated december 31, 2015.
g6055
nicotine terminated december 31, 2015.
g6056
opiate(s), drug and metabolites, each procedure terminated december 31, 2015.
g6057
phenothiazine terminated december 31, 2015.
g6058
drug confirmation, each procedure terminated december 31, 2015.
g8126
patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase terminated december 31, 2014.
g8127
patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase terminated december 31, 2014.
g8128
clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure terminated december 31, 2014.
g8395
left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function
g8396
left ventricular ejection fraction (lvef) not performed or documented
g8397
dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy
g8398
dilated macular or fundus exam not performed terminated december 31, 2020.
g8399
patient with documented results of a central dual-energy x-ray absorptiometry (dxa) ever being performed
g8400
patient with central dual-energy x-ray absorptiometry (dxa) results not documented, reason not given
g8401
clinician documented that patient was not an eligible candidate for screening terminated december 31, 2016.
g8404
lower extremity neurological exam performed and documented
g8405
lower extremity neurological exam not performed
g8406
clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure terminated december 31, 2014.
g8410
footwear evaluation performed and documented
g8415
footwear evaluation was not performed
g8416
clinician documented that patient was not an eligible candidate for footwear evaluation measure
g8417
bmi is documented above normal parameters and a follow-up plan is documented
g8418
bmi is documented below normal parameters and a follow-up plan is documented
g8419
bmi documented outside normal parameters, no follow-up plan documented, no reason given
g8420
bmi is documented within normal parameters and no follow-up plan is required
g8421
bmi not documented and no reason is given
g8422
bmi not documented, documentation the patient is not eligible for bmi calculation terminated december 31, 2021.
g8427
eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications
g8428
current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given
g8430
documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an urgent or emergent medical situation)
g8431
screening for depression is documented as being positive and a follow-up plan is documented
g8432
depression screening not documented, reason not given
g8433
screening for depression not completed, documented patient or medical reason
g8442
pain assessment not documented as being performed, documentation the patient is not eligible for a pain assessment using a standardized tool at the time of the encounter terminated december 31, 2020.
g8450
beta-blocker therapy prescribed
g8451
beta-blocker therapy for lvef < 40% not prescribed for reasons documented by the clinician (e.g., low blood pressure, fluid overload, asthma, patients recently treated with an intravenous positive inotropic agent, allergy, intolerance, other medical reasons, patient declined, other patient reasons, or other reasons attributable to the healthcare system)
g8452
beta-blocker therapy not prescribed
g8458
clinician documented that patient is not an eligible candidate for genotype testing; patient not receiving antiviral treatment for hepatitis c during the measurement period (e.g. genotype test done prior to the reporting period, patient declines, patient not a candidate for antiviral treatment) terminated december 31, 2016.
g8460
clinician documented that patient is not an eligible candidate for quantitative rna testing at week 12; patient not receiving antiviral treatment for hepatitis c terminated december 31, 2016.
g8461
patient receiving antiviral treatment for hepatitis c during the measurement period terminated december 31, 2016.
g8464
clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined terminated december 31, 2014.
g8465
high or very high risk of recurrence of prostate cancer
g8473
angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy prescribed
g8474
angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy not prescribed for reasons documented by the clinician (e.g., allergy, intolerance, pregnancy, renal failure due to ace inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (e.g., patient declined, other patient reasons) or (e.g., lack of drug availability, other reasons attributable to the health care system)
g8475
angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy not prescribed, reason not given
g8476
most recent blood pressure has a systolic measurement of < 140 mmhg and a diastolic measurement of < 90 mmhg
g8477
most recent blood pressure has a systolic measurement of >= 140 mmhg and/or a diastolic measurement of >= 90 mmhg
g8478
blood pressure measurement not performed or documented, reason not given
g8482
influenza immunization administered or previously received
g8483
influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons)
g8484
influenza immunization was not administered, reason not given
g8485
i intend to report the diabetes mellitus (dm) measures group terminated december 31, 2016.
g8486
i intend to report the preventive care measures group terminated december 31, 2016.
g8487
i intend to report the chronic kidney disease (ckd) measures group terminated december 31, 2016.
g8489
i intend to report the coronary artery disease (cad) measures group terminated december 31, 2016.
g8490
i intend to report the rheumatoid arthritis (ra) measures group terminated december 31, 2016.
g8491
i intend to report the hiv/aids measures group terminated december 31, 2016.
g8492
i intend to report the perioperative care measures group terminated december 31, 2014.
g8493
i intend to report the back pain measures group terminated december 31, 2014.
g8494
all quality actions for the applicable measures in the diabetes mellitus (dm) measures group have been performed for this patient terminated december 31, 2016.
g8495
all quality actions for the applicable measures in the chronic kidney disease (ckd) measures group have been performed for this patient terminated december 31, 2016.
g8496
all quality actions for the applicable measures in the preventive care measures group have been performed for this patient terminated december 31, 2016.
g8497
all quality actions for the applicable measures in the coronary artery bypass graft (cabg) measures group have been performed for this patient terminated december 31, 2016.
g8498
all quality actions for the applicable measures in the coronary artery disease (cad) measures group have been performed for this patient terminated december 31, 2016.
g8499
all quality actions for the applicable measures in the rheumatoid arthritis (ra) measures group have been performed for this patient terminated december 31, 2016.
g8500
all quality actions for the applicable measures in the hiv/aids measures group have been performed for this patient terminated december 31, 2016.
g8501
all quality actions for the applicable measures in the perioperative care measures group have been performed for this patient terminated december 31, 2014.
g8502
all quality actions for the applicable measures in the back pain measures group have been performed for this patient terminated december 31, 2014.
g8506
patient receiving angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy
g8509
pain assessment documented as positive using a standardized tool, follow-up plan not documented, reason not given terminated december 31, 2020.
g8510
screening for depression is documented as negative, a follow-up plan is not required
g8511
screening for depression documented as positive, follow-up plan not documented, reason not given
g8530
autogenous av fistula received terminated december 31, 2015.
g8531
clinician documented that patient was not an eligible candidate for autogenous av fistula terminated december 31, 2015.
g8532
clinician documented that patient received vascular access other than autogenous av fistula, reason not given terminated december 31, 2015.
g8535
elder maltreatment screen not documented; documentation that patient is not eligible for the elder maltreatment screen at the time of the encounter
g8536
no documentation of an elder maltreatment screen, reason not given
g8539
functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies on the date of functional outcome assessment, is documented
g8540
functional outcome assessment not documented as being performed, documentation the patient is not eligible for a functional outcome assessment using a standardized tool at the time of the encounter
g8541
functional outcome assessment using a standardized tool not documented, reason not given
g8542
functional outcome assessment using a standardized tool is documented; no functional deficiencies identified, care plan not required
g8543
documentation of a positive functional outcome assessment using a standardized tool; care plan not documented, reason not given
g8544
i intend to report the coronary artery bypass graft (cabg) measures group terminated december 31, 2016.
g8545
i intend to report the hepatitis c measures group terminated december 31, 2016.
g8547
i intend to report the ischemic vascular disease (ivd) measures group terminated december 31, 2014.
g8548
i intend to report the heart failure (hf) measures group terminated december 31, 2016.
g8549
all quality actions for the applicable measures in the hepatitis c measures group have been performed for this patient terminated december 31, 2016.
g8551
all quality actions for the applicable measures in the heart failure (hf) measures group have been performed for this patient terminated december 31, 2016.
g8552
all quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient terminated december 31, 2014.
g8559
patient referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation
g8560
patient has a history of active drainage from the ear within the previous 90 days
g8561
patient is not eligible for the referral for otologic evaluation for patients with a history of active drainage measure
g8562
patient does not have a history of active drainage from the ear within the previous 90 days
g8563
patient not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given
g8564
patient was referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not specified)
g8565
verification and documentation of sudden or rapidly progressive hearing loss
g8566
patient is not eligible for the "referral for otologic evaluation for sudden or rapidly progressive hearing loss" measure
g8567
patient does not have verification and documentation of sudden or rapidly progressive hearing loss
g8568
patient was not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given
g8569
prolonged postoperative intubation (> 24 hrs) required
g8570
prolonged postoperative intubation (> 24 hrs) not required
g8571
development of deep sternal wound infection/mediastinitis within 30 days postoperatively terminated december 31, 2020.
g8572
no deep sternal wound infection/mediastinitis terminated december 31, 2020.
g8573
stroke following isolated cabg surgery terminated december 31, 2020.
g8574
no stroke following isolated cabg surgery terminated december 31, 2020.
g8575
developed postoperative renal failure or required dialysis
g8576
no postoperative renal failure/dialysis not required
g8577
re-exploration required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason
g8578
re-exploration not required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason
g8579
antiplatelet medication at discharge terminated december 31, 2014.
g8580
antiplatelet medication contraindicated terminated december 31, 2014.
g8581
no antiplatelet medication at discharge terminated december 31, 2014.
g8582
beta-blocker at discharge terminated december 31, 2014.
g8583
beta-blocker contraindicated terminated december 31, 2014.
g8584
no beta-blocker at discharge terminated december 31, 2014.
g8585
anti-lipid treatment at discharge terminated december 31, 2014.
g8586
anti-lipid treatment contraindicated terminated december 31, 2014.
g8587
no anti-lipid treatment at discharge terminated december 31, 2014.
g8593
lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c) terminated december 31, 2014.
g8594
lipid profile not performed, reason not given terminated december 31, 2014.
g8595
most recent ldl-c < 100 mg/dl terminated december 31, 2014.
g8597
most recent ldl-c >= 100 mg/dl terminated december 31, 2014.
g8598
aspirin or another antiplatelet therapy used
g8599
aspirin or another antiplatelet therapy not used, reason not given
g8600
iv t-pa initiated within three hours (<= 180 minutes) of time last known well
g8601
iv alteplase not initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician (e.g. patient enrolled in clinical trial for stroke, patient admitted for elective carotid intervention, patient received tenecteplase (tnk))
g8602
iv t-pa not initiated within three hours (<= 180 minutes) of time last known well, reason not given
g8627
surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence) terminated december 31, 2020.
g8628
surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence) terminated december 31, 2020.
g8629
documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required) terminated december 31, 2014.
g8630
documentation that administration of prophylactic parenteral antibiotics was initiated within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required), as ordered terminated december 31, 2014.
g8631
clinician documented that patient was not an eligible candidate for ordering prophylactic parenteral antibiotics to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required) terminated december 31, 2014.
g8632
prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given terminated december 31, 2014.
g8633
pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed
g8634
clinician documented patient not an eligible candidate to receive pharmacologic therapy for osteoporosis terminated december 31, 2016.
g8635
pharmacologic therapy for osteoporosis was not prescribed, reason not given
g8645
i intend to report the asthma measures group terminated december 31, 2016.
g8646
all quality actions for the applicable measures in the asthma measures group have been performed for this patient terminated december 31, 2016.
g8647
risk-adjusted functional status change residual score for the knee impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
g8648
risk-adjusted functional status change residual score for the knee impairment successfully calculated and the score was less than zero (< 0)
g8649
risk-adjusted functional status change residual score for the knee impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate terminated december 31, 2019.
g8650
risk-adjusted functional status change residual score for the knee impairment not measured because the patient did not complete the lepf prom at initial evaluation and/or near discharge, reason not given
g8651
risk-adjusted functional status change residual score for the hip impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
g8652
risk-adjusted functional status change residual score for the hip impairment successfully calculated and the score was less than zero (< 0)
g8653
risk-adjusted functional status change residual scores for the hip impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate terminated december 31, 2019.
g8654
risk-adjusted functional status change residual score for the hip impairment not measured because the patient did not complete the lepf prom at initial evaluation and/or near discharge, reason not given
g8655
risk-adjusted functional status change residual score for the lower leg, foot or ankle impairment successfully calculated and the score was equal to zero (0) or greater than zero ( > 0)
g8656
risk-adjusted functional status change residual score for the lower leg, foot or ankle impairment successfully calculated and the score was less than zero (< 0)
g8657
risk-adjusted functional status change residual score for the lower leg, foot or ankle impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate terminated december 31, 2019.
g8658
risk-adjusted functional status change residual score for the lower leg, foot or ankle impairment not measured because the patient did not complete the lepf prom at initial evaluation and/or near discharge, reason not given
g8659
risk-adjusted functional status change residual score for the low back impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
g8660
risk-adjusted functional status change residual score for the low back impairment successfully calculated and the score was less than zero (< 0)
g8661
risk-adjusted functional status change residual score for the low back impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate
g8662
risk-adjusted functional status change residual score for the low back impairment not measured because the patient did not complete the low back fs prom at initial evaluation and/or near discharge, reason not given
g8663
risk-adjusted functional status change residual score for the shoulder impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
g8664
risk-adjusted functional status change residual score for the shoulder impairment successfully calculated and the score was less than zero (< 0)
g8665
risk-adjusted functional status change residual score for the shoulder impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate terminated december 31, 2019.
g8666
risk-adjusted functional status change residual score for the shoulder impairment not measured because the patient did not complete the shoulder fs prom at initial evaluation and/or near discharge, reason not given
g8667
risk-adjusted functional status change residual score for the elbow, wrist or hand impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
g8668
risk-adjusted functional status change residual score for the elbow, wrist or hand impairment successfully calculated and the score was less than zero (< 0)
g8669
risk-adjusted functional status change residual score for the elbow, wrist or hand impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate terminated december 31, 2019.
g8670
risk-adjusted functional status change residual score for the elbow, wrist or hand impairment not measured because the patient did not complete the elbow/wrist/hand fs prom at initial evaluation and/or near discharge, reason not given
g8671
risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs or other general orthopedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0) terminated december 31, 2020.
g8672
risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs or other general orthopedic impairment successfully calculated and the score was less than zero (< 0) terminated december 31, 2020.
g8673
risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs or other general orthopedic impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate terminated december 31, 2019.
g8674
risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs or other general orthopedic impairment not measured because the patient did not complete the general orthopedic fs prom at initial evaluation and/or near discharge, reason not given terminated december 31, 2020.
g8682
lvf testing documented as being performed prior to discharge or in the previous 12 months terminated december 31, 2014.
g8683
lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason terminated december 31, 2014.
g8685
lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given terminated december 31, 2014.
g8694
left ventricular ejection fraction (lvef) < 40% or documentation of moderate or severe lvsd
g8696
antithrombotic therapy prescribed at discharge terminated december 31, 2017.
g8697
antithrombotic therapy not prescribed for documented reasons (e.g., patient had stroke during hospital stay, patient expired during inpatient stay, other medical reason(s)); (e.g., patient left against medical advice, other patient reason(s)) terminated december 31, 2017.
g8698
antithrombotic therapy was not prescribed at discharge, reason not given terminated december 31, 2017.
g8699
rehabilitation services (occupational, physical or speech) ordered at or prior to discharge terminated december 31, 2014.
g8700
rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge terminated december 31, 2014.
g8701
rehabilitation services were not ordered, reason not otherwise specified terminated december 31, 2014.
g8702
documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or intraoperatively terminated december 31, 2014.
g8703
documentation that prophylactic antibiotics were neither given within 4 hours prior to surgical incision nor intraoperatively terminated december 31, 2014.
g8704
12-lead electrocardiogram (ecg) performed terminated december 31, 2014.
g8705
documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg) terminated december 31, 2014.
g8706
documentation of patient reason(s) for not performing a 12-lead electrocardiogram (ecg) terminated december 31, 2014.
g8707
12-lead electrocardiogram (ecg) not performed, reason not given terminated december 31, 2014.
g8708
patient not prescribed or dispensed antibiotic
g8709
uri episodes when the patient had competing diagnoses on or three days after the episode date (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, acute pharyngitis, acute tonsillitis, chronic sinusitis, infection of the pharynx/larynx/tonsils/adenoids, prostatitis, cellulitis, mastoiditis, or bone infections, acute lymphadenitis, impetigo, skin staph infections, pneumonia/gonococcal infections, venereal disease (syphilis, chlamydia, inflammatory diseases [female reproductive organs]), infections of the kidney, cystitis or uti, and acne)
g8710
patient prescribed or dispensed antibiotic
g8711
prescribed or dispensed antibiotic on or within 3 days after the episode date
g8712
antibiotic not prescribed or dispensed
g8713
spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v]) terminated december 31, 2015.
g8714
hemodialysis treatment performed exactly three times per week for > 90 days terminated december 31, 2015.
g8717
spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given terminated december 31, 2015.
g8718
total kt/v greater than or equal to 1.7 per week (total clearance of urea [kt] / volume [v]) terminated december 31, 2015.
g8720
total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v]) terminated december 31, 2015.
g8721
pt category (primary tumor), pn category (regional lymph nodes), and histologic grade were documented in pathology report
g8722
documentation of medical reason(s) for not including the pt category, the pn category or the histologic grade in the pathology report (e.g., re-excision without residual tumor; non-carcinomasanal canal)
g8723
specimen site is other than anatomic location of primary tumor
g8724
pt category, pn category and histologic grade were not documented in the pathology report, reason not given
g8725
fasting lipid profile performed (triglycerides, ldl-c, hdl-c and total cholesterol) terminated december 31, 2016.
g8726
clinician has documented reason for not performing fasting lipid profile (e.g., patient declined, other patient reasons) terminated december 31, 2016.
g8728
fasting lipid profile not performed, reason not given terminated december 31, 2016.
g8730
pain assessment documented as positive using a standardized tool and a follow-up plan is documented terminated december 31, 2020.
g8731
pain assessment using a standardized tool is documented as negative, no follow-up plan required terminated december 31, 2020.
g8732
no documentation of pain assessment, reason not given terminated december 31, 2020.
g8733
elder maltreatment screen documented as positive and a follow-up plan is documented
g8734
elder maltreatment screen documented as negative, no follow-up required
g8735
elder maltreatment screen documented as positive, follow-up plan not documented, reason not given
g8736
most current ldl-c <100mg/dl terminated december 31, 2014.
g8737
most current ldl-c >=100mg/dl terminated december 31, 2014.
g8738
left ventricular ejection fraction (lvef) < 40% or documentation of severely or moderately depressed left ventricular systolic function terminated december 31, 2014.
g8739
left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function terminated december 31, 2014.
g8740
left ventricular ejection fraction (lvef) not performed or assessed, reason not given terminated december 31, 2014.
g8749
absence of signs of melanoma (tenderness, jaundice, localized neurologic signs such as weakness, or any other sign suggesting systemic spread) or absence of symptoms of melanoma (cough, dyspnea, pain, paresthesia, or any other symptom suggesting the possibility of systemic spread of melanoma)
g8751
smoking status and exposure to second hand smoke in the home not assessed, reason not given terminated december 31, 2014.
g8752
most recent systolic blood pressure < 140 mmhg
g8753
most recent systolic blood pressure >= 140 mmhg
g8754
most recent diastolic blood pressure < 90 mmhg
g8755
most recent diastolic blood pressure >= 90 mmhg
g8756
no documentation of blood pressure measurement, reason not given
g8757
all quality actions for the applicable measures in the chronic obstructive pulmonary disease (copd) measures group have been performed for this patient terminated december 31, 2016.
g8758
all quality actions for the applicable measures in the inflammatory bowel disease (ibd) measures group have been performed for this patient terminated december 31, 2016.
g8759
all quality actions for the applicable measures in the sleep apnea measures group have been performed for this patient terminated december 31, 2016.
g8761
all quality actions for the applicable measures in the dementia measures group have been performed for this patient terminated december 31, 2016.
g8762
all quality actions for the applicable measures in the parkinson's disease measures group have been performed for this patient terminated december 31, 2016.
g8763
all quality actions for the applicable measures in the hypertension (htn) measures group have been performed for this patient terminated december 31, 2014.
g8764
all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient terminated december 31, 2014.
g8765
all quality actions for the applicable measures in the cataract measures group have been performed for this patient terminated december 31, 2016.
g8767
lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c) terminated december 31, 2014.
g8768
documentation of medical reason(s) for not performing lipid profile (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) terminated december 31, 2014.
g8769
lipid profile not performed, reason not given terminated december 31, 2014.
g8770
urine protein test result documented and reviewed terminated december 31, 2014.
g8771
documentation of diagnosis of chronic kidney disease terminated december 31, 2014.
g8772
documentation of medical reason(s) for not performing urine protein test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not cllinically appropriate) terminated december 31, 2014.
g8773
urine protein test was not performed, reason not given terminated december 31, 2014.
g8774
serum creatinine test result documented and reviewed terminated december 31, 2014.
g8775
documentation of medical reason(s) for not performing serum creatinine test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) terminated december 31, 2014.
g8776
serum creatinine test not performed, reason not given terminated december 31, 2014.
g8777
diabetes screening test performed terminated december 31, 2014.
g8778
documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) terminated december 31, 2014.
g8779
diabetes screening test not performed, reason not given terminated december 31, 2014.
g8780
counseling for diet and physical activity performed terminated december 31, 2014.
g8781
documentation of medical reason(s) for patient not receiving counseling for diet and physical activity (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) terminated december 31, 2014.
g8782
counseling for diet and physical activity not performed, reason not given terminated december 31, 2014.
g8783
normal blood pressure reading documented, follow-up not required
g8784
patient not eligible (e.g., documentation the patient is not eligible due to active diagnosis of hypertension, patient refuses, urgent or emergent situation) terminated december 31, 2016.
g8785
blood pressure reading not documented, reason not given
g8797
specimen site other than anatomic location of esophagus
g8798
specimen site other than anatomic location of prostate
g8806
performance of trans-abdominal or trans-vaginal ultrasound and pregnancy location documented
g8807
trans-abdominal or trans-vaginal ultrasound not performed for reasons documented by clinician (e.g., patient has visited the ed multiple times within 72 hours, patient has a documented intrauterine pregnancy [iup])
g8808
trans-abdominal or trans-vaginal ultrasound not performed, reason not given
g8809
rh-immunoglobulin (rhogam) ordered terminated december 31, 2020.
g8810
rh-immunoglobulin (rhogam) not ordered for reasons documented by clinician (e.g., patient had prior documented receipt of rhogam within 12 weeks, patient refusal) terminated december 31, 2020.
g8811
documentation rh-immunoglobulin (rhogam) was not ordered, reason not given terminated december 31, 2020.
g8815
documented reason in the medical records for why the statin therapy was not prescribed (i.e., lower extremity bypass was for a patient with non-artherosclerotic disease)
g8816
statin medication prescribed at discharge
g8817
statin therapy not prescribed at discharge, reason not given
g8818
patient discharge to home no later than post-operative day #7
g8825
patient not discharged to home by post-operative day #7
g8826
patient discharge to home no later than post-operative day #2 following evar
g8833
patient not discharged to home by post-operative day #2 following evar
g8834
patient discharged to home no later than post-operative day #2 following cea
g8838
patient not discharged to home by post-operative day #2 following cea
g8839
sleep apnea symptoms assessed, including presence or absence of snoring and daytime sleepiness
g8840
documentation of reason(s) for not documenting an assessment of sleep symptoms (e.g., patient didn't have initial daytime sleepiness, patient visited between initial testing and initiation of therapy)
g8841
sleep apnea symptoms not assessed, reason not given
g8842
apnea hypopnea index (ahi) or respiratory disturbance index (rdi) measured at the time of initial diagnosis
g8843
documentation of reason(s) for not measuring an apnea hypopnea index (ahi) or a respiratory disturbance index (rdi) at the time of initial diagnosis (e.g., psychiatric disease, dementia, patient declined, financial, insurance coverage, test ordered but not yet completed)
g8844
apnea hypopnea index (ahi) or respiratory disturbance index (rdi) not measured at the time of initial diagnosis, reason not given
g8845
positive airway pressure therapy prescribed
g8846
moderate or severe obstructive sleep apnea (apnea hypopnea index (ahi) or respiratory disturbance index (rdi) of 15 or greater)
g8848
mild obstructive sleep apnea (apnea hypopnea index (ahi) or respiratory disturbance index (rdi) of less than 15) terminated december 31, 2016.
g8849
documentation of reason(s) for not prescribing positive airway pressure therapy (e.g., patient unable to tolerate, alternative therapies use, patient declined, financial, insurance coverage)
g8850
positive airway pressure therapy not prescribed, reason not given
g8851
objective measurement of adherence to positive airway pressure therapy, documented
g8852
positive airway pressure therapy prescribed
g8853
positive airway pressure therapy not prescribed terminated december 31, 2016.
g8854
documentation of reason(s) for not objectively measuring adherence to positive airway pressure therapy (e.g., patient didn't bring data from continous positive airway pressure [cpap], therapy not yet initiated, not available on machine)
g8855
objective measurement of adherence to positive airway pressure therapy not performed, reason not given
g8856
referral to a physician for an otologic evaluation performed
g8857
patient is not eligible for the referral for otologic evaluation measure (e.g., patients who are already under the care of a physician for acute or chronic dizziness)
g8858
referral to a physician for an otologic evaluation not performed, reason not given
g8859
patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days terminated december 31, 2014.
g8860
patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days terminated december 31, 2014.
g8861
within the past 2 years, central dual-energy x-ray absorptiometry (dxa) ordered and documented, review of systems and medication history or pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed terminated december 31, 2019.
g8862
patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days terminated december 31, 2014.
g8863
patients not assessed for risk of bone loss, reason not given
g8864
pneumococcal vaccine administered or previously received
g8865
documentation of medical reason(s) for not administering or previously receiving pneumococcal vaccine (e.g., patient allergic reaction, potential adverse drug reaction)
g8866
documentation of patient reason(s) for not administering or previously receiving pneumococcal vaccine (e.g., patient refusal)
g8867
pneumococcal vaccine not administered or previously received, reason not given
g8868
patients receiving a first course of anti-tnf therapy terminated december 31, 2016.
g8869
patient has documented immunity to hepatitis b and initiating anti-tnf therapy
g8870
hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapy terminated december 31, 2015.
g8871
patient not receiving a first course of anti-tnf therapy terminated december 31, 2015.
g8872
excised tissue evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesion terminated december 31, 2020.
g8873
patients with needle localization specimens which are not amenable to intraoperative imaging such as mri needle wire localization, or targets which are tentatively identified on mammogram or ultrasound which do not contain a biopsy marker but which can be verified on intraoperative inspection or pathology (e.g., needle biopsy site where the biopsy marker is remote from the actual biopsy site) terminated december 31, 2020.
g8874
excised tissue not evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesion terminated december 31, 2020.
g8875
clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method
g8876
documentation of reason(s) for not performing minimally invasive biopsy to diagnose breast cancer preoperatively (e.g., lesion too close to skin, implant, chest wall, etc., lesion could not be adequately visualized for needle biopsy, patient condition prevents needle biopsy [weight, breast thickness, etc.], duct excision without imaging abnormality, prophylactic mastectomy, reduction mammoplasty, excisional biopsy performed by another physician)
g8877
clinician did not attempt to achieve the diagnosis of breast cancer preoperatively by a minimally invasive biopsy method, reason not given
g8878
sentinel lymph node biopsy procedure performed
g8879
clinically node negative (t1n0m0 or t2n0m0) invasive breast cancer terminated december 31, 2017.
g8880
documentation of reason(s) sentinel lymph node biopsy not performed (e.g., reasons could include but not limited to; non-invasive cancer, incidental discovery of breast cancer on prophylactic mastectomy, incidental discovery of breast cancer on reduction mammoplasty, pre-operative biopsy proven lymph node (ln) metastases, inflammatory carcinoma, stage 3 locally advanced cancer, recurrent invasive breast cancer, clinically node positive after neoadjuvant systemic therapy, patient refusal after informed consent, patient with significant age, comorbidities, or limited life expectancy and favorable tumor; adjuvant systemic therapy unlikely to change)
g8881
stage of breast cancer is greater than t1n0m0 or t2n0m0
g8882
sentinel lymph node biopsy procedure not performed, reason not given
g8883
biopsy results reviewed, communicated, tracked and documented
g8884
clinician documented reason that patient's biopsy results were not reviewed
g8885
biopsy results not reviewed, communicated, tracked or documented
g8886
most recent blood pressure under control terminated december 31, 2014.
g8887
documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) terminated december 31, 2014.
g8888
most recent blood pressure not under control, results documented and reviewed terminated december 31, 2014.
g8889
no documentation of blood pressure measurement, reason not given terminated december 31, 2014.
g8890
most recent ldl-c under control, results documented and reviewed terminated december 31, 2014.
g8891
documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for whom treatment of hypertension with standard treatment goals is not clinically appropriate) terminated december 31, 2014.
g8892
documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) terminated december 31, 2014.
g8893
most recent ldl-c not under control, results documented and reviewed terminated december 31, 2014.
g8894
ldl-c not performed, reason not given terminated december 31, 2014.
g8895
oral aspirin or other antithrombotic therapy prescribed terminated december 31, 2014.
g8896
documentation of medical reason(s) for not prescribing oral aspirin or other antithrombotic therapy (e.g., patient documented to be low risk or patient with terminal illness or treatment of hypertension with standard treatment goals is not clinically appropriate, or for whom risk of aspirin or other antithrombotic therapy exceeds potential benefits such as for individuals whose blood pressure is poorly controlled) terminated december 31, 2014.
g8897
oral aspirin or other antithrombotic therapy was not prescribed, reason not given terminated december 31, 2014.
g8898
i intend to report the chronic obstructive pulmonary disease (copd) measures group terminated december 31, 2016.
g8899
i intend to report the inflammatory bowel disease (ibd) measures group terminated december 31, 2016.
g8900
i intend to report the sleep apnea measures group terminated december 31, 2016.
g8902
i intend to report the dementia measures group terminated december 31, 2016.
g8903
i intend to report the parkinson's disease measures group terminated december 31, 2016.
g8904
i intend to report the hypertension (htn) measures group terminated december 31, 2014.
g8905
i intend to report the cardiovascular prevention measures group terminated december 31, 2014.
g8906
i intend to report the cataract measures group terminated december 31, 2016.
g8907
patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer or hospital admission upon discharge from the facility
g8908
patient documented to have received a burn prior to discharge
g8909
patient documented not to have received a burn prior to discharge
g8910
patient documented to have experienced a fall within asc
g8911
patient documented not to have experienced a fall within ambulatory surgical center
g8912
patient documented to have experienced a wrong site, wrong side, wrong patient, wrong procedure or wrong implant event
g8913
patient documented not to have experienced a wrong site, wrong side, wrong patient, wrong procedure or wrong implant event
g8914
patient documented to have experienced a hospital transfer or hospital admission upon discharge from asc
g8915
patient documented not to have experienced a hospital transfer or hospital admission upon discharge from asc
g8916
patient with preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis, antibiotic initiated on time
g8917
patient with preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis, antibiotic not initiated on time
g8918
patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis
g8923
left ventricular ejection fraction (lvef) < 40% or documentation of moderately or severely depressed left ventricular systolic function
g8924
spirometry test results demonstrate fev1/fvc < 70%, fev1 < 60% predicted and patient has copd symptoms (e.g., dyspnea, cough/sputum, wheezing)
g8925
spirometry test results demonstrate fev1 >= 60% fev1/fvc >= 70%, predicted or patient does not have copd symptoms terminated december 31, 2021.
g8926
spirometry test not performed or documented, reason not given terminated december 31, 2021.
g8927
adjuvant chemotherapy referred, prescribed or previously received for ajcc stage iii, colon cancer terminated december 31, 2016.
g8928
adjuvant chemotherapy not prescribed or previously received, for documented reasons (e.g., medical co-morbidities, diagnosis date more than 5 years prior to the current visit date, patient's diagnosis date is within 120 days of the end of the 12 month reporting period, patient's cancer has metastasized, medical contraindication/allergy, poor performance status, other medical reasons, patient refusal, other patient reasons, patient is currently enrolled in a clinical trial that precludes prescription of chemotherapy, other system reasons) terminated december 31, 2016.
g8929
adjuvant chemotherapy not prescribed or previously received, reason not given terminated december 31, 2016.
g8930
assessment of depression severity at the initial evaluation terminated december 31, 2014.
g8931
assessment of depression severity not documented, reason not given terminated december 31, 2014.
g8932
suicide risk assessed at the initial evaluation terminated december 31, 2014.
g8933
suicide risk not assessed at the initial evaluation, reason not given terminated december 31, 2014.
g8934
left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic function
g8935
clinician prescribed angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy
g8936
clinician documented that patient was not an eligible candidate for angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy (eg, allergy, intolerance, pregnancy, renal failure due to ace inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (eg, patient declined, other patient reasons) or (eg, lack of drug availability, other reasons attributable to the health care system)
g8937
clinician did not prescribe angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy, reason not given
g8938
bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible terminated december 31, 2021.
g8939
pain assessment documented as positive, follow-up plan not documented, documentation the patient is not eligible at the time of the encounter terminated december 31, 2020.
g8940
screening for depression documented as positive, a follow-up plan not completed, documented reason terminated december 31, 2016.
g8941
elder maltreatment screen documented as positive, follow-up plan not documented, documentation the patient is not eligible for follow-up plan at the time of the encounter
g8942
functional outcomes assessment using a standardized tool is documented within the previous 30 days and care plan, based on identified deficiencies on the date of the functional outcome assessment, is documented
g8943
ldl-c result not present or not within 12 months prior terminated december 31, 2014.
g8944
ajcc melanoma cancer stage 0 through iic melanoma
g8946
minimally invasive biopsy method attempted but not diagnostic of breast cancer (e.g., high risk lesion of breast such as atypical ductal hyperplasia, lobular neoplasia, atypical lobular hyperplasia, lobular carcinoma in situ, atypical columnar hyperplasia, flat epithelial atypia, radial scar, complex sclerosing lesion, papillary lesion, or any lesion with spindle cells)
g8947
one or more neuropsychiatric symptoms terminated december 31, 2017.
g8948
no neuropsychiatric symptoms terminated december 31, 2016.
g8949
documentation of patient reason(s) for patient not receiving counseling for diet and physical activity (e.g., patient is not willing to discuss diet or exercise interventions to help control blood pressure, or the patient said he/she refused to make these changes) terminated december 31, 2014.
g8950
elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented
g8951
pre-hypertensive or hypertensive blood pressure reading documented, indicated follow-up not documented, documentation the patient is not eligible terminated december 31, 2015.
g8952
elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given
g8953
all quality actions for the applicable measures in the oncology measures group have been performed for this patient terminated december 31, 2016.
g8955
most recent assessment of adequacy of volume management documented
g8956
patient receiving maintenance hemodialysis in an outpatient dialysis facility
g8957
patient not receiving maintenance hemodialysis in an outpatient dialysis facility terminated december 31, 2014.
g8958
assessment of adequacy of volume management not documented, reason not given
g8959
clinician treating major depressive disorder communicates to clinician treating comorbid condition terminated december 31, 2020.
g8960
clinician treating major depressive disorder did not communicate to clinician treating comorbid condition, reason not given terminated december 31, 2020.
g8961
cardiac stress imaging test primarily performed on low-risk surgery patient for preoperative evaluation within 30 days preceding this surgery
g8962
cardiac stress imaging test performed on patient for any reason including those who did not have low risk surgery or test that was performed more than 30 days preceding low risk surgery
g8963
cardiac stress imaging performed primarily for monitoring of asymptomatic patient who had pci within 2 years
g8964
cardiac stress imaging test performed primarily for any other reason than monitoring of asymptomatic patient who had pci within 2 years (e.g., symptomatic patient, patient greater than 2 years since pci, initial evaluation, etc)
g8965
cardiac stress imaging test primarily performed on low chd risk patient for initial detection and risk assessment
g8966
cardiac stress imaging test performed on symptomatic or higher than low chd risk patient or for any reason other than initial detection and risk assessment
g8967
fda approved oral anticoagulant is prescribed
g8968
documentation of medical reason(s) for not prescribing an fda-approved anticoagulant to a patient with a cha2ds2-vasc score of 0 or 1 for men; or 0, 1, or 2 for women (e.g., present or planned atrial appendage occlusion or ligation)
g8969
documentation of patient reason(s) for not prescribing an oral anticoagulant that is fda approved for the prevention of thromboembolism (e.g., patient preference for not receiving anticoagulation)
g8970
no risk factors or one moderate risk factor for thromboembolism
g8971
warfarin or another oral anticoagulant that is fda approved not prescribed, reason not given terminated december 31, 2017.
g8972
one or more high risk factors for thromboembolism or more than one moderate risk factor for thromboembolism terminated december 31, 2017.
g8973
most recent hemoglobin (hgb) level < 10 g/dl terminated december 31, 2020.
g8974
hemoglobin level measurement not documented, reason not given terminated december 31, 2020.
g8975
documentation of medical reason(s) for patient having a hemoglobin level < 10 g/dl (e.g., patients who have non-renal etiologies of anemia [e.g., sickle cell anemia or other hemoglobinopathies, hypersplenism, primary bone marrow disease, anemia related to chemotherapy for diagnosis of malignancy, postoperative bleeding, active bloodstream or peritoneal infection], other medical reasons) terminated december 31, 2020.
g8976
most recent hemoglobin (hgb) level >= 10 g/dl terminated december 31, 2020.
g8977
i intend to report the oncology measures group terminated december 31, 2016.
g8978
mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals terminated december 31, 2019.
g8979
mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g8980
mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g8981
changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals terminated december 31, 2019.
g8982
changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g8983
changing & maintaining body position functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g8984
carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals terminated december 31, 2019.
g8985
carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g8986
carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g8987
self care functional limitation, current status, at therapy episode outset and at reporting intervals terminated december 31, 2019.
g8988
self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g8989
self care functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g8990
other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals terminated december 31, 2019.
g8991
other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g8992
other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g8993
other physical or occupational therapy subsequent functional limitation, current status, at therapy episode outset and at reporting intervals terminated december 31, 2019.
g8994
other physical or occupational therapy subsequent functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g8995
other physical or occupational therapy subsequent functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g8996
swallowing functional limitation, current status at therapy episode outset and at reporting intervals terminated december 31, 2019.
g8997
swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g8998
swallowing functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g8999
motor speech functional limitation, current status at therapy episode outset and at reporting intervals terminated december 31, 2019.
g9001
coordinated care fee, initial rate
g9002
coordinated care fee, maintenance rate
g9003
coordinated care fee, risk adjusted high, initial
g9004
coordinated care fee, risk adjusted low, initial
g9005
coordinated care fee, risk adjusted maintenance
g9006
coordinated care fee, home monitoring
g9007
coordinated care fee, scheduled team conference
g9008
coordinated care fee, physician coordinated care oversight services
g9009
coordinated care fee, risk adjusted maintenance, level 3
g9010
coordinated care fee, risk adjusted maintenance, level 4
g9011
coordinated care fee, risk adjusted maintenance, level 5
g9012
other specified case management service not elsewhere classified
g9013
esrd demo basic bundle level i
g9014
esrd demo expanded bundle including venous access and related services
g9016
smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]
g9017
amantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project) terminated december 31, 2019.
g9018
zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project) terminated december 31, 2019.
g9019
oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project) terminated december 31, 2019.
g9020
rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project) terminated december 31, 2019.
g9033
amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project) terminated december 31, 2019.
g9034
zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project) terminated december 31, 2019.
g9035
oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project) terminated december 31, 2019.
g9036
rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project) terminated december 31, 2019.
g9050
oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a medicare-approved demonstration project)
g9051
oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a medicare-approved demonstration project)
g9052
oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a medicare-approved demonstration project)
g9053
oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a medicare-approved demonstration project)
g9054
oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom management, end-of-life care planning, management of palliative therapies (for use in a medicare-approved demonstration project)
g9055
oncology; primary focus of visit; other, unspecified service not otherwise listed (for use in a medicare-approved demonstration project)
g9056
oncology; practice guidelines; management adheres to guidelines (for use in a medicare-approved demonstration project)
g9057
oncology; practice guidelines; management differs from guidelines as a result of patient enrollment in an institutional review board approved clinical trial (for use in a medicare-approved demonstration project)
g9058
oncology; practice guidelines; management differs from guidelines because the treating physician disagrees with guideline recommendations (for use in a medicare-approved demonstration project)
g9059
oncology; practice guidelines; management differs from guidelines because the patient, after being offered treatment consistent with guidelines, has opted for alternative treatment or management, including no treatment (for use in a medicare-approved demonstration project)
g9060
oncology; practice guidelines; management differs from guidelines for reason(s) associated with patient comorbid illness or performance status not factored into guidelines (for use in a medicare-approved demonstration project)
g9061
oncology; practice guidelines; patient's condition not addressed by available guidelines (for use in a medicare-approved demonstration project)
g9062
oncology; practice guidelines; management differs from guidelines for other reason(s) not listed (for use in a medicare-approved demonstration project)
g9063
oncology; disease status; limited to non-small cell lung cancer; extent of disease initially established as stage i (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9064
oncology; disease status; limited to non-small cell lung cancer; extent of disease initially established as stage ii (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9065
oncology; disease status; limited to non-small cell lung cancer; extent of disease initially established as stage iii a (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9066
oncology; disease status; limited to non-small cell lung cancer; stage iii b- iv at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
g9067
oncology; disease status; limited to non-small cell lung cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9068
oncology; disease status; limited to small cell and combined small cell/non-small cell; extent of disease initially established as limited with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9069
oncology; disease status; small cell lung cancer, limited to small cell and combined small cell/non-small cell; extensive stage at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
g9070
oncology; disease status; small cell lung cancer, limited to small cell and combined small cell/non-small; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9071
oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage i or stage iia-iib; or t3, n1, m0; and er and/or pr positive; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9072
oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage i, or stage iia-iib; or t3, n1, m0; and er and pr negative; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9073
oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage iiia-iiib; and not t3, n1, m0; and er and/or pr positive; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9074
oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage iiia-iiib; and not t3, n1, m0; and er and pr negative; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9075
oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
g9077
oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t1-t2c and gleason 2-7 and psa < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9078
oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t2 or t3a gleason 8-10 or psa > 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9079
oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t3b-t4, any n; any t, n1 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9080
oncology; disease status; prostate cancer, limited to adenocarcinoma; after initial treatment with rising psa or failure of psa decline (for use in a medicare-approved demonstration project)
g9083
oncology; disease status; prostate cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9084
oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-3, n0, m0 with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9085
oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t4, n0, m0 with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9086
oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-4, n1-2, m0 with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9087
oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive with current clinical, radiologic, or biochemical evidence of disease (for use in a medicare-approved demonstration project)
g9088
oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive without current clinical, radiologic, or biochemical evidence of disease (for use in a medicare-approved demonstration project)
g9089
oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9090
oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-2, n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9091
oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t3, n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9092
oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-3, n1-2, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence or metastases (for use in a medicare-approved demonstration project)
g9093
oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t4, any n, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9094
oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
g9095
oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9096
oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as t1-t3, n0-n1 or nx (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9097
oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as t4, any n, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9098
oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
g9099
oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9100
oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; post r0 resection (with or without neoadjuvant therapy) with no evidence of disease recurrence, progression, or metastases (for use in a medicare-approved demonstration project)
g9101
oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; post r1 or r2 resection (with or without neoadjuvant therapy) with no evidence of disease progression, or metastases (for use in a medicare-approved demonstration project)
g9102
oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic m0, unresectable with no evidence of disease progression, or metastases (for use in a medicare-approved demonstration project)
g9103
oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
g9104
oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9105
oncology; disease status; pancreatic cancer, limited to adenocarcinoma as predominant cell type; post r0 resection without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9106
oncology; disease status; pancreatic cancer, limited to adenocarcinoma; post r1 or r2 resection with no evidence of disease progression, or metastases (for use in a medicare-approved demonstration project)
g9107
oncology; disease status; pancreatic cancer, limited to adenocarcinoma; unresectable at diagnosis, m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
g9108
oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9109
oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as t1-t2 and n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9110
oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as t3-4 and/or n1-3, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9111
oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
g9112
oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9113
oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage ia-b (grade 1) without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9114
oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage ia-b (grade 2-3); or stage ic (all grades); or stage ii; without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9115
oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage iii-iv; without evidence of progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
g9116
oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a medicare-approved demonstration project)
g9117
oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9123
oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
g9124
oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; accelerated phase not in hematologic cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
g9125
oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; blast phase not in hematologic, cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
g9126
oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; in hematologic, cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
g9128
oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, stage i (for use in a medicare-approved demonstration project)
g9129
oncology; disease status; limited to multiple myeloma, systemic disease; stage ii or higher (for use in a medicare-approved demonstration project)
g9130
oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9131
oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
g9132
oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-refractory/androgen-independent (e.g., rising psa on anti-androgen therapy or post-orchiectomy); clinical metastases (for use in a medicare-approved demonstration project)
g9133
oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-responsive; clinical metastases or m1 at diagnosis (for use in a medicare-approved demonstration project)
g9134
oncology; disease status; non-hodgkin's lymphoma, any cellular classification; stage i, ii at diagnosis, not relapsed, not refractory (for use in a medicare-approved demonstration project)
g9135
oncology; disease status; non-hodgkin's lymphoma, any cellular classification; stage iii, iv, not relapsed, not refractory (for use in a medicare-approved demonstration project)
g9136
oncology; disease status; non-hodgkin's lymphoma, transformed from original cellular diagnosis to a second cellular classification (for use in a medicare-approved demonstration project)
g9137
oncology; disease status; non-hodgkin's lymphoma, any cellular classification; relapsed/refractory (for use in a medicare-approved demonstration project)
g9138
oncology; disease status; non-hodgkin's lymphoma, any cellular classification; diagnostic evaluation, stage not determined, evaluation of possible relapse or non-response to therapy, or not listed (for use in a medicare-approved demonstration project)
g9139
oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; extent of disease unknown, staging in progress, not listed (for use in a medicare-approved demonstration project)
g9140
frontier extended stay clinic demonstration; for a patient stay in a clinic approved for the cms demonstration project; the following measures should be present: the stay must be equal to or greater than 4 hours; weather or other conditions must prevent transfer or the case falls into a category of monitoring and observation cases that are permitted by the rules of the demonstration; there is a maximum frontier extended stay clinic (fesc) visit of 48 hours, except in the case when weather or other conditions prevent transfer; payment is made on each period up to 4 hours, after the first 4 hours
g9143
warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)
g9147
outpatient intravenous insulin treatment (oivit) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea nitrogen (uun); and/or, arterial, venous or capillary glucose; and/or potassium concentration
g9148
national committee for quality assurance - level 1 medical home
g9149
national committee for quality assurance - level 2 medical home
g9150
national committee for quality assurance - level 3 medical home
g9151
mapcp demonstration - state provided services
g9152
mapcp demonstration - community health teams
g9153
mapcp demonstration - physician incentive pool
g9156
evaluation for wheelchair requiring face to face visit with physician
g9157
transesophageal doppler measurement of cardiac output (including probe placement, image acquisition, and interpretation per course of treatment) for monitoring purposes
g9158
motor speech functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g9159
spoken language comprehension functional limitation, current status at therapy episode outset and at reporting intervals terminated december 31, 2019.
g9160
spoken language comprehension functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g9161
spoken language comprehension functional limitation, discharge status, at discharge from therapy or to end reporting terminated december 31, 2019.
g9162
spoken language expression functional limitation, current status at therapy episode outset and at reporting intervals terminated december 31, 2019.
g9163
spoken language expression functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g9164
spoken language expression functional limitation, discharge status at discharge from therapy or to end reporting terminated december 31, 2019.
g9165
attention functional limitation, current status at therapy episode outset and at reporting intervals terminated december 31, 2019.
g9166
attention functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g9167
attention functional limitation, discharge status at discharge from therapy or to end reporting terminated december 31, 2019.
g9168
memory functional limitation, current status at therapy episode outset and at reporting intervals terminated december 31, 2019.
g9169
memory functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g9170
memory functional limitation, discharge status at discharge from therapy or to end reporting terminated december 31, 2019.
g9171
voice functional limitation, current status at therapy episode outset and at reporting intervals terminated december 31, 2019.
g9172
voice functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g9173
voice functional limitation, discharge status at discharge from therapy or to end reporting terminated december 31, 2019.
g9174
other speech language pathology functional limitation, current status at therapy episode outset and at reporting intervals terminated december 31, 2019.
g9175
other speech language pathology functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g9176
other speech language pathology functional limitation, discharge status at discharge from therapy or to end reporting terminated december 31, 2019.
g9186
motor speech functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting terminated december 31, 2019.
g9187
bundled payments for care improvement initiative home visit for patient assessment performed by a qualified health care professional for individuals not considered homebound including, but not limited to, assessment of safety, falls, clinical status, fluid status, medication reconciliation/management, patient compliance with orders/plan of care, performance of activities of daily living, appropriateness of care setting; (for use only in the meidcare-approved bundled payments for care improvement initiative); may not be billed for a 30-day period covered by a transitional care management code
g9188
beta-blocker therapy not prescribed, reason not given
g9189
beta-blocker therapy prescribed or currently being taken
g9190
documentation of medical reason(s) for not prescribing beta-blocker therapy (eg, allergy, intolerance, other medical reasons)
g9191
documentation of patient reason(s) for not prescribing beta-blocker therapy (eg, patient declined, other patient reasons)
g9192
documentation of system reason(s) for not prescribing beta-blocker therapy (eg, other reasons attributable to the health care system)
g9193
clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression terminated december 31, 2014.
g9194
patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase terminated december 31, 2014.
g9195
patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase terminated december 31, 2014.
g9196
documentation of medical reason(s) for not ordering a first or second generation cephalosporin for antimicrobial prophylaxis (e.g., patients enrolled in clinical trials, patients with documented infection prior to surgical procedure of interest, patients who were receiving antibiotics more than 24 hours prior to surgery [except colon surgery patients taking oral prophylactic antibiotics], patients who were receiving antibiotics within 24 hours prior to arrival [except colon surgery patients taking oral prophylactic antibiotics], other medical reason(s))
g9197
documentation of order for first or second generation cephalosporin for antimicrobial prophylaxis
g9198
order for first or second generation cephalosporin for antimicrobial prophylaxis was not documented, reason not given
g9199
venous thromboembolism (vte) prophylaxis not administered the day of or the day after hospital admission for documented reasons (eg, patient is ambulatory, patient expired during inpatient stay, patient already on warfarin or another anticoagulant, other medical reason(s) or eg, patient left against medical advice, other patient reason(s)) terminated december 31, 2014.
g9200
venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given terminated december 31, 2014.
g9201
venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission terminated december 31, 2014.
g9202
patients with a positive hepatitis c antibody test terminated december 31, 2014.
g9203
rna testing for hepatitis c documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis c terminated december 31, 2016.
g9204
rna testing for hepatitis c was not documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis c, reason not given terminated december 31, 2016.
g9205
patient starting antiviral treatmentfor hepatitis c during the measurement period terminated december 31, 2016.
g9206
patient starting antiviral treatment for hepatitis c during the measurement period terminated december 31, 2016.
g9207
hepatitis c genotype testing documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis c terminated december 31, 2016.
g9208
hepatitis c genotype testing was not documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis c, reason not given terminated december 31, 2016.
g9209
hepatitis c quantitative rna testing documented as performed between 4-12 weeks after the initiation of antiviral treatment terminated december 31, 2016.
g9210
hepatitis c quantitative rna testing not performed between 4-12 weeks after the initiation of antiviral treatment for documented reason(s) (e.g., patients whose treatment was discontinued during the testing period prior to testing, other medical reasons, patient declined, other patient reasons) terminated december 31, 2016.
g9211
hepatitis c quantitative rna testing was not documented as performed between 4-12 weeks after the initiation of antiviral treatment, reason not given terminated december 31, 2016.
g9212
dsm-ivtm criteria for major depressive disorder documented at the initial evaluation
g9213
dsm-iv-tr criteria for major depressive disorder not documented at the initial evaluation, reason not otherwise specified
g9214
cd4+ cell count or cd4+ cell percentage results documented terminated december 31, 2014.
g9215
cd4+ cell count or percentage not documented as performed, reason not given terminated december 31, 2014.
g9216
pcp prophylaxis was not prescribed at time of diagnosis of hiv, reason not given terminated december 31, 2014.
g9217
pcp prophylaxis was not prescribed within 3 months of low cd4+ cell count below 200 cells/mm3, reason not given terminated december 31, 2016.
g9218
pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given terminated december 31, 2014.
g9219
pneumocystis jiroveci pneumonia prophylaxis not prescribed within 3 months of low cd4+ cell count below 200 cells/mm3 for medical reason (i.e., patient's cd4+ cell count above threshold within 3 months after cd4+ cell count below threshold, indicating that the patient's cd4+ levels are within an acceptable range and the patient does not require pcp prophylaxis) terminated december 31, 2016.
g9220
pneumocystis jiroveci pneumonia prophylaxis not prescribed within 3 months of low cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15% for medical reason (i.e., patient's cd4+ cell count above threshold within 3 months after cd4+ cell count below threshold, indicating that the patient's cd4+ levels are within an acceptable range and the patient does not require pcp prophylaxis) terminated december 31, 2014.
g9221
pneumocystis jiroveci pneumonia prophlaxis prescribed terminated december 31, 2014.
g9222
pneumocystis jiroveci pneumonia prophylaxis prescribed wthin 3 months of low cd4+ cell count below 200 cells/mm3 terminated december 31, 2016.
g9223
pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%
g9224
documentation of medical reason for not performing foot exam (e.g., patient with bilateral foot/leg amputation) terminated december 31, 2014.
g9225
foot exam was not performed, reason not given
g9226
foot examination performed (includes examination through visual inspection, sensory exam with 10-g monofilament plus testing any one of the following: vibration using 128-hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold, and pulse exam; report when all of the 3 components are completed)
g9227
functional outcome assessment documented, care plan not documented, documentation the patient is not eligible for a care plan at the time of the encounter
g9228
chlamydia, gonorrhea and syphilis screening results documented (report when results are present for all of the 3 screenings)
g9229
chlamydia, gonorrhea, and syphilis screening results not documented (patient refusal is the only allowed exception)
g9230
chlamydia, gonorrhea, and syphilis not screened, reason not given
g9231
documentation of end stage renal disease (esrd), dialysis, renal transplant before or during the measurement period or pregnancy during the measurement period
g9232
clinician treating major depressive disorder did not communicate to clinician treating comorbid condition for specified patient reason (e.g., patient is unable to communicate the diagnosis of a comorbid condition; the patient is unwilling to communicate the diagnosis of a comorbid condition; or the patient is unaware of the comorbid condition, or any other specified patient reason) terminated december 31, 2020.
g9233
all quality actions for the applicable measures in the total knee replacement measures group have been performed for this patient terminated december 31, 2016.
g9234
i intend to report the total knee replacement measures group terminated december 31, 2016.
g9235
all quality actions for the applicable measures in the general surgery measures group have been performed for this patient terminated december 31, 2016.
g9236
all quality actions for the applicable measures in the optimizing patient exposure to ionizing radiation measures group have been performed for this patient terminated december 31, 2016.
g9237
i intend to report the general surgery measures group terminated december 31, 2016.
g9238
i intend to report the optimizing patient exposure to ionizing radiation measures group terminated december 31, 2016.
g9239
documentation of reasons for patient initiating maintenance hemodialysis with a catheter as the mode of vascular access (e.g., patient has a maturing arteriovenous fistula (avf)/arteriovenous graft (avg), time-limited trial of hemodialysis, other medical reasons, patient declined avf/avg, other patient reasons, patient followed by reporting nephrologist for fewer than 90 days, other system reasons) terminated december 31, 2020.
g9240
patient whose mode of vascular access is a catheter at the time maintenance hemodialysis is initiated terminated december 31, 2020.
g9241
patient whose mode of vascular access is not a catheter at the time maintenance hemodialysis is initiated terminated december 31, 2020.
g9242
documentation of viral load equal to or greater than 200 copies/ml or viral load not performed
g9243
documentation of viral load less than 200 copies/ml
g9244
antiretroviral thereapy not prescribed terminated december 31, 2016.
g9245
antiretroviral therapy prescribed terminated december 31, 2016.
g9246
patient did not have at least one medical visit in each 6 month period of the 24 month measurement period, with a minimum of 60 days between medical visits
g9247
patient had at least one medical visit in each 6 month period of the 24 month measurement period, with a minimum of 60 days between medical visits
g9248
patient did not have a medical visit in the last 6 months terminated december 31, 2014.
g9249
patient had a medical visit in the last 6 months terminated december 31, 2014.
g9250
documentation of patient pain brought to a comfortable level within 48 hours from initial assessment
g9251
documentation of patient with pain not brought to a comfortable level within 48 hours from initial assessment
g9252
adenoma(s) or other neoplasm detected during screening colonoscopy terminated december 31, 2014.
g9253
adenoma(s) or other neoplasm not detected during screening colonoscopy terminated december 31, 2014.
g9254
documentation of patient discharged to home later than post-operative day 2 following cas
g9255
documentation of patient discharged to home no later than post operative day 2 following cas
g9256
documentation of patient death following cas terminated december 31, 2020.
g9257
documentation of patient stroke following cas terminated december 31, 2020.
g9258
documentation of patient stroke following cea terminated december 31, 2020.
g9259
documentation of patient survival and absence of stroke following cas terminated december 31, 2020.
g9260
documentation of patient death following cea terminated december 31, 2020.
g9261
documentation of patient survival and absence of stroke following cea terminated december 31, 2020.
g9262
documentation of patient death in the hospital following endovascular aaa repair terminated december 31, 2020.
g9263
documentation of patient discharged alive following endovascular aaa repair terminated december 31, 2020.
g9264
documentation of patient receiving maintenance hemodialysis for greater than or equal to 90 days with a catheter for documented reasons (e.g., other medical reasons, patient declined arteriovenous fistula (avf)/arteriovenous graft (avg), other patient reasons) terminated december 31, 2020.
g9265
patient receiving maintenance hemodialysis for greater than or equal to 90 days with a catheter as the mode of vascular access terminated december 31, 2020.
g9266
patient receiving maintenance hemodialysis for greater than or equal to 90 days without a catheter as the mode of vascular access terminated december 31, 2020.
g9267
documentation of patient with one or more complications or mortality within 30 days terminated december 31, 2021.
g9268
documentation of patient with one or more complications within 90 days terminated december 31, 2021.
g9269
documentation of patient without one or more complications and without mortality within 30 days terminated december 31, 2021.
g9270
documentation of patient without one or more complications within 90 days terminated december 31, 2021.
g9271
ldl value < 100 terminated december 31, 2014.
g9272
ldl value >= 100 terminated december 31, 2014.
g9273
blood pressure has a systolic value of < 140 and a diastolic value of < 90
g9274
blood pressure has a systolic value of =140 and a diastolic value of = 90 or systolic value < 140 and diastolic value = 90 or systolic value = 140 and diastolic value < 90
g9275
documentation that patient is a current non-tobacco user
g9276
documentation that patient is a current tobacco user
g9277
documentation that the patient is on daily aspirin or anti-platelet or has documentation of a valid contraindication or exception to aspirin/anti-platelet; contraindications/exceptions include anti-coagulant use, allergy to aspirin or anti-platelets, history of gastrointestinal bleed and bleeding disorder; additionally, the following exceptions documented by the physician as a reason for not taking daily aspirin or anti-platelet are acceptable (use of non-steroidal anti-inflammatory agents, documented risk for drug interaction, uncontrolled hypertension defined as >180 systolic or >110 diastolic or gastroesophageal reflux)
g9278
documentation that the patient is not on daily aspirin or anti-platelet regimen
g9279
pneumococcal screening performed and documentation of vaccination received prior to discharge
g9280
pneumococcal vaccination not administered prior to discharge, reason not specified
g9281
screening performed and documentation that vaccination not indicated/patient refusal
g9282
documentation of medical reason(s) for not reporting the histological type or nsclc-nos classification with an explanation (e.g., biopsy taken for other purposes in a patient with a history of non-small cell lung cancer or other documented medical reasons)
g9283
non small cell lung cancer biopsy and cytology specimen report documents classification into specific histologic type or classified as nsclc-nos with an explanation
g9284
non small cell lung cancer biopsy and cytology specimen report does not document classification into specific histologic type or classified as nsclc-nos with an explanation
g9285
specimen site other than anatomic location of lung or is not classified as non small cell lung cancer
g9286
antibiotic regimen prescribed within 10 days after onset of symptoms
g9287
antibiotic regimen not prescribed within 10 days after onset of symptoms
g9288
documentation of medical reason(s) for not reporting the histological type or nsclc-nos classification with an explanation (e.g., a solitary fibrous tumor in a person with a history of non-small cell carcinoma or other documented medical reasons)
g9289
non small cell lung cancer biopsy and cytology specimen report documents classification into specific histologic type or classified as nsclc-nos with an explanation
g9290
non small cell lung cancer biopsy and cytology specimen report does not document classification into specific histologic type or classified as nsclc-nos with an explanation
g9291
specimen site other than anatomic location of lung, is not classified as non small cell lung cancer or classified as nsclc-nos
g9292
documentation of medical reason(s) for not reporting pt category and a statement on thickness and ulceration and for pt1, mitotic rate (e.g., negative skin biopsies in a patient with a history of melanoma or other documented medical reasons)
g9293
pathology report does not include the pt category and a statement on thickness and ulceration and for pt1, mitotic rate
g9294
pathology report includes the pt category and a statement on thickness and ulceration and for pt1, mitotic rate
g9295
specimen site other than anatomic cutaneous location
g9296
patients with documented shared decision-making including discussion of conservative (non-surgical) therapy (e.g., nsaids, analgesics, weight loss, exercise, injections) prior to the procedure
g9297
shared decision-making including discussion of conservative (non-surgical) therapy (e.g., nsaids, analgesics, weight loss, exercise, injections) prior to the procedure, not documented, reason not given
g9298
patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of dvt, pe, mi, arrhythmia and stroke)
g9299
patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of dvt, pe, mi, arrhythmia and stroke, reason not given)
g9300
documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used) terminated december 31, 2020.
g9301
patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet terminated december 31, 2020.
g9302
prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given terminated december 31, 2020.
g9303
operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given terminated december 31, 2020.
g9304
operative report identifies the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant terminated december 31, 2020.
g9305
intervention for presence of leak of endoluminal contents through an anastomosis not required
g9306
intervention for presence of leak of endoluminal contents through an anastomosis required
g9307
no return to the operating room for a surgical procedure, for complications of the principal operative procedure, within 30 days of the principal operative procedure
g9308
unplanned return to the operating room for a surgical procedure, for complications of the principal operative procedure, within 30 days of the principal operative procedure
g9309
no unplanned hospital readmission within 30 days of principal procedure
g9310
unplanned hospital readmission within 30 days of principal procedure
g9311
no surgical site infection
g9312
surgical site infection
g9313
amoxicillin, with or without clavulanate, not prescribed as first line antibiotic at the time of diagnosis for documented reason
g9314
amoxicillin, with or without clavulanate, not prescribed as first line antibiotic at the time of diagnosis, reason not given
g9315
documentation amoxicillin, with or without clavulanate, prescribed as a first line antibiotic at the time of diagnosis
g9316
documentation of patient-specific risk assessment with a risk calculator based on multi-institutional clinical data, the specific risk calculator used, and communication of risk assessment from risk calculator with the patient or family
g9317
documentation of patient-specific risk assessment with a risk calculator based on multi-institutional clinical data, the specific risk calculator used, and communication of risk assessment from risk calculator with the patient or family not completed
g9318
imaging study named according to standardized nomenclature
g9319
imaging study not named according to standardized nomenclature, reason not given
g9320
documentation of medical reason(s) for not naming ct studies according to a standardized nomenclature provided (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) terminated december 31, 2015.
g9321
count of previous ct (any type of ct) and cardiac nuclear medicine (myocardial perfusion) studies documented in the 12-month period prior to the current study
g9322
count of previous ct and cardiac nuclear medicine (myocardial perfusion) studies not documented in the 12-month period prior to the current study, reason not given
g9323
documentation of medical reason(s) for not counting previous ct and cardiac nuclear medicine (myocardial perfusion) studies (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) terminated december 31, 2015.
g9324
all necessary data elements not included, reason not given terminated december 31, 2016.
g9325
ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) terminated december 31, 2015.
g9326
ct studies performed not reported to a radiation dose index registry that is capable of collecting at a minimum all necessary data elements, reason not given terminated december 31, 2020.
g9327
ct studies performed reported to a radiation dose index registry that is capable of collecting at a minimum all necessary data elements terminated december 31, 2020.
g9328
dicom format image data availability not documented in final report due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) terminated december 31, 2015.
g9329
dicom format image data available to non-affiliated external healthcare facilities or entities on a secure, media free, reciprocally searchable basis with patient authorization for at least a 12-month period after the study not documented in final report, reason not given terminated december 31, 2020.
g9340
final report documented that dicom format image data available to non-affiliated external healthcare facilities or entities on a secure, media free, reciprocally searchable basis with patient authorization for at least a 12-month period after the study terminated december 31, 2020.
g9341
search conducted for prior patient ct studies completed at non-affiliated external healthcare facilities or entities within the past 12-months and are available through a secure, authorized, media-free, shared archive prior to an imaging study being performed
g9342
search not conducted prior to an imaging study being performed for prior patient ct studies completed at non-affiliated external healthcare facilities or entities within the past 12-months and are available through a secure, authorized, media-free, shared archive, reason not given
g9343
due to medical reasons, search not conducted for dicom format images for prior patient ct imaging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) terminated december 31, 2015.
g9344
due to system reasons search not conducted for dicom format images for prior patient ct imaging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., non-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)
g9345
follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up ct imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors
g9346
follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules due to medical reasons (e.g., patients with known malignant disease, patients with unexplained fever, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) terminated december 31, 2015.
g9347
follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given
g9348
ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons terminated december 31, 2021.
g9349
ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis terminated december 31, 2021.
g9350
ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis terminated december 31, 2021.
g9351
more than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis
g9352
more than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given
g9353
more than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)
g9354
one ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis
g9355
elective delivery (without medical indication) by cesarean birth or induction of labor not performed (<39 weeks of gestation)
g9356
elective delivery (without medical indication) by cesarean birth or induction of labor performed (<39 weeks of gestation)
g9357
post-partum screenings, evaluations and education performed
g9358
post-partum screenings, evaluations and education not performed
g9359
documentation of negative or managed positive tb screen with further evidence that tb is not active prior to treatment with a biologic immune response modifier
g9360
no documentation of negative or managed positive tb screen
g9361
medical indication for delivery by cesarean birth or induction of labor (<39 weeks of gestation) [documentation of reason(s) for elective delivery (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes (premature or prolonged), maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]
g9362
duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure 60 minutes or longer, as documented in the anesthesia record terminated december 31, 2015.
g9363
duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record terminated december 31, 2015.
g9364
sinusitis caused by, or presumed to be caused by, bacterial infection
g9365
one high-risk medication ordered terminated december 31, 2020.
g9366
one high-risk medication not ordered terminated december 31, 2020.
g9367
at least two orders for high-risk medications from the same drug class
g9368
at least two orders for high-risk medications from the same drug class not ordered
g9369
individual filled at least two prescriptions for any antipsychotic medication and had a pdc of 0.8 or greater terminated december 31, 2015.
g9370
individual who did not fill at least two prescriptions for any antipsychotic medication or did not have a pdc of 0.8 or greater terminated december 31, 2015.
g9376
patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery terminated december 31, 2015.
g9377
patient did not have the retina attached after 6 months following only one surgery terminated december 31, 2015.
g9378
patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) terminated december 31, 2015.
g9379
patient did not achieve flat retinas six months post surgery terminated december 31, 2015.
g9380
patient offered assistance with end of life issues during the measurement period
g9381
documentation of medical reason(s) for not offering assistance with end of life issues (e.g., patient in hospice care, patient in terminal phase) during the measurement period terminated december 31, 2017.
g9382
patient not offered assistance with end of life issues during the measurement period
g9383
patient received screening for hcv infection within the 12 month reporting period
g9384
documentation of medical reason(s) for not receiving annual screening for hcv infection (e.g., decompensated cirrhosis indicating advanced disease [i.e., ascites, esophageal variceal bleeding, hepatic encephalopathy], hepatocellular carcinoma, waitlist for organ transplant, limited life expectancy, other medical reasons)
g9385
documentation of patient reason(s) for not receiving annual screening for hcv infection (e.g., patient declined, other patient reasons)
g9386
screening for hcv infection not received within the 12 month reporting period, reason not given
g9389
unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery terminated december 31, 2020.
g9390
no unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery terminated december 31, 2020.
g9391
patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit terminated december 31, 2015.
g9392
patient does not achieve refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit terminated december 31, 2015.
g9393
patient with an initial phq-9 score greater than nine who achieves remission at twelve months as demonstrated by a twelve month (+/- 30 days) phq-9 score of less than five
g9394
patient who had a diagnosis of bipolar disorder or personality disorder, death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement or assessment period
g9395
patient with an initial phq-9 score greater than nine who did not achieve remission at twelve months as demonstrated by a twelve month (+/- 30 days) phq-9 score greater than or equal to five
g9396
patient with an initial phq-9 score greater than nine who was not assessed for remission at twelve months (+/- 30 days)
g9399
documentation in the patient record of a discussion between the physician/clinician and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward the outcome of the treatment terminated december 31, 2021.
g9400
documentation of medical or patient reason(s) for not discussing treatment options; medical reasons: patient is not a candidate for treatment due to advanced physical or mental health comorbidity (including active substance use); currently receiving antiviral treatment; successful antiviral treatment (with sustained virologic response) prior to reporting period; other documented medical reasons; patient reasons: patient unable or unwilling to participate in the discussion or other patient reasons terminated december 31, 2021.
g9401
no documentation in the patient record of a discussion between the physician or other qualified healthcare professional and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward treatment terminated december 31, 2021.
g9402
patient received follow-up within 30 days after discharge
g9403
clinician documented reason patient was not able to complete 30 day follow-up from acute inpatient setting discharge (e.g., patient death prior to follow-up visit, patient non-compliant for visit follow-up)
g9404
patient did not receive follow-up on the date of discharge or within 30 days after discharge
g9405
patient received follow-up within 7 days after discharge
g9406
clinician documented reason patient was not able to complete 7 day follow-up from acute inpatient setting discharge (i.e patient death prior to follow-up visit, patient non-compliance for visit follow-up)
g9407
patient did not receive follow-up on or within 7 days after discharge
g9408
patients with cardiac tamponade and/or pericardiocentesis occurring within 30 days
g9409
patients without cardiac tamponade and/or pericardiocentesis occurring within 30 days
g9410
patient admitted within 180 days, status post cied implantation, replacement, or revision with an infection requiring device removal or surgical revision
g9411
patient not admitted within 180 days, status post cied implantation, replacement, or revision with an infection requiring device removal or surgical revision
g9412
patient admitted within 180 days, status post cied implantation, replacement, or revision with an infection requiring device removal or surgical revision
g9413
patient not admitted within 180 days, status post cied implantation, replacement, or revision with an infection requiring device removal or surgical revision
g9414
patient had one dose of meningococcal vaccine (serogroups a, c, w, y) on or between the patient's 11th and 13th birthdays
g9415
patient did not have one dose of meningococcal vaccine (serogroups a, c, w, y) on or between the patient's 11th and 13th birthdays
g9416
patient had one tetanus, diphtheria toxoids and acellular pertussis vaccine (tdap) on or between the patient's 10th and 13th birthdays
g9417
patient did not have one tetanus, diphtheria toxoids and acellular pertussis vaccine (tdap) on or between the patient's 10th and 13th birthdays
g9418
primary non-small cell lung cancer biopsy and cytology specimen report documents classification into specific histologic type following iaslc guidance or classified as nsclc-nos with an explanation
g9419
documentation of medical reason(s) for not including the histological type or nsclc-nos classification with an explanation (e.g. specimen insufficient or non-diagnostic, specimen does not contain cancer, or other documented medical reasons)
g9420
specimen site other than anatomic location of lung or is not classified as primary non-small cell lung cancer
g9421
primary non-small cell lung cancer lung biopsy and cytology specimen report does not document classification into specific histologic type or histologic type does not follow iaslc guidance or is classified as nsclc-nos but without an explanation
g9422
primary lung carcinoma resection report documents pt category, pn category and for non-small cell lung cancer, histologic type (e.g., squamous cell carcinoma, adenocarcinoma and not nsclc-nos)
g9423
documentation of medical reason for not including pt category, pn category and histologic type [for patient with appropriate exclusion criteria (e.g., metastatic disease, benign tumors, malignant tumors other than carcinomas, inadequate surgical specimens)]
g9424
specimen site other than anatomic location of lung, or classified as nsclc-nos
g9425
primary lung carcinoma resection report does not document pt category, pn category and for non-small cell lung cancer, histologic type (e.g., squamous cell carcinoma, adenocarcinoma)
g9426
improvement in median time from ed arrival to initial ed oral or parenteral pain medication administration performed for ed admitted patients
g9427
improvement in median time from ed arrival to initial ed oral or parenteral pain medication administration not performed for ed admitted patients
g9428
pathology report includes the pt category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors
g9429
documentation of medical reason(s) for not including pt category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors (e.g., negative skin biopsies, insufficient tissue, or other documented medical reasons)
g9430
specimen site other than anatomic cutaneous location
g9431
pathology report does not include the pt category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors
g9432
asthma well-controlled based on the act, c-act, acq, or ataq score and results documented
g9433
death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period terminated december 31, 2015.
g9434
asthma not well-controlled based on the act, c-act, acq, or ataq score, or specified asthma control tool not used, reason not given
g9435
aspirin prescribed at discharge terminated december 31, 2016.
g9436
aspirin not prescribed for documented reasons (e.g., allergy, medical intolerance, history of bleed) terminated december 31, 2016.
g9437
aspirin not prescribed at discharge terminated december 31, 2016.
g9438
p2y inhibitor prescribed at discharge terminated december 31, 2016.
g9439
p2y inhibitor not prescribed for documented reasons (e.g., allergy, medical intolerance, history of bleed) terminated december 31, 2016.
g9440
p2y inhibitor not prescribed at discharge terminated december 31, 2016.
g9441
statin prescribed at discharge terminated december 31, 2016.
g9442
statin not prescribed for documented reasons (e.g., allergy, medical intolerance) terminated december 31, 2016.
g9443
statin not prescribed at discharge terminated december 31, 2016.
g9448
patients who were born in the years 1945 to 1965 terminated december 31, 2021.
g9449
history of receiving blood transfusions prior to 1992 terminated december 31, 2021.
g9450
history of injection drug use terminated december 31, 2021.
g9451
patient received one-time screening for hcv infection
g9452
documentation of medical reason(s) for not receiving one-time screening for hcv infection (e.g., decompensated cirrhosis indicating advanced disease [ie, ascites, esophageal variceal bleeding, hepatic encephalopathy], hepatocellular carcinoma, waitlist for organ transplant, limited life expectancy, other medical reasons)
g9453
documentation of patient reason(s) for not receiving one-time screening for hcv infection (e.g., patient declined, other patient reasons)
g9454
one-time screening for hcv infection not received within 12-month reporting period and no documentation of prior screening for hcv infection, reason not given
g9455
patient underwent abdominal imaging with ultrasound, contrast enhanced ct or contrast mri for hcc
g9456
documentation of medical or patient reason(s) for not ordering or performing screening for hcc. medical reason: comorbid medical conditions with expected survival < 5 years, hepatic decompensation and not a candidate for liver transplantation, or other medical reasons; patient reasons: patient declined or other patient reasons (e.g., cost of tests, time related to accessing testing equipment)
g9457
patient did not undergo abdominal imaging and did not have a documented reason for not undergoing abdominal imaging in the submission period
g9458
patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user
g9459
currently a tobacco non-user
g9460
tobacco assessment or tobacco cessation intervention not performed, reason not given
g9463
i intend to report the sinusitis measures group terminated december 31, 2016.
g9464
all quality actions for the applicable measures in the sinusitis measures group have been performed for this patient terminated december 31, 2016.
g9465
i intend to report the acute otitis externa (aoe) measures group terminated december 31, 2016.
g9466
all quality actions for the applicable measures in the aoe measures group have been performed for this patient terminated december 31, 2016.
g9467
patient who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills within the last twelve months terminated december 31, 2016.
g9468
patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills
g9469
patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 90 or greater consecutive days or a single prescription equating to 900 mg prednisone or greater for all fills terminated december 31, 2020.
g9470
patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills
g9471
within the past 2 years, central dual-energy x-ray absorptiometry (dxa) not ordered or documented
g9472
within the past 2 years, central dual-energy x-ray absorptiometry (dxa) not ordered and documented, no review of systems and no medication history or pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed terminated december 31, 2019.
g9473
services performed by chaplain in the hospice setting, each 15 minutes
g9474
services performed by dietary counselor in the hospice setting, each 15 minutes
g9475
services performed by other counselor in the hospice setting, each 15 minutes
g9476
services performed by volunteer in the hospice setting, each 15 minutes
g9477
services performed by care coordinator in the hospice setting, each 15 minutes
g9478
services performed by other qualified therapist in the hospice setting, each 15 minutes
g9479
services performed by qualified pharmacist in the hospice setting, each 15 minutes
g9480
admission to medicare care choice model program (mccm)
g9481
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9482
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9483
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9484
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9485
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9486
remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9487
remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9488
remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9489
remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved coms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9490
cms innovation center models, home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiary connections to community and other services. (for use only in medicare-approved cms innovation center models); may not be billed for a 30 day period covered by a transitional care management code
g9496
documentation of reason for not detecting adenoma(s) or other neoplasm. (e.g., neoplasm detected is only diagnosed as traditional serrated adenoma, sessile serrated polyp, or sessile serrated adenoma terminated december 31, 2017.
g9497
received instruction from the anesthesiologist or proxy prior to the day of surgery to abstain from smoking on the day of surgery
g9498
antibiotic regimen prescribed
g9499
patient did not start or is not receiving antiviral treatment for hepatitis c during the measurement period terminated december 31, 2016.
g9500
radiation exposure indices, or exposure time and number of fluorographic images in final report for procedures using fluoroscopy, documented
g9501
radiation exposure indices, or exposure time and number of fluorographic images not documented in final report for procedure using fluoroscopy, reason not given
g9502
documentation of medical reason for not performing foot exam (i.e., patients who have had either a bilateral amputation above or below the knee, or both a left and right amputation above or below the knee before or during the measurement period)
g9503
patient taking tamsulosin hydrochloride terminated december 31, 2020.
g9504
documented reason for not assessing hepatitis b virus (hbv) status (e.g., patient not initiating anti-tnf therapy, patient declined) prior to initiating anti-tnf therapy
g9505
antibiotic regimen prescribed within 10 days after onset of symptoms for documented medical reason
g9506
biologic immune response modifier prescribed
g9507
documentation that the patient is on a statin medication or has documentation of a valid contraindication or exception to statin medications; contraindications/exceptions that can be defined by diagnosis codes include pregnancy during the measurement period, active liver disease, rhabdomyolysis, end stage renal disease on dialysis and heart failure; provider documented contraindications/exceptions include breastfeeding during the measurement period, woman of child-bearing age not actively taking birth control, allergy to statin, drug interaction (hiv protease inhibitors, nefazodone, cyclosporine, gemfibrozil, and danazol) and intolerance (with supporting documentation of trying a statin at least once within the last 5 years or diagnosis codes for myostitis or toxic myopathy related to drugs)
g9508
documentation that the patient is not on a statin medication
g9509
adult patients 18 years of age or older with major depression or dysthymia who reached remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5
g9510
adult patients 18 years of age or older with major depression or dysthymia who did not reach remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5. either phq- 9 or phq-9m score was not assessed or is greater than or equal to 5
g9511
index event date phq-9 or phq-9m score greater than 9 documented during the twelve month denominator identification period
g9512
individual had a pdc of 0.8 or greater
g9513
individual did not have a pdc of 0.8 or greater
g9514
patient required a return to the operating room within 90 days of surgery
g9515
patient did not require a return to the operating room within 90 days of surgery
g9516
patient achieved an improvement in visual acuity, from their preoperative level, within 90 days of surgery
g9517
patient did not achieve an improvement in visual acuity, from their preoperative level, within 90 days of surgery, reason not given
g9518
documentation of active injection drug use
g9519
patient achieves final refraction (spherical equivalent) +/- 1.0 diopters of their planned refraction within 90 days of surgery
g9520
patient does not achieve final refraction (spherical equivalent) +/- 1.0 diopters of their planned refraction within 90 days of surgery
g9521
total number of emergency department visits and inpatient hospitalizations less than two in the past 12 months
g9522
total number of emergency department visits and inpatient hospitalizations equal to or greater than two in the past 12 months or patient not screened, reason not given
g9523
patient discontinued from hemodialysis or peritoneal dialysis terminated december 31, 2020.
g9524
patient was referred to hospice care terminated december 31, 2020.
g9525
documentation of patient reason(s) for not referring to hospice care (e.g., patient declined, other patient reasons) terminated december 31, 2020.
g9526
patient was not referred to hospice care, reason not given terminated december 31, 2020.
g9529
patient with minor blunt head trauma had an appropriate indication(s) for a head ct
g9530
patient presented with a minor blunt head trauma and had a head ct ordered for trauma by an emergency care provider
g9531
patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar
g9532
patient had a head ct for trauma ordered by someone other than an emergency care provider or was ordered for a reason other than trauma terminated december 31, 2020.
g9533
patient with minor blunt head trauma did not have an appropriate indication(s) for a head ct
g9534
advanced brain imaging (cta, ct, mra or mri) was not ordered terminated december 31, 2018.
g9535
patients with a normal neurological examination terminated december 31, 2018.
g9536
documentation of medical reason(s) for ordering an advanced brain imaging study (i.e., patient has an abnormal neurological examination; patient has the coexistence of seizures, or both; recent onset of severe headache; change in the type of headache; signs of increased intracranial pressure (e.g., papilledema, absent venous pulsations on funduscopic examination, altered mental status, focal neurologic deficits, signs of meningeal irritation); hiv-positive patients with a new type of headache; immunocompromised patient with unexplained headache symptoms; patient on coagulopathy/anti-coagulation or anti-platelet therapy; very young patients with unexplained headache symptoms) terminated december 31, 2018.
g9537
imaging needed as part of a clinical trial; or other clinician ordered the study
g9538
advanced brain imaging (cta, ct, mra or mri) was ordered terminated december 31, 2018.
g9539
intent for potential removal at time of placement
g9540
patient alive 3 months post procedure
g9541
filter removed within 3 months of placement
g9542
documented re-assessment for the appropriateness of filter removal within 3 months of placement
g9543
documentation of at least two attempts to reach the patient to arrange a clinical re-assessment for the appropriateness of filter removal within 3 months of placement
g9544
patients that do not have the filter removed, documented re-assessment for the appropriateness of filter removal, or documentation of at least two attempts to reach the patient to arrange a clinical re-assessment for the appropriateness of filter removal within 3 months of placement
g9547
cystic renal lesion that is simple appearing (bosniak i or ii) , or adrenal lesion less than or equal to 1.0 cm or adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced ct or washout protocol ct, or mri with in- and opposed-phase sequences or other equivalent institutional imaging protocols
g9548
final reports for imaging studies stating no follow-up imaging is recommended
g9549
documentation of medical reason(s) that follow-up imaging is indicated (e.g., patient has lymphadenopathy, signs of metastasis or an active diagnosis or history of cancer, and other medical reason(s))
g9550
final reports for imaging studies with follow-up imaging recommended, or final reports that do not include a specific recommendation of no follow-up
g9551
final reports for imaging studies without an incidentally found lesion noted
g9552
incidental thyroid nodule < 1.0 cm noted in report
g9553
prior thyroid disease diagnosis
g9554
final reports for ct, cta, mri or mra of the chest or neck with follow-up imaging recommended
g9555
documentation of medical reason(s) for recommending follow up imaging (e.g., patient has multiple endocrine neoplasia, patient has cervical lymphadenopathy, other medical reason(s))
g9556
final reports for ct, cta, mri or mra of the chest or neck with follow-up imaging not recommended
g9557
final reports for ct, cta, mri or mra studies of the chest or neck without an incidentally found thyroid nodule < 1.0 cm noted or no nodule found
g9558
patient treated with a beta-lactam antibiotic as definitive therapy terminated december 31, 2020.
g9559
documentation of medical reason(s) for not prescribing a beta-lactam antibiotic (e.g., allergy, intolerance to beta-lactam antibiotics) terminated december 31, 2020.
g9560
patient not treated with a beta-lactam antibiotic as definitive therapy, reason not given terminated december 31, 2020.
g9561
patients prescribed opiates for longer than six weeks terminated december 31, 2021.
g9562
patients who had a follow-up evaluation conducted at least every three months during opioid therapy terminated december 31, 2021.
g9563
patients who did not have a follow-up evaluation conducted at least every three months during opioid therapy terminated december 31, 2021.
g9572
index date phq-score greater than 9 documented during the twelve month denominator identification period terminated december 31, 2016.
g9573
adult patients 18 years of age or older with major depression or dysthymia who did not reach remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five terminated december 31, 2020.
g9574
adult patients 18 years of age or older with major depression or dysthymia who did not reach remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five; either phq-9 or phq-9m score was not assessed or is greater than or equal to five terminated december 31, 2020.
g9577
patients prescribed opiates for longer than six weeks terminated december 31, 2021.
g9578
documentation of signed opioid treatment agreement at least once during opioid therapy terminated december 31, 2021.
g9579
no documentation of signed an opioid treatment agreement at least once during opioid therapy terminated december 31, 2021.
g9580
door to puncture time of 90 minutes or less
g9581
door to puncture time of greater than 2 hours for reasons documented by clinician (e.g., patients who are transferred from one institution to another with a known diagnosis of cva for endovascular stroke treatment; hospitalized patients with newly diagnosed cva considered for endovascular stroke treatment) terminated december 31, 2016.
g9582
door to puncture time of greater than 90 minutes, no reason given
g9583
patients prescribed opiates for longer than six weeks terminated december 31, 2021.
g9584
patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy terminated december 31, 2021.
g9585
patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy terminated december 31, 2021.
g9593
pediatric patient with minor blunt head trauma classified as low risk according to the pecarn prediction rules
g9594
patient presented with a minor blunt head trauma and had a head ct ordered for trauma by an emergency care provider
g9595
patient has documentation of ventricular shunt, brain tumor, or coagulopathy
g9596
pediatric patient had a head ct for trauma ordered by someone other than an emergency care provider or was ordered for a reason other than trauma
g9597
pediatric patient with minor blunt head trauma not classified as low risk according to the pecarn prediction rules
g9598
aortic aneurysm 5.5 - 5.9 cm maximum diameter on centerline formatted ct or minor diameter on axial formatted ct
g9599
aortic aneurysm 6.0 cm or greater maximum diameter on centerline formatted ct or minor diameter on axial formatted ct
g9600
symptomatic aaas that required urgent/emergent (non-elective) repair terminated december 31, 2020.
g9601
patient discharge to home no later than post-operative day #7 terminated december 31, 2020.
g9602
patient not discharged to home by post-operative day #7 terminated december 31, 2020.
g9603
patient survey score improved from baseline following treatment
g9604
patient survey results not available
g9605
patient survey score did not improve from baseline following treatment
g9606
intraoperative cystoscopy performed to evaluate for lower tract injury
g9607
documented medical reasons for not performing intraoperative cystoscopy (e.g., urethral pathology precluding cystoscopy, any patient who has a congenital or acquired absence of the urethra) or in the case of patient death
g9608
intraoperative cystoscopy not performed to evaluate for lower tract injury
g9609
documentation of an order for anti-platelet agents
g9610
documentation of medical reason(s) in the patient's record for not ordering anti-platelet agents
g9611
order for anti-platelet agents was not documented in the patient's record, reason not given
g9612
photodocumentation of two or more cecal landmarks to establish a complete examination
g9613
documentation of post-surgical anatomy (e.g., right hemicolectomy, ileocecal resection, etc.)
g9614
photodocumentation of less than two cecal landmarks (i.e., no cecal landmarks or only one cecal landmark) to establish a complete examination
g9615
preoperative assessment documented terminated december 31, 2020.
g9616
documentation of reason(s) for not documenting a preoperative assessment (e.g., patient with a gynecologic or other pelvic malignancy noted at the time of surgery) terminated december 31, 2020.
g9617
preoperative assessment not documented, reason not given terminated december 31, 2020.
g9618
documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind
g9619
documentation of reason(s) for not screening for uterine malignancy (e.g., prior hysterectomy) terminated december 31, 2016.
g9620
patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given
g9621
patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling
g9622
patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method
g9623
documentation of medical reason(s) for not screening for unhealthy alcohol use (e.g., limited life expectancy, other medical reasons)
g9624
patient not screened for unhealthy alcohol use using a systematic screening method or patient did not receive brief counseling if identified as an unhealthy alcohol user, reason not given
g9625
patient sustained bladder injury at the time of surgery or discovered subsequently up to 30 days post-surgery
g9626
documented medical reason for not reporting bladder injury (e.g., gynecologic or other pelvic malignancy documented, concurrent surgery involving bladder pathology, injury that occurs during urinary incontinence procedure, patient death from non-medical causes not related to surgery, patient died during procedure without evidence of bladder injury)
g9627
patient did not sustain bladder injury at the time of surgery nor discovered subsequently up to 30 days post-surgery
g9628
patient sustained bowel injury at the time of surgery or discovered subsequently up to 30 days post-surgery
g9629
documented medical reasons for not reporting bowel injury (e.g., gynecologic or other pelvic malignancy documented, planned (e.g., not due to an unexpected bowel injury) resection and/or re-anastomosis of bowel, or patient death from non-medical causes not related to surgery, patient died during procedure without evidence of bowel injury)
g9630
patient did not sustain a bowel injury at the time of surgery nor discovered subsequently up to 30 days post-surgery
g9631
patient sustained ureter injury at the time of surgery or discovered subsequently up to 30 days post-surgery
g9632
documented medical reasons for not reporting ureter injury (e.g., gynecologic or other pelvic malignancy documented, concurrent surgery involving bladder pathology, injury that occurs during a urinary incontinence procedure, patient death from non-medical causes not related to surgery, patient died during procedure without evidence of ureter injury)
g9633
patient did not sustain ureter injury at the time of surgery nor discovered subsequently up to 30 days post-surgery
g9634
health-related quality of life assessed with tool during at least two visits and quality of life score remained the same or improved terminated december 31, 2021.
g9635
health-related quality of life not assessed with tool for documented reason(s) (e.g., patient has a cognitive or neuropsychiatric impairment that impairs his/her ability to complete the hrqol survey, patient has the inability to read and/or write in order to complete the hrqol questionnaire) terminated december 31, 2021.
g9636
health-related quality of life not assessed with tool during at least two visits or quality of life score declined terminated december 31, 2021.
g9637
final reports with documentation of one or more dose reduction techniques (e.g., automated exposure control, adjustment of the ma and/or kv according to patient size, use of iterative reconstruction technique)
g9638
final reports without documentation of one or more dose reduction techniques (e.g., automated exposure control, adjustment of the ma and/or kv according to patient size, use of iterative reconstruction technique)
g9639
major amputation or open surgical bypass not required within 48 hours of the index endovascular lower extremity revascularization procedure terminated december 31, 2021.
g9640
documentation of planned hybrid or staged procedure terminated december 31, 2021.
g9641
major amputation or open surgical bypass required within 48 hours of the index endovascular lower extremity revascularization procedure terminated december 31, 2021.
g9642
current smoker (e.g., cigarette, cigar, pipe, e-cigarette or marijuana)
g9643
elective surgery
g9644
patients who abstained from smoking prior to anesthesia on the day of surgery or procedure
g9645
patients who did not abstain from smoking prior to anesthesia on the day of surgery or procedure
g9646
patients with 90 day mrs score of 0 to 2
g9647
patients in whom mrs score could not be obtained at 90 day follow-up terminated december 31, 2021.
g9648
patients with 90 day mrs score greater than 2
g9649
psoriasis assessment tool documented meeting any one of the specified benchmarks (e.g., (pga; 5-point or 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi))
g9650
documentation that the patient declined therapy change or has documented contraindications (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by pga, bsa, pasi, or dlqi terminated december 31, 2016.
g9651
psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (pga; 5-point or 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi)) or psoriasis assessment tool not documented
g9652
patient has been treated with a systemic or biologic medication for psoriasis for at least six months terminated december 31, 2016.
g9653
patient has not been treated with a systemic or biologic medication for psoriasis for at least six months terminated december 31, 2016.
g9654
monitored anesthesia care (mac)
g9655
a transfer of care protocol or handoff tool/checklist that includes the required key handoff elements is used
g9656
patient transferred directly from anesthetizing location to pacu or other non-icu location
g9657
transfer of care during an anesthetic or to the intensive care unit terminated december 31, 2016.
g9658
a transfer of care protocol or handoff tool/checklist that includes the required key handoff elements is not used
g9659
patients greater than or equal to 86 years of age who underwent a screening colonoscopy and did not have a history of colorectal cancer or other valid medical reason for the colonoscopy, including: iron deficiency anemia, lower gastrointestinal bleeding, crohn's disease (i.e., regional enteritis), familial adenomatous polyposis, lynch syndrome (i.e., hereditary non-polyposis colorectal cancer), inflammatory bowel disease, ulcerative colitis, abnormal finding of gastrointestinal tract, or changes in bowel habits
g9660
documentation of medical reason(s) for a colonoscopy performed on a patient greater than or equal to 86 years of age (e.g., iron deficiency anemia, lower gastrointestinal bleeding, crohn's disease (i.e., regional enteritis), familial history of adenomatous polyposis, lynch syndrome (i.e., hereditary non-polyposis colorectal cancer), inflammatory bowel disease, ulcerative colitis, abnormal finding of gastrointestinal tract, or changes in bowel habits)
g9661
patients greater than or equal to 86 years of age who received a colonoscopy for an assessment of signs/symptoms of gi tract illness, and/or because the patient meets high risk criteria, and/or to follow-up on previously diagnosed advanced lesions
g9662
previously diagnosed or have an active diagnosis of clinical ascvd, including ascvd procedure
g9663
any ldl-c laboratory test result >= 190 mg/dl
g9664
patients who are currently statin therapy users or received an order (prescription) for statin therapy
g9665
patients who are not currently statin therapy users or did not receive an order (prescription) for statin therapy
g9666
patient's highest fasting or direct ldl-c laboratory test result in the measurement period or two years prior to the beginning of the measurement period is 70-189 mg/dl terminated december 31, 2021.
g9667
documentation of medical reason(s) for not currently being a statin therapy user or receive an order (prescription) for statin therapy (e.g., patient with adverse effect, allergy or intolerance to statin medication therapy, patients who have an active diagnosis of pregnancy or who are breastfeeding, patients who are receiving palliative care, patients with active liver disease or hepatic disease or insufficiency, patients with end stage renal disease (esrd), and patients with diabetes who have a fasting or direct ldl-c laboratory test result < 70 mg/dl and are not taking statin therapy) terminated december 31, 2016.
g9669
i intend to report the multiple chronic conditions measures group terminated december 31, 2016.
g9670
all quality actions for the applicable measures in the multiple chronic conditions measures group have been performed for this patient terminated december 31, 2016.
g9671
i intend to report the diabetic retinopathy measures group terminated december 31, 2016.
g9672
all quality actions for the applicable measures in the diabetic retinopathy measures group have been performed for this patient terminated december 31, 2016.
g9673
i intend to report the cardiovascular prevention measures group terminated december 31, 2016.
g9674
patients with clinical ascvd diagnosis
g9675
patients who have ever had a fasting or direct laboratory result of ldl-c = 190 mg/dl
g9676
patients aged 40 to 75 years at the beginning of the measurement period with type 1 or type 2 diabetes and with an ldl-c result of 70-189 mg/dl recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period
g9677
all quality actions for the applicable measures in the cardiovascular prevention measures group have been performed for this patient terminated december 31, 2016.
g9678
oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement terminated june 30, 2022.
g9679
this code is for onsite acute care treatment of a nursing facility resident with pneumonia; may only be billed once per day per beneficiary
g9680
this code is for onsite acute care treatment of a nursing facility resident with chf; may only be billed once per day per beneficiary
g9681
this code is for onsite acute care treatment of a resident with copd or asthma; may only be billed once per day per beneficiary
g9682
this code is for the onsite acute care treatment a nursing facility resident with a skin infection; may only be billed once per day per beneficiary
g9683
facility service(s) for the onsite acute care treatment of a nursing facility resident with fluid or electrolyte disorder. (may only be billed once per day per beneficiary). this service is for a demonstration project
g9684
this code is for the onsite acute care treatment of a nursing facility resident for a uti; may only be billed once per day per beneficiary
g9685
physician service or other qualified health care professional for the evaluation and management of a beneficiary's acute change in condition in a nursing facility. this service is for a demonstration project
g9686
onsite nursing facility conference, that is separate and distinct from an evaluation and management visit, including qualified practitioner and at least one member of the nursing facility interdisciplinary care team terminated december 31, 2018.
g9687
hospice services provided to patient any time during the measurement period
g9688
patients using hospice services any time during the measurement period
g9689
patient admitted for performance of elective carotid intervention
g9690
patient receiving hospice services any time during the measurement period
g9691
patient had hospice services any time during the measurement period
g9692
hospice services received by patient any time during the measurement period
g9693
patient use of hospice services any time during the measurement period
g9694
hospice services utilized by patient any time during the measurement period
g9695
long-acting inhaled bronchodilator prescribed
g9696
documentation of medical reason(s) for not prescribing a long-acting inhaled bronchodilator
g9697
documentation of patient reason(s) for not prescribing a long-acting inhaled bronchodilator
g9698
documentation of system reason(s) for not prescribing a long-acting inhaled bronchodilator
g9699
long-acting inhaled bronchodilator not prescribed, reason not otherwise specified
g9700
patients who use hospice services any time during the measurement period
g9701
children who are taking antibiotics in the 30 days prior to the date of the encounter during which the diagnosis was established terminated december 31, 2020.
g9702
patients who use hospice services any time during the measurement period
g9703
episodes where the patient is taking antibiotics (table 1) in the 30 days prior to the episode date, or had an active prescription on the episode date
g9704
ajcc breast cancer stage i: t1 mic or t1a documented
g9705
ajcc breast cancer stage i: t1b (tumor > 0.5 cm but <= 1 cm in greatest dimension) documented
g9706
low (or very low) risk of recurrence, prostate cancer
g9707
patient received hospice services any time during the measurement period
g9708
women who had a bilateral mastectomy or who have a history of a bilateral mastectomy or for whom there is evidence of a right and a left unilateral mastectomy
g9709
hospice services used by patient any time during the measurement period
g9710
patient was provided hospice services any time during the measurement period
g9711
patients with a diagnosis or past history of total colectomy or colorectal cancer
g9712
documentation of medical reason(s) for prescribing or dispensing antibiotic (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, acute pharyngitis, acute tonsillitis, chronic sinusitis, infection of the pharynx/larynx/tonsils/adenoids, prostatitis, cellulitis/ mastoiditis/bone infections, acute lymphadenitis, impetigo, skin staph infections, pneumonia, gonococcal infections/venereal disease (syphilis, chlamydia, inflammatory diseases [female reproductive organs]), infections of the kidney, cystitis/uti, acne, hiv disease/asymptomatic hiv, cystic fibrosis, disorders of the immune system, malignancy neoplasms, chronic bronchitis, emphysema, bronchiectasis, extrinsic allergic alveolitis, chronic airway obstruction, chronic obstructive asthma, pneumoconiosis and other lung disease due to external agents, other diseases of the respiratory system, and tuberculosis
g9713
patients who use hospice services any time during the measurement period
g9714
patient is using hospice services any time during the measurement period
g9715
patients who use hospice services any time during the measurement period
g9716
bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason
g9717
documentation stating the patient has had a diagnosis of depression or has had a diagnosis of bipolar disorder
g9718
hospice services for patient provided any time during the measurement period
g9719
patient is not ambulatory, bed ridden, immobile, confined to chair, wheelchair bound, dependent on helper pushing wheelchair, independent in wheelchair or minimal help in wheelchair
g9720
hospice services for patient occurred any time during the measurement period
g9721
patient not ambulatory, bed ridden, immobile, confined to chair, wheelchair bound, dependent on helper pushing wheelchair, independent in wheelchair or minimal help in wheelchair
g9722
documented history of renal failure or baseline serum creatinine >= 4.0 mg/dl; renal transplant recipients are not considered to have preoperative renal failure, unless, since transplantation the cr has been or is 4.0 or higher
g9723
hospice services for patient received any time during the measurement period
g9724
patients who had documentation of use of anticoagulant medications overlapping the measurement year
g9725
patients who use hospice services any time during the measurement period
g9726
patient refused to participate
g9727
patient unable to complete the lepf prom at initial evaluation and/or discharge due to blindness, illiteracy, severe mental incapacity or language incompatibility and an adequate proxy is not available
g9728
patient refused to participate
g9729
patient unable to complete the lepf prom at initial evaluation and/or discharge due to blindness, illiteracy, severe mental incapacity or language incompatibility and an adequate proxy is not available
g9730
patient refused to participate
g9731
patient unable to complete the lepf prom at initial evaluation and/or discharge due to blindness, illiteracy, severe mental incapacity or language incompatibility and an adequate proxy is not available
g9732
patient refused to participate
g9733
patient unable to complete the low back fs prom at initial evaluation and/or discharge due to blindness, illiteracy, severe mental incapacity or language incompatibility and an adequate proxy is not available
g9734
patient refused to participate
g9735
patient unable to complete the shoulder fs prom at initial evaluation and/or discharge due to blindness, illiteracy, severe mental incapacity or language incompatibility and an adequate proxy is not available
g9736
patient refused to participate
g9737
patient unable to complete the elbow/wrist/hand fs prom at initial evaluation and/or discharge due to blindness, illiteracy, severe mental incapacity or language incompatibility and an adequate proxy is not available
g9738
patient refused to participate terminated december 31, 2020.
g9739
patient unable to complete the general orthopedic fs prom at initial evaluation and/or discharge due to blindness, illiteracy, severe mental incapacity or language incompatibility and an adequate proxy is not available terminated december 31, 2020.
g9740
hospice services given to patient any time during the measurement period
g9741
patients who use hospice services any time during the measurement period
g9742
psychiatric symptoms assessed terminated december 31, 2019.
g9743
psychiatric symptoms not assessed, reason not otherwise specified terminated december 31, 2019.
g9744
patient not eligible due to active diagnosis of hypertension
g9745
documented reason for not screening or recommending a follow-up for high blood pressure
g9746
patient has mitral stenosis or prosthetic heart valves or patient has transient or reversible cause of af (e.g., pneumonia, hyperthyroidism, pregnancy, cardiac surgery)
g9747
patient is undergoing palliative dialysis with a catheter terminated december 31, 2020.
g9748
patient approved by a qualified transplant program and scheduled to receive a living donor kidney transplant terminated december 31, 2020.
g9749
patient is undergoing palliative dialysis with a catheter terminated december 31, 2020.
g9750
patient approved by a qualified transplant program and scheduled to receive a living donor kidney transplant terminated december 31, 2020.
g9751
patient died at any time during the 24-month measurement period
g9752
emergency surgery
g9753
documentation of medical reason for not conducting a search for dicom format images for prior patient ct imaging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., trauma, acute myocardial infarction, stroke, aortic aneurysm where time is of the essence)
g9754
a finding of an incidental pulmonary nodule
g9755
documentation of medical reason(s) for not including a recommended interval and modality for follow-up or for no follow-up, and source of recommendations (e.g., patients with unexplained fever, immunocompromised patients who are at risk for infection)
g9756
surgical procedures that included the use of silicone oil
g9757
surgical procedures that included the use of silicone oil
g9758
patient in hospice at any time during the measurement period
g9759
history of preoperative posterior capsule rupture terminated december 31, 2020.
g9760
patients who use hospice services any time during the measurement period
g9761
patients who use hospice services any time during the measurement period
g9762
patient had at least two hpv vaccines (with at least 146 days between the two) or three hpv vaccines on or between the patient's 9th and 13th birthdays
g9763
patient did not have at least two hpv vaccines (with at least 146 days between the two) or three hpv vaccines on or between the patient's 9th and 13th birthdays
g9764
patient has been treated with a systemic medication for psoriasis vulgaris
g9765
documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by pga, bsa, pasi, or dlqi
g9766
patients who are transferred from one institution to another with a known diagnosis of cva for endovascular stroke treatment
g9767
hospitalized patients with newly diagnosed cva considered for endovascular stroke treatment
g9768
patients who utilize hospice services any time during the measurement period
g9769
patient had a bone mineral density test in the past two years or received osteoporosis medication or therapy in the past 12 months
g9770
peripheral nerve block (pnb)
g9771
at least 1 body temperature measurement equal to or greater than 35.5 degrees celsius (or 95.9 degrees fahrenheit) achieved within the 30 minutes immediately before or the 15 minutes immediately after anesthesia end time
g9772
documentation of medical reason(s) for not achieving at least 1 body temperature measurement equal to or greater than 35.5 degrees celsius (or 95.9 degrees fahrenheit) within the 30 minutes immediately before or the 15 minutes immediately after anesthesia end time (e.g., emergency cases, intentional hypothermia, etc.)
g9773
at least 1 body temperature measurement equal to or greater than 35.5 degrees celsius (or 95.9 degrees fahrenheit) not achieved within the 30 minutes immediately before or the 15 minutes immediately after anesthesia end time, reason not given
g9774
patients who have had a hysterectomy
g9775
patient received at least 2 prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively
g9776
documentation of medical reason for not receiving at least 2 prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively (e.g., intolerance or other medical reason)
g9777
patient did not receive at least 2 prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively
g9778
patients who have a diagnosis of pregnancy at any time during the measurement period
g9779
patients who are breastfeeding at any time during the measurement period
g9780
patients who have a diagnosis of rhabdomyolysis at any time during the measurement period
g9781
documentation of medical reason(s) for not currently being a statin therapy user or receiving an order (prescription) for statin therapy (e.g., patients with statin-associated muscle symptoms or an allergy to statin medication therapy, patients who are receiving palliative or hospice care, patients with active liver disease or hepatic disease or insufficiency, and patients with end stage renal disease [esrd])
g9782
history of or active diagnosis of familial hypercholesterolemia
g9783
documentation of patients with diabetes who have a most recent fasting or direct ldl- c laboratory test result < 70 mg/dl and are not taking statin therapy terminated december 31, 2021.
g9784
pathologists/dermatopathologists providing a second opinion on a biopsy
g9785
pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) sent from the pathologist/ dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist
g9786
pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) was not sent from the pathologist/ dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist
g9787
patient alive as of the last day of the measurement year
g9788
most recent bp is less than or equal to 140/90 mm hg
g9789
blood pressure recorded during inpatient stays, emergency room visits, urgent care visits, and patient self-reported bp's (home and health fair bp results)
g9790
most recent bp is greater than 140/90 mm hg, or blood pressure not documented
g9791
most recent tobacco status is tobacco free
g9792
most recent tobacco status is not tobacco free
g9793
patient is currently on a daily aspirin or other antiplatelet
g9794
documentation of medical reason(s) for not on a daily aspirin or other antiplatelet (e.g., history of gastrointestinal bleed, intra-cranial bleed, idiopathic thrombocytopenic purpura (itp), gastric bypass or documentation of active anticoagulant use during the measurement period)
g9795
patient is not currently on a daily aspirin or other antiplatelet
g9796
patient is currently on a statin therapy
g9797
patient is not on a statin therapy
g9798
discharge(s) for ami between july 1 of the year prior measurement period to june 30 of the measurement period terminated december 31, 2020.
g9799
patients with a medication dispensing event indicator of a history of asthma any time during the patient's history through the end of the measure period terminated december 31, 2020.
g9800
patients who are identified as having an intolerance or allergy to beta-blocker therapy terminated december 31, 2020.
g9801
hospitalizations in which the patient was transferred directly to a non-acute care facility for any diagnosis terminated december 31, 2020.
g9802
patients who use hospice services any time during the measurement period terminated december 31, 2020.
g9803
patient prescribed at least a 135 day treatment within the 180-day measurement interval with beta-blockers post-discharge for ami terminated december 31, 2020.
g9804
patient was not prescribed at least a 135 day treatment within the 180-day measurement interval with beta-blockers post-discharge for ami terminated december 31, 2020.
g9805
patients who use hospice services any time during the measurement period
g9806
patients who received cervical cytology or an hpv test
g9807
patients who did not receive cervical cytology or an hpv test
g9808
any patients who had no asthma controller medications dispensed during the measurement year
g9809
patients who use hospice services any time during the measurement period
g9810
patient achieved a pdc of at least 75% for their asthma controller medication
g9811
patient did not achieve a pdc of at least 75% for their asthma controller medication
g9812
patient died including all deaths occurring during the hospitalization in which the operation was performed, even if after 30 days, and those deaths occurring after discharge from the hospital, but within 30 days of the procedure
g9813
patient did not die within 30 days of the procedure or during the index hospitalization
g9814
death occurring during the index acute care hospitalization terminated december 31, 2020.
g9815
death did not occur during the index acute care hospitalization terminated december 31, 2020.
g9816
death occurring after discharge from the hospital but within 30 days post procedure terminated december 31, 2020.
g9817
death did not occur after discharge from the hospital within 30 days post procedure terminated december 31, 2020.
g9818
documentation of sexual activity
g9819
patients who use hospice services any time during the measurement period
g9820
documentation of a chlamydia screening test with proper follow-up
g9821
no documentation of a chlamydia screening test with proper follow-up
g9822
patients who had an endometrial ablation procedure during the 12 months prior to the index date (exclusive of the index date)
g9823
endometrial sampling or hysteroscopy with biopsy and results documented during the 12 months prior to the index date (exclusive of the index date) of the endometrial ablation
g9824
endometrial sampling or hysteroscopy with biopsy and results not documented during the 12 months prior to the index date (exclusive of the index date) of the endometrial ablation
g9825
her-2/neu negative or undocumented/unknown terminated december 31, 2020.
g9826
patient transferred to practice after initiation of chemotherapy terminated december 31, 2020.
g9827
her2-targeted therapies not administered during the initial course of treatment terminated december 31, 2020.
g9828
her2-targeted therapies administered during the initial course of treatment terminated december 31, 2020.
g9829
breast adjuvant chemotherapy administered terminated december 31, 2020.
g9830
her-2/neu positive
g9831
ajcc stage at breast cancer diagnosis = ii or iii
g9832
ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis does not equal = t1, t1a, t1b
g9833
patient transfer to practice after initiation of chemotherapy terminated december 31, 2020.
g9834
patient has metastatic disease at diagnosis terminated december 31, 2020.
g9835
trastuzumab administered within 12 months of diagnosis terminated december 31, 2020.
g9836
reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant chemotherapy or radiation not complete) terminated december 31, 2020.
g9837
trastuzumab not administered within 12 months of diagnosis terminated december 31, 2020.
g9838
patient has metastatic disease at diagnosis
g9839
anti-egfr monoclonal antibody therapy
g9840
ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moab
g9841
ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moab
g9842
patient has metastatic disease at diagnosis
g9843
ras (kras or nras) gene mutation
g9844
patient did not receive anti-egfr monoclonal antibody therapy
g9845
patient received anti-egfr monoclonal antibody therapy
g9846
patients who died from cancer
g9847
patient received chemotherapy in the last 14 days of life
g9848
patient did not receive chemotherapy in the last 14 days of life
g9849
patients who died from cancer terminated december 31, 2020.
g9850
patient had more than one emergency department visit in the last 30 days of life terminated december 31, 2020.
g9851
patient had one or less emergency department visits in the last 30 days of life terminated december 31, 2020.
g9852
patients who died from cancer
g9853
patient admitted to the icu in the last 30 days of life
g9854
patient was not admitted to the icu in the last 30 days of life
g9855
patients who died from cancer terminated december 31, 2020.
g9856
patient was not admitted to hospice terminated december 31, 2020.
g9857
patient admitted to hospice terminated december 31, 2020.
g9858
patient enrolled in hospice
g9859
patients who died from cancer
g9860
patient spent less than three days in hospice care
g9861
patient spent greater than or equal to three days in hospice care
g9862
documentation of medical reason(s) for not recommending at least a 10 year follow-up interval (e.g., inadequate prep, familial or personal history of colonic polyps, patient had no adenoma and age is = 66 years old, or life expectancy < 10 years old, other medical reasons)
g9868
receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, less than 10 minutes
g9869
receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, 10-20 minutes
g9870
receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, more than 20 minutes
g9873
first medicare diabetes prevention program (mdpp) core session was attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions
g9874
four total medicare diabetes prevention program (mdpp) core sessions were attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions
g9875
nine total medicare diabetes prevention program (mdpp) core sessions were attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions
g9876
two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 7-9 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary did not achieve at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 7-9
g9877
two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 10-12 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary did not achieve at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 10-12
g9878
two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 7-9 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions.the beneficiary achieved at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 7-9
g9879
two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 10-12 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary achieved at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 10-12
g9880
the mdpp beneficiary achieved at least 5% weight loss (wl) from his/her baseline weight in months 1-12 of the mdpp services period under the mdpp expanded model (em). this is a one-time payment available when a beneficiary first achieves at least 5% weight loss from baseline as measured by an in-person weight measurement at a core session or core maintenance session
g9881
the mdpp beneficiary achieved at least 9% weight loss (wl) from his/her baseline weight in months 1-24 under the mdpp expanded model (em). this is a one-time payment available when a beneficiary first achieves at least 9% weight loss from baseline as measured by an in-person weight measurement at a core session, core maintenance session, or ongoing maintenance session
g9882
two medicare diabetes prevention program (mdpp) ongoing maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 13-15 under the mdpp expanded model (em). an ongoing maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 13 through 24 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary maintained at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 13-15
g9883
two medicare diabetes prevention program (mdpp) ongoing maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 16-18 under the mdpp expanded model (em). an ongoing maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 13 through 24 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary maintained at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 16-18
g9884
two medicare diabetes prevention program (mdpp) ongoing maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 19-21 under the mdpp expanded model (em). an ongoing maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 13 through 24 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary maintained at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 19-21
g9885
two medicare diabetes prevention program (mdpp) ongoing maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 22-24 under the mdpp expanded model (em). an ongoing maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 13 through 24 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary maintained at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 22-24
g9890
bridge payment: a one-time payment for the first medicare diabetes prevention program (mdpp) core session, core maintenance session, or ongoing maintenance session furnished by an mdpp supplier to an mdpp beneficiary during months 1-24 of the mdpp expanded model (em) who has previously received mdpp services from a different mdpp supplier under the mdpp expanded model. a supplier may only receive one bridge payment per mdpp beneficiary
g9891
mdpp session reported as a line-item on a claim for a payable mdpp expanded model (em) hcpcs code for a session furnished by the billing supplier under the mdpp expanded model and counting toward achievement of the attendance performance goal for the payable mdpp expanded model hcpcs code (this code is for reporting purposes only)
g9892
documentation of patient reason(s) for not performing a dilated macular examination
g9893
dilated macular exam was not performed, reason not otherwise specified
g9894
androgen deprivation therapy prescribed/administered in combination with external beam radiotherapy to the prostate
g9895
documentation of medical reason(s) for not prescribing/administering androgen deprivation therapy in combination with external beam radiotherapy to the prostate (e.g., salvage therapy)
g9896
documentation of patient reason(s) for not prescribing/administering androgen deprivation therapy in combination with external beam radiotherapy to the prostate
g9897
patients who were not prescribed/administered androgen deprivation therapy in combination with external beam radiotherapy to the prostate, reason not given
g9898
patients age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period
g9899
screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed
g9900
screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified
g9901
patient age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period
g9902
patient screened for tobacco use and identified as a tobacco user
g9903
patient screened for tobacco use and identified as a tobacco non-user
g9904
documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reason)
g9905
patient not screened for tobacco use, reason not given
g9906
patient identified as a tobacco user received tobacco cessation intervention on the date of the encounter or within the previous 12 months (counseling and/or pharmacotherapy)
g9907
documentation of medical reason(s) for not providing tobacco cessation intervention on the date of the encounter or within the previous 12 months (e.g., limited life expectancy, other medical reason)
g9908
patient identified as tobacco user did not receive tobacco cessation intervention on the date of the encounter or within the previous 12 months (counseling and/or pharmacotherapy), reason not given
g9909
documentation of medical reason(s) for not providing tobacco cessation intervention on the date of the encounter or within the previous 12 months if identified as a tobacco user (e.g., limited life expectancy, other medical reason)
g9910
patients age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period
g9911
clinically node negative (t1n0m0 or t2n0m0) invasive breast cancer before or after neoadjuvant systemic therapy
g9912
hepatitis b virus (hbv) status assessed and results interpreted prior to initiating anti-tnf (tumor necrosis factor) therapy
g9913
hepatitis b virus (hbv) status not assessed and results interpreted prior to initiating anti-tnf (tumor necrosis factor) therapy, reason not given
g9914
patient receiving an anti-tnf agent
g9915
no record of hbv results documented
g9916
functional status performed once in the last 12 months
g9917
documentation of advanced stage dementia and caregiver knowledge is limited
g9918
functional status not performed, reason not otherwise specified
g9919
screening performed and positive and provision of recommendations
g9920
screening performed and negative
g9921
no screening performed, partial screening performed or positive screen without recommendations and reason is not given or otherwise specified
g9922
safety concerns screen provided and if positive then documented mitigation recommendations
g9923
safety concerns screen provided and negative
g9924
documentation of medical reason(s) for not providing safety concerns screen or for not providing recommendations, orders or referrals for positive screen (e.g., patient in palliative care, other medical reason) terminated december 31, 2020.
g9925
safety concerns screening not provided, reason not otherwise specified
g9926
safety concerns screening positive screen is without provision of mitigation recommendations, including but not limited to referral to other resources
g9927
documentation of system reason(s) for not prescribing an fda-approved anticoagulation due to patient being currently enrolled in a clinical trial related to af/atrial flutter treatment
g9928
fda-approved anticoagulant not prescribed, reason not given
g9929
patient with transient or reversible cause of af (e.g., pneumonia, hyperthyroidism, pregnancy, cardiac surgery)
g9930
patients who are receiving comfort care only
g9931
documentation of cha2ds2-vasc risk score of 0 or 1 for men; or 0, 1, or 2 for women
g9932
documentation of patient reason(s) for not having records of negative or managed positive tb screen (e.g., patient does not return for mantoux (ppd) skin test evaluation)
g9933
adenoma(s) or colorectal cancer detected during screening colonoscopy terminated december 31, 2020.
g9934
documentation that neoplasm detected is only diagnosed as traditional serrated adenoma, sessile serrated polyp, or sessile serrated adenoma terminated december 31, 2020.
g9935
adenoma(s) or colorectal cancer not detected during screening colonoscopy terminated december 31, 2020.
g9936
surveillance colonoscopy - personal history of colonic polyps, colon cancer, or other malignant neoplasm of rectum, rectosigmoid junction, and anus terminated december 31, 2020.
g9937
diagnostic colonoscopy terminated december 31, 2020.
g9938
patients age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the six months prior to the measurement period through december 31 of the measurement period
g9939
pathologists/dermatopathologists is the same clinician who performed the biopsy
g9940
documentation of medical reason(s) for not on a statin (e.g., pregnancy, in vitro fertilization, clomiphene rx, esrd, cirrhosis, muscular pain and disease during the measurement period or prior year)
g9941
back pain was measured by the visual analog scale (vas) within three months preoperatively and at three months (6 - 20 weeks) postoperatively terminated december 31, 2019.
g9942
patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminectomy
g9943
back pain was not measured by the visual analog scale (vas) within three months preoperatively and at three months ( 6 - 20 weeks) postoperatively
g9944
back pain was measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively terminated december 31, 2019.
g9945
patient had cancer, acute fracture or infection related to the lumbar spine or patient had neuromuscular, idiopathic or congenital lumbar scoliosis
g9946
back pain was not measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively
g9947
leg pain was measured by the visual analog scale (vas) within three months preoperatively and at three months (6 to 20 weeks) postoperatively terminated december 31, 2019.
g9948
patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminectomy
g9949
leg pain was not measured by the visual analog scale (vas) at three months (6 - 20 weeks) postoperatively
g9954
patient exhibits 2 or more risk factors for post-operative vomiting
g9955
cases in which an inhalational anesthetic is used only for induction
g9956
patient received combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively
g9957
documentation of medical reason for not receiving combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively (e.g., intolerance or other medical reason)
g9958
patient did not receive combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively
g9959
systemic antimicrobials not prescribed
g9960
documentation of medical reason(s) for prescribing systemic antimicrobials
g9961
systemic antimicrobials prescribed
g9962
embolization endpoints are documented separately for each embolized vessel and ovarian artery angiography or embolization performed in the presence of variant uterine artery anatomy
g9963
embolization endpoints are not documented separately for each embolized vessel or ovarian artery angiography or embolization not performed in the presence of variant uterine artery anatomy
g9964
patient received at least one well-child visit with a pcp during the performance period
g9965
patient did not receive at least one well-child visit with a pcp during the performance period
g9966
children who were screened for risk of developmental, behavioral and social delays using a standardized tool with interpretation and report terminated december 31, 2020.
g9967
children who were not screened for risk of developmental, behavioral and social delays using a standardized tool with interpretation and report terminated december 31, 2020.
g9968
patient was referred to another provider or specialist during the performance period
g9969
provider who referred the patient to another provider received a report from the provider to whom the patient was referred
g9970
provider who referred the patient to another provider did not receive a report from the provider to whom the patient was referred
g9974
dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity
g9975
documentation of medical reason(s) for not performing a dilated macular examination
g9978
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9979
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9980
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9981
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9982
remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9983
remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9984
remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9985
remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9986
remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved bundled payments for care improvement advanced (bpci advanced) model episode of care, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology
g9987
bundled payments for care improvement advanced (bpci advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiary connections to community and other services; for use only for a bpci advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code
g9988
palliative care services provided to patient any time during the measurement period
g9989
documentation of medical reason(s) for not administering pneumococcal vaccine (e.g., adverse reaction to vaccine)
g9990
pneumococcal vaccine was not administered on or after patient's 60th birthday and before the end of the measurement period, reason not otherwise specified
g9991
pneumococcal vaccine administered on or after patient's 60th birthday and before the end of the measurement period
g9992
palliative care services used by patient any time during the measurement period
g9993
patient was provided pallative care services any time during the measurement period
g9994
patient is using palliative care services any time during the measurement period
g9995
patients who use palliative care services any time during the measurement period
g9996
documentation stating the patient has received or is currently receiving palliative or hospice care
g9997
documentation of patient pregnancy anytime during the measurement period prior to and including the current encounter
g9998
documentation of medical reason(s) for an interval of less than 3 years since the last colonoscopy (e.g., last colonoscopy incomplete, last colonoscopy had inadequate prep, piecemeal removal of adenomas, last colonoscopy found greater than 10 adenomas, or patient at high risk for colon cancer [crohn's disease, ulcerative colitis, lower gastrointestinal bleeding, personal or family history of colon cancer, hereditary colorectal cancer syndromes])
g9999
documentation of system reason(s) for an interval of less than 3 years since the last colonoscopy (e.g., unable to locate previous colonoscopy report, previous colonoscopy report was incomplete)
h0001
alcohol and/or drug assessment
h0002
behavioral health screening to determine eligibility for admission to treatment program
h0003
alcohol and/or drug screening; laboratory analysis of specimens for presence of alcohol and/or drugs
h0004
behavioral health counseling and therapy, per 15 minutes
h0005
alcohol and/or drug services; group counseling by a clinician
h0006
alcohol and/or drug services; case management
h0007
alcohol and/or drug services; crisis intervention (outpatient)
h0008
alcohol and/or drug services; sub-acute detoxification (hospital inpatient)
h0009
alcohol and/or drug services; acute detoxification (hospital inpatient)
h0010
alcohol and/or drug services; sub-acute detoxification (residential addiction program inpatient)
h0011
alcohol and/or drug services; acute detoxification (residential addiction program inpatient)
h0012
alcohol and/or drug services; sub-acute detoxification (residential addiction program outpatient)
h0013
alcohol and/or drug services; acute detoxification (residential addiction program outpatient)
h0014
alcohol and/or drug services; ambulatory detoxification
h0015
alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education
h0016
alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting)
h0017
behavioral health; residential (hospital residential treatment program), without room and board, per diem
h0018
behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem
h0019
behavioral health; long-term residential (non-medical, non-acute care in a residential treatment program where stay is typically longer than 30 days), without room and board, per diem
h0020
alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)
h0021
alcohol and/or drug training service (for staff and personnel not employed by providers)
h0022
alcohol and/or drug intervention service (planned facilitation)
h0023
behavioral health outreach service (planned approach to reach a targeted population)
h0024
behavioral health prevention information dissemination service (one-way direct or non-direct contact with service audiences to affect knowledge and attitude)
h0025
behavioral health prevention education service (delivery of services with target population to affect knowledge, attitude and/or behavior)
h0026
alcohol and/or drug prevention process service, community-based (delivery of services to develop skills of impactors)
h0027
alcohol and/or drug prevention environmental service (broad range of external activities geared toward modifying systems in order to mainstream prevention through policy and law)
h0028
alcohol and/or drug prevention problem identification and referral service (e.g., student assistance and employee assistance programs), does not include assessment
h0029
alcohol and/or drug prevention alternatives service (services for populations that exclude alcohol and other drug use e.g., alcohol free social events)
h0030
behavioral health hotline service
h0031
mental health assessment, by non-physician
h0032
mental health service plan development by non-physician
h0033
oral medication administration, direct observation
h0034
medication training and support, per 15 minutes
h0035
mental health partial hospitalization, treatment, less than 24 hours
h0036
community psychiatric supportive treatment, face-to-face, per 15 minutes
h0037
community psychiatric supportive treatment program, per diem
h0038
self-help/peer services, per 15 minutes
h0039
assertive community treatment, face-to-face, per 15 minutes
h0040
assertive community treatment program, per diem
h0041
foster care, child, non-therapeutic, per diem
h0042
foster care, child, non-therapeutic, per month
h0043
supported housing, per diem
h0044
supported housing, per month
h0045
respite care services, not in the home, per diem
h0046
mental health services, not otherwise specified
h0047
alcohol and/or other drug abuse services, not otherwise specified
h0048
alcohol and/or other drug testing: collection and handling only, specimens other than blood
h0049
alcohol and/or drug screening
h0050
alcohol and/or drug services, brief intervention, per 15 minutes
h1000
prenatal care, at-risk assessment
h1001
prenatal care, at-risk enhanced service; antepartum management
h1002
prenatal care, at risk enhanced service; care coordination
h1003
prenatal care, at-risk enhanced service; education
h1004
prenatal care, at-risk enhanced service; follow-up home visit
h1005
prenatal care, at-risk enhanced service package (includes h1001-h1004)
h1010
non-medical family planning education, per session
h1011
family assessment by licensed behavioral health professional for state defined purposes
h2000
comprehensive multidisciplinary evaluation
h2001
rehabilitation program, per 1/2 day
h2010
comprehensive medication services, per 15 minutes
h2011
crisis intervention service, per 15 minutes
h2012
behavioral health day treatment, per hour
h2013
psychiatric health facility service, per diem
h2014
skills training and development, per 15 minutes
h2015
comprehensive community support services, per 15 minutes
h2016
comprehensive community support services, per diem
h2017
psychosocial rehabilitation services, per 15 minutes
h2018
psychosocial rehabilitation services, per diem
h2019
therapeutic behavioral services, per 15 minutes
h2020
therapeutic behavioral services, per diem
h2021
community-based wrap-around services, per 15 minutes
h2022
community-based wrap-around services, per diem
h2023
supported employment, per 15 minutes
h2024
supported employment, per diem
h2025
ongoing support to maintain employment, per 15 minutes
h2026
ongoing support to maintain employment, per diem
h2027
psychoeducational service, per 15 minutes
h2028
sexual offender treatment service, per 15 minutes
h2029
sexual offender treatment service, per diem
h2030
mental health clubhouse services, per 15 minutes
h2031
mental health clubhouse services, per diem
h2032
activity therapy, per 15 minutes
h2033
multisystemic therapy for juveniles, per 15 minutes
h2034
alcohol and/or drug abuse halfway house services, per diem
h2035
alcohol and/or other drug treatment program, per hour
h2036
alcohol and/or other drug treatment program, per diem
h2037
developmental delay prevention activities, dependent child of client, per 15 minutes
h2038
skills training and development, per diem
j0120
injection, tetracycline, up to 250 mg
j0121
injection, omadacycline, 1 mg
j0122
injection, eravacycline, 1 mg
j0129
injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
j0130
injection abciximab, 10 mg
j0131
injection, acetaminophen, 10 mg
j0132
injection, acetylcysteine, 100 mg
j0133
injection, acyclovir, 5 mg
j0135
injection, adalimumab, 20 mg
j0150
injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) terminated december 31, 2014.
j0151
injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) terminated december 31, 2014.
j0153
injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)
j0171
injection, adrenalin, epinephrine, 0.1 mg
j0172
injection, aducanumab-avwa, 2 mg
j0178
injection, aflibercept, 1 mg
j0179
injection, brolucizumab-dbll, 1 mg
j0180
injection, agalsidase beta, 1 mg
j0185
injection, aprepitant, 1 mg
j0190
injection, biperiden lactate, per 5 mg
j0200
injection, alatrofloxacin mesylate, 100 mg
j0202
injection, alemtuzumab, 1 mg
j0205
injection, alglucerase, per 10 units
j0207
injection, amifostine, 500 mg
j0210
injection, methyldopate hcl, up to 250 mg
j0215
injection, alefacept, 0.5 mg
j0219
injection, avalglucosidase alfa-ngpt, 4 mg
j0220
injection, alglucosidase alfa, 10 mg, not otherwise specified
j0221
injection, alglucosidase alfa, (lumizyme), 10 mg
j0222
injection, patisiran, 0.1 mg
j0223
injection, givosiran, 0.5 mg
j0224
injection, lumasiran, 0.5 mg
j0248
injection, remdesivir, 1 mg
j0256
injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg
j0257
injection, alpha 1 proteinase inhibitor (human), (glassia), 10 mg
j0270
injection, alprostadil, 1.25 mcg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
j0275
alprostadil urethral suppository (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
j0278
injection, amikacin sulfate, 100 mg
j0280
injection, aminophyllin, up to 250 mg
j0282
injection, amiodarone hydrochloride, 30 mg
j0285
injection, amphotericin b, 50 mg
j0287
injection, amphotericin b lipid complex, 10 mg
j0288
injection, amphotericin b cholesteryl sulfate complex, 10 mg
j0289
injection, amphotericin b liposome, 10 mg
j0290
injection, ampicillin sodium, 500 mg
j0291
injection, plazomicin, 5 mg
j0295
injection, ampicillin sodium/sulbactam sodium, per 1.5 gm
j0300
injection, amobarbital, up to 125 mg
j0330
injection, succinylcholine chloride, up to 20 mg
j0348
injection, anidulafungin, 1 mg
j0350
injection, anistreplase, per 30 units
j0360
injection, hydralazine hcl, up to 20 mg
j0364
injection, apomorphine hydrochloride, 1 mg
j0365
injection, aprotonin, 10,000 kiu
j0380
injection, metaraminol bitartrate, per 10 mg
j0390
injection, chloroquine hydrochloride, up to 250 mg
j0395
injection, arbutamine hcl, 1 mg
j0400
injection, aripiprazole, intramuscular, 0.25 mg
j0401
injection, aripiprazole, extended release, 1 mg
j0456
injection, azithromycin, 500 mg
j0461
injection, atropine sulfate, 0.01 mg
j0470
injection, dimercaprol, per 100 mg
j0475
injection, baclofen, 10 mg
j0476
injection, baclofen, 50 mcg for intrathecal trial
j0480
injection, basiliximab, 20 mg
j0485
injection, belatacept, 1 mg
j0490
injection, belimumab, 10 mg
j0491
injection, anifrolumab-fnia, 1 mg
j0500
injection, dicyclomine hcl, up to 20 mg
j0515
injection, benztropine mesylate, per 1 mg
j0517
injection, benralizumab, 1 mg
j0520
injection, bethanechol chloride, myotonachol or urecholine, up to 5 mg
j0558
injection, penicillin g benzathine and penicillin g procaine, 100,000 units
j0561
injection, penicillin g benzathine, 100,000 units
j0565
injection, bezlotoxumab, 10 mg
j0567
injection, cerliponase alfa, 1 mg
j0570
buprenorphine implant, 74.2 mg
j0571
buprenorphine, oral, 1 mg
j0572
buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine
j0573
buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine
j0574
buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine
j0575
buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
j0583
injection, bivalirudin, 1 mg
j0584
injection, burosumab-twza 1 mg
j0585
injection, onabotulinumtoxina, 1 unit
j0586
injection, abobotulinumtoxina, 5 units
j0587
injection, rimabotulinumtoxinb, 100 units
j0588
injection, incobotulinumtoxin a, 1 unit
j0591
injection, deoxycholic acid, 1 mg
j0592
injection, buprenorphine hydrochloride, 0.1 mg
j0593
injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
j0594
injection, busulfan, 1 mg
j0595
injection, butorphanol tartrate, 1 mg
j0596
injection, c1 esterase inhibitor (recombinant), ruconest, 10 units
j0597
injection, c-1 esterase inhibitor (human), berinert, 10 units
j0598
injection, c-1 esterase inhibitor (human), cinryze, 10 units
j0599
injection, c-1 esterase inhibitor (human), (haegarda), 10 units
j0600
injection, edetate calcium disodium, up to 1000 mg
j0604
cinacalcet, oral, 1 mg, (for esrd on dialysis)
j0606
injection, etelcalcetide, 0.1 mg
j0610
injection, calcium gluconate, per 10 ml
j0620
injection, calcium glycerophosphate and calcium lactate, per 10 ml
j0630
injection, calcitonin salmon, up to 400 units
j0636
injection, calcitriol, 0.1 mcg
j0637
injection, caspofungin acetate, 5 mg
j0638
injection, canakinumab, 1 mg
j0640
injection, leucovorin calcium, per 50 mg
j0641
injection, levoleucovorin, not otherwise specified, 0.5 mg
j0642
injection, levoleucovorin (khapzory), 0.5 mg
j0670
injection, mepivacaine hydrochloride, per 10 ml
j0690
injection, cefazolin sodium, 500 mg
j0691
injection, lefamulin, 1 mg
j0692
injection, cefepime hydrochloride, 500 mg
j0693
injection, cefiderocol, 5 mg terminated september 30, 2021.
j0694
injection, cefoxitin sodium, 1 gm
j0695
injection, ceftolozane 50 mg and tazobactam 25 mg
j0696
injection, ceftriaxone sodium, per 250 mg
j0697
injection, sterile cefuroxime sodium, per 750 mg
j0698
injection, cefotaxime sodium, per gm
j0699
injection, cefiderocol, 10 mg
j0702
injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
j0706
injection, caffeine citrate, 5 mg
j0710
injection, cephapirin sodium, up to 1 gm
j0712
injection, ceftaroline fosamil, 10 mg
j0713
injection, ceftazidime, per 500 mg
j0714
injection, ceftazidime and avibactam, 0.5 g/0.125 g
j0715
injection, ceftizoxime sodium, per 500 mg
j0716
injection, centruroides immune f(ab)2, up to 120 milligrams
j0717
injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
j0720
injection, chloramphenicol sodium succinate, up to 1 gm
j0725
injection, chorionic gonadotropin, per 1,000 usp units
j0735
injection, clonidine hydrochloride, 1 mg
j0739
injection, cabotegravir, 1 mg
j0740
injection, cidofovir, 375 mg
j0741
injection, cabotegravir and rilpivirine, 2mg/3mg
j0742
injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
j0743
injection, cilastatin sodium; imipenem, per 250 mg
j0744
injection, ciprofloxacin for intravenous infusion, 200 mg
j0745
injection, codeine phosphate, per 30 mg
j0760
injection, colchicine, per 1 mg terminated december 31, 2016.
j0770
injection, colistimethate sodium, up to 150 mg
j0775
injection, collagenase, clostridium histolyticum, 0.01 mg
j0780
injection, prochlorperazine, up to 10 mg
j0791
injection, crizanlizumab-tmca, 5 mg
j0795
injection, corticorelin ovine triflutate, 1 microgram
j0800
injection, corticotropin, up to 40 units
j0833
injection, cosyntropin, not otherwise specified, 0.25 mg terminated december 31, 2018.
j0834
injection, cosyntropin, 0.25 mg
j0840
injection, crotalidae polyvalent immune fab (ovine), up to 1 gram
j0841
injection, crotalidae immune f(ab')2 (equine), 120 mg
j0850
injection, cytomegalovirus immune globulin intravenous (human), per vial
j0875
injection, dalbavancin, 5 mg
j0878
injection, daptomycin, 1 mg
j0879
injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)
j0881
injection, darbepoetin alfa, 1 microgram (non-esrd use)
j0882
injection, darbepoetin alfa, 1 microgram (for esrd on dialysis)
j0883
injection, argatroban, 1 mg (for non-esrd use)
j0884
injection, argatroban, 1 mg (for esrd on dialysis)
j0885
injection, epoetin alfa, (for non-esrd use), 1000 units
j0886
injection, epoetin alfa, 1000 units (for esrd on dialysis) terminated december 31, 2015.
j0887
injection, epoetin beta, 1 microgram, (for esrd on dialysis)
j0888
injection, epoetin beta, 1 microgram, (for non esrd use)
j0890
injection, peginesatide, 0.1 mg (for esrd on dialysis)
j0894
injection, decitabine, 1 mg
j0895
injection, deferoxamine mesylate, 500 mg
j0896
injection, luspatercept-aamt, 0.25 mg
j0897
injection, denosumab, 1 mg
j0900
injection, testosterone enanthate and estradiol valerate, up to 1 cc terminated december 31, 2014.
j0945
injection, brompheniramine maleate, per 10 mg
j1000
injection, depo-estradiol cypionate, up to 5 mg
j1020
injection, methylprednisolone acetate, 20 mg
j1030
injection, methylprednisolone acetate, 40 mg
j1040
injection, methylprednisolone acetate, 80 mg
j1050
injection, medroxyprogesterone acetate, 1 mg
j1060
injection, testosterone cypionate and estradiol cypionate, up to 1 ml terminated december 31, 2014.
j1070
injection, testosterone cypionate, up to 100 mg terminated december 31, 2014.
j1071
injection, testosterone cypionate, 1 mg
j1080
injection, testosterone cypionate, 1 cc, 200 mg terminated december 31, 2014.
j1094
injection, dexamethasone acetate, 1 mg
j1095
injection, dexamethasone 9 percent, intraocular, 1 microgram
j1096
dexamethasone, lacrimal ophthalmic insert, 0.1 mg
j1097
phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml
j1100
injection, dexamethasone sodium phosphate, 1 mg
j1110
injection, dihydroergotamine mesylate, per 1 mg
j1120
injection, acetazolamide sodium, up to 500 mg
j1130
injection, diclofenac sodium, 0.5 mg
j1160
injection, digoxin, up to 0.5 mg
j1162
injection, digoxin immune fab (ovine), per vial
j1165
injection, phenytoin sodium, per 50 mg
j1170
injection, hydromorphone, up to 4 mg
j1180
injection, dyphylline, up to 500 mg
j1190
injection, dexrazoxane hydrochloride, per 250 mg
j1200
injection, diphenhydramine hcl, up to 50 mg
j1201
injection, cetirizine hydrochloride, 0.5 mg
j1205
injection, chlorothiazide sodium, per 500 mg
j1212
injection, dmso, dimethyl sulfoxide, 50%, 50 ml
j1230
injection, methadone hcl, up to 10 mg
j1240
injection, dimenhydrinate, up to 50 mg
j1245
injection, dipyridamole, per 10 mg
j1250
injection, dobutamine hydrochloride, per 250 mg
j1260
injection, dolasetron mesylate, 10 mg
j1265
injection, dopamine hcl, 40 mg
j1267
injection, doripenem, 10 mg
j1270
injection, doxercalciferol, 1 mcg
j1290
injection, ecallantide, 1 mg
j1300
injection, eculizumab, 10 mg
j1301
injection, edaravone, 1 mg
j1302
injection, sutimlimab-jome, 10 mg
j1303
injection, ravulizumab-cwvz, 10 mg
j1305
injection, evinacumab-dgnb, 5mg
j1306
injection, inclisiran, 1 mg
j1320
injection, amitriptyline hcl, up to 20 mg
j1322
injection, elosulfase alfa, 1 mg
j1324
injection, enfuvirtide, 1 mg
j1325
injection, epoprostenol, 0.5 mg
j1327
injection, eptifibatide, 5 mg
j1330
injection, ergonovine maleate, up to 0.2 mg
j1335
injection, ertapenem sodium, 500 mg
j1364
injection, erythromycin lactobionate, per 500 mg
j1380
injection, estradiol valerate, up to 10 mg
j1410
injection, estrogen conjugated, per 25 mg
j1426
injection, casimersen, 10 mg
j1427
injection, viltolarsen, 10 mg
j1428
injection, eteplirsen, 10 mg
j1429
injection, golodirsen, 10 mg
j1430
injection, ethanolamine oleate, 100 mg
j1435
injection, estrone, per 1 mg
j1436
injection, etidronate disodium, per 300 mg
j1437
injection, ferric derisomaltose, 10 mg
j1438
injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
j1439
injection, ferric carboxymaltose, 1 mg
j1442
injection, filgrastim (g-csf), excludes biosimilars, 1 microgram
j1443
injection, ferric pyrophosphate citrate solution (triferic), 0.1 mg of iron
j1444
injection, ferric pyrophosphate citrate powder, 0.1 mg of iron
j1445
injection, ferric pyrophosphate citrate solution (triferic avnu), 0.1 mg of iron
j1446
injection, tbo-filgrastim, 5 micrograms terminated december 31, 2015.
j1447
injection, tbo-filgrastim, 1 microgram
j1448
injection, trilaciclib, 1mg
j1450
injection fluconazole, 200 mg
j1451
injection, fomepizole, 15 mg
j1452
injection, fomivirsen sodium, intraocular, 1.65 mg
j1453
injection, fosaprepitant, 1 mg
j1454
injection, fosnetupitant 235 mg and palonosetron 0.25 mg
j1455
injection, foscarnet sodium, per 1000 mg
j1457
injection, gallium nitrate, 1 mg
j1458
injection, galsulfase, 1 mg
j1459
injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg
j1460
injection, gamma globulin, intramuscular, 1 cc
j1551
injection, immune globulin (cutaquig), 100 mg
j1554
injection, immune globulin (asceniv), 500 mg
j1555
injection, immune globulin (cuvitru), 100 mg
j1556
injection, immune globulin (bivigam), 500 mg
j1557
injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg
j1558
injection, immune globulin (xembify), 100 mg
j1559
injection, immune globulin (hizentra), 100 mg
j1560
injection, gamma globulin, intramuscular, over 10 cc
j1561
injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg
j1562
injection, immune globulin (vivaglobin), 100 mg
j1566
injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
j1568
injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
j1569
injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
j1570
injection, ganciclovir sodium, 500 mg
j1571
injection, hepatitis b immune globulin (hepagam b), intramuscular, 0.5 ml
j1572
injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg
j1573
injection, hepatitis b immune globulin (hepagam b), intravenous, 0.5 ml
j1575
injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin
j1580
injection, garamycin, gentamicin, up to 80 mg
j1590
injection, gatifloxacin, 10 mg terminated december 31, 2016.
j1595
injection, glatiramer acetate, 20 mg
j1599
injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg
j1600
injection, gold sodium thiomalate, up to 50 mg
j1602
injection, golimumab, 1 mg, for intravenous use
j1610
injection, glucagon hydrochloride, per 1 mg
j1620
injection, gonadorelin hydrochloride, per 100 mcg
j1626
injection, granisetron hydrochloride, 100 mcg
j1627
injection, granisetron, extended-release, 0.1 mg
j1628
injection, guselkumab, 1 mg
j1630
injection, haloperidol, up to 5 mg
j1631
injection, haloperidol decanoate, per 50 mg
j1632
injection, brexanolone, 1 mg
j1640
injection, hemin, 1 mg
j1642
injection, heparin sodium, (heparin lock flush), per 10 units
j1644
injection, heparin sodium, per 1000 units
j1645
injection, dalteparin sodium, per 2500 iu
j1650
injection, enoxaparin sodium, 10 mg
j1652
injection, fondaparinux sodium, 0.5 mg
j1655
injection, tinzaparin sodium, 1000 iu
j1670
injection, tetanus immune globulin, human, up to 250 units
j1675
injection, histrelin acetate, 10 micrograms
j1700
injection, hydrocortisone acetate, up to 25 mg
j1710
injection, hydrocortisone sodium phosphate, up to 50 mg
j1720
injection, hydrocortisone sodium succinate, up to 100 mg
j1725
injection, hydroxyprogesterone caproate, 1 mg terminated december 31, 2017.
j1726
injection, hydroxyprogesterone caproate, (makena), 10 mg
j1729
injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
j1730
injection, diazoxide, up to 300 mg
j1738
injection, meloxicam, 1 mg
j1740
injection, ibandronate sodium, 1 mg
j1741
injection, ibuprofen, 100 mg
j1742
injection, ibutilide fumarate, 1 mg
j1743
injection, idursulfase, 1 mg
j1744
injection, icatibant, 1 mg
j1745
injection, infliximab, excludes biosimilar, 10 mg
j1746
injection, ibalizumab-uiyk, 10 mg
j1750
injection, iron dextran, 50 mg
j1756
injection, iron sucrose, 1 mg
j1786
injection, imiglucerase, 10 units
j1790
injection, droperidol, up to 5 mg
j1800
injection, propranolol hcl, up to 1 mg
j1810
injection, droperidol and fentanyl citrate, up to 2 ml ampule
j1815
injection, insulin, per 5 units
j1817
insulin for administration through dme (i.e., insulin pump) per 50 units
j1823
injection, inebilizumab-cdon, 1 mg
j1826
injection, interferon beta-1a, 30 mcg
j1830
injection, interferon beta-1b, 0.25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
j1833
injection, isavuconazonium, 1 mg
j1835
injection, itraconazole, 50 mg
j1840
injection, kanamycin sulfate, up to 500 mg
j1850
injection, kanamycin sulfate, up to 75 mg
j1885
injection, ketorolac tromethamine, per 15 mg
j1890
injection, cephalothin sodium, up to 1 gram
j1930
injection, lanreotide, 1 mg
j1931
injection, laronidase, 0.1 mg
j1932
injection, lanreotide, (cipla), 1 mg
j1940
injection, furosemide, up to 20 mg
j1942
injection, aripiprazole lauroxil, 1 mg terminated september 30, 2019.
j1943
injection, aripiprazole lauroxil, (aristada initio), 1 mg
j1944
injection, aripiprazole lauroxil, (aristada), 1 mg
j1945
injection, lepirudin, 50 mg
j1950
injection, leuprolide acetate (for depot suspension), per 3.75 mg
j1951
injection, leuprolide acetate for depot suspension (fensolvi), 0.25 mg
j1952
leuprolide injectable, camcevi, 1 mg
j1953
injection, levetiracetam, 10 mg
j1955
injection, levocarnitine, per 1 gm
j1956
injection, levofloxacin, 250 mg
j1960
injection, levorphanol tartrate, up to 2 mg
j1980
injection, hyoscyamine sulfate, up to 0.25 mg
j1990
injection, chlordiazepoxide hcl, up to 100 mg
j2001
injection, lidocaine hcl for intravenous infusion, 10 mg
j2010
injection, lincomycin hcl, up to 300 mg
j2020
injection, linezolid, 200 mg
j2060
injection, lorazepam, 2 mg
j2062
loxapine for inhalation, 1 mg
j2150
injection, mannitol, 25% in 50 ml
j2170
injection, mecasermin, 1 mg
j2175
injection, meperidine hydrochloride, per 100 mg
j2180
injection, meperidine and promethazine hcl, up to 50 mg
j2182
injection, mepolizumab, 1 mg
j2185
injection, meropenem, 100 mg
j2186
injection, meropenem and vaborbactam, 10mg/10mg (20mg)
j2210
injection, methylergonovine maleate, up to 0.2 mg
j2212
injection, methylnaltrexone, 0.1 mg
j2248
injection, micafungin sodium, 1 mg
j2250
injection, midazolam hydrochloride, per 1 mg
j2260
injection, milrinone lactate, 5 mg
j2265
injection, minocycline hydrochloride, 1 mg
j2270
injection, morphine sulfate, up to 10 mg
j2271
injection, morphine sulfate, 100mg terminated december 31, 2014.
j2274
injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
j2275
injection, morphine sulfate (preservative-free sterile solution), per 10 mg terminated december 31, 2014.
j2278
injection, ziconotide, 1 microgram
j2280
injection, moxifloxacin, 100 mg
j2300
injection, nalbuphine hydrochloride, per 10 mg
j2310
injection, naloxone hydrochloride, per 1 mg
j2315
injection, naltrexone, depot form, 1 mg
j2320
injection, nandrolone decanoate, up to 50 mg
j2323
injection, natalizumab, 1 mg
j2325
injection, nesiritide, 0.1 mg
j2326
injection, nusinersen, 0.1 mg
j2350
injection, ocrelizumab, 1 mg
j2353
injection, octreotide, depot form for intramuscular injection, 1 mg
j2354
injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
j2355
injection, oprelvekin, 5 mg
j2356
injection, tezepelumab-ekko, 1 mg
j2357
injection, omalizumab, 5 mg
j2358
injection, olanzapine, long-acting, 1 mg
j2360
injection, orphenadrine citrate, up to 60 mg
j2370
injection, phenylephrine hcl, up to 1 ml
j2400
injection, chloroprocaine hydrochloride, per 30 ml
j2405
injection, ondansetron hydrochloride, per 1 mg
j2406
injection, oritavancin (kimyrsa), 10 mg
j2407
injection, oritavancin (orbactiv), 10 mg
j2410
injection, oxymorphone hcl, up to 1 mg
j2425
injection, palifermin, 50 micrograms
j2426
injection, paliperidone palmitate extended release, 1 mg
j2430
injection, pamidronate disodium, per 30 mg
j2440
injection, papaverine hcl, up to 60 mg
j2460
injection, oxytetracycline hcl, up to 50 mg
j2469
injection, palonosetron hcl, 25 mcg
j2501
injection, paricalcitol, 1 mcg
j2502
injection, pasireotide long acting, 1 mg
j2503
injection, pegaptanib sodium, 0.3 mg
j2504
injection, pegademase bovine, 25 iu
j2505
injection, pegfilgrastim, 6 mg terminated december 31, 2021.
j2506
injection, pegfilgrastim, excludes biosimilar, 0.5 mg
j2507
injection, pegloticase, 1 mg
j2510
injection, penicillin g procaine, aqueous, up to 600,000 units
j2513
injection, pentastarch, 10% solution, 100 ml
j2515
injection, pentobarbital sodium, per 50 mg
j2540
injection, penicillin g potassium, up to 600,000 units
j2543
injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)
j2545
pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg
j2547
injection, peramivir, 1 mg
j2550
injection, promethazine hcl, up to 50 mg
j2560
injection, phenobarbital sodium, up to 120 mg
j2562
injection, plerixafor, 1 mg
j2590
injection, oxytocin, up to 10 units
j2597
injection, desmopressin acetate, per 1 mcg
j2650
injection, prednisolone acetate, up to 1 ml
j2670
injection, tolazoline hcl, up to 25 mg
j2675
injection, progesterone, per 50 mg
j2680
injection, fluphenazine decanoate, up to 25 mg
j2690
injection, procainamide hcl, up to 1 gm
j2700
injection, oxacillin sodium, up to 250 mg
j2704
injection, propofol, 10 mg
j2710
injection, neostigmine methylsulfate, up to 0.5 mg
j2720
injection, protamine sulfate, per 10 mg
j2724
injection, protein c concentrate, intravenous, human, 10 iu
j2725
injection, protirelin, per 250 mcg
j2730
injection, pralidoxime chloride, up to 1 gm
j2760
injection, phentolamine mesylate, up to 5 mg
j2765
injection, metoclopramide hcl, up to 10 mg
j2770
injection, quinupristin/dalfopristin, 500 mg (150/350)
j2777
injection, faricimab-svoa, 0.1 mg
j2778
injection, ranibizumab, 0.1 mg
j2779
injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
j2780
injection, ranitidine hydrochloride, 25 mg
j2783
injection, rasburicase, 0.5 mg
j2785
injection, regadenoson, 0.1 mg
j2786
injection, reslizumab, 1 mg
j2787
riboflavin 5'-phosphate, ophthalmic solution, up to 3 ml
j2788
injection, rho d immune globulin, human, minidose, 50 micrograms (250 i.u.)
j2790
injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.)
j2791
injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu
j2792
injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu
j2793
injection, rilonacept, 1 mg
j2794
injection, risperidone (risperdal consta), 0.5 mg
j2795
injection, ropivacaine hydrochloride, 1 mg
j2796
injection, romiplostim, 10 micrograms
j2797
injection, rolapitant, 0.5 mg
j2798
injection, risperidone, (perseris), 0.5 mg
j2800
injection, methocarbamol, up to 10 ml
j2805
injection, sincalide, 5 micrograms
j2810
injection, theophylline, per 40 mg
j2820
injection, sargramostim (gm-csf), 50 mcg
j2840
injection, sebelipase alfa, 1 mg
j2850
injection, secretin, synthetic, human, 1 microgram
j2860
injection, siltuximab, 10 mg
j2910
injection, aurothioglucose, up to 50 mg
j2916
injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg
j2920
injection, methylprednisolone sodium succinate, up to 40 mg
j2930
injection, methylprednisolone sodium succinate, up to 125 mg
j2940
injection, somatrem, 1 mg
j2941
injection, somatropin, 1 mg
j2950
injection, promazine hcl, up to 25 mg
j2993
injection, reteplase, 18.1 mg
j2995
injection, streptokinase, per 250,000 iu
j2997
injection, alteplase recombinant, 1 mg
j2998
injection, plasminogen, human-tvmh, 1 mg
j3000
injection, streptomycin, up to 1 gm
j3010
injection, fentanyl citrate, 0.1 mg
j3030
injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
j3031
injection, fremanezumab-vfrm, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
j3032
injection, eptinezumab-jjmr, 1 mg
j3060
injection, taliglucerase alfa, 10 units
j3070
injection, pentazocine, 30 mg
j3090
injection, tedizolid phosphate, 1 mg
j3095
injection, telavancin, 10 mg
j3101
injection, tenecteplase, 1 mg
j3105
injection, terbutaline sulfate, up to 1 mg
j3110
injection, teriparatide, 10 mcg
j3111
injection, romosozumab-aqqg, 1 mg
j3120
injection, testosterone enanthate, up to 100 mg terminated december 31, 2014.
j3121
injection, testosterone enanthate, 1 mg
j3130
injection, testosterone enanthate, up to 200 mg terminated december 31, 2014.
j3140
injection, testosterone suspension, up to 50 mg terminated december 31, 2014.
j3145
injection, testosterone undecanoate, 1 mg
j3150
injection, testosterone propionate, up to 100 mg terminated december 31, 2014.
j3230
injection, chlorpromazine hcl, up to 50 mg
j3240
injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial
j3241
injection, teprotumumab-trbw, 10 mg
j3243
injection, tigecycline, 1 mg
j3245
injection, tildrakizumab, 1 mg
j3246
injection, tirofiban hcl, 0.25 mg
j3250
injection, trimethobenzamide hcl, up to 200 mg
j3260
injection, tobramycin sulfate, up to 80 mg
j3262
injection, tocilizumab, 1 mg
j3265
injection, torsemide, 10 mg/ml
j3280
injection, thiethylperazine maleate, up to 10 mg
j3285
injection, treprostinil, 1 mg
j3299
injection, triamcinolone acetonide (xipere), 1 mg
j3300
injection, triamcinolone acetonide, preservative free, 1 mg
j3301
injection, triamcinolone acetonide, not otherwise specified, 10 mg
j3302
injection, triamcinolone diacetate, per 5 mg
j3303
injection, triamcinolone hexacetonide, per 5 mg
j3304
injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
j3305
injection, trimetrexate glucuronate, per 25 mg
j3310
injection, perphenazine, up to 5 mg
j3315
injection, triptorelin pamoate, 3.75 mg
j3316
injection, triptorelin, extended-release, 3.75 mg
j3320
injection, spectinomycin dihydrochloride, up to 2 gm
j3350
injection, urea, up to 40 gm
j3355
injection, urofollitropin, 75 iu
j3357
ustekinumab, for subcutaneous injection, 1 mg
j3358
ustekinumab, for intravenous injection, 1 mg
j3360
injection, diazepam, up to 5 mg
j3364
injection, urokinase, 5000 iu vial
j3365
injection, iv, urokinase, 250,000 i.u. vial
j3370
injection, vancomycin hcl, 500 mg
j3380
injection, vedolizumab, 1 mg
j3385
injection, velaglucerase alfa, 100 units
j3396
injection, verteporfin, 0.1 mg
j3397
injection, vestronidase alfa-vjbk, 1 mg
j3398
injection, voretigene neparvovec-rzyl, 1 billion vector genomes
j3399
injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes
j3400
injection, triflupromazine hcl, up to 20 mg
j3410
injection, hydroxyzine hcl, up to 25 mg
j3411
injection, thiamine hcl, 100 mg
j3415
injection, pyridoxine hcl, 100 mg
j3420
injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
j3430
injection, phytonadione (vitamin k), per 1 mg
j3465
injection, voriconazole, 10 mg
j3470
injection, hyaluronidase, up to 150 units
j3471
injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units)
j3472
injection, hyaluronidase, ovine, preservative free, per 1000 usp units
j3473
injection, hyaluronidase, recombinant, 1 usp unit
j3475
injection, magnesium sulfate, per 500 mg
j3480
injection, potassium chloride, per 2 meq
j3485
injection, zidovudine, 10 mg
j3486
injection, ziprasidone mesylate, 10 mg
j3489
injection, zoledronic acid, 1 mg
j3490
unclassified drugs
j3520
edetate disodium, per 150 mg
j3530
nasal vaccine inhalation
j3535
drug administered through a metered dose inhaler
j3570
laetrile, amygdalin, vitamin b17
j3590
unclassified biologics
j3591
unclassified drug or biological used for esrd on dialysis
j7030
infusion, normal saline solution , 1000 cc
j7040
infusion, normal saline solution, sterile (500 ml = 1 unit)
j7042
5% dextrose/normal saline (500 ml = 1 unit)
j7050
infusion, normal saline solution, 250 cc
j7060
5% dextrose/water (500 ml = 1 unit)
j7070
infusion, d5w, 1000 cc
j7100
infusion, dextran 40, 500 ml
j7110
infusion, dextran 75, 500 ml
j7120
ringers lactate infusion, up to 1000 cc
j7121
5% dextrose in lactated ringers infusion, up to 1000 cc
j7131
hypertonic saline solution, 1 ml
j7168
prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity
j7169
injection, coagulation factor xa (recombinant), inactivated-zhzo (andexxa), 10 mg
j7170
injection, emicizumab-kxwh, 0.5 mg
j7175
injection, factor x, (human), 1 i.u.
j7177
injection, human fibrinogen concentrate (fibryga), 1 mg
j7178
injection, human fibrinogen concentrate, not otherwise specified, 1 mg
j7179
injection, von willebrand factor (recombinant), (vonvendi), 1 i.u. vwf:rco
j7180
injection, factor xiii (antihemophilic factor, human), 1 i.u.
j7181
injection, factor xiii a-subunit, (recombinant), per iu
j7182
injection, factor viii, (antihemophilic factor, recombinant), (novoeight), per iu
j7183
injection, von willebrand factor complex (human), wilate, 1 i.u. vwf:rco
j7185
injection, factor viii (antihemophilic factor, recombinant) (xyntha), per i.u.
j7186
injection, antihemophilic factor viii/von willebrand factor complex (human), per factor viii i.u.
j7187
injection, von willebrand factor complex (humate-p), per iu vwf:rco
j7188
injection, factor viii (antihemophilic factor, recombinant), (obizur), per i.u.
j7189
factor viia (antihemophilic factor, recombinant), (novoseven rt), 1 microgram
j7190
factor viii (antihemophilic factor, human) per i.u.
j7191
factor viii (antihemophilic factor (porcine)), per i.u.
j7192
factor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified
j7193
factor ix (antihemophilic factor, purified, non-recombinant) per i.u.
j7194
factor ix, complex, per i.u.
j7195
injection, factor ix (antihemophilic factor, recombinant) per iu, not otherwise specified
j7196
injection, antithrombin recombinant, 50 i.u.
j7197
antithrombin iii (human), per i.u.
j7198
anti-inhibitor, per i.u.
j7199
hemophilia clotting factor, not otherwise classified
j7200
injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu
j7201
injection, factor ix, fc fusion protein, (recombinant), alprolix, 1 i.u.
j7202
injection, factor ix, albumin fusion protein, (recombinant), idelvion, 1 i.u.
j7203
injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu
j7204
injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu
j7205
injection, factor viii fc fusion protein (recombinant), per iu
j7207
injection, factor viii, (antihemophilic factor, recombinant), pegylated, 1 i.u.
j7208
injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.
j7209
injection, factor viii, (antihemophilic factor, recombinant), (nuwiq), 1 i.u.
j7210
injection, factor viii, (antihemophilic factor, recombinant), (afstyla), 1 i.u.
j7211
injection, factor viii, (antihemophilic factor, recombinant), (kovaltry), 1 i.u.
j7212
factor viia (antihemophilic factor, recombinant)-jncw (sevenfact), 1 microgram
j7294
segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hours; yearly vaginal system, each
j7295
ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each
j7296
levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg
j7297
levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg
j7298
levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg
j7300
intrauterine copper contraceptive
j7301
levonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg
j7302
levonorgestrel-releasing intrauterine contraceptive system, 52 mg terminated december 31, 2015.
j7303
contraceptive supply, hormone containing vaginal ring, each terminated september 30, 2021.
j7304
contraceptive supply, hormone containing patch, each
j7306
levonorgestrel (contraceptive) implant system, including implants and supplies
j7307
etonogestrel (contraceptive) implant system, including implant and supplies
j7308
aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)
j7309
methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gram
j7310
ganciclovir, 4.5 mg, long-acting implant
j7311
injection, fluocinolone acetonide, intravitreal implant (retisert), 0.01 mg
j7312
injection, dexamethasone, intravitreal implant, 0.1 mg
j7313
injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg
j7314
injection, fluocinolone acetonide, intravitreal implant (yutiq), 0.01 mg
j7315
mitomycin, ophthalmic, 0.2 mg
j7316
injection, ocriplasmin, 0.125 mg
j7318
hyaluronan or derivative, durolane, for intra-articular injection, 1 mg
j7320
hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg
j7321
hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose
j7322
hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg
j7323
hyaluronan or derivative, euflexxa, for intra-articular injection, per dose
j7324
hyaluronan or derivative, orthovisc, for intra-articular injection, per dose
j7325
hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg
j7326
hyaluronan or derivative, gel-one, for intra-articular injection, per dose
j7327
hyaluronan or derivative, monovisc, for intra-articular injection, per dose
j7328
hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg
j7329
hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg
j7330
autologous cultured chondrocytes, implant
j7331
hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg
j7332
hyaluronan or derivative, triluron, for intra-articular injection, 1 mg
j7333
hyaluronan or derivative, visco-3, for intra-articular injection, per dose terminated march 31, 2021.
j7335
capsaicin 8% patch, per 10 square centimeters terminated december 31, 2014.
j7336
capsaicin 8% patch, per square centimeter
j7340
carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml
j7342
instillation, ciprofloxacin otic suspension, 6 mg
j7345
aminolevulinic acid hcl for topical administration, 10% gel, 10 mg
j7351
injection, bimatoprost, intracameral implant, 1 microgram
j7352
afamelanotide implant, 1 mg
j7401
mometasone furoate sinus implant, 10 micrograms terminated march 31, 2021.
j7402
mometasone furoate sinus implant, (sinuva), 10 micrograms
j7500
azathioprine, oral, 50 mg
j7501
azathioprine, parenteral, 100 mg
j7502
cyclosporine, oral, 100 mg
j7503
tacrolimus, extended release, (envarsus xr), oral, 0.25 mg
j7504
lymphocyte immune globulin, antithymocyte globulin, equine, parenteral, 250 mg
j7505
muromonab-cd3, parenteral, 5 mg
j7506
prednisone, oral, per 5 mg terminated december 31, 2015.
j7507
tacrolimus, immediate release, oral, 1 mg
j7508
tacrolimus, extended release, (astagraf xl), oral, 0.1 mg
j7509
methylprednisolone oral, per 4 mg
j7510
prednisolone oral, per 5 mg
j7511
lymphocyte immune globulin, antithymocyte globulin, rabbit, parenteral, 25 mg
j7512
prednisone, immediate release or delayed release, oral, 1 mg
j7513
daclizumab, parenteral, 25 mg
j7515
cyclosporine, oral, 25 mg
j7516
cyclosporin, parenteral, 250 mg
j7517
mycophenolate mofetil, oral, 250 mg
j7518
mycophenolic acid, oral, 180 mg
j7520
sirolimus, oral, 1 mg
j7525
tacrolimus, parenteral, 5 mg
j7527
everolimus, oral, 0.25 mg
j7599
immunosuppressive drug, not otherwise classified
j7604
acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gram
j7605
arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms
j7606
formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms
j7607
levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mg
j7608
acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
j7609
albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg
j7610
albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg
j7611
albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg
j7612
levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg
j7613
albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg
j7614
levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg
j7615
levalbuterol, inhalation solution, compounded product, administered through dme, unit dose, 0.5 mg
j7620
albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme
j7622
beclomethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7624
betamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7626
budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg
j7627
budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg
j7628
bitolterol mesylate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
j7629
bitolterol mesylate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7631
cromolyn sodium, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligrams
j7632
cromolyn sodium, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligrams
j7633
budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligram
j7634
budesonide, inhalation solution, compounded product, administered through dme, concentrated form, per 0.25 milligram
j7635
atropine, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
j7636
atropine, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7637
dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
j7638
dexamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7639
dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram
j7640
formoterol, inhalation solution, compounded product, administered through dme, unit dose form, 12 micrograms
j7641
flunisolide, inhalation solution, compounded product, administered through dme, unit dose, per milligram
j7642
glycopyrrolate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
j7643
glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7644
ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram
j7645
ipratropium bromide, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7647
isoetharine hcl, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
j7648
isoetharine hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per milligram
j7649
isoetharine hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram
j7650
isoetharine hcl, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7657
isoproterenol hcl, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
j7658
isoproterenol hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per milligram
j7659
isoproterenol hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram
j7660
isoproterenol hcl, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7665
mannitol, administered through an inhaler, 5 mg
j7667
metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligrams
j7668
metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 10 milligrams
j7669
metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligrams
j7670
metaproterenol sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligrams
j7674
methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg
j7676
pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mg
j7677
revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
j7680
terbutaline sulfate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
j7681
terbutaline sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7682
tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligrams
j7683
triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
j7684
triamcinolone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
j7685
tobramycin, inhalation solution, compounded product, administered through dme, unit dose form, per 300 milligrams
j7686
treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg
j7699
noc drugs, inhalation solution administered through dme
j7799
noc drugs, other than inhalation drugs, administered through dme
j7999
compounded drug, not otherwise classified
j8498
antiemetic drug, rectal/suppository, not otherwise specified
j8499
prescription drug, oral, non chemotherapeutic, nos
j8501
aprepitant, oral, 5 mg
j8510
busulfan; oral, 2 mg
j8515
cabergoline, oral, 0.25 mg
j8520
capecitabine, oral, 150 mg
j8521
capecitabine, oral, 500 mg
j8530
cyclophosphamide; oral, 25 mg
j8540
dexamethasone, oral, 0.25 mg
j8560
etoposide; oral, 50 mg
j8562
fludarabine phosphate, oral, 10 mg
j8565
gefitinib, oral, 250 mg
j8597
antiemetic drug, oral, not otherwise specified
j8600
melphalan; oral, 2 mg
j8610
methotrexate; oral, 2.5 mg
j8650
nabilone, oral, 1 mg
j8655
netupitant 300 mg and palonosetron 0.5 mg, oral
j8670
rolapitant, oral, 1 mg
j8700
temozolomide, oral, 5 mg
j8705
topotecan, oral, 0.25 mg
j8999
prescription drug, oral, chemotherapeutic, nos
j9000
injection, doxorubicin hydrochloride, 10 mg
j9010
injection, alemtuzumab, 10 mg terminated december 31, 2015.
j9015
injection, aldesleukin, per single use vial
j9017
injection, arsenic trioxide, 1 mg
j9019
injection, asparaginase (erwinaze), 1,000 iu
j9020
injection, asparaginase, not otherwise specified, 10,000 units
j9021
injection, asparaginase, recombinant, (rylaze), 0.1 mg
j9022
injection, atezolizumab, 10 mg
j9023
injection, avelumab, 10 mg
j9025
injection, azacitidine, 1 mg
j9027
injection, clofarabine, 1 mg
j9030
bcg live intravesical instillation, 1 mg
j9031
bcg (intravesical) per instillation terminated june 30, 2019.
j9032
injection, belinostat, 10 mg
j9033
injection, bendamustine hcl (treanda), 1 mg
j9034
injection, bendamustine hcl (bendeka), 1 mg
j9035
injection, bevacizumab, 10 mg
j9036
injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg
j9037
injection, belantamab mafodotin-blmf, 0.5 mg
j9039
injection, blinatumomab, 1 microgram
j9040
injection, bleomycin sulfate, 15 units
j9041
injection, bortezomib (velcade), 0.1 mg
j9042
injection, brentuximab vedotin, 1 mg
j9043
injection, cabazitaxel, 1 mg
j9044
injection, bortezomib, not otherwise specified, 0.1 mg
j9045
injection, carboplatin, 50 mg
j9047
injection, carfilzomib, 1 mg
j9050
injection, carmustine, 100 mg
j9055
injection, cetuximab, 10 mg
j9057
injection, copanlisib, 1 mg
j9060
injection, cisplatin, powder or solution, 10 mg
j9061
injection, amivantamab-vmjw, 2 mg
j9065
injection, cladribine, per 1 mg
j9070
cyclophosphamide, 100 mg
j9071
injection, cyclophosphamide, (auromedics), 5 mg
j9098
injection, cytarabine liposome, 10 mg
j9100
injection, cytarabine, 100 mg
j9118
injection, calaspargase pegol-mknl, 10 units
j9119
injection, cemiplimab-rwlc, 1 mg
j9120
injection, dactinomycin, 0.5 mg
j9130
dacarbazine, 100 mg
j9144
injection, daratumumab, 10 mg and hyaluronidase-fihj
j9145
injection, daratumumab, 10 mg
j9150
injection, daunorubicin, 10 mg
j9151
injection, daunorubicin citrate, liposomal formulation, 10 mg
j9153
injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
j9155
injection, degarelix, 1 mg
j9160
injection, denileukin diftitox, 300 micrograms
j9165
injection, diethylstilbestrol diphosphate, 250 mg
j9171
injection, docetaxel, 1 mg
j9173
injection, durvalumab, 10 mg
j9175
injection, elliotts' b solution, 1 ml
j9176
injection, elotuzumab, 1 mg
j9177
injection, enfortumab vedotin-ejfv, 0.25 mg
j9178
injection, epirubicin hcl, 2 mg
j9179
injection, eribulin mesylate, 0.1 mg
j9181
injection, etoposide, 10 mg
j9185
injection, fludarabine phosphate, 50 mg
j9190
injection, fluorouracil, 500 mg
j9198
injection, gemcitabine hydrochloride, (infugem), 100 mg
j9199
injection, gemcitabine hydrochloride (infugem), 200 mg terminated june 30, 2020.
j9200
injection, floxuridine, 500 mg
j9201
injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
j9202
goserelin acetate implant, per 3.6 mg
j9203
injection, gemtuzumab ozogamicin, 0.1 mg
j9204
injection, mogamulizumab-kpkc, 1 mg
j9205
injection, irinotecan liposome, 1 mg
j9206
injection, irinotecan, 20 mg
j9207
injection, ixabepilone, 1 mg
j9208
injection, ifosfamide, 1 gram
j9209
injection, mesna, 200 mg
j9210
injection, emapalumab-lzsg, 1 mg
j9211
injection, idarubicin hydrochloride, 5 mg
j9212
injection, interferon alfacon-1, recombinant, 1 microgram
j9213
injection, interferon, alfa-2a, recombinant, 3 million units
j9214
injection, interferon, alfa-2b, recombinant, 1 million units
j9215
injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu
j9216
injection, interferon, gamma 1-b, 3 million units
j9217
leuprolide acetate (for depot suspension), 7.5 mg
j9218
leuprolide acetate, per 1 mg
j9219
leuprolide acetate implant, 65 mg
j9223
injection, lurbinectedin, 0.1 mg
j9225
histrelin implant (vantas), 50 mg
j9226
histrelin implant (supprelin la), 50 mg
j9227
injection, isatuximab-irfc, 10 mg
j9228
injection, ipilimumab, 1 mg
j9229
injection, inotuzumab ozogamicin, 0.1 mg
j9230
injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg
j9245
injection, melphalan hydrochloride, not otherwise specified, 50 mg
j9246
injection, melphalan (evomela), 1 mg
j9247
injection, melphalan flufenamide, 1mg
j9250
methotrexate sodium, 5 mg
j9260
methotrexate sodium, 50 mg
j9261
injection, nelarabine, 50 mg
j9262
injection, omacetaxine mepesuccinate, 0.01 mg
j9263
injection, oxaliplatin, 0.5 mg
j9264
injection, paclitaxel protein-bound particles, 1 mg
j9265
injection, paclitaxel, 30 mg terminated december 31, 2014.
j9266
injection, pegaspargase, per single dose vial
j9267
injection, paclitaxel, 1 mg
j9268
injection, pentostatin, 10 mg
j9269
injection, tagraxofusp-erzs, 10 micrograms
j9270
injection, plicamycin, 2.5 mg
j9271
injection, pembrolizumab, 1 mg
j9272
injection, dostarlimab-gxly, 10 mg
j9273
injection, tisotumab vedotin-tftv, 1 mg
j9274
injection, tebentafusp-tebn, 1 microgram
j9280
injection, mitomycin, 5 mg
j9281
mitomycin pyelocalyceal instillation, 1 mg
j9285
injection, olaratumab, 10 mg
j9293
injection, mitoxantrone hydrochloride, per 5 mg
j9295
injection, necitumumab, 1 mg
j9298
injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
j9299
injection, nivolumab, 1 mg
j9300
injection, gemtuzumab ozogamicin, 5 mg terminated december 31, 2017.
j9301
injection, obinutuzumab, 10 mg
j9302
injection, ofatumumab, 10 mg
j9303
injection, panitumumab, 10 mg
j9304
injection, pemetrexed (pemfexy), 10 mg
j9305
injection, pemetrexed, not otherwise specified, 10 mg
j9306
injection, pertuzumab, 1 mg
j9307
injection, pralatrexate, 1 mg
j9308
injection, ramucirumab, 5 mg
j9309
injection, polatuzumab vedotin-piiq, 1 mg
j9310
injection, rituximab, 100 mg terminated december 31, 2018.
j9311
injection, rituximab 10 mg and hyaluronidase
j9312
injection, rituximab, 10 mg
j9313
injection, moxetumomab pasudotox-tdfk, 0.01 mg
j9315
injection, romidepsin, 1 mg terminated september 30, 2021.
j9316
injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg
j9317
injection, sacituzumab govitecan-hziy, 2.5 mg
j9318
injection, romidepsin, non-lyophilized, 0.1 mg
j9319
injection, romidepsin, lyophilized, 0.1 mg
j9320
injection, streptozocin, 1 gram
j9325
injection, talimogene laherparepvec, per 1 million plaque forming units
j9328
injection, temozolomide, 1 mg
j9330
injection, temsirolimus, 1 mg
j9331
injection, sirolimus protein-bound particles, 1 mg
j9332
injection, efgartigimod alfa-fcab, 2mg
j9340
injection, thiotepa, 15 mg
j9348
injection, naxitamab-gqgk, 1 mg
j9349
injection, tafasitamab-cxix, 2 mg
j9351
injection, topotecan, 0.1 mg
j9352
injection, trabectedin, 0.1 mg
j9353
injection, margetuximab-cmkb, 5 mg
j9354
injection, ado-trastuzumab emtansine, 1 mg
j9355
injection, trastuzumab, excludes biosimilar, 10 mg
j9356
injection, trastuzumab, 10 mg and hyaluronidase-oysk
j9357
injection, valrubicin, intravesical, 200 mg
j9358
injection, fam-trastuzumab deruxtecan-nxki, 1 mg
j9359
injection, loncastuximab tesirine-lpyl, 0.075 mg
j9360
injection, vinblastine sulfate, 1 mg
j9370
vincristine sulfate, 1 mg
j9371
injection, vincristine sulfate liposome, 1 mg
j9390
injection, vinorelbine tartrate, 10 mg
j9395
injection, fulvestrant, 25 mg
j9400
injection, ziv-aflibercept, 1 mg
j9600
injection, porfimer sodium, 75 mg
j9999
not otherwise classified, antineoplastic drugs
k0001
standard wheelchair
k0002
standard hemi (low seat) wheelchair
k0003
lightweight wheelchair
k0004
high strength, lightweight wheelchair
k0005
ultralightweight wheelchair
k0006
heavy duty wheelchair
k0007
extra heavy duty wheelchair
k0008
custom manual wheelchair/base
k0009
other manual wheelchair/base
k0010
standard - weight frame motorized/power wheelchair
k0011
standard - weight frame motorized/power wheelchair with programmable control parameters for speed adjustment, tremor dampening, acceleration control and braking
k0012
lightweight portable motorized/power wheelchair
k0013
custom motorized/power wheelchair base
k0014
other motorized/power wheelchair base
k0015
detachable, non-adjustable height armrest, replacement only, each
k0017
detachable, adjustable height armrest, base, replacement only, each
k0018
detachable, adjustable height armrest, upper portion, replacement only, each
k0019
arm pad, replacement only, each
k0020
fixed, adjustable height armrest, pair
k0037
high mount flip-up footrest, each
k0038
leg strap, each
k0039
leg strap, h style, each
k0040
adjustable angle footplate, each
k0041
large size footplate, each
k0042
standard size footplate, replacement only, each
k0043
footrest, lower extension tube, replacement only, each
k0044
footrest, upper hanger bracket, replacement only, each
k0045
footrest, complete assembly, replacement only, each
k0046
elevating legrest, lower extension tube, replacement only, each
k0047
elevating legrest, upper hanger bracket, replacement only, each
k0050
ratchet assembly, replacement only
k0051
cam release assembly, footrest or legrest, replacement only, each
k0052
swingaway, detachable footrests, replacement only, each
k0053
elevating footrests, articulating (telescoping), each
k0056
seat height less than 17" or equal to or greater than 21" for a high strength, lightweight, or ultralightweight wheelchair
k0065
spoke protectors, each
k0069
rear wheel assembly, complete, with solid tire, spokes or molded, replacement only, each
k0070
rear wheel assembly, complete, with pneumatic tire, spokes or molded, replacement only, each
k0071
front caster assembly, complete, with pneumatic tire, replacement only, each
k0072
front caster assembly, complete, with semi-pneumatic tire, replacement only, each
k0073
caster pin lock, each
k0077
front caster assembly, complete, with solid tire, replacement only, each
k0098
drive belt for power wheelchair, replacement only
k0105
iv hanger, each
k0108
wheelchair component or accessory, not otherwise specified
k0195
elevating leg rests, pair (for use with capped rental wheelchair base)
k0455
infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol)
k0462
temporary replacement for patient owned equipment being repaired, any type
k0552
supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each
k0553
supply allowance for therapeutic continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service
k0554
receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system
k0601
replacement battery for external infusion pump owned by patient, silver oxide, 1.5 volt, each
k0602
replacement battery for external infusion pump owned by patient, silver oxide, 3 volt, each
k0603
replacement battery for external infusion pump owned by patient, alkaline, 1.5 volt, each
k0604
replacement battery for external infusion pump owned by patient, lithium, 3.6 volt, each
k0605
replacement battery for external infusion pump owned by patient, lithium, 4.5 volt, each
k0606
automatic external defibrillator, with integrated electrocardiogram analysis, garment type
k0607
replacement battery for automated external defibrillator, garment type only, each
k0608
replacement garment for use with automated external defibrillator, each
k0609
replacement electrodes for use with automated external defibrillator, garment type only, each
k0669
wheelchair accessory, wheelchair seat or back cushion, does not meet specific code criteria or no written coding verification from dme pdac
k0672
addition to lower extremity orthosis, removable soft interface, all components, replacement only, each
k0730
controlled dose inhalation drug delivery system
k0733
power wheelchair accessory, 12 to 24 amp hour sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)
k0738
portable gaseous oxygen system, rental; home compressor used to fill portable oxygen cylinders; includes portable containers, regulator, flowmeter, humidifier, cannula or mask, and tubing
k0739
repair or nonroutine service for durable medical equipment other than oxygen equipment requiring the skill of a technician, labor component, per 15 minutes
k0740
repair or nonroutine service for oxygen equipment requiring the skill of a technician, labor component, per 15 minutes
k0743
suction pump, home model, portable, for use on wounds
k0744
absorptive wound dressing for use with suction pump, home model, portable, pad size 16 square inches or less
k0745
absorptive wound dressing for use with suction pump, home model, portable, pad size more than 16 square inches but less than or equal to 48 square inches
k0746
absorptive wound dressing for use with suction pump, home model, portable, pad size greater than 48 square inches
k0800
power operated vehicle, group 1 standard, patient weight capacity up to and including 300 pounds
k0801
power operated vehicle, group 1 heavy duty, patient weight capacity 301 to 450 pounds
k0802
power operated vehicle, group 1 very heavy duty, patient weight capacity 451 to 600 pounds
k0806
power operated vehicle, group 2 standard, patient weight capacity up to and including 300 pounds
k0807
power operated vehicle, group 2 heavy duty, patient weight capacity 301 to 450 pounds
k0808
power operated vehicle, group 2 very heavy duty, patient weight capacity 451 to 600 pounds
k0812
power operated vehicle, not otherwise classified
k0813
power wheelchair, group 1 standard, portable, sling/solid seat and back, patient weight capacity up to and including 300 pounds
k0814
power wheelchair, group 1 standard, portable, captains chair, patient weight capacity up to and including 300 pounds
k0815
power wheelchair, group 1 standard, sling/solid seat and back, patient weight capacity up to and including 300 pounds
k0816
power wheelchair, group 1 standard, captains chair, patient weight capacity up to and including 300 pounds
k0820
power wheelchair, group 2 standard, portable, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0821
power wheelchair, group 2 standard, portable, captains chair, patient weight capacity up to and including 300 pounds
k0822
power wheelchair, group 2 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0823
power wheelchair, group 2 standard, captains chair, patient weight capacity up to and including 300 pounds
k0824
power wheelchair, group 2 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds
k0825
power wheelchair, group 2 heavy duty, captains chair, patient weight capacity 301 to 450 pounds
k0826
power wheelchair, group 2 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds
k0827
power wheelchair, group 2 very heavy duty, captains chair, patient weight capacity 451 to 600 pounds
k0828
power wheelchair, group 2 extra heavy duty, sling/solid seat/back, patient weight capacity 601 pounds or more
k0829
power wheelchair, group 2 extra heavy duty, captains chair, patient weight 601 pounds or more
k0830
power wheelchair, group 2 standard, seat elevator, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0831
power wheelchair, group 2 standard, seat elevator, captains chair, patient weight capacity up to and including 300 pounds
k0835
power wheelchair, group 2 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0836
power wheelchair, group 2 standard, single power option, captains chair, patient weight capacity up to and including 300 pounds
k0837
power wheelchair, group 2 heavy duty, single power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
k0838
power wheelchair, group 2 heavy duty, single power option, captains chair, patient weight capacity 301 to 450 pounds
k0839
power wheelchair, group 2 very heavy duty, single power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds
k0840
power wheelchair, group 2 extra heavy duty, single power option, sling/solid seat/back, patient weight capacity 601 pounds or more
k0841
power wheelchair, group 2 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0842
power wheelchair, group 2 standard, multiple power option, captains chair, patient weight capacity up to and including 300 pounds
k0843
power wheelchair, group 2 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
k0848
power wheelchair, group 3 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0849
power wheelchair, group 3 standard, captains chair, patient weight capacity up to and including 300 pounds
k0850
power wheelchair, group 3 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds
k0851
power wheelchair, group 3 heavy duty, captains chair, patient weight capacity 301 to 450 pounds
k0852
power wheelchair, group 3 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds
k0853
power wheelchair, group 3 very heavy duty, captains chair, patient weight capacity 451 to 600 pounds
k0854
power wheelchair, group 3 extra heavy duty, sling/solid seat/back, patient weight capacity 601 pounds or more
k0855
power wheelchair, group 3 extra heavy duty, captains chair, patient weight capacity 601 pounds or more
k0856
power wheelchair, group 3 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0857
power wheelchair, group 3 standard, single power option, captains chair, patient weight capacity up to and including 300 pounds
k0858
power wheelchair, group 3 heavy duty, single power option, sling/solid seat/back, patient weight 301 to 450 pounds
k0859
power wheelchair, group 3 heavy duty, single power option, captains chair, patient weight capacity 301 to 450 pounds
k0860
power wheelchair, group 3 very heavy duty, single power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds
k0861
power wheelchair, group 3 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0862
power wheelchair, group 3 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
k0863
power wheelchair, group 3 very heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds
k0864
power wheelchair, group 3 extra heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 601 pounds or more
k0868
power wheelchair, group 4 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0869
power wheelchair, group 4 standard, captains chair, patient weight capacity up to and including 300 pounds
k0870
power wheelchair, group 4 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds
k0871
power wheelchair, group 4 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds
k0877
power wheelchair, group 4 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0878
power wheelchair, group 4 standard, single power option, captains chair, patient weight capacity up to and including 300 pounds
k0879
power wheelchair, group 4 heavy duty, single power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
k0880
power wheelchair, group 4 very heavy duty, single power option, sling/solid seat/back, patient weight 451 to 600 pounds
k0884
power wheelchair, group 4 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
k0885
power wheelchair, group 4 standard, multiple power option, captains chair, patient weight capacity up to and including 300 pounds
k0886
power wheelchair, group 4 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
k0890
power wheelchair, group 5 pediatric, single power option, sling/solid seat/back, patient weight capacity up to and including 125 pounds
k0891
power wheelchair, group 5 pediatric, multiple power option, sling/solid seat/back, patient weight capacity up to and including 125 pounds
k0898
power wheelchair, not otherwise classified
k0899
power mobility device, not coded by dme pdac or does not meet criteria
k0900
customized durable medical equipment, other than wheelchair
k0901
knee orthosis (ko), single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated, off-the-shelf terminated december 31, 2016.
k0902
knee orthosis (ko), double upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated, off-the-shelf terminated december 31, 2016.
k0903
for diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each terminated december 31, 2018.
k1001
electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type
k1002
cranial electrotherapy stimulation (ces) system, any type
k1003
whirlpool tub, walk-in, portable
k1004
low frequency ultrasonic diathermy treatment device for home use, includes all components and accessories
k1005
disposable collection and storage bag for breast milk, any size, any type, each
k1006
suction pump, home model, portable or stationary, electric, any type, for use with external urine management system
k1007
bilateral hip, knee, ankle, foot device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors
k1009
speech volume modulation system, any type, including all components and accessories
k1010
indwelling intraurethral drainage device with valve, patient inserted, replacement only, each terminated march 31, 2021.
k1011
activation device for intraurethral drainage device with valve, replacement only, each terminated march 31, 2021.
k1012
charger and base station for intraurethral activation device, replacement only terminated march 31, 2021.
k1013
enema tube, with or without adapter, any type, replacement only, each
k1014
addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control
k1015
foot, adductus positioning device, adjustable
k1016
transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
k1017
monthly supplies for use of device coded at k1016
k1018
external upper limb tremor stimulator of the peripheral nerves of the wrist
k1019
replacement supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist
k1020
non-invasive vagus nerve stimulator
k1021
exsufflation belt, includes all supplies and accessories
k1022
addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type
k1023
distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm
k1024
non-pneumatic compression controller with sequential calibrated gradient pressure
k1025
non-pneumatic sequential compression garment, full arm
k1026
mechanical allergen particle barrier/inhalation filter, cream, nasal, topical
k1027
oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting and adjustment
k1028
power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle for the reduction of snoring and obstructive sleep apnea, controlled by phone application
k1029
oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply
k1030
external recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only
k1031
non-pneumatic compression controller without calibrated gradient pressure
k1032
non-pneumatic sequential compression garment, full leg
k1033
non-pneumatic sequential compression garment, half leg
k1034
provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count
l0112
cranial cervical orthosis, congenital torticollis type, with or without soft interface material, adjustable range of motion joint, custom fabricated
l0113
cranial cervical orthosis, torticollis type, with or without joint, with or without soft interface material, prefabricated, includes fitting and adjustment
l0120
cervical, flexible, non-adjustable, prefabricated, off-the-shelf (foam collar)
l0130
cervical, flexible, thermoplastic collar, molded to patient
l0140
cervical, semi-rigid, adjustable (plastic collar)
l0150
cervical, semi-rigid, adjustable molded chin cup (plastic collar with mandibular/occipital piece)
l0160
cervical, semi-rigid, wire frame occipital/mandibular support, prefabricated, off-the-shelf
l0170
cervical, collar, molded to patient model
l0172
cervical, collar, semi-rigid thermoplastic foam, two-piece, prefabricated, off-the-shelf
l0174
cervical, collar, semi-rigid, thermoplastic foam, two piece with thoracic extension, prefabricated, off-the-shelf
l0180
cervical, multiple post collar, occipital/mandibular supports, adjustable
l0190
cervical, multiple post collar, occipital/mandibular supports, adjustable cervical bars (somi, guilford, taylor types)
l0200
cervical, multiple post collar, occipital/mandibular supports, adjustable cervical bars, and thoracic extension
l0220
thoracic, rib belt, custom fabricated
l0450
tlso, flexible, provides trunk support, upper thoracic region, produces intracavitary pressure to reduce load on the intervertebral disks with rigid stays or panel(s), includes shoulder straps and closures, prefabricated, off-the-shelf
l0452
tlso, flexible, provides trunk support, upper thoracic region, produces intracavitary pressure to reduce load on the intervertebral disks with rigid stays or panel(s), includes shoulder straps and closures, custom fabricated
l0454
tlso flexible, provides trunk support, extends from sacrococcygeal junction to above t-9 vertebra, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks with rigid stays or panel(s), includes shoulder straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0455
tlso, flexible, provides trunk support, extends from sacrococcygeal junction to above t-9 vertebra, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks with rigid stays or panel(s), includes shoulder straps and closures, prefabricated, off-the-shelf
l0456
tlso, flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0457
tlso, flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated, off-the-shelf
l0458
tlso, triplanar control, modular segmented spinal system, two rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the xiphoid, soft liner, restricts gross trunk motion in the sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment
l0460
tlso, triplanar control, modular segmented spinal system, two rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the sternal notch, soft liner, restricts gross trunk motion in the sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0462
tlso, triplanar control, modular segmented spinal system, three rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the sternal notch, soft liner, restricts gross trunk motion in the sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment
l0464
tlso, triplanar control, modular segmented spinal system, four rigid plastic shells, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to the sternal notch, soft liner, restricts gross trunk motion in sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment
l0466
tlso, sagittal control, rigid posterior frame and flexible soft anterior apron with straps, closures and padding, restricts gross trunk motion in sagittal plane, produces intracavitary pressure to reduce load on intervertebral disks, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0467
tlso, sagittal control, rigid posterior frame and flexible soft anterior apron with straps, closures and padding, restricts gross trunk motion in sagittal plane, produces intracavitary pressure to reduce load on intervertebral disks, prefabricated, off-the-shelf
l0468
tlso, sagittal-coronal control, rigid posterior frame and flexible soft anterior apron with straps, closures and padding, extends from sacrococcygeal junction over scapulae, lateral strength provided by pelvic, thoracic, and lateral frame pieces, restricts gross trunk motion in sagittal, and coronal planes, produces intracavitary pressure to reduce load on intervertebral disks, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0469
tlso, sagittal-coronal control, rigid posterior frame and flexible soft anterior apron with straps, closures and padding, extends from sacrococcygeal junction over scapulae, lateral strength provided by pelvic, thoracic, and lateral frame pieces, restricts gross trunk motion in sagittal and coronal planes, produces intracavitary pressure to reduce load on intervertebral disks, prefabricated, off-the-shelf
l0470
tlso, triplanar control, rigid posterior frame and flexible soft anterior apron with straps, closures and padding, extends from sacrococcygeal junction to scapula, lateral strength provided by pelvic, thoracic, and lateral frame pieces, rotational strength provided by subclavicular extensions, restricts gross trunk motion in sagittal, coronal, and transverse planes, provides intracavitary pressure to reduce load on the intervertebral disks, includes fitting and shaping the frame, prefabricated, includes fitting and adjustment
l0472
tlso, triplanar control, hyperextension, rigid anterior and lateral frame extends from symphysis pubis to sternal notch with two anterior components (one pubic and one sternal), posterior and lateral pads with straps and closures, limits spinal flexion, restricts gross trunk motion in sagittal, coronal, and transverse planes, includes fitting and shaping the frame, prefabricated, includes fitting and adjustment
l0480
tlso, triplanar control, one piece rigid plastic shell without interface liner, with multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, anterior or posterior opening, restricts gross trunk motion in sagittal, coronal, and transverse planes, includes a carved plaster or cad-cam model, custom fabricated
l0482
tlso, triplanar control, one piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, anterior or posterior opening, restricts gross trunk motion in sagittal, coronal, and transverse planes, includes a carved plaster or cad-cam model, custom fabricated
l0484
tlso, triplanar control, two piece rigid plastic shell without interface liner, with multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or cad-cam model, custom fabricated
l0486
tlso, triplanar control, two piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or cad-cam model, custom fabricated
l0488
tlso, triplanar control, one piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, anterior or posterior opening, restricts gross trunk motion in sagittal, coronal, and transverse planes, prefabricated, includes fitting and adjustment
l0490
tlso, sagittal-coronal control, one piece rigid plastic shell, with overlapping reinforced anterior, with multiple straps and closures, posterior extends from sacrococcygeal junction and terminates at or before the t-9 vertebra, anterior extends from symphysis pubis to xiphoid, anterior opening, restricts gross trunk motion in sagittal and coronal planes, prefabricated, includes fitting and adjustment
l0491
tlso, sagittal-coronal control, modular segmented spinal system, two rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the xiphoid, soft liner, restricts gross trunk motion in the sagittal and coronal planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment
l0492
tlso, sagittal-coronal control, modular segmented spinal system, three rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the xiphoid, soft liner, restricts gross trunk motion in the sagittal and coronal planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment
l0621
sacroiliac orthosis, flexible, provides pelvic-sacral support, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, prefabricated, off-the-shelf
l0622
sacroiliac orthosis, flexible, provides pelvic-sacral support, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, custom fabricated
l0623
sacroiliac orthosis, provides pelvic-sacral support, with rigid or semi-rigid panels over the sacrum and abdomen, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, prefabricated, off-the-shelf
l0624
sacroiliac orthosis, provides pelvic-sacral support, with rigid or semi-rigid panels placed over the sacrum and abdomen, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, custom fabricated
l0625
lumbar orthosis, flexible, provides lumbar support, posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include pendulous abdomen design, shoulder straps, stays, prefabricated, off-the-shelf
l0626
lumbar orthosis, sagittal control, with rigid posterior panel(s), posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0627
lumbar orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0628
lumbar-sacral orthosis, flexible, provides lumbo-sacral support, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include stays, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf
l0629
lumbar-sacral orthosis, flexible, provides lumbo-sacral support, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include stays, shoulder straps, pendulous abdomen design, custom fabricated
l0630
lumbar-sacral orthosis, sagittal control, with rigid posterior panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0631
lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0632
lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, custom fabricated
l0633
lumbar-sacral orthosis, sagittal-coronal control, with rigid posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0634
lumbar-sacral orthosis, sagittal-coronal control, with rigid posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, custom fabricated
l0635
lumbar-sacral orthosis, sagittal-coronal control, lumbar flexion, rigid posterior frame/panel(s), lateral articulating design to flex the lumbar spine, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, anterior panel, pendulous abdomen design, prefabricated, includes fitting and adjustment
l0636
lumbar sacral orthosis, sagittal-coronal control, lumbar flexion, rigid posterior frame/panels, lateral articulating design to flex the lumbar spine, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, anterior panel, pendulous abdomen design, custom fabricated
l0637
lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0638
lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, custom fabricated
l0639
lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l0640
lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, custom fabricated
l0641
lumbar orthosis, sagittal control, with rigid posterior panel(s), posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf
l0642
lumbar orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf
l0643
lumbar-sacral orthosis, sagittal control, with rigid posterior panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf
l0648
lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf
l0649
lumbar-sacral orthosis, sagittal-coronal control, with rigid posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf
l0650
lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf
l0651
lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated, off-the-shelf
l0700
cervical-thoracic-lumbar-sacral-orthoses (ctlso), anterior-posterior-lateral control, molded to patient model, (minerva type)
l0710
ctlso, anterior-posterior-lateral-control, molded to patient model, with interface material, (minerva type)
l0810
halo procedure, cervical halo incorporated into jacket vest
l0820
halo procedure, cervical halo incorporated into plaster body jacket
l0830
halo procedure, cervical halo incorporated into milwaukee type orthosis
l0859
addition to halo procedure, magnetic resonance image compatible systems, rings and pins, any material
l0861
addition to halo procedure, replacement liner/interface material
l0970
tlso, corset front
l0972
lso, corset front
l0974
tlso, full corset
l0976
lso, full corset
l0978
axillary crutch extension
l0980
peroneal straps, prefabricated, off-the-shelf, pair
l0982
stocking supporter grips, prefabricated, off-the-shelf, set of four (4)
l0984
protective body sock, prefabricated, off-the-shelf, each
l0999
addition to spinal orthosis, not otherwise specified
l1000
cervical-thoracic-lumbar-sacral orthosis (ctlso) (milwaukee), inclusive of furnishing initial orthosis, including model
l1001
cervical thoracic lumbar sacral orthosis, immobilizer, infant size, prefabricated, includes fitting and adjustment
l1005
tension based scoliosis orthosis and accessory pads, includes fitting and adjustment
l1010
addition to cervical-thoracic-lumbar-sacral orthosis (ctlso) or scoliosis orthosis, axilla sling
l1020
addition to ctlso or scoliosis orthosis, kyphosis pad
l1025
addition to ctlso or scoliosis orthosis, kyphosis pad, floating
l1030
addition to ctlso or scoliosis orthosis, lumbar bolster pad
l1040
addition to ctlso or scoliosis orthosis, lumbar or lumbar rib pad
l1050
addition to ctlso or scoliosis orthosis, sternal pad
l1060
addition to ctlso or scoliosis orthosis, thoracic pad
l1070
addition to ctlso or scoliosis orthosis, trapezius sling
l1080
addition to ctlso or scoliosis orthosis, outrigger
l1085
addition to ctlso or scoliosis orthosis, outrigger, bilateral with vertical extensions
l1090
addition to ctlso or scoliosis orthosis, lumbar sling
l1100
addition to ctlso or scoliosis orthosis, ring flange, plastic or leather
l1110
addition to ctlso or scoliosis orthosis, ring flange, plastic or leather, molded to patient model
l1120
addition to ctlso, scoliosis orthosis, cover for upright, each
l1200
thoracic-lumbar-sacral-orthosis (tlso), inclusive of furnishing initial orthosis only
l1210
addition to tlso, (low profile), lateral thoracic extension
l1220
addition to tlso, (low profile), anterior thoracic extension
l1230
addition to tlso, (low profile), milwaukee type superstructure
l1240
addition to tlso, (low profile), lumbar derotation pad
l1250
addition to tlso, (low profile), anterior asis pad
l1260
addition to tlso, (low profile), anterior thoracic derotation pad
l1270
addition to tlso, (low profile), abdominal pad
l1280
addition to tlso, (low profile), rib gusset (elastic), each
l1290
addition to tlso, (low profile), lateral trochanteric pad
l1300
other scoliosis procedure, body jacket molded to patient model
l1310
other scoliosis procedure, post-operative body jacket
l1499
spinal orthosis, not otherwise specified
l1600
hip orthosis, abduction control of hip joints, flexible, frejka type with cover, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an inidividual with expertise
l1610
hip orthosis, abduction control of hip joints, flexible, (frejka cover only), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l1620
hip orthosis, abduction control of hip joints, flexible, (pavlik harness), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l1630
hip orthosis, abduction control of hip joints, semi-flexible (von rosen type), custom fabricated
l1640
hip orthosis, abduction control of hip joints, static, pelvic band or spreader bar, thigh cuffs, custom fabricated
l1650
hip orthosis, abduction control of hip joints, static, adjustable, (ilfled type), prefabricated, includes fitting and adjustment
l1652
hip orthosis, bilateral thigh cuffs with adjustable abductor spreader bar, adult size, prefabricated, includes fitting and adjustment, any type
l1660
hip orthosis, abduction control of hip joints, static, plastic, prefabricated, includes fitting and adjustment
l1680
hip orthosis, abduction control of hip joints, dynamic, pelvic control, adjustable hip motion control, thigh cuffs (rancho hip action type), custom fabricated
l1685
hip orthosis, abduction control of hip joint, postoperative hip abduction type, custom fabricated
l1686
hip orthosis, abduction control of hip joint, postoperative hip abduction type, prefabricated, includes fitting and adjustment
l1690
combination, bilateral, lumbo-sacral, hip, femur orthosis providing adduction and internal rotation control, prefabricated, includes fitting and adjustment
l1700
legg perthes orthosis, (toronto type), custom fabricated
l1710
legg perthes orthosis, (newington type), custom fabricated
l1720
legg perthes orthosis, trilateral, (tachdijan type), custom fabricated
l1730
legg perthes orthosis, (scottish rite type), custom fabricated
l1755
legg perthes orthosis, (patten bottom type), custom fabricated
l1810
knee orthosis, elastic with joints, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l1812
knee orthosis, elastic with joints, prefabricated, off-the-shelf
l1820
knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated, includes fitting and adjustment
l1830
knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf
l1831
knee orthosis, locking knee joint(s), positional orthosis, prefabricated, includes fitting and adjustment
l1832
knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l1833
knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated, off-the shelf
l1834
knee orthosis, without knee joint, rigid, custom fabricated
l1836
knee orthosis, rigid, without joint(s), includes soft interface material, prefabricated, off-the-shelf
l1840
knee orthosis, derotation, medial-lateral, anterior cruciate ligament, custom fabricated
l1843
knee orthosis, single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l1844
knee orthosis, single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, custom fabricated
l1845
knee orthosis, double upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l1846
knee orthosis, double upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, custom fabricated
l1847
knee orthosis, double upright with adjustable joint, with inflatable air support chamber(s), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l1848
knee orthosis, double upright with adjustable joint, with inflatable air support chamber(s), prefabricated, off-the-shelf
l1850
knee orthosis, swedish type, prefabricated, off-the-shelf
l1851
knee orthosis (ko), single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated, off-the-shelf
l1852
knee orthosis (ko), double upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated, off-the-shelf
l1860
knee orthosis, modification of supracondylar prosthetic socket, custom fabricated (sk)
l1900
ankle foot orthosis, spring wire, dorsiflexion assist calf band, custom fabricated
l1902
ankle orthosis, ankle gauntlet or similar, with or without joints, prefabricated, off-the-shelf
l1904
ankle orthosis, ankle gauntlet or similar, with or without joints, custom fabricated
l1906
ankle foot orthosis, multiligamentous ankle support, prefabricated, off-the-shelf
l1907
ankle orthosis, supramalleolar with straps, with or without interface/pads, custom fabricated
l1910
ankle foot orthosis, posterior, single bar, clasp attachment to shoe counter, prefabricated, includes fitting and adjustment
l1920
ankle foot orthosis, single upright with static or adjustable stop (phelps or perlstein type), custom fabricated
l1930
ankle foot orthosis, plastic or other material, prefabricated, includes fitting and adjustment
l1932
afo, rigid anterior tibial section, total carbon fiber or equal material, prefabricated, includes fitting and adjustment
l1940
ankle foot orthosis, plastic or other material, custom fabricated
l1945
ankle foot orthosis, plastic, rigid anterior tibial section (floor reaction), custom fabricated
l1950
ankle foot orthosis, spiral, (institute of rehabilitative medicine type), plastic, custom fabricated
l1951
ankle foot orthosis, spiral, (institute of rehabilitative medicine type), plastic or other material, prefabricated, includes fitting and adjustment
l1960
ankle foot orthosis, posterior solid ankle, plastic, custom fabricated
l1970
ankle foot orthosis, plastic with ankle joint, custom fabricated
l1971
ankle foot orthosis, plastic or other material with ankle joint, prefabricated, includes fitting and adjustment
l1980
ankle foot orthosis, single upright free plantar dorsiflexion, solid stirrup, calf band/cuff (single bar 'bk' orthosis), custom fabricated
l1990
ankle foot orthosis, double upright free plantar dorsiflexion, solid stirrup, calf band/cuff (double bar 'bk' orthosis), custom fabricated
l2000
knee ankle foot orthosis, single upright, free knee, free ankle, solid stirrup, thigh and calf bands/cuffs (single bar 'ak' orthosis), custom fabricated
l2005
knee ankle foot orthosis, any material, single or double upright, stance control, automatic lock and swing phase release, any type activation, includes ankle joint, any type, custom fabricated
l2006
knee ankle foot device, any material, single or double upright, swing and stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated
l2010
knee ankle foot orthosis, single upright, free ankle, solid stirrup, thigh and calf bands/cuffs (single bar 'ak' orthosis), without knee joint, custom fabricated
l2020
knee ankle foot orthosis, double upright, free ankle, solid stirrup, thigh and calf bands/cuffs (double bar 'ak' orthosis), custom fabricated
l2030
knee ankle foot orthosis, double upright, free ankle, solid stirrup, thigh and calf bands/cuffs, (double bar 'ak' orthosis), without knee joint, custom fabricated
l2034
knee ankle foot orthosis, full plastic, single upright, with or without free motion knee, medial lateral rotation control, with or without free motion ankle, custom fabricated
l2035
knee ankle foot orthosis, full plastic, static (pediatric size), without free motion ankle, prefabricated, includes fitting and adjustment
l2036
knee ankle foot orthosis, full plastic, double upright, with or without free motion knee, with or without free motion ankle, custom fabricated
l2037
knee ankle foot orthosis, full plastic, single upright, with or without free motion knee, with or without free motion ankle, custom fabricated
l2038
knee ankle foot orthosis, full plastic, with or without free motion knee, multi-axis ankle, custom fabricated
l2040
hip knee ankle foot orthosis, torsion control, bilateral rotation straps, pelvic band/belt, custom fabricated
l2050
hip knee ankle foot orthosis, torsion control, bilateral torsion cables, hip joint, pelvic band/belt, custom fabricated
l2060
hip knee ankle foot orthosis, torsion control, bilateral torsion cables, ball bearing hip joint, pelvic band/ belt, custom fabricated
l2070
hip knee ankle foot orthosis, torsion control, unilateral rotation straps, pelvic band/belt, custom fabricated
l2080
hip knee ankle foot orthosis, torsion control, unilateral torsion cable, hip joint, pelvic band/belt, custom fabricated
l2090
hip knee ankle foot orthosis, torsion control, unilateral torsion cable, ball bearing hip joint, pelvic band/ belt, custom fabricated
l2106
ankle foot orthosis, fracture orthosis, tibial fracture cast orthosis, thermoplastic type casting material, custom fabricated
l2108
ankle foot orthosis, fracture orthosis, tibial fracture cast orthosis, custom fabricated
l2112
ankle foot orthosis, fracture orthosis, tibial fracture orthosis, soft, prefabricated, includes fitting and adjustment
l2114
ankle foot orthosis, fracture orthosis, tibial fracture orthosis, semi-rigid, prefabricated, includes fitting and adjustment
l2116
ankle foot orthosis, fracture orthosis, tibial fracture orthosis, rigid, prefabricated, includes fitting and adjustment
l2126
knee ankle foot orthosis, fracture orthosis, femoral fracture cast orthosis, thermoplastic type casting material, custom fabricated
l2128
knee ankle foot orthosis, fracture orthosis, femoral fracture cast orthosis, custom fabricated
l2132
kafo, fracture orthosis, femoral fracture cast orthosis, soft, prefabricated, includes fitting and adjustment
l2134
kafo, fracture orthosis, femoral fracture cast orthosis, semi-rigid, prefabricated, includes fitting and adjustment
l2136
kafo, fracture orthosis, femoral fracture cast orthosis, rigid, prefabricated, includes fitting and adjustment
l2180
addition to lower extremity fracture orthosis, plastic shoe insert with ankle joints
l2182
addition to lower extremity fracture orthosis, drop lock knee joint
l2184
addition to lower extremity fracture orthosis, limited motion knee joint
l2186
addition to lower extremity fracture orthosis, adjustable motion knee joint, lerman type
l2188
addition to lower extremity fracture orthosis, quadrilateral brim
l2190
addition to lower extremity fracture orthosis, waist belt
l2192
addition to lower extremity fracture orthosis, hip joint, pelvic band, thigh flange, and pelvic belt
l2200
addition to lower extremity, limited ankle motion, each joint
l2210
addition to lower extremity, dorsiflexion assist (plantar flexion resist), each joint
l2220
addition to lower extremity, dorsiflexion and plantar flexion assist/resist, each joint
l2230
addition to lower extremity, split flat caliper stirrups and plate attachment
l2232
addition to lower extremity orthosis, rocker bottom for total contact ankle foot orthosis, for custom fabricated orthosis only
l2240
addition to lower extremity, round caliper and plate attachment
l2250
addition to lower extremity, foot plate, molded to patient model, stirrup attachment
l2260
addition to lower extremity, reinforced solid stirrup (scott-craig type)
l2265
addition to lower extremity, long tongue stirrup
l2270
addition to lower extremity, varus/valgus correction ('t') strap, padded/lined or malleolus pad
l2275
addition to lower extremity, varus/valgus correction, plastic modification, padded/lined
l2280
addition to lower extremity, molded inner boot
l2300
addition to lower extremity, abduction bar (bilateral hip involvement), jointed, adjustable
l2310
addition to lower extremity, abduction bar-straight
l2320
addition to lower extremity, non-molded lacer, for custom fabricated orthosis only
l2330
addition to lower extremity, lacer molded to patient model, for custom fabricated orthosis only
l2335
addition to lower extremity, anterior swing band
l2340
addition to lower extremity, pre-tibial shell, molded to patient model
l2350
addition to lower extremity, prosthetic type, (bk) socket, molded to patient model, (used for 'ptb' 'afo' orthoses)
l2360
addition to lower extremity, extended steel shank
l2370
addition to lower extremity, patten bottom
l2375
addition to lower extremity, torsion control, ankle joint and half solid stirrup
l2380
addition to lower extremity, torsion control, straight knee joint, each joint
l2385
addition to lower extremity, straight knee joint, heavy duty, each joint
l2387
addition to lower extremity, polycentric knee joint, for custom fabricated knee ankle foot orthosis, each joint
l2390
addition to lower extremity, offset knee joint, each joint
l2395
addition to lower extremity, offset knee joint, heavy duty, each joint
l2397
addition to lower extremity orthosis, suspension sleeve
l2405
addition to knee joint, drop lock, each
l2415
addition to knee lock with integrated release mechanism (bail, cable, or equal), any material, each joint
l2425
addition to knee joint, disc or dial lock for adjustable knee flexion, each joint
l2430
addition to knee joint, ratchet lock for active and progressive knee extension, each joint
l2492
addition to knee joint, lift loop for drop lock ring
l2500
addition to lower extremity, thigh/weight bearing, gluteal/ ischial weight bearing, ring
l2510
addition to lower extremity, thigh/weight bearing, quadri- lateral brim, molded to patient model
l2520
addition to lower extremity, thigh/weight bearing, quadri- lateral brim, custom fitted
l2525
addition to lower extremity, thigh/weight bearing, ischial containment/narrow m-l brim molded to patient model
l2526
addition to lower extremity, thigh/weight bearing, ischial containment/narrow m-l brim, custom fitted
l2530
addition to lower extremity, thigh-weight bearing, lacer, non-molded
l2540
addition to lower extremity, thigh/weight bearing, lacer, molded to patient model
l2550
addition to lower extremity, thigh/weight bearing, high roll cuff
l2570
addition to lower extremity, pelvic control, hip joint, clevis type two position joint, each
l2580
addition to lower extremity, pelvic control, pelvic sling
l2600
addition to lower extremity, pelvic control, hip joint, clevis type, or thrust bearing, free, each
l2610
addition to lower extremity, pelvic control, hip joint, clevis or thrust bearing, lock, each
l2620
addition to lower extremity, pelvic control, hip joint, heavy duty, each
l2622
addition to lower extremity, pelvic control, hip joint, adjustable flexion, each
l2624
addition to lower extremity, pelvic control, hip joint, adjustable flexion, extension, abduction control, each
l2627
addition to lower extremity, pelvic control, plastic, molded to patient model, reciprocating hip joint and cables
l2628
addition to lower extremity, pelvic control, metal frame, reciprocating hip joint and cables
l2630
addition to lower extremity, pelvic control, band and belt, unilateral
l2640
addition to lower extremity, pelvic control, band and belt, bilateral
l2650
addition to lower extremity, pelvic and thoracic control, gluteal pad, each
l2660
addition to lower extremity, thoracic control, thoracic band
l2670
addition to lower extremity, thoracic control, paraspinal uprights
l2680
addition to lower extremity, thoracic control, lateral support uprights
l2750
addition to lower extremity orthosis, plating chrome or nickel, per bar
l2755
addition to lower extremity orthosis, high strength, lightweight material, all hybrid lamination/prepreg composite, per segment, for custom fabricated orthosis only
l2760
addition to lower extremity orthosis, extension, per extension, per bar (for lineal adjustment for growth)
l2768
orthotic side bar disconnect device, per bar
l2780
addition to lower extremity orthosis, non-corrosive finish, per bar
l2785
addition to lower extremity orthosis, drop lock retainer, each
l2795
addition to lower extremity orthosis, knee control, full kneecap
l2800
addition to lower extremity orthosis, knee control, knee cap, medial or lateral pull, for use with custom fabricated orthosis only
l2810
addition to lower extremity orthosis, knee control, condylar pad
l2820
addition to lower extremity orthosis, soft interface for molded plastic, below knee section
l2830
addition to lower extremity orthosis, soft interface for molded plastic, above knee section
l2840
addition to lower extremity orthosis, tibial length sock, fracture or equal, each
l2850
addition to lower extremity orthosis, femoral length sock, fracture or equal, each
l2861
addition to lower extremity joint, knee or ankle, concentric adjustable torsion style mechanism for custom fabricated orthotics only, each
l2999
lower extremity orthoses, not otherwise specified
l3000
foot, insert, removable, molded to patient model, 'ucb' type, berkeley shell, each
l3001
foot, insert, removable, molded to patient model, spenco, each
l3002
foot, insert, removable, molded to patient model, plastazote or equal, each
l3003
foot, insert, removable, molded to patient model, silicone gel, each
l3010
foot, insert, removable, molded to patient model, longitudinal arch support, each
l3020
foot, insert, removable, molded to patient model, longitudinal/ metatarsal support, each
l3030
foot, insert, removable, formed to patient foot, each
l3031
foot, insert/plate, removable, addition to lower extremity orthosis, high strength, lightweight material, all hybrid lamination/prepreg composite, each
l3040
foot, arch support, removable, premolded, longitudinal, each
l3050
foot, arch support, removable, premolded, metatarsal, each
l3060
foot, arch support, removable, premolded, longitudinal/ metatarsal, each
l3070
foot, arch support, non-removable attached to shoe, longitudinal, each
l3080
foot, arch support, non-removable attached to shoe, metatarsal, each
l3090
foot, arch support, non-removable attached to shoe, longitudinal/metatarsal, each
l3100
hallus-valgus night dynamic splint, prefabricated, off-the-shelf
l3140
foot, abduction rotation bar, including shoes
l3150
foot, abduction rotation bar, without shoes
l3160
foot, adjustable shoe-styled positioning device
l3170
foot, plastic, silicone or equal, heel stabilizer, prefabricated, off-the-shelf, each
l3201
orthopedic shoe, oxford with supinator or pronator, infant
l3202
orthopedic shoe, oxford with supinator or pronator, child
l3203
orthopedic shoe, oxford with supinator or pronator, junior
l3204
orthopedic shoe, hightop with supinator or pronator, infant
l3206
orthopedic shoe, hightop with supinator or pronator, child
l3207
orthopedic shoe, hightop with supinator or pronator, junior
l3208
surgical boot, each, infant
l3209
surgical boot, each, child
l3211
surgical boot, each, junior
l3212
benesch boot, pair, infant
l3213
benesch boot, pair, child
l3214
benesch boot, pair, junior
l3215
orthopedic footwear, ladies shoe, oxford, each
l3216
orthopedic footwear, ladies shoe, depth inlay, each
l3217
orthopedic footwear, ladies shoe, hightop, depth inlay, each
l3219
orthopedic footwear, mens shoe, oxford, each
l3221
orthopedic footwear, mens shoe, depth inlay, each
l3222
orthopedic footwear, mens shoe, hightop, depth inlay, each
l3224
orthopedic footwear, woman's shoe, oxford, used as an integral part of a brace (orthosis)
l3225
orthopedic footwear, man's shoe, oxford, used as an integral part of a brace (orthosis)
l3230
orthopedic footwear, custom shoe, depth inlay, each
l3250
orthopedic footwear, custom molded shoe, removable inner mold, prosthetic shoe, each
l3251
foot, shoe molded to patient model, silicone shoe, each
l3252
foot, shoe molded to patient model, plastazote (or similar), custom fabricated, each
l3253
foot, molded shoe plastazote (or similar) custom fitted, each
l3254
non-standard size or width
l3255
non-standard size or length
l3257
orthopedic footwear, additional charge for split size
l3260
surgical boot/shoe, each
l3265
plastazote sandal, each
l3300
lift, elevation, heel, tapered to metatarsals, per inch
l3310
lift, elevation, heel and sole, neoprene, per inch
l3320
lift, elevation, heel and sole, cork, per inch
l3330
lift, elevation, metal extension (skate)
l3332
lift, elevation, inside shoe, tapered, up to one-half inch
l3334
lift, elevation, heel, per inch
l3340
heel wedge, sach
l3350
heel wedge
l3360
sole wedge, outside sole
l3370
sole wedge, between sole
l3380
clubfoot wedge
l3390
outflare wedge
l3400
metatarsal bar wedge, rocker
l3410
metatarsal bar wedge, between sole
l3420
full sole and heel wedge, between sole
l3430
heel, counter, plastic reinforced
l3440
heel, counter, leather reinforced
l3450
heel, sach cushion type
l3455
heel, new leather, standard
l3460
heel, new rubber, standard
l3465
heel, thomas with wedge
l3470
heel, thomas extended to ball
l3480
heel, pad and depression for spur
l3485
heel, pad, removable for spur
l3500
orthopedic shoe addition, insole, leather
l3510
orthopedic shoe addition, insole, rubber
l3520
orthopedic shoe addition, insole, felt covered with leather
l3530
orthopedic shoe addition, sole, half
l3540
orthopedic shoe addition, sole, full
l3550
orthopedic shoe addition, toe tap standard
l3560
orthopedic shoe addition, toe tap, horseshoe
l3570
orthopedic shoe addition, special extension to instep (leather with eyelets)
l3580
orthopedic shoe addition, convert instep to velcro closure
l3590
orthopedic shoe addition, convert firm shoe counter to soft counter
l3595
orthopedic shoe addition, march bar
l3600
transfer of an orthosis from one shoe to another, caliper plate, existing
l3610
transfer of an orthosis from one shoe to another, caliper plate, new
l3620
transfer of an orthosis from one shoe to another, solid stirrup, existing
l3630
transfer of an orthosis from one shoe to another, solid stirrup, new
l3640
transfer of an orthosis from one shoe to another, dennis browne splint (riveton), both shoes
l3649
orthopedic shoe, modification, addition or transfer, not otherwise specified
l3650
shoulder orthosis, figure of eight design abduction restrainer, prefabricated, off-the-shelf
l3660
shoulder orthosis, figure of eight design abduction restrainer, canvas and webbing, prefabricated, off-the-shelf
l3670
shoulder orthosis, acromio/clavicular (canvas and webbing type), prefabricated, off-the-shelf
l3671
shoulder orthosis, shoulder joint design, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3674
shoulder orthosis, abduction positioning (airplane design), thoracic component and support bar, with or without nontorsion joint/turnbuckle, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3675
shoulder orthosis, vest type abduction restrainer, canvas webbing type or equal, prefabricated, off-the-shelf
l3677
shoulder orthosis, shoulder joint design, without joints, may include soft interface, straps, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l3678
shoulder orthosis, shoulder joint design, without joints, may include soft interface, straps, prefabricated, off-the-shelf
l3702
elbow orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3710
elbow orthosis, elastic with metal joints, prefabricated, off-the-shelf
l3720
elbow orthosis, double upright with forearm/arm cuffs, free motion, custom fabricated
l3730
elbow orthosis, double upright with forearm/arm cuffs, extension/ flexion assist, custom fabricated
l3740
elbow orthosis, double upright with forearm/arm cuffs, adjustable position lock with active control, custom fabricated
l3760
elbow orthosis (eo), with adjustable position locking joint(s), prefabricated, item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l3761
elbow orthosis (eo), with adjustable position locking joint(s), prefabricated, off-the-shelf
l3762
elbow orthosis, rigid, without joints, includes soft interface material, prefabricated, off-the-shelf
l3763
elbow wrist hand orthosis, rigid, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3764
elbow wrist hand orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3765
elbow wrist hand finger orthosis, rigid, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3766
elbow wrist hand finger orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3806
wrist hand finger orthosis, includes one or more nontorsion joint(s), turnbuckles, elastic bands/springs, may include soft interface material, straps, custom fabricated, includes fitting and adjustment
l3807
wrist hand finger orthosis, without joint(s), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l3808
wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment
l3809
wrist hand finger orthosis, without joint(s), prefabricated, off-the-shelf, any type
l3891
addition to upper extremity joint, wrist or elbow, concentric adjustable torsion style mechanism for custom fabricated orthotics only, each
l3900
wrist hand finger orthosis, dynamic flexor hinge, reciprocal wrist extension/ flexion, finger flexion/extension, wrist or finger driven, custom fabricated
l3901
wrist hand finger orthosis, dynamic flexor hinge, reciprocal wrist extension/ flexion, finger flexion/extension, cable driven, custom fabricated
l3904
wrist hand finger orthosis, external powered, electric, custom fabricated
l3905
wrist hand orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3906
wrist hand orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3908
wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf
l3912
hand finger orthosis (hfo), flexion glove with elastic finger control, prefabricated, off-the-shelf
l3913
hand finger orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3915
wrist hand orthosis, includes one or more nontorsion joint(s), elastic bands, turnbuckles, may include soft interface, straps, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l3916
wrist hand orthosis, includes one or more nontorsion joint(s), elastic bands, turnbuckles, may include soft interface, straps, prefabricated, off-the-shelf
l3917
hand orthosis, metacarpal fracture orthosis, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l3918
hand orthosis, metacarpal fracture orthosis, prefabricated, off-the-shelf
l3919
hand orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3921
hand finger orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3923
hand finger orthosis, without joints, may include soft interface, straps, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l3924
hand finger orthosis, without joints, may include soft interface, straps, prefabricated, off-the-shelf
l3925
finger orthosis, proximal interphalangeal (pip)/distal interphalangeal (dip), non torsion joint/spring, extension/flexion, may include soft interface material, prefabricated, off-the-shelf
l3927
finger orthosis, proximal interphalangeal (pip)/distal interphalangeal (dip), without joint/spring, extension/flexion (e.g., static or ring type), may include soft interface material, prefabricated, off-the-shelf
l3929
hand finger orthosis, includes one or more nontorsion joint(s), turnbuckles, elastic bands/springs, may include soft interface material, straps, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l3930
hand finger orthosis, includes one or more nontorsion joint(s), turnbuckles, elastic bands/springs, may include soft interface material, straps, prefabricated, off-the-shelf
l3931
wrist hand finger orthosis, includes one or more nontorsion joint(s), turnbuckles, elastic bands/springs, may include soft interface material, straps, prefabricated, includes fitting and adjustment
l3933
finger orthosis, without joints, may include soft interface, custom fabricated, includes fitting and adjustment
l3935
finger orthosis, nontorsion joint, may include soft interface, custom fabricated, includes fitting and adjustment
l3956
addition of joint to upper extremity orthosis, any material; per joint
l3960
shoulder elbow wrist hand orthosis, abduction positioning, airplane design, prefabricated, includes fitting and adjustment
l3961
shoulder elbow wrist hand orthosis, shoulder cap design, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3962
shoulder elbow wrist hand orthosis, abduction positioning, erb's palsey design, prefabricated, includes fitting and adjustment
l3967
shoulder elbow wrist hand orthosis, abduction positioning (airplane design), thoracic component and support bar, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3971
shoulder elbow wrist hand orthosis, shoulder cap design, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3973
shoulder elbow wrist hand orthosis, abduction positioning (airplane design), thoracic component and support bar, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3975
shoulder elbow wrist hand finger orthosis, shoulder cap design, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3976
shoulder elbow wrist hand finger orthosis, abduction positioning (airplane design), thoracic component and support bar, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3977
shoulder elbow wrist hand finger orthosis, shoulder cap design, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3978
shoulder elbow wrist hand finger orthosis, abduction positioning (airplane design), thoracic component and support bar, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
l3980
upper extremity fracture orthosis, humeral, prefabricated, includes fitting and adjustment
l3981
upper extremity fracture orthosis, humeral, prefabricated, includes shoulder cap design, with or without joints, forearm section, may include soft interface, straps, includes fitting and adjustments
l3982
upper extremity fracture orthosis, radius/ulnar, prefabricated, includes fitting and adjustment
l3984
upper extremity fracture orthosis, wrist, prefabricated, includes fitting and adjustment
l3995
addition to upper extremity orthosis, sock, fracture or equal, each
l3999
upper limb orthosis, not otherwise specified
l4000
replace girdle for spinal orthosis (ctlso or so)
l4002
replacement strap, any orthosis, includes all components, any length, any type
l4010
replace trilateral socket brim
l4020
replace quadrilateral socket brim, molded to patient model
l4030
replace quadrilateral socket brim, custom fitted
l4040
replace molded thigh lacer, for custom fabricated orthosis only
l4045
replace non-molded thigh lacer, for custom fabricated orthosis only
l4050
replace molded calf lacer, for custom fabricated orthosis only
l4055
replace non-molded calf lacer, for custom fabricated orthosis only
l4060
replace high roll cuff
l4070
replace proximal and distal upright for kafo
l4080
replace metal bands kafo, proximal thigh
l4090
replace metal bands kafo-afo, calf or distal thigh
l4100
replace leather cuff kafo, proximal thigh
l4110
replace leather cuff kafo-afo, calf or distal thigh
l4130
replace pretibial shell
l4205
repair of orthotic device, labor component, per 15 minutes
l4210
repair of orthotic device, repair or replace minor parts
l4350
ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf
l4360
walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l4361
walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf
l4370
pneumatic full leg splint, prefabricated, off-the-shelf
l4386
walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l4387
walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated, off-the-shelf
l4392
replacement, soft interface material, static afo
l4394
replace soft interface material, foot drop splint
l4396
static or dynamic ankle foot orthosis, including soft interface material, adjustable for fit, for positioning, may be used for minimal ambulation, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
l4397
static or dynamic ankle foot orthosis, including soft interface material, adjustable for fit, for positioning, may be used for minimal ambulation, prefabricated, off-the-shelf
l4398
foot drop splint, recumbent positioning device, prefabricated, off-the-shelf
l4631
ankle foot orthosis, walking boot type, varus/valgus correction, rocker bottom, anterior tibial shell, soft interface, custom arch support, plastic or other material, includes straps and closures, custom fabricated
l5000
partial foot, shoe insert with longitudinal arch, toe filler
l5010
partial foot, molded socket, ankle height, with toe filler
l5020
partial foot, molded socket, tibial tubercle height, with toe filler
l5050
ankle, symes, molded socket, sach foot
l5060
ankle, symes, metal frame, molded leather socket, articulated ankle/foot
l5100
below knee, molded socket, shin, sach foot
l5105
below knee, plastic socket, joints and thigh lacer, sach foot
l5150
knee disarticulation (or through knee), molded socket, external knee joints, shin, sach foot
l5160
knee disarticulation (or through knee), molded socket, bent knee configuration, external knee joints, shin, sach foot
l5200
above knee, molded socket, single axis constant friction knee, shin, sach foot
l5210
above knee, short prosthesis, no knee joint ('stubbies'), with foot blocks, no ankle joints, each
l5220
above knee, short prosthesis, no knee joint ('stubbies'), with articulated ankle/foot, dynamically aligned, each
l5230
above knee, for proximal femoral focal deficiency, constant friction knee, shin, sach foot
l5250
hip disarticulation, canadian type; molded socket, hip joint, single axis constant friction knee, shin, sach foot
l5270
hip disarticulation, tilt table type; molded socket, locking hip joint, single axis constant friction knee, shin, sach foot
l5280
hemipelvectomy, canadian type; molded socket, hip joint, single axis constant friction knee, shin, sach foot
l5301
below knee, molded socket, shin, sach foot, endoskeletal system
l5312
knee disarticulation (or through knee), molded socket, single axis knee, pylon, sach foot, endoskeletal system
l5321
above knee, molded socket, open end, sach foot, endoskeletal system, single axis knee
l5331
hip disarticulation, canadian type, molded socket, endoskeletal system, hip joint, single axis knee, sach foot
l5341
hemipelvectomy, canadian type, molded socket, endoskeletal system, hip joint, single axis knee, sach foot
l5400
immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment, suspension, and one cast change, below knee
l5410
immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment and suspension, below knee, each additional cast change and realignment
l5420
immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment and suspension and one cast change 'ak' or knee disarticulation
l5430
immediate post surgical or early fitting, application of initial rigid dressing, incl. fitting, alignment and supension, 'ak' or knee disarticulation, each additional cast change and realignment
l5450
immediate post surgical or early fitting, application of non-weight bearing rigid dressing, below knee
l5460
immediate post surgical or early fitting, application of non-weight bearing rigid dressing, above knee
l5500
initial, below knee 'ptb' type socket, non-alignable system, pylon, no cover, sach foot, plaster socket, direct formed
l5505
initial, above knee - knee disarticulation, ischial level socket, non-alignable system, pylon, no cover, sach foot, plaster socket, direct formed
l5510
preparatory, below knee 'ptb' type socket, non-alignable system, pylon, no cover, sach foot, plaster socket, molded to model
l5520
preparatory, below knee 'ptb' type socket, non-alignable system, pylon, no cover, sach foot, thermoplastic or equal, direct formed
l5530
preparatory, below knee 'ptb' type socket, non-alignable system, pylon, no cover, sach foot, thermoplastic or equal, molded to model
l5535
preparatory, below knee 'ptb' type socket, non-alignable system, no cover, sach foot, prefabricated, adjustable open end socket
l5540
preparatory, below knee 'ptb' type socket, non-alignable system, pylon, no cover, sach foot, laminated socket, molded to model
l5560
preparatory, above knee- knee disarticulation, ischial level socket, non-alignable system, pylon, no cover, sach foot, plaster socket, molded to model
l5570
preparatory, above knee - knee disarticulation, ischial level socket, non-alignable system, pylon, no cover, sach foot, thermoplastic or equal, direct formed
l5580
preparatory, above knee - knee disarticulation ischial level socket, non-alignable system, pylon, no cover, sach foot, thermoplastic or equal, molded to model
l5585
preparatory, above knee - knee disarticulation, ischial level socket, non-alignable system, pylon, no cover, sach foot, prefabricated adjustable open end socket
l5590
preparatory, above knee - knee disarticulation ischial level socket, non-alignable system, pylon no cover, sach foot, laminated socket, molded to model
l5595
preparatory, hip disarticulation-hemipelvectomy, pylon, no cover, sach foot, thermoplastic or equal, molded to patient model
l5600
preparatory, hip disarticulation-hemipelvectomy, pylon, no cover, sach foot, laminated socket, molded to patient model
l5610
addition to lower extremity, endoskeletal system, above knee, hydracadence system
l5611
addition to lower extremity, endoskeletal system, above knee - knee disarticulation, 4 bar linkage, with friction swing phase control
l5613
addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control
l5614
addition to lower extremity, exoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control
l5616
addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control
l5617
addition to lower extremity, quick change self-aligning unit, above knee or below knee, each
l5618
addition to lower extremity, test socket, symes
l5620
addition to lower extremity, test socket, below knee
l5622
addition to lower extremity, test socket, knee disarticulation
l5624
addition to lower extremity, test socket, above knee
l5626
addition to lower extremity, test socket, hip disarticulation
l5628
addition to lower extremity, test socket, hemipelvectomy
l5629
addition to lower extremity, below knee, acrylic socket
l5630
addition to lower extremity, symes type, expandable wall socket
l5631
addition to lower extremity, above knee or knee disarticulation, acrylic socket
l5632
addition to lower extremity, symes type, 'ptb' brim design socket
l5634
addition to lower extremity, symes type, posterior opening (canadian) socket
l5636
addition to lower extremity, symes type, medial opening socket
l5637
addition to lower extremity, below knee, total contact
l5638
addition to lower extremity, below knee, leather socket
l5639
addition to lower extremity, below knee, wood socket
l5640
addition to lower extremity, knee disarticulation, leather socket
l5642
addition to lower extremity, above knee, leather socket
l5643
addition to lower extremity, hip disarticulation, flexible inner socket, external frame
l5644
addition to lower extremity, above knee, wood socket
l5645
addition to lower extremity, below knee, flexible inner socket, external frame
l5646
addition to lower extremity, below knee, air, fluid, gel or equal, cushion socket
l5647
addition to lower extremity, below knee suction socket
l5648
addition to lower extremity, above knee, air, fluid, gel or equal, cushion socket
l5649
addition to lower extremity, ischial containment/narrow m-l socket
l5650
additions to lower extremity, total contact, above knee or knee disarticulation socket
l5651
addition to lower extremity, above knee, flexible inner socket, external frame
l5652
addition to lower extremity, suction suspension, above knee or knee disarticulation socket
l5653
addition to lower extremity, knee disarticulation, expandable wall socket
l5654
addition to lower extremity, socket insert, symes, (kemblo, pelite, aliplast, plastazote or equal)
l5655
addition to lower extremity, socket insert, below knee (kemblo, pelite, aliplast, plastazote or equal)
l5656
addition to lower extremity, socket insert, knee disarticulation (kemblo, pelite, aliplast, plastazote or equal)
l5658
addition to lower extremity, socket insert, above knee (kemblo, pelite, aliplast, plastazote or equal)
l5661
addition to lower extremity, socket insert, multi-durometer symes
l5665
addition to lower extremity, socket insert, multi-durometer, below knee
l5666
addition to lower extremity, below knee, cuff suspension
l5668
addition to lower extremity, below knee, molded distal cushion
l5670
addition to lower extremity, below knee, molded supracondylar suspension ('pts' or similar)
l5671
addition to lower extremity, below knee / above knee suspension locking mechanism (shuttle, lanyard or equal), excludes socket insert
l5672
addition to lower extremity, below knee, removable medial brim suspension
l5673
addition to lower extremity, below knee/above knee, custom fabricated from existing mold or prefabricated, socket insert, silicone gel, elastomeric or equal, for use with locking mechanism
l5676
additions to lower extremity, below knee, knee joints, single axis, pair
l5677
additions to lower extremity, below knee, knee joints, polycentric, pair
l5678
additions to lower extremity, below knee, joint covers, pair
l5679
addition to lower extremity, below knee/above knee, custom fabricated from existing mold or prefabricated, socket insert, silicone gel, elastomeric or equal, not for use with locking mechanism
l5680
addition to lower extremity, below knee, thigh lacer, nonmolded
l5681
addition to lower extremity, below knee/above knee, custom fabricated socket insert for congenital or atypical traumatic amputee, silicone gel, elastomeric or equal, for use with or without locking mechanism, initial only (for other than initial, use code l5673 or l5679)
l5682
addition to lower extremity, below knee, thigh lacer, gluteal/ischial, molded
l5683
addition to lower extremity, below knee/above knee, custom fabricated socket insert for other than congenital or atypical traumatic amputee, silicone gel, elastomeric or equal, for use with or without locking mechanism, initial only (for other than initial, use code l5673 or l5679)
l5684
addition to lower extremity, below knee, fork strap
l5685
addition to lower extremity prosthesis, below knee, suspension/sealing sleeve, with or without valve, any material, each
l5686
addition to lower extremity, below knee, back check (extension control)
l5688
addition to lower extremity, below knee, waist belt, webbing
l5690
addition to lower extremity, below knee, waist belt, padded and lined
l5692
addition to lower extremity, above knee, pelvic control belt, light
l5694
addition to lower extremity, above knee, pelvic control belt, padded and lined
l5695
addition to lower extremity, above knee, pelvic control, sleeve suspension, neoprene or equal, each
l5696
addition to lower extremity, above knee or knee disarticulation, pelvic joint
l5697
addition to lower extremity, above knee or knee disarticulation, pelvic band
l5698
addition to lower extremity, above knee or knee disarticulation, silesian bandage
l5699
all lower extremity prostheses, shoulder harness
l5700
replacement, socket, below knee, molded to patient model
l5701
replacement, socket, above knee/knee disarticulation, including attachment plate, molded to patient model
l5702
replacement, socket, hip disarticulation, including hip joint, molded to patient model
l5703
ankle, symes, molded to patient model, socket without solid ankle cushion heel (sach) foot, replacement only
l5704
custom shaped protective cover, below knee
l5705
custom shaped protective cover, above knee
l5706
custom shaped protective cover, knee disarticulation
l5707
custom shaped protective cover, hip disarticulation
l5710
addition, exoskeletal knee-shin system, single axis, manual lock
l5711
additions exoskeletal knee-shin system, single axis, manual lock, ultra-light material
l5712
addition, exoskeletal knee-shin system, single axis, friction swing and stance phase control (safety knee)
l5714
addition, exoskeletal knee-shin system, single axis, variable friction swing phase control
l5716
addition, exoskeletal knee-shin system, polycentric, mechanical stance phase lock
l5718
addition, exoskeletal knee-shin system, polycentric, friction swing and stance phase control
l5722
addition, exoskeletal knee-shin system, single axis, pneumatic swing, friction stance phase control
l5724
addition, exoskeletal knee-shin system, single axis, fluid swing phase control
l5726
addition, exoskeletal knee-shin system, single axis, external joints fluid swing phase control
l5728
addition, exoskeletal knee-shin system, single axis, fluid swing and stance phase control
l5780
addition, exoskeletal knee-shin system, single axis, pneumatic/hydra pneumatic swing phase control
l5781
addition to lower limb prosthesis, vacuum pump, residual limb volume management and moisture evacuation system
l5782
addition to lower limb prosthesis, vacuum pump, residual limb volume management and moisture evacuation system, heavy duty
l5785
addition, exoskeletal system, below knee, ultra-light material (titanium, carbon fiber or equal)
l5790
addition, exoskeletal system, above knee, ultra-light material (titanium, carbon fiber or equal)
l5795
addition, exoskeletal system, hip disarticulation, ultra-light material (titanium, carbon fiber or equal)
l5810
addition, endoskeletal knee-shin system, single axis, manual lock
l5811
addition, endoskeletal knee-shin system, single axis, manual lock, ultra-light material
l5812
addition, endoskeletal knee-shin system, single axis, friction swing and stance phase control (safety knee)
l5814
addition, endoskeletal knee-shin system, polycentric, hydraulic swing phase control, mechanical stance phase lock
l5816
addition, endoskeletal knee-shin system, polycentric, mechanical stance phase lock
l5818
addition, endoskeletal knee-shin system, polycentric, friction swing, and stance phase control
l5822
addition, endoskeletal knee-shin system, single axis, pneumatic swing, friction stance phase control
l5824
addition, endoskeletal knee-shin system, single axis, fluid swing phase control
l5826
addition, endoskeletal knee-shin system, single axis, hydraulic swing phase control, with miniature high activity frame
l5828
addition, endoskeletal knee-shin system, single axis, fluid swing and stance phase control
l5830
addition, endoskeletal knee-shin system, single axis, pneumatic/ swing phase control
l5840
addition, endoskeletal knee/shin system, 4-bar linkage or multiaxial, pneumatic swing phase control
l5845
addition, endoskeletal, knee-shin system, stance flexion feature, adjustable
l5848
addition to endoskeletal knee-shin system, fluid stance extension, dampening feature, with or without adjustability
l5850
addition, endoskeletal system, above knee or hip disarticulation, knee extension assist
l5855
addition, endoskeletal system, hip disarticulation, mechanical hip extension assist
l5856
addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing and stance phase, includes electronic sensor(s), any type
l5857
addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing phase only, includes electronic sensor(s), any type
l5858
addition to lower extremity prosthesis, endoskeletal knee shin system, microprocessor control feature, stance phase only, includes electronic sensor(s), any type
l5859
addition to lower extremity prosthesis, endoskeletal knee-shin system, powered and programmable flexion/extension assist control, includes any type motor(s)
l5910
addition, endoskeletal system, below knee, alignable system
l5920
addition, endoskeletal system, above knee or hip disarticulation, alignable system
l5925
addition, endoskeletal system, above knee, knee disarticulation or hip disarticulation, manual lock
l5930
addition, endoskeletal system, high activity knee control frame
l5940
addition, endoskeletal system, below knee, ultra-light material (titanium, carbon fiber or equal)
l5950
addition, endoskeletal system, above knee, ultra-light material (titanium, carbon fiber or equal)
l5960
addition, endoskeletal system, hip disarticulation, ultra-light material (titanium, carbon fiber or equal)
l5961
addition, endoskeletal system, polycentric hip joint, pneumatic or hydraulic control, rotation control, with or without flexion and/or extension control
l5962
addition, endoskeletal system, below knee, flexible protective outer surface covering system
l5964
addition, endoskeletal system, above knee, flexible protective outer surface covering system
l5966
addition, endoskeletal system, hip disarticulation, flexible protective outer surface covering system
l5968
addition to lower limb prosthesis, multiaxial ankle with swing phase active dorsiflexion feature
l5969
addition, endoskeletal ankle-foot or ankle system, power assist, includes any type motor(s)
l5970
all lower extremity prostheses, foot, external keel, sach foot
l5971
all lower extremity prosthesis, solid ankle cushion heel (sach) foot, replacement only
l5972
all lower extremity prostheses, foot, flexible keel
l5973
endoskeletal ankle foot system, microprocessor controlled feature, dorsiflexion and/or plantar flexion control, includes power source
l5974
all lower extremity prostheses, foot, single axis ankle/foot
l5975
all lower extremity prosthesis, combination single axis ankle and flexible keel foot
l5976
all lower extremity prostheses, energy storing foot (seattle carbon copy ii or equal)
l5978
all lower extremity prostheses, foot, multiaxial ankle/foot
l5979
all lower extremity prosthesis, multi-axial ankle, dynamic response foot, one piece system
l5980
all lower extremity prostheses, flex foot system
l5981
all lower extremity prostheses, flex-walk system or equal
l5982
all exoskeletal lower extremity prostheses, axial rotation unit
l5984
all endoskeletal lower extremity prosthesis, axial rotation unit, with or without adjustability
l5985
all endoskeletal lower extremity prostheses, dynamic prosthetic pylon
l5986
all lower extremity prostheses, multi-axial rotation unit ('mcp' or equal)
l5987
all lower extremity prosthesis, shank foot system with vertical loading pylon
l5988
addition to lower limb prosthesis, vertical shock reducing pylon feature
l5990
addition to lower extremity prosthesis, user adjustable heel height
l5999
lower extremity prosthesis, not otherwise specified
l6000
partial hand, thumb remaining
l6010
partial hand, little and/or ring finger remaining
l6020
partial hand, no finger remaining
l6025
transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device terminated december 31, 2014.
l6026
transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device, excludes terminal device(s)
l6050
wrist disarticulation, molded socket, flexible elbow hinges, triceps pad
l6055
wrist disarticulation, molded socket with expandable interface, flexible elbow hinges, triceps pad
l6100
below elbow, molded socket, flexible elbow hinge, triceps pad
l6110
below elbow, molded socket, (muenster or northwestern suspension types)
l6120
below elbow, molded double wall split socket, step-up hinges, half cuff
l6130
below elbow, molded double wall split socket, stump activated locking hinge, half cuff
l6200
elbow disarticulation, molded socket, outside locking hinge, forearm
l6205
elbow disarticulation, molded socket with expandable interface, outside locking hinges, forearm
l6250
above elbow, molded double wall socket, internal locking elbow, forearm
l6300
shoulder disarticulation, molded socket, shoulder bulkhead, humeral section, internal locking elbow, forearm
l6310
shoulder disarticulation, passive restoration (complete prosthesis)
l6320
shoulder disarticulation, passive restoration (shoulder cap only)
l6350
interscapular thoracic, molded socket, shoulder bulkhead, humeral section, internal locking elbow, forearm
l6360
interscapular thoracic, passive restoration (complete prosthesis)
l6370
interscapular thoracic, passive restoration (shoulder cap only)
l6380
immediate post surgical or early fitting, application of initial rigid dressing, including fitting alignment and suspension of components, and one cast change, wrist disarticulation or below elbow
l6382
immediate post surgical or early fitting, application of initial rigid dressing including fitting alignment and suspension of components, and one cast change, elbow disarticulation or above elbow
l6384
immediate post surgical or early fitting, application of initial rigid dressing including fitting alignment and suspension of components, and one cast change, shoulder disarticulation or interscapular thoracic
l6386
immediate post surgical or early fitting, each additional cast change and realignment
l6388
immediate post surgical or early fitting, application of rigid dressing only
l6400
below elbow, molded socket, endoskeletal system, including soft prosthetic tissue shaping
l6450
elbow disarticulation, molded socket, endoskeletal system, including soft prosthetic tissue shaping
l6500
above elbow, molded socket, endoskeletal system, including soft prosthetic tissue shaping
l6550
shoulder disarticulation, molded socket, endoskeletal system, including soft prosthetic tissue shaping
l6570
interscapular thoracic, molded socket, endoskeletal system, including soft prosthetic tissue shaping
l6580
preparatory, wrist disarticulation or below elbow, single wall plastic socket, friction wrist, flexible elbow hinges, figure of eight harness, humeral cuff, bowden cable control, usmc or equal pylon, no cover, molded to patient model
l6582
preparatory, wrist disarticulation or below elbow, single wall socket, friction wrist, flexible elbow hinges, figure of eight harness, humeral cuff, bowden cable control, usmc or equal pylon, no cover, direct formed
l6584
preparatory, elbow disarticulation or above elbow, single wall plastic socket, friction wrist, locking elbow, figure of eight harness, fair lead cable control, usmc or equal pylon, no cover, molded to patient model
l6586
preparatory, elbow disarticulation or above elbow, single wall socket, friction wrist, locking elbow, figure of eight harness, fair lead cable control, usmc or equal pylon, no cover, direct formed
l6588
preparatory, shoulder disarticulation or interscapular thoracic, single wall plastic socket, shoulder joint, locking elbow, friction wrist, chest strap, fair lead cable control, usmc or equal pylon, no cover, molded to patient model
l6590
preparatory, shoulder disarticulation or interscapular thoracic, single wall socket, shoulder joint, locking elbow, friction wrist, chest strap, fair lead cable control, usmc or equal pylon, no cover, direct formed
l6600
upper extremity additions, polycentric hinge, pair
l6605
upper extremity additions, single pivot hinge, pair
l6610
upper extremity additions, flexible metal hinge, pair
l6611
addition to upper extremity prosthesis, external powered, additional switch, any type
l6615
upper extremity addition, disconnect locking wrist unit
l6616
upper extremity addition, additional disconnect insert for locking wrist unit, each
l6620
upper extremity addition, flexion/extension wrist unit, with or without friction
l6621
upper extremity prosthesis addition, flexion/extension wrist with or without friction, for use with external powered terminal device
l6623
upper extremity addition, spring assisted rotational wrist unit with latch release
l6624
upper extremity addition, flexion/extension and rotation wrist unit
l6625
upper extremity addition, rotation wrist unit with cable lock
l6628
upper extremity addition, quick disconnect hook adapter, otto bock or equal
l6629
upper extremity addition, quick disconnect lamination collar with coupling piece, otto bock or equal
l6630
upper extremity addition, stainless steel, any wrist
l6632
upper extremity addition, latex suspension sleeve, each
l6635
upper extremity addition, lift assist for elbow
l6637
upper extremity addition, nudge control elbow lock
l6638
upper extremity addition to prosthesis, electric locking feature, only for use with manually powered elbow
l6640
upper extremity additions, shoulder abduction joint, pair
l6641
upper extremity addition, excursion amplifier, pulley type
l6642
upper extremity addition, excursion amplifier, lever type
l6645
upper extremity addition, shoulder flexion-abduction joint, each
l6646
upper extremity addition, shoulder joint, multipositional locking, flexion, adjustable abduction friction control, for use with body powered or external powered system
l6647
upper extremity addition, shoulder lock mechanism, body powered actuator
l6648
upper extremity addition, shoulder lock mechanism, external powered actuator
l6650
upper extremity addition, shoulder universal joint, each
l6655
upper extremity addition, standard control cable, extra
l6660
upper extremity addition, heavy duty control cable
l6665
upper extremity addition, teflon, or equal, cable lining
l6670
upper extremity addition, hook to hand, cable adapter
l6672
upper extremity addition, harness, chest or shoulder, saddle type
l6675
upper extremity addition, harness, (e.g., figure of eight type), single cable design
l6676
upper extremity addition, harness, (e.g., figure of eight type), dual cable design
l6677
upper extremity addition, harness, triple control, simultaneous operation of terminal device and elbow
l6680
upper extremity addition, test socket, wrist disarticulation or below elbow
l6682
upper extremity addition, test socket, elbow disarticulation or above elbow
l6684
upper extremity addition, test socket, shoulder disarticulation or interscapular thoracic
l6686
upper extremity addition, suction socket
l6687
upper extremity addition, frame type socket, below elbow or wrist disarticulation
l6688
upper extremity addition, frame type socket, above elbow or elbow disarticulation
l6689
upper extremity addition, frame type socket, shoulder disarticulation
l6690
upper extremity addition, frame type socket, interscapular-thoracic
l6691
upper extremity addition, removable insert, each
l6692
upper extremity addition, silicone gel insert or equal, each
l6693
upper extremity addition, locking elbow, forearm counterbalance
l6694
addition to upper extremity prosthesis, below elbow/above elbow, custom fabricated from existing mold or prefabricated, socket insert, silicone gel, elastomeric or equal, for use with locking mechanism
l6695
addition to upper extremity prosthesis, below elbow/above elbow, custom fabricated from existing mold or prefabricated, socket insert, silicone gel, elastomeric or equal, not for use with locking mechanism
l6696
addition to upper extremity prosthesis, below elbow/above elbow, custom fabricated socket insert for congenital or atypical traumatic amputee, silicone gel, elastomeric or equal, for use with or without locking mechanism, initial only (for other than initial, use code l6694 or l6695)
l6697
addition to upper extremity prosthesis, below elbow/above elbow, custom fabricated socket insert for other than congenital or atypical traumatic amputee, silicone gel, elastomeric or equal, for use with or without locking mechanism, initial only (for other than initial, use code l6694 or l6695)
l6698
addition to upper extremity prosthesis, below elbow/above elbow, lock mechanism, excludes socket insert
l6703
terminal device, passive hand/mitt, any material, any size
l6704
terminal device, sport/recreational/work attachment, any material, any size
l6706
terminal device, hook, mechanical, voluntary opening, any material, any size, lined or unlined
l6707
terminal device, hook, mechanical, voluntary closing, any material, any size, lined or unlined
l6708
terminal device, hand, mechanical, voluntary opening, any material, any size
l6709
terminal device, hand, mechanical, voluntary closing, any material, any size
l6711
terminal device, hook, mechanical, voluntary opening, any material, any size, lined or unlined, pediatric
l6712
terminal device, hook, mechanical, voluntary closing, any material, any size, lined or unlined, pediatric
l6713
terminal device, hand, mechanical, voluntary opening, any material, any size, pediatric
l6714
terminal device, hand, mechanical, voluntary closing, any material, any size, pediatric
l6715
terminal device, multiple articulating digit, includes motor(s), initial issue or replacement
l6721
terminal device, hook or hand, heavy duty, mechanical, voluntary opening, any material, any size, lined or unlined
l6722
terminal device, hook or hand, heavy duty, mechanical, voluntary closing, any material, any size, lined or unlined
l6805
addition to terminal device, modifier wrist unit
l6810
addition to terminal device, precision pinch device
l6880
electric hand, switch or myoelectric controlled, independently articulating digits, any grasp pattern or combination of grasp patterns, includes motor(s)
l6881
automatic grasp feature, addition to upper limb electric prosthetic terminal device
l6882
microprocessor control feature, addition to upper limb prosthetic terminal device
l6883
replacement socket, below elbow/wrist disarticulation, molded to patient model, for use with or without external power
l6884
replacement socket, above elbow/elbow disarticulation, molded to patient model, for use with or without external power
l6885
replacement socket, shoulder disarticulation/interscapular thoracic, molded to patient model, for use with or without external power
l6890
addition to upper extremity prosthesis, glove for terminal device, any material, prefabricated, includes fitting and adjustment
l6895
addition to upper extremity prosthesis, glove for terminal device, any material, custom fabricated
l6900
hand restoration (casts, shading and measurements included), partial hand, with glove, thumb or one finger remaining
l6905
hand restoration (casts, shading and measurements included), partial hand, with glove, multiple fingers remaining
l6910
hand restoration (casts, shading and measurements included), partial hand, with glove, no fingers remaining
l6915
hand restoration (shading, and measurements included), replacement glove for above
l6920
wrist disarticulation, external power, self-suspended inner socket, removable forearm shell, otto bock or equal, switch, cables, two batteries and one charger, switch control of terminal device
l6925
wrist disarticulation, external power, self-suspended inner socket, removable forearm shell, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device
l6930
below elbow, external power, self-suspended inner socket, removable forearm shell, otto bock or equal switch, cables, two batteries and one charger, switch control of terminal device
l6935
below elbow, external power, self-suspended inner socket, removable forearm shell, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device
l6940
elbow disarticulation, external power, molded inner socket, removable humeral shell, outside locking hinges, forearm, otto bock or equal switch, cables, two batteries and one charger, switch control of terminal device
l6945
elbow disarticulation, external power, molded inner socket, removable humeral shell, outside locking hinges, forearm, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device
l6950
above elbow, external power, molded inner socket, removable humeral shell, internal locking elbow, forearm, otto bock or equal switch, cables, two batteries and one charger, switch control of terminal device
l6955
above elbow, external power, molded inner socket, removable humeral shell, internal locking elbow, forearm, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device
l6960
shoulder disarticulation, external power, molded inner socket, removable shoulder shell, shoulder bulkhead, humeral section, mechanical elbow, forearm, otto bock or equal switch, cables, two batteries and one charger, switch control of terminal device
l6965
shoulder disarticulation, external power, molded inner socket, removable shoulder shell, shoulder bulkhead, humeral section, mechanical elbow, forearm, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device
l6970
interscapular-thoracic, external power, molded inner socket, removable shoulder shell, shoulder bulkhead, humeral section, mechanical elbow, forearm, otto bock or equal switch, cables, two batteries and one charger, switch control of terminal device
l6975
interscapular-thoracic, external power, molded inner socket, removable shoulder shell, shoulder bulkhead, humeral section, mechanical elbow, forearm, otto bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device
l7007
electric hand, switch or myoelectric controlled, adult
l7008
electric hand, switch or myoelectric, controlled, pediatric
l7009
electric hook, switch or myoelectric controlled, adult
l7040
prehensile actuator, switch controlled
l7045
electric hook, switch or myoelectric controlled, pediatric
l7170
electronic elbow, hosmer or equal, switch controlled
l7180
electronic elbow, microprocessor sequential control of elbow and terminal device
l7181
electronic elbow, microprocessor simultaneous control of elbow and terminal device
l7185
electronic elbow, adolescent, variety village or equal, switch controlled
l7186
electronic elbow, child, variety village or equal, switch controlled
l7190
electronic elbow, adolescent, variety village or equal, myoelectronically controlled
l7191
electronic elbow, child, variety village or equal, myoelectronically controlled
l7259
electronic wrist rotator, any type
l7260
electronic wrist rotator, otto bock or equal terminated december 31, 2014.
l7261
electronic wrist rotator, for utah arm terminated december 31, 2014.
l7360
six volt battery, each
l7362
battery charger, six volt, each
l7364
twelve volt battery, each
l7366
battery charger, twelve volt, each
l7367
lithium ion battery, rechargeable, replacement
l7368
lithium ion battery charger, replacement only
l7400
addition to upper extremity prosthesis, below elbow/wrist disarticulation, ultralight material (titanium, carbon fiber or equal)
l7401
addition to upper extremity prosthesis, above elbow disarticulation, ultralight material (titanium, carbon fiber or equal)
l7402
addition to upper extremity prosthesis, shoulder disarticulation/interscapular thoracic, ultralight material (titanium, carbon fiber or equal)
l7403
addition to upper extremity prosthesis, below elbow/wrist disarticulation, acrylic material
l7404
addition to upper extremity prosthesis, above elbow disarticulation, acrylic material
l7405
addition to upper extremity prosthesis, shoulder disarticulation/interscapular thoracic, acrylic material
l7499
upper extremity prosthesis, not otherwise specified
l7510
repair of prosthetic device, repair or replace minor parts
l7520
repair prosthetic device, labor component, per 15 minutes
l7600
prosthetic donning sleeve, any material, each
l7700
gasket or seal, for use with prosthetic socket insert, any type, each
l7900
male vacuum erection system
l7902
tension ring, for vacuum erection device, any type, replacement only, each
l8000
breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type
l8001
breast prosthesis, mastectomy bra, with integrated breast prosthesis form, unilateral, any size, any type
l8002
breast prosthesis, mastectomy bra, with integrated breast prosthesis form, bilateral, any size, any type
l8010
breast prosthesis, mastectomy sleeve
l8015
external breast prosthesis garment, with mastectomy form, post mastectomy
l8020
breast prosthesis, mastectomy form
l8030
breast prosthesis, silicone or equal, without integral adhesive
l8031
breast prosthesis, silicone or equal, with integral adhesive
l8032
nipple prosthesis, prefabricated, reusable, any type, each
l8033
nipple prosthesis, custom fabricated, reusable, any material, any type, each
l8035
custom breast prosthesis, post mastectomy, molded to patient model
l8039
breast prosthesis, not otherwise specified
l8040
nasal prosthesis, provided by a non-physician
l8041
midfacial prosthesis, provided by a non-physician
l8042
orbital prosthesis, provided by a non-physician
l8043
upper facial prosthesis, provided by a non-physician
l8044
hemi-facial prosthesis, provided by a non-physician
l8045
auricular prosthesis, provided by a non-physician
l8046
partial facial prosthesis, provided by a non-physician
l8047
nasal septal prosthesis, provided by a non-physician
l8048
unspecified maxillofacial prosthesis, by report, provided by a non-physician
l8049
repair or modification of maxillofacial prosthesis, labor component, 15 minute increments, provided by a non-physician
l8300
truss, single with standard pad
l8310
truss, double with standard pads
l8320
truss, addition to standard pad, water pad
l8330
truss, addition to standard pad, scrotal pad
l8400
prosthetic sheath, below knee, each
l8410
prosthetic sheath, above knee, each
l8415
prosthetic sheath, upper limb, each
l8417
prosthetic sheath/sock, including a gel cushion layer, below knee or above knee, each
l8420
prosthetic sock, multiple ply, below knee, each
l8430
prosthetic sock, multiple ply, above knee, each
l8435
prosthetic sock, multiple ply, upper limb, each
l8440
prosthetic shrinker, below knee, each
l8460
prosthetic shrinker, above knee, each
l8465
prosthetic shrinker, upper limb, each
l8470
prosthetic sock, single ply, fitting, below knee, each
l8480
prosthetic sock, single ply, fitting, above knee, each
l8485
prosthetic sock, single ply, fitting, upper limb, each
l8499
unlisted procedure for miscellaneous prosthetic services
l8500
artificial larynx, any type
l8501
tracheostomy speaking valve
l8505
artificial larynx replacement battery / accessory, any type
l8507
tracheo-esophageal voice prosthesis, patient inserted, any type, each
l8509
tracheo-esophageal voice prosthesis, inserted by a licensed health care provider, any type
l8510
voice amplifier
l8511
insert for indwelling tracheoesophageal prosthesis, with or without valve, replacement only, each
l8512
gelatin capsules or equivalent, for use with tracheoesophageal voice prosthesis, replacement only, per 10
l8513
cleaning device used with tracheoesophageal voice prosthesis, pipet, brush, or equal, replacement only, each
l8514
tracheoesophageal puncture dilator, replacement only, each
l8515
gelatin capsule, application device for use with tracheoesophageal voice prosthesis, each
l8600
implantable breast prosthesis, silicone or equal
l8603
injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies
l8604
injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies
l8605
injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies
l8606
injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies
l8607
injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies
l8608
miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system
l8609
artificial cornea
l8610
ocular implant
l8612
aqueous shunt
l8613
ossicula implant
l8614
cochlear device, includes all internal and external components
l8615
headset/headpiece for use with cochlear implant device, replacement
l8616
microphone for use with cochlear implant device, replacement
l8617
transmitting coil for use with cochlear implant device, replacement
l8618
transmitter cable for use with cochlear implant device or auditory osseointegrated device, replacement
l8619
cochlear implant, external speech processor and controller, integrated system, replacement
l8621
zinc air battery for use with cochlear implant device and auditory osseointegrated sound processors, replacement, each
l8622
alkaline battery for use with cochlear implant device, any size, replacement, each
l8623
lithium ion battery for use with cochlear implant device speech processor, other than ear level, replacement, each
l8624
lithium ion battery for use with cochlear implant or auditory osseointegrated device speech processor, ear level, replacement, each
l8625
external recharging system for battery for use with cochlear implant or auditory osseointegrated device, replacement only, each
l8627
cochlear implant, external speech processor, component, replacement
l8628
cochlear implant, external controller component, replacement
l8629
transmitting coil and cable, integrated, for use with cochlear implant device, replacement
l8630
metacarpophalangeal joint implant
l8631
metacarpal phalangeal joint replacement, two or more pieces, metal (e.g., stainless steel or cobalt chrome), ceramic-like material (e.g., pyrocarbon), for surgical implantation (all sizes, includes entire system)
l8641
metatarsal joint implant
l8642
hallux implant
l8658
interphalangeal joint spacer, silicone or equal, each
l8659
interphalangeal finger joint replacement, 2 or more pieces, metal (e.g., stainless steel or cobalt chrome), ceramic-like material (e.g., pyrocarbon) for surgical implantation, any size
l8670
vascular graft material, synthetic, implant
l8679
implantable neurostimulator, pulse generator, any type
l8680
implantable neurostimulator electrode, each
l8681
patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
l8682
implantable neurostimulator radiofrequency receiver
l8683
radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver
l8684
radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement
l8685
implantable neurostimulator pulse generator, single array, rechargeable, includes extension
l8686
implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
l8687
implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
l8688
implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension
l8689
external recharging system for battery (internal) for use with implantable neurostimulator, replacement only
l8690
auditory osseointegrated device, includes all internal and external components
l8691
auditory osseointegrated device, external sound processor, excludes transducer/actuator, replacement only, each
l8692
auditory osseointegrated device, external sound processor, used without osseointegration, body worn, includes headband or other means of external attachment
l8693
auditory osseointegrated device abutment, any length, replacement only
l8694
auditory osseointegrated device, transducer/actuator, replacement only, each
l8695
external recharging system for battery (external) for use with implantable neurostimulator, replacement only
l8696
antenna (external) for use with implantable diaphragmatic/phrenic nerve stimulation device, replacement, each
l8698
miscellaneous component, supply or accessory for use with total artificial heart system
l8699
prosthetic implant, not otherwise specified
l8701
powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated
l8702
powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated
l9900
orthotic and prosthetic supply, accessory, and/or service component of another hcpcs "l" code
m0064
brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders terminated december 31, 2014.
m0075
cellular therapy
m0076
prolotherapy
m0100
intragastric hypothermia using gastric freezing
m0201
covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home
m0220
injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring
m0221
injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
m0222
intravenous injection, bebtelovimab, includes injection and post administration monitoring
m0223
intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
m0239
intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring terminated april 16, 2021.
m0240
intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
m0241
intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
m0243
intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring
m0244
intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
m0245
intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
m0246
intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency
m0247
intravenous infusion, sotrovimab, includes infusion and post administration monitoring
m0248
intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
m0249
intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
m0250
intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
m0300
iv chelation therapy (chemical endarterectomy)
m0301
fabric wrapping of abdominal aneurysm
m1000
pain screened as moderate to severe terminated december 31, 2019.
m1001
plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinician terminated december 31, 2019.
m1002
plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not given terminated december 31, 2019.
m1003
tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic disease modifying anti-rheumatic drug therapy
m1004
documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently completed a course of anti-tb therapy)
m1005
tb screening not performed or results not interpreted, reason not given
m1006
disease activity not assessed, reason not given
m1007
>=50% of total number of a patient's outpatient ra encounters assessed
m1008
<50% of total number of a patient's outpatient ra encounters assessed
m1009
discharge/discontinuation of the episode of care documented in the medical record
m1010
discharge/discontinuation of the episode of care documented in the medical record
m1011
discharge/discontinuation of the episode of care documented in the medical record
m1012
discharge/discontinuation of the episode of care documented in the medical record
m1013
discharge/discontinuation of the episode of care documented in the medical record
m1014
discharge/discontinuation of the episode of care documented in the medical record
m1015
discharge/discontinuation of the episode of care documented in the medical record terminated december 31, 2020.
m1016
female patients unable to bear children
m1017
patient admitted to palliative care services
m1018
patients with an active diagnosis or history of cancer (except basal cell and squamous cell skin carcinoma), patients who are heavy tobacco smokers, lung cancer screening patients
m1019
adolescent patients 12 to 17 years of age with major depression or dysthymia who reached remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5
m1020
adolescent patients 12 to 17 years of age with major depression or dysthymia who did not reach remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5. either phq-9 or phq-9m score was not assessed or is greater than or equal to 5
m1021
patient had only urgent care visits during the performance period
m1022
patients who were in hospice at any time during the performance period terminated december 31, 2021.
m1023
adolescent patients 12 to 17 years of age with major depression or dysthymia who reached remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five terminated december 31, 2020.
m1024
adolescent patients 12 to 17 years of age with major depression or dysthymia who did not reach remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five. either phq-9 or phq-9m score was not assessed or is greater than or equal to five terminated december 31, 2020.
m1025
patients who were in hospice at any time during the performance period terminated december 31, 2021.
m1026
patients who were in hospice at any time during the performance period terminated december 31, 2021.
m1027
imaging of the head (ct or mri) was obtained
m1028
documentation of patients with primary headache diagnosis and imaging other than ct or mri obtained
m1029
imaging of the head (ct or mri) was not obtained, reason not given
m1030
patients with clinical indications for imaging of the head terminated december 31, 2019.
m1031
patients with no clinical indications for imaging of the head terminated december 31, 2021.
m1032
adults currently taking pharmacotherapy for oud
m1033
pharmacotherapy for oud initiated after june 30th of performance period terminated december 31, 2020.
m1034
adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days
m1035
adults who are deliberately phased out of medication assisted treatment (mat) prior to 180 days of continuous treatment
m1036
adults who have not had at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days
m1037
patients with a diagnosis of lumbar spine region cancer at the time of the procedure
m1038
patients with a diagnosis of lumbar spine region fracture at the time of the procedure
m1039
patients with a diagnosis of lumbar spine region infection at the time of the procedure
m1040
patients with a diagnosis of lumbar idiopathic or congenital scoliosis
m1041
patient had cancer, acute fracture or infection related to the lumbar spine or patient had neuromuscular, idiopathic or congenital lumbar scoliosis
m1042
functional status measurement with score was obtained utilizing the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively terminated december 31, 2019.
m1043
functional status was not measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively
m1044
functional status was measured by the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively terminated december 31, 2019.
m1045
functional status measured by the oxford knee score (oks) at one year (9 to 15 months) postoperatively was greater than or equal to 37 or knee injury and osteoarthritis outcome score joint replacement (koos, jr.) was greater than or equal to 71
m1046
functional status measured by the oxford knee score (oks) at one year (9 to 15 months) postoperatively was less than 37 or the knee injury and osteoarthritis outcome score joint replacement (koos, jr.) was less than 71 postoperatively
m1047
functional status was measured by the oxford knee score (oks) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively terminated december 31, 2019.
m1048
functional status measurement with score was obtained utilizing the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at three months (6 to 20 weeks) postoperatively terminated december 31, 2019.
m1049
functional status was not measured by the oswestry disability index (odi version 2.1a) at three months (6 - 20 weeks) postoperatively
m1050
functional status was measured by the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at three months (6 to 20 weeks) postoperatively terminated december 31, 2019.
m1051
patient had cancer, acute fracture or infection related to the lumbar spine or patient had neuromuscular, idiopathic or congenital lumbar scoliosis
m1052
leg pain was not measured by the visual analog scale (vas) at one year (9 to 15 months) postoperatively
m1053
leg pain was measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively terminated december 31, 2019.
m1054
patient had only urgent care visits during the performance period
m1055
aspirin or another antiplatelet therapy used
m1056
prescribed anticoagulant medication during the performance period, history of gi bleeding, history of intracranial bleeding, bleeding disorder and specific provider documented reasons: allergy to aspirin or anti-platelets, use of non-steroidal anti-inflammatory agents, drug-drug interaction, uncontrolled hypertension > 180/110 mmhg or gastroesophageal reflux disease
m1057
aspirin or another antiplatelet therapy not used, reason not given
m1058
patient was a permanent nursing home resident at any time during the performance period
m1059
patient was in hospice or receiving palliative care at any time during the performance period
m1060
patient died prior to the end of the performance period
m1061
patient pregnancy terminated december 31, 2020.
m1062
patient immunocompromised terminated december 31, 2020.
m1063
patients receiving high doses of immunosuppressive therapy terminated december 31, 2020.
m1064
shingrix vaccine documented as administered or previously received terminated december 31, 2020.
m1065
shingrix vaccine was not administered for reasons documented by clinician (e.g. patient administered vaccine other than shingrix, patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) terminated december 31, 2020.
m1066
shingrix vaccine not documented as administered, reason not given terminated december 31, 2020.
m1067
hospice services for patient provided any time during the measurement period
m1068
adults who are not ambulatory
m1069
patient screened for future fall risk
m1070
patient not screened for future fall risk, reason not given
m1071
patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminotomy
m1106
the start of an episode of care documented in the medical record
m1107
documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care
m1108
ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record
m1109
ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery
m1110
ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown)
m1111
the start of an episode of care documented in the medical record
m1112
documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care
m1113
ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record
m1114
ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery
m1115
ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown)
m1116
the start of an episode of care documented in the medical record
m1117
documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care
m1118
ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record
m1119
ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery
m1120
ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown)
m1121
the start of an episode of care documented in the medical record
m1122
documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care
m1123
ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record
m1124
ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery
m1125
ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown)
m1126
the start of an episode of care documented in the medical record
m1127
documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care
m1128
ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record
m1129
ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery
m1130
ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown)
m1131
documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care
m1132
ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record
m1133
ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery
m1134
ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown)
m1135
the start of an episode of care documented in the medical record
m1136
the start of an episode of care documented in the medical record terminated december 31, 2020.
m1137
documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care terminated december 31, 2020.
m1138
ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only) terminated december 31, 2020.
m1139
ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown) terminated december 31, 2020.
m1140
ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery for surgery or hospitalized terminated december 31, 2020.
m1141
functional status was not measured by the oxford knee score (oks) or the knee injury and osteoarthritis outcome score joint replacement (koos, jr.) at one year (9 to 15 months) postoperatively
m1142
emergent cases
m1143
initiated episode of rehabilitation therapy, medical, or chiropractic care for neck impairment
m1144
ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only terminated december 31, 2020.
m1145
most favored nation (mfn) model drug add-on amount, per dose, (do not bill with line items that have the jw modifier) terminated february 27, 2022.
m1146
ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record
m1147
ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery
m1148
ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown)
m1149
patient unable to complete the neck fs prom at initial evaluation and/or discharge due to blindness, illiteracy, severe mental incapacity or language incompatibility, and an adequate proxy is not available
p2028
cephalin floculation, blood
p2029
congo red, blood
p2031
hair analysis (excluding arsenic)
p2033
thymol turbidity, blood
p2038
mucoprotein, blood (seromucoid) (medical necessity procedure)
p3000
screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision
p3001
screening papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician
p7001
culture, bacterial, urine; quantitative, sensitivity study
p9010
blood (whole), for transfusion, per unit
p9011
blood, split unit
p9012
cryoprecipitate, each unit
p9016
red blood cells, leukocytes reduced, each unit
p9017
fresh frozen plasma (single donor), frozen within 8 hours of collection, each unit
p9019
platelets, each unit
p9020
platelet rich plasma, each unit
p9021
red blood cells, each unit
p9022
red blood cells, washed, each unit
p9023
plasma, pooled multiple donor, solvent/detergent treated, frozen, each unit
p9025
plasma, cryoprecipitate reduced, pathogen reduced, each unit
p9026
cryoprecipitated fibrinogen complex, pathogen reduced, each unit
p9031
platelets, leukocytes reduced, each unit
p9032
platelets, irradiated, each unit
p9033
platelets, leukocytes reduced, irradiated, each unit
p9034
platelets, pheresis, each unit
p9035
platelets, pheresis, leukocytes reduced, each unit
p9036
platelets, pheresis, irradiated, each unit
p9037
platelets, pheresis, leukocytes reduced, irradiated, each unit
p9038
red blood cells, irradiated, each unit
p9039
red blood cells, deglycerolized, each unit
p9040
red blood cells, leukocytes reduced, irradiated, each unit
p9041
infusion, albumin (human), 5%, 50 ml
p9043
infusion, plasma protein fraction (human), 5%, 50 ml
p9044
plasma, cryoprecipitate reduced, each unit
p9045
infusion, albumin (human), 5%, 250 ml
p9046
infusion, albumin (human), 25%, 20 ml
p9047
infusion, albumin (human), 25%, 50 ml
p9048
infusion, plasma protein fraction (human), 5%, 250 ml
p9050
granulocytes, pheresis, each unit
p9051
whole blood or red blood cells, leukocytes reduced, cmv-negative, each unit
p9052
platelets, hla-matched leukocytes reduced, apheresis/pheresis, each unit
p9053
platelets, pheresis, leukocytes reduced, cmv-negative, irradiated, each unit
p9054
whole blood or red blood cells, leukocytes reduced, frozen, deglycerol, washed, each unit
p9055
platelets, leukocytes reduced, cmv-negative, apheresis/pheresis, each unit
p9056
whole blood, leukocytes reduced, irradiated, each unit
p9057
red blood cells, frozen/deglycerolized/washed, leukocytes reduced, irradiated, each unit
p9058
red blood cells, leukocytes reduced, cmv-negative, irradiated, each unit
p9059
fresh frozen plasma between 8-24 hours of collection, each unit
p9060
fresh frozen plasma, donor retested, each unit
p9070
plasma, pooled multiple donor, pathogen reduced, frozen, each unit
p9071
plasma (single donor), pathogen reduced, frozen, each unit
p9072
platelets, pheresis, pathogen reduced or rapid bacterial tested, each unit terminated december 31, 2017.
p9073
platelets, pheresis, pathogen-reduced, each unit
p9099
blood component or product not otherwise classified
p9100
pathogen(s) test for platelets
p9603
travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled
p9604
travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge
p9612
catheterization for collection of specimen, single patient, all places of service
p9615
catheterization for collection of specimen(s) (multiple patients)
q0035
cardiokymography
q0081
infusion therapy, using other than chemotherapeutic drugs, per visit
q0083
chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit
q0084
chemotherapy administration by infusion technique only, per visit
q0085
chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit
q0091
screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory
q0092
set-up portable x-ray equipment
q0111
wet mounts, including preparations of vaginal, cervical or skin specimens
q0112
all potassium hydroxide (koh) preparations
q0113
pinworm examinations
q0114
fern test
q0115
post-coital direct, qualitative examinations of vaginal or cervical mucous
q0138
injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
q0139
injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
q0144
azithromycin dihydrate, oral, capsules/powder, 1 gram
q0161
chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0162
ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0163
diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
q0164
prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0166
granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
q0167
dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0169
promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0173
trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0174
thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0175
perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0177
hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0180
dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
q0181
unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
q0220
injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg
q0221
injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
q0222
injection, bebtelovimab, 175 mg
q0239
injection, bamlanivimab-xxxx, 700 mg terminated april 16, 2021.
q0240
injection, casirivimab and imdevimab, 600 mg
q0243
injection, casirivimab and imdevimab, 2400 mg
q0244
injection, casirivimab and imdevimab, 1200 mg
q0245
injection, bamlanivimab and etesevimab, 2100 mg
q0247
injection, sotrovimab, 500 mg
q0249
injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
q0477
power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
q0478
power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
q0479
power module for use with electric or electric/pneumatic ventricular assist device, replacement only
q0480
driver for use with pneumatic ventricular assist device, replacement only
q0481
microprocessor control unit for use with electric ventricular assist device, replacement only
q0482
microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only
q0483
monitor/display module for use with electric ventricular assist device, replacement only
q0484
monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only
q0485
monitor control cable for use with electric ventricular assist device, replacement only
q0486
monitor control cable for use with electric/pneumatic ventricular assist device, replacement only
q0487
leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only
q0488
power pack base for use with electric ventricular assist device, replacement only
q0489
power pack base for use with electric/pneumatic ventricular assist device, replacement only
q0490
emergency power source for use with electric ventricular assist device, replacement only
q0491
emergency power source for use with electric/pneumatic ventricular assist device, replacement only
q0492
emergency power supply cable for use with electric ventricular assist device, replacement only
q0493
emergency power supply cable for use with electric/pneumatic ventricular assist device, replacement only
q0494
emergency hand pump for use with electric or electric/pneumatic ventricular assist device, replacement only
q0495
battery/power pack charger for use with electric or electric/pneumatic ventricular assist device, replacement only
q0496
battery, other than lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
q0497
battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only
q0498
holster for use with electric or electric/pneumatic ventricular assist device, replacement only
q0499
belt/vest/bag for use to carry external peripheral components of any type ventricular assist device, replacement only
q0500
filters for use with electric or electric/pneumatic ventricular assist device, replacement only
q0501
shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only
q0502
mobility cart for pneumatic ventricular assist device, replacement only
q0503
battery for pneumatic ventricular assist device, replacement only, each
q0504
power adapter for pneumatic ventricular assist device, replacement only, vehicle type
q0506
battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
q0507
miscellaneous supply or accessory for use with an external ventricular assist device
q0508
miscellaneous supply or accessory for use with an implanted ventricular assist device
q0509
miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part a
q0510
pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant
q0511
pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period
q0512
pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
q0513
pharmacy dispensing fee for inhalation drug(s); per 30 days
q0514
pharmacy dispensing fee for inhalation drug(s); per 90 days
q0515
injection, sermorelin acetate, 1 microgram
q1004
new technology intraocular lens category 4 as defined in federal register notice
q1005
new technology intraocular lens category 5 as defined in federal register notice
q2004
irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
q2009
injection, fosphenytoin, 50 mg phenytoin equivalent
q2017
injection, teniposide, 50 mg
q2026
injection, radiesse, 0.1 ml
q2028
injection, sculptra, 0.5 mg
q2034
influenza virus vaccine, split virus, for intramuscular use (agriflu)
q2035
influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
q2036
influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
q2037
influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
q2038
influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
q2039
influenza virus vaccine, not otherwise specified
q2040
tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion terminated december 31, 2018.
q2041
axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
q2042
tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
q2043
sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
q2049
injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
q2050
injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
q2052
services, supplies and accessories used in the home under the medicare intravenous immune globulin (ivig) demonstration
q2053
brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
q2054
lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
q2055
idecabtagene vicleucel, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
q2056
ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
q3001
radioelements for brachytherapy, any type, each
q3014
telehealth originating site facility fee
q3027
injection, interferon beta-1a, 1 mcg for intramuscular use
q3028
injection, interferon beta-1a, 1 mcg for subcutaneous use
q3031
collagen skin test
q4001
casting supplies, body cast adult, with or without head, plaster
q4002
cast supplies, body cast adult, with or without head, fiberglass
q4003
cast supplies, shoulder cast, adult (11 years +), plaster
q4004
cast supplies, shoulder cast, adult (11 years +), fiberglass
q4005
cast supplies, long arm cast, adult (11 years +), plaster
q4006
cast supplies, long arm cast, adult (11 years +), fiberglass
q4007
cast supplies, long arm cast, pediatric (0-10 years), plaster
q4008
cast supplies, long arm cast, pediatric (0-10 years), fiberglass
q4009
cast supplies, short arm cast, adult (11 years +), plaster
q4010
cast supplies, short arm cast, adult (11 years +), fiberglass
q4011
cast supplies, short arm cast, pediatric (0-10 years), plaster
q4012
cast supplies, short arm cast, pediatric (0-10 years), fiberglass
q4013
cast supplies, gauntlet cast (includes lower forearm and hand), adult (11 years +), plaster
q4014
cast supplies, gauntlet cast (includes lower forearm and hand), adult (11 years +), fiberglass
q4015
cast supplies, gauntlet cast (includes lower forearm and hand), pediatric (0-10 years), plaster
q4016
cast supplies, gauntlet cast (includes lower forearm and hand), pediatric (0-10 years), fiberglass
q4017
cast supplies, long arm splint, adult (11 years +), plaster
q4018
cast supplies, long arm splint, adult (11 years +), fiberglass
q4019
cast supplies, long arm splint, pediatric (0-10 years), plaster
q4020
cast supplies, long arm splint, pediatric (0-10 years), fiberglass
q4021
cast supplies, short arm splint, adult (11 years +), plaster
q4022
cast supplies, short arm splint, adult (11 years +), fiberglass
q4023
cast supplies, short arm splint, pediatric (0-10 years), plaster
q4024
cast supplies, short arm splint, pediatric (0-10 years), fiberglass
q4025
cast supplies, hip spica (one or both legs), adult (11 years +), plaster
q4026
cast supplies, hip spica (one or both legs), adult (11 years +), fiberglass
q4027
cast supplies, hip spica (one or both legs), pediatric (0-10 years), plaster
q4028
cast supplies, hip spica (one or both legs), pediatric (0-10 years), fiberglass
q4029
cast supplies, long leg cast, adult (11 years +), plaster
q4030
cast supplies, long leg cast, adult (11 years +), fiberglass
q4031
cast supplies, long leg cast, pediatric (0-10 years), plaster
q4032
cast supplies, long leg cast, pediatric (0-10 years), fiberglass
q4033
cast supplies, long leg cylinder cast, adult (11 years +), plaster
q4034
cast supplies, long leg cylinder cast, adult (11 years +), fiberglass
q4035
cast supplies, long leg cylinder cast, pediatric (0-10 years), plaster
q4036
cast supplies, long leg cylinder cast, pediatric (0-10 years), fiberglass
q4037
cast supplies, short leg cast, adult (11 years +), plaster
q4038
cast supplies, short leg cast, adult (11 years +), fiberglass
q4039
cast supplies, short leg cast, pediatric (0-10 years), plaster
q4040
cast supplies, short leg cast, pediatric (0-10 years), fiberglass
q4041
cast supplies, long leg splint, adult (11 years +), plaster
q4042
cast supplies, long leg splint, adult (11 years +), fiberglass
q4043
cast supplies, long leg splint, pediatric (0-10 years), plaster
q4044
cast supplies, long leg splint, pediatric (0-10 years), fiberglass
q4045
cast supplies, short leg splint, adult (11 years +), plaster
q4046
cast supplies, short leg splint, adult (11 years +), fiberglass
q4047
cast supplies, short leg splint, pediatric (0-10 years), plaster
q4048
cast supplies, short leg splint, pediatric (0-10 years), fiberglass
q4049
finger splint, static
q4050
cast supplies, for unlisted types and materials of casts
q4051
splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies)
q4074
iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms
q4081
injection, epoetin alfa, 100 units (for esrd on dialysis)
q4082
drug or biological, not otherwise classified, part b drug competitive acquisition program (cap)
q4100
skin substitute, not otherwise specified
q4101
apligraf, per square centimeter
q4102
oasis wound matrix, per square centimeter
q4103
oasis burn matrix, per square centimeter
q4104
integra bilayer matrix wound dressing (bmwd), per square centimeter
q4105
integra dermal regeneration template (drt) or integra omnigraft dermal regeneration matrix, per square centimeter
q4106
dermagraft, per square centimeter
q4107
graftjacket, per square centimeter
q4108
integra matrix, per square centimeter
q4110
primatrix, per square centimeter
q4111
gammagraft, per square centimeter
q4112
cymetra, injectable, 1 cc
q4113
graftjacket xpress, injectable, 1 cc
q4114
integra flowable wound matrix, injectable, 1 cc
q4115
alloskin, per square centimeter
q4116
alloderm, per square centimeter
q4117
hyalomatrix, per square centimeter
q4118
matristem micromatrix, 1 mg
q4119
matristem wound matrix, per square centimeter terminated december 31, 2016.
q4120
matristem burn matrix, per square centimeter terminated december 31, 2016.
q4121
theraskin, per square centimeter
q4122
dermacell, dermacell awm or dermacell awm porous, per square centimeter
q4123
alloskin rt, per square centimeter
q4124
oasis ultra tri-layer wound matrix, per square centimeter
q4125
arthroflex, per square centimeter
q4126
memoderm, dermaspan, tranzgraft or integuply, per square centimeter
q4127
talymed, per square centimeter
q4128
flex hd, or allopatch hd, per square centimeter
q4129
unite biomatrix, per square centimeter terminated december 31, 2016.
q4130
strattice tm, per square centimeter
q4131
epifix or epicord, per square centimeter terminated december 31, 2018.
q4132
grafix core and grafixpl core, per square centimeter
q4133
grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter
q4134
hmatrix, per square centimeter
q4135
mediskin, per square centimeter
q4136
ez-derm, per square centimeter
q4137
amnioexcel, amnioexcel plus or biodexcel, per square centimeter
q4138
biodfence dryflex, per square centimeter
q4139
amniomatrix or biodmatrix, injectable, 1 cc
q4140
biodfence, per square centimeter
q4141
alloskin ac, per square centimeter
q4142
xcm biologic tissue matrix, per square centimeter
q4143
repriza, per square centimeter
q4145
epifix, injectable, 1 mg
q4146
tensix, per square centimeter
q4147
architect, architect px, or architect fx, extracellular matrix, per square centimeter
q4148
neox cord 1k, neox cord rt, or clarix cord 1k, per square centimeter
q4149
excellagen, 0.1 cc
q4150
allowrap ds or dry, per square centimeter
q4151
amnioband or guardian, per square centimeter
q4152
dermapure, per square centimeter
q4153
dermavest and plurivest, per square centimeter
q4154
biovance, per square centimeter
q4155
neoxflo or clarixflo, 1 mg
q4156
neox 100 or clarix 100, per square centimeter
q4157
revitalon, per square centimeter
q4158
kerecis omega3, per square centimeter
q4159
affinity, per square centimeter
q4160
nushield, per square centimeter
q4161
bio-connekt wound matrix, per square centimeter
q4162
woundex flow, bioskin flow, 0.5 cc
q4163
woundex, bioskin, per square centimeter
q4164
helicoll, per square centimeter
q4165
keramatrix or kerasorb, per square centimeter
q4166
cytal, per square centimeter
q4167
truskin, per square centimeter
q4168
amnioband, 1 mg
q4169
artacent wound, per square centimeter
q4170
cygnus, per square centimeter
q4171
interfyl, 1 mg
q4172
puraply or puraply am, per square centimeter terminated december 31, 2018.
q4173
palingen or palingen xplus, per square centimeter
q4174
palingen or promatrx, 0.36 mg per 0.25 cc
q4175
miroderm, per square centimeter
q4176
neopatch or therion, per square centimeter
q4177
floweramnioflo, 0.1 cc
q4178
floweramniopatch, per square centimeter
q4179
flowerderm, per square centimeter
q4180
revita, per square centimeter
q4181
amnio wound, per square centimeter
q4182
transcyte, per square centimeter
q4183
surgigraft, per square centimeter
q4184
cellesta or cellesta duo, per square centimeter
q4185
cellesta flowable amnion (25 mg per cc); per 0.5 cc
q4186
epifix, per square centimeter
q4187
epicord, per square centimeter
q4188
amnioarmor, per square centimeter
q4189
artacent ac, 1 mg
q4190
artacent ac, per square centimeter
q4191
restorigin, per square centimeter
q4192
restorigin, 1 cc
q4193
coll-e-derm, per square centimeter
q4194
novachor, per square centimeter
q4195
puraply, per square centimeter
q4196
puraply am, per square centimeter
q4197
puraply xt, per square centimeter
q4198
genesis amniotic membrane, per square centimeter
q4199
cygnus matrix, per square centimeter
q4200
skin te, per square centimeter
q4201
matrion, per square centimeter
q4202
keroxx (2.5g/cc), 1cc
q4203
derma-gide, per square centimeter
q4204
xwrap, per square centimeter
q4205
membrane graft or membrane wrap, per square centimeter
q4206
fluid flow or fluid gf, 1 cc
q4208
novafix, per square cenitmeter
q4209
surgraft, per square centimeter
q4210
axolotl graft or axolotl dualgraft, per square centimeter
q4211
amnion bio or axobiomembrane, per square centimeter
q4212
allogen, per cc
q4213
ascent, 0.5 mg
q4214
cellesta cord, per square centimeter
q4215
axolotl ambient or axolotl cryo, 0.1 mg
q4216
artacent cord, per square centimeter
q4217
woundfix, biowound, woundfix plus, biowound plus, woundfix xplus or biowound xplus, per square centimeter
q4218
surgicord, per square centimeter
q4219
surgigraft-dual, per square centimeter
q4220
bellacell hd or surederm, per square centimeter
q4221
amniowrap2, per square centimeter
q4222
progenamatrix, per square centimeter
q4224
human health factor 10 amniotic patch (hhf10-p), per square centimeter
q4225
amniobind, per square centimeter
q4226
myown skin, includes harvesting and preparation procedures, per square centimeter
q4227
amniocore, per square centimeter
q4228
bionextpatch, per square centimeter terminated september 30, 2021.
q4229
cogenex amniotic membrane, per square centimeter
q4230
cogenex flowable amnion, per 0.5 cc
q4231
corplex p, per cc
q4232
corplex, per square centimeter
q4233
surfactor or nudyn, per 0.5 cc
q4234
xcellerate, per square centimeter
q4235
amniorepair or altiply, per square centimeter
q4236
carepatch, per square centimeter terminated september 30, 2021.
q4237
cryo-cord, per square centimeter
q4238
derm-maxx, per square centimeter
q4239
amnio-maxx or amnio-maxx lite, per square centimeter
q4240
corecyte, for topical use only, per 0.5 cc
q4241
polycyte, for topical use only, per 0.5 cc
q4242
amniocyte plus, per 0.5 cc
q4244
procenta, per 200 mg
q4245
amniotext, per cc
q4246
coretext or protext, per cc
q4247
amniotext patch, per square centimeter
q4248
dermacyte amniotic membrane allograft, per square centimeter
q4249
amniply, for topical use only, per square centimeter
q4250
amnioamp-mp, per square centimeter
q4251
vim, per square centimeter
q4252
vendaje, per square centimeter
q4253
zenith amniotic membrane, per square centimeter
q4254
novafix dl, per square centimeter
q4255
reguard, for topical use only, per square centimeter
q4256
mlg-complete, per square centimeter
q4257
relese, per square centimeter
q4258
enverse, per square centimeter
q4259
celera dual layer or celera dual membrane, per square centimeter
q4260
signature apatch, per square centimeter
q4261
tag, per square centimeter
q5001
hospice or home health care provided in patient's home/residence
q5002
hospice or home health care provided in assisted living facility
q5003
hospice care provided in nursing long term care facility (ltc) or non-skilled nursing facility (nf)
q5004
hospice care provided in skilled nursing facility (snf)
q5005
hospice care provided in inpatient hospital
q5006
hospice care provided in inpatient hospice facility
q5007
hospice care provided in long term care facility
q5008
hospice care provided in inpatient psychiatric facility
q5009
hospice or home health care provided in place not otherwise specified (nos)
q5010
hospice home care provided in a hospice facility
q5101
injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
q5102
injection, infliximab, biosimilar, 10 mg terminated march 31, 2018.
q5103
injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
q5104
injection, infliximab-abda, biosimilar, (renflexis), 10 mg
q5105
injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
q5106
injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
q5107
injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
q5108
injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg
q5109
injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
q5110
injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
q5111
injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg
q5112
injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
q5113
injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
q5114
injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
q5115
injection, rituximab-abbs, biosimilar, (truxima), 10 mg
q5116
injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
q5117
injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
q5118
injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
q5119
injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
q5120
injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg
q5121
injection, infliximab-axxq, biosimilar, (avsola), 10 mg
q5122
injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg
q5123
injection, rituximab-arrx, biosimilar, (riabni), 10 mg
q5124
injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
q5125
injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
q9001
assessment by chaplain services
q9002
counseling, individual, by chaplain services
q9003
counseling, group, by chaplain services
q9004
department of veterans affairs whole health partner services
q9950
injection, sulfur hexafluoride lipid microspheres, per ml
q9951
low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
q9953
injection, iron-based magnetic resonance contrast agent, per ml
q9954
oral magnetic resonance contrast agent, per 100 ml
q9955
injection, perflexane lipid microspheres, per ml
q9956
injection, octafluoropropane microspheres, per ml
q9957
injection, perflutren lipid microspheres, per ml
q9958
high osmolar contrast material, up to 149 mg/ml iodine concentration, per ml
q9959
high osmolar contrast material, 150-199 mg/ml iodine concentration, per ml
q9960
high osmolar contrast material, 200-249 mg/ml iodine concentration, per ml
q9961
high osmolar contrast material, 250-299 mg/ml iodine concentration, per ml
q9962
high osmolar contrast material, 300-349 mg/ml iodine concentration, per ml
q9963
high osmolar contrast material, 350-399 mg/ml iodine concentration, per ml
q9964
high osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
q9965
low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml
q9966
low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml
q9967
low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
q9968
injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg
q9969
tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose
q9970
injection, ferric carboxymaltose, 1mg terminated december 31, 2014.
q9972
injection, epoetin beta, 1 microgram, (for esrd on dialysis) terminated december 31, 2014.
q9973
injection, epoetin beta, 1 microgram, (non-esrd use) terminated december 31, 2014.
q9974
injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg terminated december 31, 2014.
q9975
injection, factor viii fc fusion protein (recombinant), per iu terminated december 31, 2015.
q9976
injection, ferric pyrophosphate citrate solution, 0.1 mg of iron terminated december 31, 2015.
q9977
compounded drug, not otherwise classified terminated december 31, 2015.
q9978
netupitant 300 mg and palonosetron 0.5 mg terminated december 31, 2015.
q9979
injection, alemtuzumab, 1 mg terminated december 31, 2015.
q9980
hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mg terminated december 31, 2016.
q9981
rolapitant, oral, 1 mg terminated december 31, 2016.
q9982
flutemetamol f18, diagnostic, per study dose, up to 5 millicuries
q9983
florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
q9984
levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg terminated december 31, 2017.
q9985
injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg terminated december 31, 2017.
q9986
injection, hydroxyprogesterone caproate, (makena), 10 mg terminated december 31, 2017.
q9987
pathogen(s) test for platelets terminated december 31, 2017.
q9988
platelets, pheresis, pathogen-reduced, each unit terminated december 31, 2017.
q9989
ustekinumab, for intravenous injection, 1 mg terminated december 31, 2017.
q9991
injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg
q9992
injection, buprenorphine extended-release (sublocade), greater than 100 mg
q9993
injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg terminated december 31, 2018.
q9994
in-line cartridge containing digestive enzyme(s) for enteral feeding, each terminated december 31, 2018.
q9995
injection, emicizumab-kxwh, 0.5 mg terminated december 31, 2018.
r0070
transportation of portable x-ray equipment and personnel to home or nursing home, per trip to facility or location, one patient seen
r0075
transportation of portable x-ray equipment and personnel to home or nursing home, per trip to facility or location, more than one patient seen
r0076
transportation of portable ekg to facility or location, per patient
s0012
butorphanol tartrate, nasal spray, 25 mg
s0013
esketamine, nasal spray, 1 mg
s0014
tacrine hydrochloride, 10 mg
s0017
injection, aminocaproic acid, 5 grams
s0020
injection, bupivicaine hydrochloride, 30 ml
s0021
injection, cefoperazone sodium, 1 gram
s0023
injection, cimetidine hydrochloride, 300 mg
s0028
injection, famotidine, 20 mg
s0030
injection, metronidazole, 500 mg
s0032
injection, nafcillin sodium, 2 grams
s0034
injection, ofloxacin, 400 mg
s0039
injection, sulfamethoxazole and trimethoprim, 10 ml
s0040
injection, ticarcillin disodium and clavulanate potassium, 3.1 grams
s0073
injection, aztreonam, 500 mg
s0074
injection, cefotetan disodium, 500 mg
s0077
injection, clindamycin phosphate, 300 mg
s0078
injection, fosphenytoin sodium, 750 mg
s0080
injection, pentamidine isethionate, 300 mg
s0081
injection, piperacillin sodium, 500 mg
s0088
imatinib, 100 mg
s0090
sildenafil citrate, 25 mg
s0091
granisetron hydrochloride, 1 mg (for circumstances falling under the medicare statute, use q0166)
s0092
injection, hydromorphone hydrochloride, 250 mg (loading dose for infusion pump)
s0093
injection, morphine sulfate, 500 mg (loading dose for infusion pump)
s0104
zidovudine, oral, 100 mg
s0106
bupropion hcl sustained release tablet, 150 mg, per bottle of 60 tablets
s0108
mercaptopurine, oral, 50 mg
s0109
methadone, oral, 5 mg
s0117
tretinoin, topical, 5 grams
s0119
ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code)
s0122
injection, menotropins, 75 iu
s0126
injection, follitropin alfa, 75 iu
s0128
injection, follitropin beta, 75 iu
s0132
injection, ganirelix acetate, 250 mcg
s0136
clozapine, 25 mg
s0137
didanosine (ddi), 25 mg
s0138
finasteride, 5 mg
s0139
minoxidil, 10 mg
s0140
saquinavir, 200 mg
s0142
colistimethate sodium, inhalation solution administered through dme, concentrated form, per mg
s0144
injection, propofol, 10 mg terminated december 31, 2014.
s0145
injection, pegylated interferon alfa-2a, 180 mcg per ml
s0148
injection, pegylated interferon alfa-2b, 10 mcg
s0155
sterile dilutant for epoprostenol, 50 ml
s0156
exemestane, 25 mg
s0157
becaplermin gel 0.01%, 0.5 gm
s0160
dextroamphetamine sulfate, 5 mg
s0164
injection, pantoprazole sodium, 40 mg
s0166
injection, olanzapine, 2.5 mg
s0169
calcitrol, 0.25 microgram
s0170
anastrozole, oral, 1 mg
s0171
injection, bumetanide, 0.5 mg
s0172
chlorambucil, oral, 2 mg
s0174
dolasetron mesylate, oral 50 mg (for circumstances falling under the medicare statute, use q0180)
s0175
flutamide, oral, 125 mg
s0176
hydroxyurea, oral, 500 mg
s0177
levamisole hydrochloride, oral, 50 mg
s0178
lomustine, oral, 10 mg
s0179
megestrol acetate, oral, 20 mg
s0182
procarbazine hydrochloride, oral, 50 mg
s0183
prochlorperazine maleate, oral, 5 mg (for circumstances falling under the medicare statute, use q0164)
s0187
tamoxifen citrate, oral, 10 mg
s0189
testosterone pellet, 75 mg
s0190
mifepristone, oral, 200 mg
s0191
misoprostol, oral, 200 mcg
s0194
dialysis/stress vitamin supplement, oral, 100 capsules
s0195
pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine terminated december 31, 2015.
s0197
prenatal vitamins, 30-day supply
s0199
medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by hcg, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs
s0201
partial hospitalization services, less than 24 hours, per diem
s0207
paramedic intercept, non-hospital-based als service (non-voluntary), non-transport
s0208
paramedic intercept, hospital-based als service (non-voluntary), non-transport
s0209
wheelchair van, mileage, per mile
s0215
non-emergency transportation; mileage, per mile
s0220
medical conference by a physician with interdisciplinary team of health professionals or representatives of community agencies to coordinate activities of patient care (patient is present); approximately 30 minutes
s0221
medical conference by a physician with interdisciplinary team of health professionals or representatives of community agencies to coordinate activities of patient care (patient is present); approximately 60 minutes
s0250
comprehensive geriatric assessment and treatment planning performed by assessment team
s0255
hospice referral visit (advising patient and family of care options) performed by nurse, social worker, or other designated staff
s0257
counseling and discussion regarding advance directives or end of life care planning and decisions, with patient and/or surrogate (list separately in addition to code for appropriate evaluation and management service)
s0260
history and physical (outpatient or office) related to surgical procedure (list separately in addition to code for appropriate evaluation and management service)
s0265
genetic counseling, under physician supervision, each 15 minutes
s0270
physician management of patient home care, standard monthly case rate (per 30 days)
s0271
physician management of patient home care, hospice monthly case rate (per 30 days)
s0272
physician management of patient home care, episodic care monthly case rate (per 30 days)
s0273
physician visit at member's home, outside of a capitation arrangement
s0274
nurse practitioner visit at member's home, outside of a capitation arrangement
s0280
medical home program, comprehensive care coordination and planning, initial plan
s0281
medical home program, comprehensive care coordination and planning, maintenance of plan
s0285
colonoscopy consultation performed prior to a screening colonoscopy procedure
s0302
completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service)
s0310
hospitalist services (list separately in addition to code for appropriate evaluation and management service)
s0311
comprehensive management and care coordination for advanced illness, per calendar month
s0315
disease management program; initial assessment and initiation of the program
s0316
disease management program, follow-up/reassessment
s0317
disease management program; per diem
s0320
telephone calls by a registered nurse to a disease management program member for monitoring purposes; per month
s0340
lifestyle modification program for management of coronary artery disease, including all supportive services; first quarter / stage
s0341
lifestyle modification program for management of coronary artery disease, including all supportive services; second or third quarter / stage
s0342
lifestyle modification program for management of coronary artery disease, including all supportive services; fourth quarter / stage
s0353
treatment planning and care coordination management for cancer, initial treatment
s0354
treatment planning and care coordination management for cancer, established patient with a change of regimen
s0390
routine foot care; removal and/or trimming of corns, calluses and/or nails and preventive maintenance in specific medical conditions (e.g., diabetes), per visit
s0395
impression casting of a foot performed by a practitioner other than the manufacturer of the orthotic
s0400
global fee for extracorporeal shock wave lithotripsy treatment of kidney stone(s)
s0500
disposable contact lens, per lens
s0504
single vision prescription lens (safety, athletic, or sunglass), per lens
s0506
bifocal vision prescription lens (safety, athletic, or sunglass), per lens
s0508
trifocal vision prescription lens (safety, athletic, or sunglass), per lens
s0510
non-prescription lens (safety, athletic, or sunglass), per lens
s0512
daily wear specialty contact lens, per lens
s0514
color contact lens, per lens
s0515
scleral lens, liquid bandage device, per lens
s0516
safety eyeglass frames
s0518
sunglasses frames
s0580
polycarbonate lens (list this code in addition to the basic code for the lens)
s0581
nonstandard lens (list this code in addition to the basic code for the lens)
s0590
integral lens service, miscellaneous services reported separately
s0592
comprehensive contact lens evaluation
s0595
dispensing new spectacle lenses for patient supplied frame
s0596
phakic intraocular lens for correction of refractive error
s0601
screening proctoscopy
s0610
annual gynecological examination, new patient
s0612
annual gynecological examination, established patient
s0613
annual gynecological examination; clinical breast examination without pelvic evaluation
s0618
audiometry for hearing aid evaluation to determine the level and degree of hearing loss
s0620
routine ophthalmological examination including refraction; new patient
s0621
routine ophthalmological examination including refraction; established patient
s0622
physical exam for college, new or established patient (list separately in addition to appropriate evaluation and management code)
s0630
removal of sutures; by a physician other than the physician who originally closed the wound
s0800
laser in situ keratomileusis (lasik)
s0810
photorefractive keratectomy (prk)
s0812
phototherapeutic keratectomy (ptk)
s1001
deluxe item, patient aware (list in addition to code for basic item)
s1002
customized item (list in addition to code for basic item)
s1015
iv tubing extension set
s1016
non-pvc (polyvinyl chloride) intravenous administration set, for use with drugs that are not stable in pvc e.g., paclitaxel
s1030
continuous noninvasive glucose monitoring device, purchase (for physician interpretation of data, use cpt code)
s1031
continuous noninvasive glucose monitoring device, rental, including sensor, sensor replacement, and download to monitor (for physician interpretation of data, use cpt code)
s1034
artificial pancreas device system (e.g., low glucose suspend (lgs) feature) including continuous glucose monitor, blood glucose device, insulin pump and computer algorithm that communicates with all of the devices
s1035
sensor; invasive (e.g., subcutaneous), disposable, for use with artificial pancreas device system
s1036
transmitter; external, for use with artificial pancreas device system
s1037
receiver (monitor); external, for use with artificial pancreas device system
s1040
cranial remolding orthosis, pediatric, rigid, with soft interface material, custom fabricated, includes fitting and adjustment(s)
s1090
mometasone furoate sinus implant, 370 micrograms terminated september 30, 2019.
s1091
stent, non-coronary, temporary, with delivery system (propel)
s2053
transplantation of small intestine and liver allografts
s2054
transplantation of multivisceral organs
s2055
harvesting of donor multivisceral organs, with preparation and maintenance of allografts; from cadaver donor
s2060
lobar lung transplantation
s2061
donor lobectomy (lung) for transplantation, living donor
s2065
simultaneous pancreas kidney transplantation
s2066
breast reconstruction with gluteal artery perforator (gap) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral
s2067
breast reconstruction of a single breast with "stacked" deep inferior epigastric perforator (diep) flap(s) and/or gluteal artery perforator (gap) flap(s), including harvesting of the flap(s), microvascular transfer, closure of donor site(s) and shaping the flap into a breast, unilateral
s2068
breast reconstruction with deep inferior epigastric perforator (diep) flap or superficial inferior epigastric artery (siea) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral
s2070
cystourethroscopy, with ureteroscopy and/or pyeloscopy; with endoscopic laser treatment of ureteral calculi (includes ureteral catheterization)
s2079
laparoscopic esophagomyotomy (heller type)
s2080
laser-assisted uvulopalatoplasty (laup)
s2083
adjustment of gastric band diameter via subcutaneous port by injection or aspiration of saline
s2095
transcatheter occlusion or embolization for tumor destruction, percutaneous, any method, using yttrium-90 microspheres
s2102
islet cell tissue transplant from pancreas; allogeneic
s2103
adrenal tissue transplant to brain
s2107
adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment
s2112
arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)
s2115
osteotomy, periacetabular, with internal fixation
s2117
arthroereisis, subtalar
s2118
metal-on-metal total hip resurfacing, including acetabular and femoral components
s2120
low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitation
s2140
cord blood harvesting for transplantation, allogeneic
s2142
cord blood-derived stem-cell transplantation, allogeneic
s2150
bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition
s2152
solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor(s), procurement, transplantation, and related complications; including: drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre- and post-transplant care in the global definition
s2202
echosclerotherapy
s2205
minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft
s2206
minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), two coronary arterial grafts
s2207
minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft
s2208
minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft
s2209
minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using two arterial grafts and single venous graft
s2225
myringotomy, laser-assisted
s2230
implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear
s2235
implantation of auditory brain stem implant
s2260
induced abortion, 17 to 24 weeks
s2265
induced abortion, 25 to 28 weeks
s2266
induced abortion, 29 to 31 weeks
s2267
induced abortion, 32 weeks or greater
s2300
arthroscopy, shoulder, surgical; with thermally-induced capsulorrhaphy
s2325
hip core decompression
s2340
chemodenervation of abductor muscle(s) of vocal cord
s2341
chemodenervation of adductor muscle(s) of vocal cord
s2342
nasal endoscopy for post-operative debridement following functional endoscopic sinus surgery, nasal and/or sinus cavity(s), unilateral or bilateral
s2348
decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar
s2350
diskectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; lumbar, single interspace
s2351
diskectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; lumbar, each additional interspace (list separately in addition to code for primary procedure)
s2360
percutaneous vertebroplasty, one vertebral body, unilateral or bilateral injection; cervical terminated december 31, 2015.
s2361
each additional cervical vertebral body (list separately in addition to code for primary procedure) terminated december 31, 2015.
s2400
repair, congenital diaphragmatic hernia in the fetus using temporary tracheal occlusion, procedure performed in utero
s2401
repair, urinary tract obstruction in the fetus, procedure performed in utero
s2402
repair, congenital cystic adenomatoid malformation in the fetus, procedure performed in utero
s2403
repair, extralobar pulmonary sequestration in the fetus, procedure performed in utero
s2404
repair, myelomeningocele in the fetus, procedure performed in utero
s2405
repair of sacrococcygeal teratoma in the fetus, procedure performed in utero
s2409
repair, congenital malformation of fetus, procedure performed in utero, not otherwise classified
s2411
fetoscopic laser therapy for treatment of twin-to-twin transfusion syndrome
s2900
surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure)
s3000
diabetic indicator; retinal eye exam, dilated, bilateral
s3005
performance measurement, evaluation of patient self assessment, depression
s3600
stat laboratory request (situations other than s3601)
s3601
emergency stat laboratory charge for patient who is homebound or residing in a nursing facility
s3620
newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total)
s3630
eosinophil count, blood, direct
s3645
hiv-1 antibody testing of oral mucosal transudate
s3650
saliva test, hormone level; during menopause
s3652
saliva test, hormone level; to assess preterm labor risk
s3655
antisperm antibodies test (immunobead)
s3708
gastrointestinal fat absorption study
s3721
prostate cancer antigen 3 (pca3) testing terminated december 31, 2015.
s3722
dose optimization by area under the curve (auc) analysis, for infusional 5-fluorouracil
s3800
genetic testing for amyotrophic lateral sclerosis (als)
s3840
dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
s3841
genetic testing for retinoblastoma
s3842
genetic testing for von hippel-lindau disease
s3844
dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness
s3845
genetic testing for alpha-thalassemia
s3846
genetic testing for hemoglobin e beta-thalassemia
s3849
genetic testing for niemann-pick disease
s3850
genetic testing for sickle cell anemia
s3852
dna analysis for apoe epsilon 4 allele for susceptibility to alzheimer's disease
s3853
genetic testing for myotonic muscular dystrophy
s3854
gene expression profiling panel for use in the management of breast cancer treatment
s3855
genetic testing for detection of mutations in the presenilin - 1 gene terminated december 31, 2014.
s3861
genetic testing, sodium channel, voltage-gated, type v, alpha subunit (scn5a) and variants for suspected brugada syndrome
s3865
comprehensive gene sequence analysis for hypertrophic cardiomyopathy
s3866
genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (hcm) in an individual with a known hcm mutation in the family
s3870
comparative genomic hybridization (cgh) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability
s3890
dna analysis, fecal, for colorectal cancer screening terminated december 31, 2015.
s3900
surface electromyography (emg)
s3902
ballistocardiogram
s3904
masters two step
s4005
interim labor facility global (labor occurring but not resulting in delivery)
s4011
in vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development
s4013
complete cycle, gamete intrafallopian transfer (gift), case rate
s4014
complete cycle, zygote intrafallopian transfer (zift), case rate
s4015
complete in vitro fertilization cycle, not otherwise specified, case rate
s4016
frozen in vitro fertilization cycle, case rate
s4017
incomplete cycle, treatment cancelled prior to stimulation, case rate
s4018
frozen embryo transfer procedure cancelled before transfer, case rate
s4020
in vitro fertilization procedure cancelled before aspiration, case rate
s4021
in vitro fertilization procedure cancelled after aspiration, case rate
s4022
assisted oocyte fertilization, case rate
s4023
donor egg cycle, incomplete, case rate
s4025
donor services for in vitro fertilization (sperm or embryo), case rate
s4026
procurement of donor sperm from sperm bank
s4027
storage of previously frozen embryos
s4028
microsurgical epididymal sperm aspiration (mesa)
s4030
sperm procurement and cryopreservation services; initial visit
s4031
sperm procurement and cryopreservation services; subsequent visit
s4035
stimulated intrauterine insemination (iui), case rate
s4037
cryopreserved embryo transfer, case rate
s4040
monitoring and storage of cryopreserved embryos, per 30 days
s4042
management of ovulation induction (interpretation of diagnostic tests and studies, non-face-to-face medical management of the patient), per cycle
s4981
insertion of levonorgestrel-releasing intrauterine system
s4989
contraceptive intrauterine device (e.g., progestacert iud), including implants and supplies
s4990
nicotine patches, legend
s4991
nicotine patches, non-legend
s4993
contraceptive pills for birth control
s4995
smoking cessation gum
s5000
prescription drug, generic
s5001
prescription drug, brand name
s5010
5% dextrose and 0.45% normal saline, 1000 ml
s5011
5% dextrose in lactated ringer's, 1000 ml terminated december 31, 2015.
s5012
5% dextrose with potassium chloride, 1000 ml
s5013
5% dextrose/0.45% normal saline with potassium chloride and magnesium sulfate, 1000 ml
s5014
5% dextrose/0.45% normal saline with potassium chloride and magnesium sulfate, 1500 ml
s5035
home infusion therapy, routine service of infusion device (e.g., pump maintenance)
s5036
home infusion therapy, repair of infusion device (e.g., pump repair)
s5100
day care services, adult; per 15 minutes
s5101
day care services, adult; per half day
s5102
day care services, adult; per diem
s5105
day care services, center-based; services not included in program fee, per diem
s5108
home care training to home care client, per 15 minutes
s5109
home care training to home care client, per session
s5110
home care training, family; per 15 minutes
s5111
home care training, family; per session
s5115
home care training, non-family; per 15 minutes
s5116
home care training, non-family; per session
s5120
chore services; per 15 minutes
s5121
chore services; per diem
s5125
attendant care services; per 15 minutes
s5126
attendant care services; per diem
s5130
homemaker service, nos; per 15 minutes
s5131
homemaker service, nos; per diem
s5135
companion care, adult (e.g., iadl/adl); per 15 minutes
s5136
companion care, adult (e.g., iadl/adl); per diem
s5140
foster care, adult; per diem
s5141
foster care, adult; per month
s5145
foster care, therapeutic, child; per diem
s5146
foster care, therapeutic, child; per month
s5150
unskilled respite care, not hospice; per 15 minutes
s5151
unskilled respite care, not hospice; per diem
s5160
emergency response system; installation and testing
s5161
emergency response system; service fee, per month (excludes installation and testing)
s5162
emergency response system; purchase only
s5165
home modifications; per service
s5170
home delivered meals, including preparation; per meal
s5175
laundry service, external, professional; per order
s5180
home health respiratory therapy, initial evaluation
s5181
home health respiratory therapy, nos, per diem
s5185
medication reminder service, non-face-to-face; per month
s5190
wellness assessment, performed by non-physician
s5199
personal care item, nos, each
s5497
home infusion therapy, catheter care / maintenance, not otherwise classified; includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s5498
home infusion therapy, catheter care / maintenance, simple (single lumen), includes administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment, (drugs and nursing visits coded separately), per diem
s5501
home infusion therapy, catheter care / maintenance, complex (more than one lumen), includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s5502
home infusion therapy, catheter care / maintenance, implanted access device, includes administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment, (drugs and nursing visits coded separately), per diem (use this code for interim maintenance of vascular access not currently in use)
s5517
home infusion therapy, all supplies necessary for restoration of catheter patency or declotting
s5518
home infusion therapy, all supplies necessary for catheter repair
s5520
home infusion therapy, all supplies (including catheter) necessary for a peripherally inserted central venous catheter (picc) line insertion
s5521
home infusion therapy, all supplies (including catheter) necessary for a midline catheter insertion
s5522
home infusion therapy, insertion of peripherally inserted central venous catheter (picc), nursing services only (no supplies or catheter included)
s5523
home infusion therapy, insertion of midline venous catheter, nursing services only (no supplies or catheter included)
s5550
insulin, rapid onset, 5 units
s5551
insulin, most rapid onset (lispro or aspart); 5 units
s5552
insulin, intermediate acting (nph or lente); 5 units
s5553
insulin, long acting; 5 units
s5560
insulin delivery device, reusable pen; 1.5 ml size
s5561
insulin delivery device, reusable pen; 3 ml size
s5565
insulin cartridge for use in insulin delivery device other than pump; 150 units
s5566
insulin cartridge for use in insulin delivery device other than pump; 300 units
s5570
insulin delivery device, disposable pen (including insulin); 1.5 ml size
s5571
insulin delivery device, disposable pen (including insulin); 3 ml size
s8030
scleral application of tantalum ring(s) for localization of lesions for proton beam therapy
s8032
low-dose computed tomography for lung cancer screening terminated september 30, 2016.
s8035
magnetic source imaging
s8037
magnetic resonance cholangiopancreatography (mrcp)
s8040
topographic brain mapping
s8042
magnetic resonance imaging (mri), low-field
s8055
ultrasound guidance for multifetal pregnancy reduction(s), technical component (only to be used when the physician doing the reduction procedure does not perform the ultrasound, guidance is included in the cpt code for multifetal pregnancy reduction - 59866)
s8080
scintimammography (radioimmunoscintigraphy of the breast), unilateral, including supply of radiopharmaceutical
s8085
fluorine-18 fluorodeoxyglucose (f-18 fdg) imaging using dual-head coincidence detection system (non-dedicated pet scan)
s8092
electron beam computed tomography (also known as ultrafast ct, cine ct)
s8096
portable peak flow meter
s8097
asthma kit (including but not limited to portable peak expiratory flow meter, instructional video, brochure, and/or spacer)
s8100
holding chamber or spacer for use with an inhaler or nebulizer; without mask
s8101
holding chamber or spacer for use with an inhaler or nebulizer; with mask
s8110
peak expiratory flow rate (physician services)
s8120
oxygen contents, gaseous, 1 unit equals 1 cubic foot
s8121
oxygen contents, liquid, 1 unit equals 1 pound
s8130
interferential current stimulator, 2 channel
s8131
interferential current stimulator, 4 channel
s8185
flutter device
s8186
swivel adapter
s8189
tracheostomy supply, not otherwise classified
s8210
mucus trap
s8262
mandibular orthopedic repositioning device, each terminated june 30, 2015.
s8265
haberman feeder for cleft lip/palate
s8270
enuresis alarm, using auditory buzzer and/or vibration device
s8301
infection control supplies, not otherwise specified
s8415
supplies for home delivery of infant
s8420
gradient pressure aid (sleeve and glove combination), custom made
s8421
gradient pressure aid (sleeve and glove combination), ready made
s8422
gradient pressure aid (sleeve), custom made, medium weight
s8423
gradient pressure aid (sleeve), custom made, heavy weight
s8424
gradient pressure aid (sleeve), ready made
s8425
gradient pressure aid (glove), custom made, medium weight
s8426
gradient pressure aid (glove), custom made, heavy weight
s8427
gradient pressure aid (glove), ready made
s8428
gradient pressure aid (gauntlet), ready made
s8429
gradient pressure exterior wrap
s8430
padding for compression bandage, roll
s8431
compression bandage, roll
s8450
splint, prefabricated, digit (specify digit by use of modifier)
s8451
splint, prefabricated, wrist or ankle
s8452
splint, prefabricated, elbow
s8460
camisole, post-mastectomy
s8490
insulin syringes (100 syringes, any size)
s8930
electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-one contact with the patient
s8940
equestrian/hippotherapy, per session
s8948
application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes
s8950
complex lymphedema therapy, each 15 minutes
s8990
physical or manipulative therapy performed for maintenance rather than restoration
s8999
resuscitation bag (for use by patient on artificial respiration during power failure or other catastrophic event)
s9001
home uterine monitor with or without associated nursing services
s9007
ultrafiltration monitor
s9015
automated eeg monitoring terminated december 31, 2015.
s9024
paranasal sinus ultrasound
s9025
omnicardiogram/cardiointegram
s9034
extracorporeal shockwave lithotripsy for gall stones (if performed with ercp, use 43265)
s9055
procuren or other growth factor preparation to promote wound healing
s9056
coma stimulation per diem
s9061
home administration of aerosolized drug therapy (e.g., pentamidine); administrative services, professional pharmacy services, care coordination, all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9083
global fee urgent care centers
s9088
services provided in an urgent care center (list in addition to code for service)
s9090
vertebral axial decompression, per session
s9097
home visit for wound care
s9098
home visit, phototherapy services (e.g., bili-lite), including equipment rental, nursing services, blood draw, supplies, and other services, per diem
s9110
telemonitoring of patient in their home, including all necessary equipment; computer system, connections, and software; maintenance; patient education and support; per month
s9117
back school, per visit
s9122
home health aide or certified nurse assistant, providing care in the home; per hour
s9123
nursing care, in the home; by registered nurse, per hour (use for general nursing care only, not to be used when cpt codes 99500-99602 can be used)
s9124
nursing care, in the home; by licensed practical nurse, per hour
s9125
respite care, in the home, per diem
s9126
hospice care, in the home, per diem
s9127
social work visit, in the home, per diem
s9128
speech therapy, in the home, per diem
s9129
occupational therapy, in the home, per diem
s9131
physical therapy; in the home, per diem
s9140
diabetic management program, follow-up visit to non-md provider
s9141
diabetic management program, follow-up visit to md provider
s9145
insulin pump initiation, instruction in initial use of pump (pump not included)
s9150
evaluation by ocularist
s9152
speech therapy, re-evaluation
s9208
home management of preterm labor, including administrative services, professional pharmacy services, care coordination, and all necessary supplies or equipment (drugs and nursing visits coded separately), per diem (do not use this code with any home infusion per diem code)
s9209
home management of preterm premature rupture of membranes (pprom), including administrative services, professional pharmacy services, care coordination, and all necessary supplies or equipment (drugs and nursing visits coded separately), per diem (do not use this code with any home infusion per diem code)
s9211
home management of gestational hypertension, includes administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (drugs and nursing visits coded separately); per diem (do not use this code with any home infusion per diem code)
s9212
home management of postpartum hypertension, includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with any home infusion per diem code)
s9213
home management of preeclampsia, includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services coded separately); per diem (do not use this code with any home infusion per diem code)
s9214
home management of gestational diabetes, includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately); per diem (do not use this code with any home infusion per diem code)
s9325
home infusion therapy, pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, (drugs and nursing visits coded separately), per diem (do not use this code with s9326, s9327 or s9328)
s9326
home infusion therapy, continuous (twenty-four hours or more) pain management infusion; administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9327
home infusion therapy, intermittent (less than twenty-four hours) pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9328
home infusion therapy, implanted pump pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9329
home infusion therapy, chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with s9330 or s9331)
s9330
home infusion therapy, continuous (twenty-four hours or more) chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9331
home infusion therapy, intermittent (less than twenty-four hours) chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9335
home therapy, hemodialysis; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services coded separately), per diem
s9336
home infusion therapy, continuous anticoagulant infusion therapy (e.g., heparin), administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9338
home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9339
home therapy; peritoneal dialysis, administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9340
home therapy; enteral nutrition; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (enteral formula and nursing visits coded separately), per diem
s9341
home therapy; enteral nutrition via gravity; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (enteral formula and nursing visits coded separately), per diem
s9342
home therapy; enteral nutrition via pump; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (enteral formula and nursing visits coded separately), per diem
s9343
home therapy; enteral nutrition via bolus; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (enteral formula and nursing visits coded separately), per diem
s9345
home infusion therapy, anti-hemophilic agent infusion therapy (e.g., factor viii); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9346
home infusion therapy, alpha-1-proteinase inhibitor (e.g., prolastin); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9347
home infusion therapy, uninterrupted, long-term, controlled rate intravenous or subcutaneous infusion therapy (e.g., epoprostenol); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9348
home infusion therapy, sympathomimetic/inotropic agent infusion therapy (e.g., dobutamine); administrative services, professional pharmacy services, care coordination, all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9349
home infusion therapy, tocolytic infusion therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9351
home infusion therapy, continuous or intermittent anti-emetic infusion therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and visits coded separately), per diem
s9353
home infusion therapy, continuous insulin infusion therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9355
home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9357
home infusion therapy, enzyme replacement intravenous therapy; (e.g., imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9359
home infusion therapy, anti-tumor necrosis factor intravenous therapy; (e.g., infliximab); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9361
home infusion therapy, diuretic intravenous therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9363
home infusion therapy, anti-spasmotic therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9364
home infusion therapy, total parenteral nutrition (tpn); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem (do not use with home infusion codes s9365-s9368 using daily volume scales)
s9365
home infusion therapy, total parenteral nutrition (tpn); one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem
s9366
home infusion therapy, total parenteral nutrition (tpn); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem
s9367
home infusion therapy, total parenteral nutrition (tpn); more than two liters but no more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem
s9368
home infusion therapy, total parenteral nutrition (tpn); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem
s9370
home therapy, intermittent anti-emetic injection therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9372
home therapy; intermittent anticoagulant injection therapy (e.g., heparin); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code for flushing of infusion devices with heparin to maintain patency)
s9373
home infusion therapy, hydration therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use with hydration therapy codes s9374-s9377 using daily volume scales)
s9374
home infusion therapy, hydration therapy; one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9375
home infusion therapy, hydration therapy; more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9376
home infusion therapy, hydration therapy; more than two liters but no more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9377
home infusion therapy, hydration therapy; more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies (drugs and nursing visits coded separately), per diem
s9379
home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9381
delivery or service to high risk areas requiring escort or extra protection, per visit
s9401
anticoagulation clinic, inclusive of all services except laboratory tests, per session
s9430
pharmacy compounding and dispensing services
s9432
medical foods for non-inborn errors of metabolism
s9433
medical food nutritionally complete, administered orally, providing 100% of nutritional intake
s9434
modified solid food supplements for inborn errors of metabolism
s9435
medical foods for inborn errors of metabolism
s9436
childbirth preparation/lamaze classes, non-physician provider, per session
s9437
childbirth refresher classes, non-physician provider, per session
s9438
cesarean birth classes, non-physician provider, per session
s9439
vbac (vaginal birth after cesarean) classes, non-physician provider, per session
s9441
asthma education, non-physician provider, per session
s9442
birthing classes, non-physician provider, per session
s9443
lactation classes, non-physician provider, per session
s9444
parenting classes, non-physician provider, per session
s9445
patient education, not otherwise classified, non-physician provider, individual, per session
s9446
patient education, not otherwise classified, non-physician provider, group, per session
s9447
infant safety (including cpr) classes, non-physician provider, per session
s9449
weight management classes, non-physician provider, per session
s9451
exercise classes, non-physician provider, per session
s9452
nutrition classes, non-physician provider, per session
s9453
smoking cessation classes, non-physician provider, per session
s9454
stress management classes, non-physician provider, per session
s9455
diabetic management program, group session
s9460
diabetic management program, nurse visit
s9465
diabetic management program, dietitian visit
s9470
nutritional counseling, dietitian visit
s9472
cardiac rehabilitation program, non-physician provider, per diem
s9473
pulmonary rehabilitation program, non-physician provider, per diem
s9474
enterostomal therapy by a registered nurse certified in enterostomal therapy, per diem
s9475
ambulatory setting substance abuse treatment or detoxification services, per diem
s9476
vestibular rehabilitation program, non-physician provider, per diem
s9480
intensive outpatient psychiatric services, per diem
s9482
family stabilization services, per 15 minutes
s9484
crisis intervention mental health services, per hour
s9485
crisis intervention mental health services, per diem
s9490
home infusion therapy, corticosteroid infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9494
home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules s9497-s9504)
s9497
home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9500
home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9501
home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9502
home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9503
home infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9504
home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9529
routine venipuncture for collection of specimen(s), single home bound, nursing home, or skilled nursing facility patient
s9537
home therapy; hematopoietic hormone injection therapy (e.g., erythropoietin, g-csf, gm-csf); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9538
home transfusion of blood product(s); administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (blood products, drugs, and nursing visits coded separately), per diem
s9542
home injectable therapy, not otherwise classified, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9558
home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9559
home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9560
home injectable therapy; hormonal therapy (e.g.; leuprolide, goserelin), including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9562
home injectable therapy, palivizumab, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9590
home therapy, irrigation therapy (e.g., sterile irrigation of an organ or anatomical cavity); including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
s9810
home therapy; professional pharmacy services for provision of infusion, specialty drug administration, and/or disease state management, not otherwise classified, per hour (do not use this code with any per diem code)
s9900
services by a journal-listed christian science practitioner for the purpose of healing, per diem
s9901
services by a journal-listed christian science nurse, per hour
s9960
ambulance service, conventional air service, nonemergency transport, one way (fixed wing)
s9961
ambulance service, conventional air service, nonemergency transport, one way (rotary wing)
s9970
health club membership, annual
s9975
transplant related lodging, meals and transportation, per diem
s9976
lodging, per diem, not otherwise classified
s9977
meals, per diem, not otherwise specified
s9981
medical records copying fee, administrative
s9982
medical records copying fee, per page
s9986
not medically necessary service (patient is aware that service not medically necessary)
s9988
services provided as part of a phase i clinical trial
s9989
services provided outside of the united states of america (list in addition to code(s) for service(s))
s9990
services provided as part of a phase ii clinical trial
s9991
services provided as part of a phase iii clinical trial
s9992
transportation costs to and from trial location and local transportation costs (e.g., fares for taxicab or bus) for clinical trial participant and one caregiver/companion
s9994
lodging costs (e.g., hotel charges) for clinical trial participant and one caregiver/companion
s9996
meals for clinical trial participant and one caregiver/companion
s9999
sales tax
t1000
private duty / independent nursing service(s) - licensed, up to 15 minutes
t1001
nursing assessment / evaluation
t1002
rn services, up to 15 minutes
t1003
lpn/lvn services, up to 15 minutes
t1004
services of a qualified nursing aide, up to 15 minutes
t1005
respite care services, up to 15 minutes
t1006
alcohol and/or substance abuse services, family/couple counseling
t1007
alcohol and/or substance abuse services, treatment plan development and/or modification
t1009
child sitting services for children of the individual receiving alcohol and/or substance abuse services
t1010
meals for individuals receiving alcohol and/or substance abuse services (when meals not included in the program)
t1012
alcohol and/or substance abuse services, skills development
t1013
sign language or oral interpretive services, per 15 minutes
t1014
telehealth transmission, per minute, professional services bill separately
t1015
clinic visit/encounter, all-inclusive
t1016
case management, each 15 minutes
t1017
targeted case management, each 15 minutes
t1018
school-based individualized education program (iep) services, bundled
t1019
personal care services, per 15 minutes, not for an inpatient or resident of a hospital, nursing facility, icf/mr or imd, part of the individualized plan of treatment (code may not be used to identify services provided by home health aide or certified nurse assistant)
t1020
personal care services, per diem, not for an inpatient or resident of a hospital, nursing facility, icf/mr or imd, part of the individualized plan of treatment (code may not be used to identify services provided by home health aide or certified nurse assistant)
t1021
home health aide or certified nurse assistant, per visit
t1022
contracted home health agency services, all services provided under contract, per day
t1023
screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter
t1024
evaluation and treatment by an integrated, specialty team contracted to provide coordinated care to multiple or severely handicapped children, per encounter
t1025
intensive, extended multidisciplinary services provided in a clinic setting to children with complex medical, physical, mental and psychosocial impairments, per diem
t1026
intensive, extended multidisciplinary services provided in a clinic setting to children with complex medical, physical, medical and psychosocial impairments, per hour
t1027
family training and counseling for child development, per 15 minutes
t1028
assessment of home, physical and family environment, to determine suitability to meet patient's medical needs
t1029
comprehensive environmental lead investigation, not including laboratory analysis, per dwelling
t1030
nursing care, in the home, by registered nurse, per diem
t1031
nursing care, in the home, by licensed practical nurse, per diem
t1032
services performed by a doula birth worker, per 15 minutes
t1033
services performed by a doula birth worker, per diem
t1040
medicaid certified community behavioral health clinic services, per diem
t1041
medicaid certified community behavioral health clinic services, per month
t1502
administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit
t1503
administration of medication, other than oral and/or injectable, by a health care agency/professional, per visit
t1505
electronic medication compliance management device, includes all components and accessories, not otherwise classified
t1999
miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks"
t2001
non-emergency transportation; patient attendant/escort
t2002
non-emergency transportation; per diem
t2003
non-emergency transportation; encounter/trip
t2004
non-emergency transport; commercial carrier, multi-pass
t2005
non-emergency transportation; stretcher van
t2007
transportation waiting time, air ambulance and non-emergency vehicle, one-half (1/2) hour increments
t2010
preadmission screening and resident review (pasrr) level i identification screening, per screen
t2011
preadmission screening and resident review (pasrr) level ii evaluation, per evaluation
t2012
habilitation, educational; waiver, per diem
t2013
habilitation, educational, waiver; per hour
t2014
habilitation, prevocational, waiver; per diem
t2015
habilitation, prevocational, waiver; per hour
t2016
habilitation, residential, waiver; per diem
t2017
habilitation, residential, waiver; 15 minutes
t2018
habilitation, supported employment, waiver; per diem
t2019
habilitation, supported employment, waiver; per 15 minutes
t2020
day habilitation, waiver; per diem
t2021
day habilitation, waiver; per 15 minutes
t2022
case management, per month
t2023
targeted case management; per month
t2024
service assessment/plan of care development, waiver
t2025
waiver services; not otherwise specified (nos)
t2026
specialized childcare, waiver; per diem
t2027
specialized childcare, waiver; per 15 minutes
t2028
specialized supply, not otherwise specified, waiver
t2029
specialized medical equipment, not otherwise specified, waiver
t2030
assisted living, waiver; per month
t2031
assisted living; waiver, per diem
t2032
residential care, not otherwise specified (nos), waiver; per month
t2033
residential care, not otherwise specified (nos), waiver; per diem
t2034
crisis intervention, waiver; per diem
t2035
utility services to support medical equipment and assistive technology/devices, waiver
t2036
therapeutic camping, overnight, waiver; each session
t2037
therapeutic camping, day, waiver; each session
t2038
community transition, waiver; per service
t2039
vehicle modifications, waiver; per service
t2040
financial management, self-directed, waiver; per 15 minutes
t2041
supports brokerage, self-directed, waiver; per 15 minutes
t2042
hospice routine home care; per diem
t2043
hospice continuous home care; per hour
t2044
hospice inpatient respite care; per diem
t2045
hospice general inpatient care; per diem
t2046
hospice long term care, room and board only; per diem
t2047
habilitation, prevocational, waiver; per 15 minutes
t2048
behavioral health; long-term care residential (non-acute care in a residential treatment program where stay is typically longer than 30 days), with room and board, per diem
t2049
non-emergency transportation; stretcher van, mileage; per mile
t2050
financial management, self-directed, waiver; per diem
t2051
supports brokerage, self-directed, waiver; per diem
t2101
human breast milk processing, storage and distribution only
t4521
adult sized disposable incontinence product, brief/diaper, small, each
t4522
adult sized disposable incontinence product, brief/diaper, medium, each
t4523
adult sized disposable incontinence product, brief/diaper, large, each
t4524
adult sized disposable incontinence product, brief/diaper, extra large, each
t4525
adult sized disposable incontinence product, protective underwear/pull-on, small size, each
t4526
adult sized disposable incontinence product, protective underwear/pull-on, medium size, each
t4527
adult sized disposable incontinence product, protective underwear/pull-on, large size, each
t4528
adult sized disposable incontinence product, protective underwear/pull-on, extra large size, each
t4529
pediatric sized disposable incontinence product, brief/diaper, small/medium size, each
t4530
pediatric sized disposable incontinence product, brief/diaper, large size, each
t4531
pediatric sized disposable incontinence product, protective underwear/pull-on, small/medium size, each
t4532
pediatric sized disposable incontinence product, protective underwear/pull-on, large size, each
t4533
youth sized disposable incontinence product, brief/diaper, each
t4534
youth sized disposable incontinence product, protective underwear/pull-on, each
t4535
disposable liner/shield/guard/pad/undergarment, for incontinence, each
t4536
incontinence product, protective underwear/pull-on, reusable, any size, each
t4537
incontinence product, protective underpad, reusable, bed size, each
t4538
diaper service, reusable diaper, each diaper
t4539
incontinence product, diaper/brief, reusable, any size, each
t4540
incontinence product, protective underpad, reusable, chair size, each
t4541
incontinence product, disposable underpad, large, each
t4542
incontinence product, disposable underpad, small size, each
t4543
adult sized disposable incontinence product, protective brief/diaper, above extra large, each
t4544
adult sized disposable incontinence product, protective underwear/pull-on, above extra large, each
t4545
incontinence product, disposable, penile wrap, each
t5001
positioning seat for persons with special orthopedic needs
t5999
supply, not otherwise specified
u0001
cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel
u0002
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc
u0003
infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r
u0004
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r
u0005
infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2
v2020
frames, purchases
v2025
deluxe frame
v2100
sphere, single vision, plano to plus or minus 4.00, per lens
v2101
sphere, single vision, plus or minus 4.12 to plus or minus 7.00d, per lens
v2102
sphere, single vision, plus or minus 7.12 to plus or minus 20.00d, per lens
v2103
spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens
v2104
spherocylinder, single vision, plano to plus or minus 4.00d sphere, 2.12 to 4.00d cylinder, per lens
v2105
spherocylinder, single vision, plano to plus or minus 4.00d sphere, 4.25 to 6.00d cylinder, per lens
v2106
spherocylinder, single vision, plano to plus or minus 4.00d sphere, over 6.00d cylinder, per lens
v2107
spherocylinder, single vision, plus or minus 4.25 to plus or minus 7.00 sphere, .12 to 2.00d cylinder, per lens
v2108
spherocylinder, single vision, plus or minus 4.25d to plus or minus 7.00d sphere, 2.12 to 4.00d cylinder, per lens
v2109
spherocylinder, single vision, plus or minus 4.25 to plus or minus 7.00d sphere, 4.25 to 6.00d cylinder, per lens
v2110
spherocylinder, single vision, plus or minus 4.25 to 7.00d sphere, over 6.00d cylinder, per lens
v2111
spherocylinder, single vision, plus or minus 7.25 to plus or minus 12.00d sphere, .25 to 2.25d cylinder, per lens
v2112
spherocylinder, single vision, plus or minus 7.25 to plus or minus 12.00d sphere, 2.25d to 4.00d cylinder, per lens
v2113
spherocylinder, single vision, plus or minus 7.25 to plus or minus 12.00d sphere, 4.25 to 6.00d cylinder, per lens
v2114
spherocylinder, single vision, sphere over plus or minus 12.00d, per lens
v2115
lenticular, (myodisc), per lens, single vision
v2118
aniseikonic lens, single vision
v2121
lenticular lens, per lens, single
v2199
not otherwise classified, single vision lens
v2200
sphere, bifocal, plano to plus or minus 4.00d, per lens
v2201
sphere, bifocal, plus or minus 4.12 to plus or minus 7.00d, per lens
v2202
sphere, bifocal, plus or minus 7.12 to plus or minus 20.00d, per lens
v2203
spherocylinder, bifocal, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens
v2204
spherocylinder, bifocal, plano to plus or minus 4.00d sphere, 2.12 to 4.00d cylinder, per lens
v2205
spherocylinder, bifocal, plano to plus or minus 4.00d sphere, 4.25 to 6.00d cylinder, per lens
v2206
spherocylinder, bifocal, plano to plus or minus 4.00d sphere, over 6.00d cylinder, per lens
v2207
spherocylinder, bifocal, plus or minus 4.25 to plus or minus 7.00d sphere,.12 to 2.00d cylinder, per lens
v2208
spherocylinder, bifocal, plus or minus 4.25 to plus or minus 7.00d sphere, 2.12 to 4.00d cylinder, per lens
v2209
spherocylinder, bifocal, plus or minus 4.25 to plus or minus 7.00d sphere, 4.25 to 6.00d cylinder, per lens
v2210
spherocylinder, bifocal, plus or minus 4.25 to plus or minus 7.00d sphere, over 6.00d cylinder, per lens
v2211
spherocylinder, bifocal, plus or minus 7.25 to plus or minus 12.00d sphere, .25 to 2.25d cylinder, per lens
v2212
spherocylinder, bifocal, plus or minus 7.25 to plus or minus 12.00d sphere, 2.25 to 4.00d cylinder, per lens
v2213
spherocylinder, bifocal, plus or minus 7.25 to plus or minus 12.00d sphere, 4.25 to 6.00d cylinder, per lens
v2214
spherocylinder, bifocal, sphere over plus or minus 12.00d, per lens
v2215
lenticular (myodisc), per lens, bifocal
v2218
aniseikonic, per lens, bifocal
v2219
bifocal seg width over 28 mm
v2220
bifocal add over 3.25d
v2221
lenticular lens, per lens, bifocal
v2299
specialty bifocal (by report)
v2300
sphere, trifocal, plano to plus or minus 4.00d, per lens
v2301
sphere, trifocal, plus or minus 4.12 to plus or minus 7.00d, per lens
v2302
sphere, trifocal, plus or minus 7.12 to plus or minus 20.00, per lens
v2303
spherocylinder, trifocal, plano to plus or minus 4.00d sphere, .12-2.00d cylinder, per lens
v2304
spherocylinder, trifocal, plano to plus or minus 4.00d sphere, 2.25-4.00d cylinder, per lens
v2305
spherocylinder, trifocal, plano to plus or minus 4.00d sphere, 4.25 to 6.00 cylinder, per lens
v2306
spherocylinder, trifocal, plano to plus or minus 4.00d sphere, over 6.00d cylinder, per lens
v2307
spherocylinder, trifocal, plus or minus 4.25 to plus or minus 7.00d sphere, .12 to 2.00d cylinder, per lens
v2308
spherocylinder, trifocal, plus or minus 4.25 to plus or minus 7.00d sphere, 2.12 to 4.00d cylinder, per lens
v2309
spherocylinder, trifocal, plus or minus 4.25 to plus or minus 7.00d sphere, 4.25 to 6.00d cylinder, per lens
v2310
spherocylinder, trifocal, plus or minus 4.25 to plus or minus 7.00d sphere, over 6.00d cylinder, per lens
v2311
spherocylinder, trifocal, plus or minus 7.25 to plus or minus 12.00d sphere, .25 to 2.25d cylinder, per lens
v2312
spherocylinder, trifocal, plus or minus 7.25 to plus or minus 12.00d sphere, 2.25 to 4.00d cylinder, per lens
v2313
spherocylinder, trifocal, plus or minus 7.25 to plus or minus 12.00d sphere, 4.25 to 6.00d cylinder, per lens
v2314
spherocylinder, trifocal, sphere over plus or minus 12.00d, per lens
v2315
lenticular, (myodisc), per lens, trifocal
v2318
aniseikonic lens, trifocal
v2319
trifocal seg width over 28 mm
v2320
trifocal add over 3.25d
v2321
lenticular lens, per lens, trifocal
v2399
specialty trifocal (by report)
v2410
variable asphericity lens, single vision, full field, glass or plastic, per lens
v2430
variable asphericity lens, bifocal, full field, glass or plastic, per lens
v2499
variable sphericity lens, other type
v2500
contact lens, pmma, spherical, per lens
v2501
contact lens, pmma, toric or prism ballast, per lens
v2502
contact lens, pmma, bifocal, per lens
v2503
contact lens, pmma, color vision deficiency, per lens
v2510
contact lens, gas permeable, spherical, per lens
v2511
contact lens, gas permeable, toric, prism ballast, per lens
v2512
contact lens, gas permeable, bifocal, per lens
v2513
contact lens, gas permeable, extended wear, per lens
v2520
contact lens, hydrophilic, spherical, per lens
v2521
contact lens, hydrophilic, toric, or prism ballast, per lens
v2522
contact lens, hydrophilic, bifocal, per lens
v2523
contact lens, hydrophilic, extended wear, per lens
v2524
contact lens, hydrophilic, spherical, photochromic additive, per lens
v2525
contact lens, hydrophilic, dual focus, per lens
v2530
contact lens, scleral, gas impermeable, per lens (for contact lens modification, see 92325)
v2531
contact lens, scleral, gas permeable, per lens (for contact lens modification, see 92325)
v2599
contact lens, other type
v2600
hand held low vision aids and other nonspectacle mounted aids
v2610
single lens spectacle mounted low vision aids
v2615
telescopic and other compound lens system, including distance vision telescopic, near vision telescopes and compound microscopic lens system
v2623
prosthetic eye, plastic, custom
v2624
polishing/resurfacing of ocular prosthesis
v2625
enlargement of ocular prosthesis
v2626
reduction of ocular prosthesis
v2627
scleral cover shell
v2628
fabrication and fitting of ocular conformer
v2629
prosthetic eye, other type
v2630
anterior chamber intraocular lens
v2631
iris supported intraocular lens
v2632
posterior chamber intraocular lens
v2700
balance lens, per lens
v2702
deluxe lens feature
v2710
slab off prism, glass or plastic, per lens
v2715
prism, per lens
v2718
press-on lens, fresnell prism, per lens
v2730
special base curve, glass or plastic, per lens
v2744
tint, photochromatic, per lens
v2745
addition to lens; tint, any color, solid, gradient or equal, excludes photochromatic, any lens material, per lens
v2750
anti-reflective coating, per lens
v2755
u-v lens, per lens
v2756
eye glass case
v2760
scratch resistant coating, per lens
v2761
mirror coating, any type, solid, gradient or equal, any lens material, per lens
v2762
polarization, any lens material, per lens
v2770
occluder lens, per lens
v2780
oversize lens, per lens
v2781
progressive lens, per lens
v2782
lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens
v2783
lens, index greater than or equal to 1.66 plastic or greater than or equal to 1.80 glass, excludes polycarbonate, per lens
v2784
lens, polycarbonate or equal, any index, per lens
v2785
processing, preserving and transporting corneal tissue
v2786
specialty occupational multifocal lens, per lens
v2787
astigmatism correcting function of intraocular lens
v2788
presbyopia correcting function of intraocular lens
v2790
amniotic membrane for surgical reconstruction, per procedure
v2797
vision supply, accessory and/or service component of another hcpcs vision code
v2799
vision item or service, miscellaneous
v5008
hearing screening
v5010
assessment for hearing aid
v5011
fitting/orientation/checking of hearing aid
v5014
repair/modification of a hearing aid
v5020
conformity evaluation
v5030
hearing aid, monaural, body worn, air conduction
v5040
hearing aid, monaural, body worn, bone conduction
v5050
hearing aid, monaural, in the ear
v5060
hearing aid, monaural, behind the ear
v5070
glasses, air conduction
v5080
glasses, bone conduction
v5090
dispensing fee, unspecified hearing aid
v5095
semi-implantable middle ear hearing prosthesis
v5100
hearing aid, bilateral, body worn
v5110
dispensing fee, bilateral
v5120
binaural, body
v5130
binaural, in the ear
v5140
binaural, behind the ear
v5150
binaural, glasses
v5160
dispensing fee, binaural
v5170
hearing aid, cros, in the ear terminated december 31, 2018.
v5171
hearing aid, contralateral routing device, monaural, in the ear (ite)
v5172
hearing aid, contralateral routing device, monaural, in the canal (itc)
v5180
hearing aid, cros, behind the ear terminated december 31, 2018.
v5181
hearing aid, contralateral routing device, monaural, behind the ear (bte)
v5190
hearing aid, contralateral routing, monaural, glasses
v5200
dispensing fee, contralateral, monaural
v5210
hearing aid, bicros, in the ear terminated december 31, 2018.
v5211
hearing aid, contralateral routing system, binaural, ite/ite
v5212
hearing aid, contralateral routing system, binaural, ite/itc
v5213
hearing aid, contralateral routing system, binaural, ite/bte
v5214
hearing aid, contralateral routing system, binaural, itc/itc
v5215
hearing aid, contralateral routing system, binaural, itc/bte
v5220
hearing aid, bicros, behind the ear terminated december 31, 2018.
v5221
hearing aid, contralateral routing system, binaural, bte/bte
v5230
hearing aid, contralateral routing system, binaural, glasses
v5240
dispensing fee, contralateral routing system, binaural
v5241
dispensing fee, monaural hearing aid, any type
v5242
hearing aid, analog, monaural, cic (completely in the ear canal)
v5243
hearing aid, analog, monaural, itc (in the canal)
v5244
hearing aid, digitally programmable analog, monaural, cic
v5245
hearing aid, digitally programmable, analog, monaural, itc
v5246
hearing aid, digitally programmable analog, monaural, ite (in the ear)
v5247
hearing aid, digitally programmable analog, monaural, bte (behind the ear)
v5248
hearing aid, analog, binaural, cic
v5249
hearing aid, analog, binaural, itc
v5250
hearing aid, digitally programmable analog, binaural, cic
v5251
hearing aid, digitally programmable analog, binaural, itc
v5252
hearing aid, digitally programmable, binaural, ite
v5253
hearing aid, digitally programmable, binaural, bte
v5254
hearing aid, digital, monaural, cic
v5255
hearing aid, digital, monaural, itc
v5256
hearing aid, digital, monaural, ite
v5257
hearing aid, digital, monaural, bte
v5258
hearing aid, digital, binaural, cic
v5259
hearing aid, digital, binaural, itc
v5260
hearing aid, digital, binaural, ite
v5261
hearing aid, digital, binaural, bte
v5262
hearing aid, disposable, any type, monaural
v5263
hearing aid, disposable, any type, binaural
v5264
ear mold/insert, not disposable, any type
v5265
ear mold/insert, disposable, any type
v5266
battery for use in hearing device
v5267
hearing aid or assistive listening device/supplies/accessories, not otherwise specified
v5268
assistive listening device, telephone amplifier, any type
v5269
assistive listening device, alerting, any type
v5270
assistive listening device, television amplifier, any type
v5271
assistive listening device, television caption decoder
v5272
assistive listening device, tdd
v5273
assistive listening device, for use with cochlear implant
v5274
assistive listening device, not otherwise specified
v5275
ear impression, each
v5281
assistive listening device, personal fm/dm system, monaural, (1 receiver, transmitter, microphone), any type
v5282
assistive listening device, personal fm/dm system, binaural, (2 receivers, transmitter, microphone), any type
v5283
assistive listening device, personal fm/dm neck, loop induction receiver
v5284
assistive listening device, personal fm/dm, ear level receiver
v5285
assistive listening device, personal fm/dm, direct audio input receiver
v5286
assistive listening device, personal blue tooth fm/dm receiver
v5287
assistive listening device, personal fm/dm receiver, not otherwise specified
v5288
assistive listening device, personal fm/dm transmitter assistive listening device
v5289
assistive listening device, personal fm/dm adapter/boot coupling device for receiver, any type
v5290
assistive listening device, transmitter microphone, any type
v5298
hearing aid, not otherwise classified
v5299
hearing service, miscellaneous
v5336
repair/modification of augmentative communicative system or device (excludes adaptive hearing aid)
v5362
speech screening
v5363
language screening
v5364
dysphagia screening
